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Abstract 
 
Polycystic ovary syndrome or PCOS was first described in 1935 by Irving F. Stein and Michael 
L. Leventhal as Stein Leventhal Syndrome; ‘women with ovarian hyperthecosis presenting 
with persistent anovulation, obesity and hirsutism.’ Today, PCOS is the most common 
reproductive endocrinopathy of women, the most common cause of ovarian infertility and 
the cause of significant distress. PCOS is associated with serious health risks in the short and 
long term including significantly increased risks for diabetes, cancer and cardiovascular 
disease, independent to body weight. For the health care system, the annual cost of PCOS in 
Australia was conservatively estimated as AU$400 million. The negative personal impact of 
PCOS on women’s quality of life and self-esteem is well defined and recognised.  
Current evidence-based medical management emphasises a multidisciplinary approach with 
lifestyle intervention recommended as first-line treatment. However, the strength of 
evidence for lifestyle intervention is limited by high attrition in RCTs and the clinical uptake 
remains impeded by the lack of evidence for optimal dietary and exercise practices. 
Additional forms of management are often needed. Pharmaceuticals and surgery may be 
used to regulate menstruation, reduce androgens and treat infertility and hyperinsulinaemia 
however these have limited capacity to address the range of PCOS symptoms, are often 
contra-indicated due to increased risk of co-morbidities or have high adverse effect profiles. 
In addition, women with PCOS have expressed preferences for alternatives to birth control 
pills and fertility drugs. 
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Naturopathy is a type of complementary medicine with traditional origins in ancient 
western civilisations. Naturopaths could be described as complementary ‘general 
practitioners’ as they provide health care for a wide range of conditions using a variety of 
treatment modalities to enhance well-being and support the natural healing capabilities of 
the body. The case for naturopathy for PCOS is presented here based on three rationales; 
first on the basis of a clinical gap in medical management; second based on the clinical 
potential for naturopathic herbal medicine and nutritional supplements in women’s 
reproductive pathology, and third based on the increasingly high use and acceptability of 
complementary medicines by women throughout the world. This thesis examined the role 
of naturopathy in women with PCOS by answering the following questions. 
1. What is the prevalence of use and attitudes towards complementary medicine and self-
help measures by women with PCOS? 
2. What is the evidence from randomised controlled trials for naturopathic herbal medicines 
and nutritional supplements for women with PCOS? 
3. What is the pre-clinical and corroborating clinical evidence for the therapeutic effects of 
herbal medicine for treatment of oligo/amenorrhoea, hyperandrogenism and PCOS? 
4. Does the addition of five herbal medicines (Tribulus terrestris, Glycyrrhiza glabra, Paeonia 
lactiflora, Hypeicum perforatum and Cinnamomum cassia) to a lifestyle intervention 
compared with lifestyle intervention alone improve menstrual regularity in overweight 
women PCOS?  
Methods: These questions were addressed following the survey of women with PCOS, two 
separate reviews of the literature and through a randomised controlled trial examining the 
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effectiveness of a naturopathic herbal formula plus lifestyle intervention on a broad range 
of outcomes in overweight women with polycystic ovary syndrome.  
An electronic survey of 493 women with PCOS assessed women’s use and attitudes towards 
complementary medicine and self-care (diet and exercise). Women were recruited from the 
polycystic ovary syndrome association of Australia (POSAA) and through PCOS support 
groups on social media. 
The evidence base for nutritional supplements and herbal medicine was examined through 
two literature reviews. The randomised controlled trial (RCT) evidence for nutritional 
supplements and herbal medicine for clinical effects in women with PCOS was identified 
following the systematic review of the literature. Consistent pre-clinical and clinical 
evidence of physiological effects in PCOS for herbal medicine used in naturopathic clinical 
practice was sought to explain the mechanism of action of herbal medicine on menstrual 
regulation, hyperandrogenism and PCOS.  
A randomised controlled trial (RCT) examined the clinical effectiveness and safety of the 
addition of a new herbal combination to lifestyle intervention compared to lifestyle 
intervention alone in 122 overweight women with medically diagnosed PCOS. The primary 
outcome was menstrual regularity. A range of secondary physical, reproductive and mental 
health outcomes were examined following three months intervention. 
Results: Over two thirds of women surveyed reported regular use of nutritional and herbal 
supplements to manage their PCOS. Although most respondents reported regular 
engagement with lifestyle interventions (diet and exercise) few reported satisfaction, and 
most expressed a desire for transparent information about complementary medicines.  
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The systematic review of the literature revealed evidence from 18 RCTs (1109 women) for 
six types of nutritional supplements (vitamin D, Omega 3, calcium, chromium,  vitamins and 
inositol) and four herbal medicines (Camellia sinensis, Cimicifuga racemosa Cinnamon cassia 
and  Mentha spicata) for the management of symptoms associated with PCOS. The quality 
of studies was low to moderate, 11 meta-analyses were applied to 11 outcomes. The 
strongest evidence was found for inositol for treatment of a hyperandrogenism, 
reproduction, metabolic hormones and for omega three fish oils for treatment of high 
cholesterol in women with PCOS. Findings highlighted the lack of robust evidence for many 
natural health supplements and that outcomes for inositol and omega three may contribute 
lower graded evidence to the evidence based guidelines for the management of women 
with PCOS.  
The review of the literature for the mechanism of effect of herbal medicines in 
oligo/amenorrhoea, hyperandrogenism and PCOS revealed consistent pre-clinical and 
clinical evidence for six herbal medicines (Cimicifuga racemosa, Cinnamomum cassia, 
Glycyrrhiza spp, Paeonia lactiflora Tribulus terrestris and Vitex agnus-castus). Reproductive 
endocrinological effects were reduced LH (Cimicifuga racemosa, Paeonia lactiflora and 
Cinnamomum cassia), raised FSH (Tribulus terrestris), reduced testosterone (Glycorrhizza 
spp. and Paeonia lactiflora) and improved fasting insulin (Cinnamomum cassia). Findings of 
the literature reviews and naturopathic clinical practice informed the development of a new 
herbal combination for investigation in the RCT. 
One hundred and twenty two women with PCOS were randomised to receive herbal 
medicine plus lifestyle intervention or lifestyle intervention alone. At three months there 
was a significant difference between groups for the number of days in the menstrual cycle 
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with a moderate to large treatment effect found for herbal medicine in addition to lifestyle 
intervention. Significant improvements for secondary outcomes included fasting insulin, 
anthropometric characteristics (BMI, body weight and waist circumference), quality of life 
(PCOSQ), depression, anxiety and stress (DASS 21) and pregnancy rates. The herbal 
medicine was well tolerated and two women were withdrawn due to non-serious side 
effects. Methodological strengths included sufficient power, low attrition and intention to 
treat analyses 
Conclusion: This thesis provides new evidence for the therapeutic role and safety of 
naturopathy for the management of PCOS. It demonstrates that women with PCOS are 
frequent users of complementary medicine, cites evidence of reproductive endocrine 
effects of some herbal extracts and presents evidence from RCTs for the clinical efficacy of 
two nutritional supplements (inositol and omega three fish oils) and two herbal medicines 
(Cimicifuga racemosa and Mentha spicata) for improved hormone profile, reproduction and 
risk factors.  This thesis presents preliminary evidence for the enhanced effectiveness of 
lifestyle intervention following the addition of a new herbal formulation for overweight 
women with PCOS.  Significantly improved outcomes included menstrual regularity, 
metabolic hormones, anthropometry, blood pressure, pregnancy rates, psychological profile 
and quality of life. The herbal treatment was well tolerated and likely to have high 
acceptability by women with PCOS.    
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Chapter 1:  Introduction 
 
 
This chapter presents the case for the need to conduct rigorous research to examine the 
possible role naturopathy may offer women with polycystic ovary syndrome (PCOS). It starts 
by defining PCOS, and describes the epidemiology, aetiology, pathogenesis and health risks 
of PCOS with an overview of current treatment strategies. Naturopathy is subsequently 
defined with attention drawn to the naturopathic interventions of nutritional supplements 
and herbal medicine. An introduction is provided for the proposed studies addressed in this 
thesis.  
1.1 Definition 
PCOS is a multifactorial, complex, reproductive and endocrine disorder, characterised by 
heterogonous presentation of polycystic ovaries on ultrasound, ovarian dysfunction, 
menstrual irregularity and hyperandrogenism, metabolic and psychological disorders. The 
definition and clinical diagnostic criteria for PCOS has been subject to debate and a new 
consensus was achieved at Rotterdam by the European Society of Human Reproduction and 
Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) in 2003 
(ESHRE 2004). The criteria for diagnosis were adjusted to include at least two of the 
following features; 1) polycystic ovaries on ultrasound; 2) clinical or biochemical 
hyperandrogenism; 3) oligomenorrhoea (menses ≥ 35 days) or amenorrhoea, (no menses 
for three to six months).  In 2009 the Androgen Excess and PCOS Society (AE-PCOS) 
proposed an additional change (Azziz, Carmina et al. 2009). They argued that PCOS should 
be defined by the presence of clinical or biochemical hyperandrogenism in combination with 
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ovulatory disorders (oligo/amenorrhoea and/or polycystic ovaries on ultrasound) in 
recognition that hyperandrogenism is a central feature of the disease. However the 
diagnostic criterion for PCOS described at Rotterdam remains more widely accepted and 
referred to in treatment guidelines and  subsequent research (Norman, Dewailly et al. 2007, 
ESHRE 2008, AAPCOS 2011, Moran, Hutchison et al. 2011, ESHRE 2012, Tang, Lord et al. 
2012, Legro, Arslanian et al. 2013). ESHRE acknowledges the complex multi-morbidity 
associated with PCOS and the need for a multidisciplinary evidence-based management 
(ESHRE 2008, ESHRE 2012).  
1.2 Epidemiology 
PCOS affects between 8-22% of reproductive-aged women (March, Moore et al. 2010, Joshi, 
Mukherjee et al. 2014), this variation in prevalence is influenced by the diagnostic criterion 
applied. Prevalence estimates using the Rotterdam criteria are consistently higher 
compared to the androgen excess society (AES) and National Institutes of Health (NIH) 
diagnostic criterion (March, Moore et al. 2010, Tehrani, Simbar et al. 2011). A year of birth 
cohort study undertaken in Australia identified PCOS in 17.8% ±2.8 of women aged 27-34 
according to the Rotterdam criterion (n=728). When the NIH criteria was applied to the 
same sample, 8.7% ± 2.0 of women were estimated to have PCOS, and 12.0% ± 2.4 of 
women when using the AES diagnostic criteria,  (March, Moore et al. 2010).  
1.3 Aetiology 
The exact aetiology of PCOS remains unknown. The most compelling argument is genetic 
and stems from the aggregation of PCOS within families. There is a significantly increased 
prevalence observed between siblings (32-66%) and their mothers (24-52%) (Kahsar-Miller, 
Nixon et al. 2001, Yildiz, Goodarzi et al. 2006). Another familial association reported by 
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Legro and colleagues (2002) indicated that first degree male relatives of women with PCOS 
had significantly higher dehydroepiandrosterone sulphate (DHEAS) levels compared to 
controls. This finding suggests that PCOS has an autosomal dominant inheritance with both 
females and males. Several genes are reportedly linked with PCOS including single 
nucleotide mutations associated with hyperandrogenism, follicular-genesis, steroidogenesis 
(Franks 2006, Nelson et al 1999) and insulin signalling (Ehrmann 2004).  However, whilst 
there is strong evidence for the mutation of candidate genes, the genetic basis for PCOS is 
thought to be polygenic, multifactorial and complicated by epigenetic alteration (genetic 
methylation and acetylation of DNA and messenger RNA) in response to  environmental 
stimulus  (Abbott, Barnett et al. 2005, Sarkar C 2008, Jones, Xu et al. 2014). 
1.4 Pathogenesis  
The pathogenic presentation of PCOS includes oligo/amenorrhoea, hyperandrogenism and 
polycystic ovaries. These signs and symptoms develop due to ovarian morphological 
changes mediated and augmented by a range of pathological processes. Polycystic ovaries 
display hypertrophic thecal and stromal cell layers surrounding ovarian follicles (Norman 
2002). Elevated luteinising hormone (LH), hyperandrogenism, insulin resistance (IR), 
hyperinsulinaemia and increased body weight are believed to play key roles in the 
pathogenesis of PCOS (ESHRE 2004, AACE 2005, Hart and Norman 2006, Legro, Zaino et al. 
2007, Norman, Dewailly et al. 2007, Tang, Lord Jonathan et al. 2010).  
Insulin has been shown to selectively bind with receptors on the membranes of theca cells 
within the follicles of ovary’s (Azziz, Ehrmann et al. 2003), and enhance theca cell 
proliferation, ovarian androgen biosynthesis and increased secretion of androgens into the 
general circulation (Panides 2005, Legro, Zaino et al. 2007).  Combined with insulin’s 
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inhibiting effect on hepatic production of sex hormone binding globulin (SHBG) (Pugeat, 
Crave et al. 1991), an increased serum concentration of total and free androgens persists.  
Elevated LH in relation to FSH is a common pathological finding in women with PCOS 
(Ehrmann 2005). Although not completely explained, elevated LH in PCOS is believed to be 
associated with more frequent pulsatile secretion of gonadotropic releasing hormone 
(GnRH) from the hypothalamus which favours LH secretion over FSH (Taylor, Adams et al. 
1997). It is not known however whether this is due to insufficient suppression of GnRH 
(from the pituitary) or increased sensitivity of the hypothalamus in women with PCOS 
(Goodarzi, Dumesic et al. 2011). Elevated LH is a stimulant of ovarian hyperthecosis and 
plays a key role in the perpetuation of the disorder and complications of the condition. 
1.5 Risk factors  
PCOS is associated with the risk of developing a range of serious diseases in the near future 
and later life. Over 60% of women with PCOS are overweight or obese (Lim, Davies et al. 
2012) and central adiposity or an increased waist to hip ratio (W:H >0.8) is particularly 
common  (ESHRE 2012, Lim, Davies et al. 2012). These characteristics coincide with insulin 
resistance and metabolic syndrome and represent independent risk factors for the 
development of type two diabetes (NIDDM), hypertension and cardiovascular disease (Hart, 
Hickey et al. 2004, AACE 2005, De Groot, Dekkers et al. 2011, Hudecova, Holte et al. 2011, 
Moran, Strauss et al. 2011). 
The metabolic derangements of glucose intolerance and hyperinsulinaemia are significantly 
higher in both obese and non-obese women with PCOS compared to BMI matched controls 
Odds Ratio (OR) 2.76, 95% CI 1.23-6.57, p=0.01 (Legro, Kunselman et al. 1999). By age 40, it 
is estimated that up to 40% of women with PCOS will have developed impaired glucose 
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tolerance or non-insulin dependent diabetes mellitus (NIDDM) (Dunaif 1995, AACE 2005). 
Although insulin resistance occurs in both overweight and slim women, obesity significantly 
contributes to metabolic disease with a ten-fold increase in the risk of developing insulin 
resistance and NIDDM compared with non-obese (BMI <24 kg/m2) women with PCOS (Hart 
and Norman 2006).  
Elevated inflammatory markers such as C-reactive protein (CRP) combined with 
hyperinsulinaemia, directly increases the risk of vascular endothelial dysfunction (Paradisi, 
Steinberg et al. 2003) and coronary artery calcification (CAC) independent of BMI (Christian, 
Dumesic et al. 2003, Talbott, Zborowski et al. 2004). Other health risks for women with 
PCOS include sleep apnoea (Nitsche and Ehrmann 2010) and associated complications. 
Oligomenorrhoea and amenorrhoea are prominent features in women with PCOS and 
associated with infertility (Norman 2008). Approximately 40% of women with PCOS are 
infertile and whilst anovulation accounts for at least 21% of female infertility, and ovulatory 
dysfunction affects approximately 25% of infertile couples (ACOG 2002), 95% of secondary 
ovarian causes of infertility are attributable to PCOS (Baird, Balen et al. 2012). Overweight 
and obese women with PCOS have an increased risk for infertility (Norman, Noakes et al. 
2004). In addition women with anovulatory PCOS are at an increased risk of endometrial 
hyperplasia and endometrial carcinoma (Schmeler, Soliman et al. 2005, Giudice 2006, 
Costello, Shrestha et al. 2007). 
During pregnancy, women with PCOS have an increased risk of maternal morbidity and 
neonatal morbidity and mortality.  Pregnant women are at greater risk of gestational 
diabetes OR2.94, CI 95%, 1.70-5.08), pre-eclampsia (OR 3.67; CI 95%; 1.98-6.81) and pre-
term labour (OR 1.75; CI 95%; 1.16-2.62) (Boomsma, Eijkemans et al. 2006).  
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Psychological morbidity including depression and anxiety are reportedly higher in women 
with PCOS compared to their non PCOS counterparts (Deeks, Gibson-Helm et al. 2010 Barry, 
Kuczmierczyk et al. 2011). Hirsutism, acne and obesity are obvious physical manifestations 
that may negatively influence the personal identity of women (Moreira and Azevedo 2006). 
These signs have been associated with significant depression for women with PCOS (OR 
4.03, 95% CI 2.96-5.5 P <0.01) (Dokras A 2011). The development of anxiety and depression 
negatively influences women’s self-efficacy and health related quality of life (Kerchner, 
Lester et al. 2009, Deeks, Gibson-Helm et al. 2010,  Barry, Kuczmierczyk et al. 2011).  
1.6 Evidence based interventions  
The management of PCOS is aimed at treating metabolic and reproductive derangements, 
presenting signs and symptoms including hirsutism, acne, oligomenorrhoea, amenorrhoea 
and infertility and preventing the development of chronic disease. This is achieved through 
normalising androgen levels, supressing ovarian steroidogenesis and managing metabolic 
morbidity particularly the management of hyperglycaemia through body composition 
improvements using lifestyle, surgical or pharmacological interventions and may be 
determined by the reproductive desires of women.  
The current interventions for women with PCOS not wanting to conceive includes anti-
androgens, insulin sensitising medications and the oral contraceptive pills (OCP). Surgical 
options include laparoscopic ovarian drilling (LOD) or gastric banding (ESHRE 2008). Recently 
there has been evidence supporting the effectiveness of lifestyle interventions which are 
recommended as the first appropriate intervention particularly for overweight women with 
PCOS (ESHRE 2004, AACE 2005, ESHRE 2008, AAPCOS 2011, ESHRE 2012). Pharmaceuticals 
for women wanting to conceive include the anti-oestrogen Clomiphene citrate (clomiphene) 
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and human menopausal gonadotropin (hMG) which stimulate the maturation of a dominant 
ovarian follicle and induce ovulation (Beck, Boothroyd et al. 2013). Surgical treatments 
include laparoscopic ovarian drilling (LOD) which causes atrophy of selected follicles, 
normalisation of androgenaemia and restoration of regular ovulation. Lifestyle 
interventions, including dietary and exercise behaviours, reduce adiposity, normalise insulin 
and androgens, restore menstruation and improve mental health (Thomson, Buckley et al. 
2009, Thomson, Buckley et al. 2010, Moran, Hutchison et al. 2011). 
Limitations of pharmaceutical management include contraindications for the OCP due 
concomitant cardiovascular disease and increased thromboembolism and ischaemic stroke 
risks (Diamanti-Karandarakis, Baillargeonet al. 2003, Kemmeren, Tanis et al. 2002, Abdollahi, 
Cushman et al. 2003, van Hylckama Vlieg, Helmerhorst et al. 2009). These serious risks are 
increased for overweight and obese women (Hickson, Miles et al. 2011, ESHRE 2012). 
Pregnancies achieved with clomiphene assistance are at increased risk for multiple births 
(Cantineau Astrid and Cohlen Ben 2007, Legro, Barnhart et al. 2007) and some studies 
suggest an increased risk for spontaneous abortion (miscarriage) (Dickey, Taylor et al. 1996, 
Kousta, White et al. 1997). The ovaries of up to 40% of women with PCOS are resistant to 
clomiphene stimulation (Kousta, White et al. 1997, NICE 2004). Clomiphene resistance (CR) 
is defined as “women who do not ovulate whilst receiving a 150 mg dose of clomiphene 
citrate” is primarily attributable to body weight. Although CR may be reduced by weight 
loss, alternatives including gonadotropins, and adjuncts such as insulin sensitising 
medications and corticosteroids have been sought (Brown, Farquhar et al. 2009, Beck, 
Boothroyd et al. 2013). Higher risks are associated with the gonadotropins which are 
associated with the risk of ovarian hyperstimulation syndrome (OHSS) (Farquhar, Lilford et 
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al. 2007). Consequently the adjunctive medications have been the main pharmaceutical 
treatment option for women with CR. Many however have an unknown safety profile in 
pregnancy (Friedman, Kim et al. 2008, Brown, Farquhar et al. 2009).  
Few pharmaceuticals address the increased risks of pregnancy and birth associated with 
PCOS and associated overweight and obesity. Although conception rates may be improved 
with pharmaceutical assistance, there is limited evidence for improved pregnancy outcomes 
and live birth rates (ESHRE 2012). In addition women with PCOS have highlighted their 
desire for treatment alternatives to some pharmaceuticals. A confidential survey 
administered to 657 women with PCOS sought women’s attitudes towards pharmaceutical 
management (Sills, Perloe et al. 2001).  Ninety nine percent of women expressed their 
desire for effective treatment alternatives to birth control pills and fertility drugs. Although 
more research is needed to evaluate the subjective views of women with PCOS  (Jones, Hall 
et al. 2008), investigations into the effectiveness of alternatives to birth control pills and 
fertility drugs is needed to inform womens treatment decisions and to enable clinicians to 
provide treatment options to satisfy women’s desires. 
Hypoglycaemic pharmaceuticals have less evidence of effectiveness for treatment of 
infertility compared to clomiphene (Legro, Barnhart et al. 2007, AAPCOS 2011, Tang, Lord et 
al. 2012, Misso, Costello et al. 2013) and high rates of unpleasant non-serious side effects 
(Tang, Lord et al. 2012). Metformin is associated with nausea, abdominal discomfort, pain 
and diarrhoea that occur in up to 60% of women with PCOS (Legro, Barnhart et al. 2007). 
Whilst unpleasant side effects are not necessarily serious in themselves, compliance with 
medication protocol may be compromised rendering the pharmaceutical ineffective. In 
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addition there is limited evidence for hypoglycaemic effectiveness for reduced maternal 
morbidity and improved live birth rates (ESHRE 2012, Tang, Lord et al. 2012). 
Whilst medical intervention targets specific biochemical metabolic or morphological 
markers of PCOS the inclusion of lifestyle intervention, specifically behaviours that enhance 
weight loss and prevent weight gain, have the capacity to resolve several features of 
morbidity in women with PCOS including hyperinsulinaemia, hyperlipidaemia, obesity, 
hyperandrogenism, depression and quality of life. Lifestyle interventions may actively 
prevent the long term risks associated with PCOS including NIDDM and CVD (Thomson, 
Buckley et al. 2009, Thomson, Buckley et al. 2010, Moran, Hutchison et al. 2011). Lifestyle 
intervention is identified as first-line treatment in several expert consensus statements 
(ESHRE 2004, AACE 2005, ESHRE 2008, AAPCOS 2011, ESHRE 2012). Lifestyle interventions 
include single and combined approaches of diet, exercise and behavioural interventions that 
target weight loss in overweight and obese women with PCOS and prevent weight gain in 
lean women with PCOS. 
1.7 Evidence for lifestyle interventions  
Evidence based practice for the management of PCOS supports lifestyle intervention having 
the capacity to concurrently target anthropometric, metabolic and endocrine co-morbidities 
associated with PCOS. A systematic review examining the effect of lifestyle interventions, 
including diet, exercise and behavioural interventions (six RCTs,164 women) found 
significant improvements for lifestyle intervention compared with controls, for total 
testosterone MD0.27 nmol/L, 95% CI, 0.46 to 0.09, p =0.004); hirsutism (Ferriman Gallwey 
score) (MD-1.19,95% CI -2.35 to -0.03, p=0.04); body weight (MD -3.47 kg, 95% CI -4.94 to -
2.00, p = <0.00001); waist to hip ratio (MD -0.04, 95% CI, -0.04 to -0.00, p = 0.02); per cent 
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of weight change (MD 7.0%, 95% CI  -10.1 to -3.9, p<0.00001); fasting  insulin (MD 
2.02µU/mL, 95% CI -3.28 to -0.77, P = 0.002) and oral glucose tolerance test insulin 
(standard mean difference (SMD) -1.32, 95% CI, -1.73 to -0.92, P <0.00001) (Moran, 
Hutchison et al. 2011).   
However Moran and colleagues review (Moran, Hutchison et al. 2011) found limited 
evidence supporting the effect of lifestyle intervention on primary fertility outcomes. Few of 
the trials reported the stage of the menstrual cycle of the participants at trial entry, 
(Vigorito, Giallauria et al. 2007, Brown, Setji et al. 2009, Stener-Victorin, Jedel et al. 2009) 
and participants’ use of oral contraceptives was not disclosed in two trials (Guzick, Wing et 
al. 1994, Stener-Victorin, Jedel et al. 2009). The authors concluded that “there are no 
existing RCT data identified in this review, to assess whether lifestyle intervention improves 
reproductive outcomes.” This review only included six studies and 164 women with PCOS 
and findings were limited by the methodological shortcomings due to high participant drop-
out rates and attrition bias. Inclusion of subsequent RCTs with less participant attrition may 
provide more data for meta-analyses and alternative findings. A subsequent systematic 
review of five clinical trials investigating dietary interventions in women with PCOS (Moran 
2013) found evidence for improved reproductive outcomes (menstrual regularity) for low 
glycaemic index diets (Marsh 2010). However this review also found studies were at 
moderate to high risk of bias and study participant attrition rates were high (ranged 
between 26% (Stamets, Taylor et al. 2004) and 49% (Marsh 2010)). 
Whilst Moran and colleagues found no evidence for improvements in reproductive 
outcomes from efficacy RCT’s, evidence from RCT’s comparing lifestyle with 
pharmaceuticals, have shown improvements in reproductive outcomes for lifestyle (dietary 
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and exercise) interventions. Qublan and colleagues (2007) demonstrated significant 
differences over time for menstrual cycle improvements for clomiphene resistant women 
receiving lifestyle intervention (low calorie diet) compared to treatment with Metformin 
(1700mg per day). At baseline 12.5% of women in the lifestyle group and 18.2% of women 
in the metformin group had regular menstrual cycles (24-35 days long). At six months, 
67.7% of women in the lifestyle group and 68.2% of women taking metformin had regular 
menstrual cycles.  There were no significant differences between the groups however 
changes over time within each group were significant (p<0.01) (Qublan, Yannakoula et al. 
2007). In another RCT Karimzadeh and colleagues reported improvements in clinical 
pregnancy rates for lifestyle intervention alone compared to lifestyle plus pharmaceutical 
management in 343 overweight infertile women with PCOS. A four arm trial compared 
lifestyle intervention alone with lifestyle intervention plus clomiphene, lifestyle plus 
metformin, and lifestyle plus clomiphene and metformin over three to six months Although 
conception rates were not significantly different at endpoint the highest rates were 
demonstrated for women in the lifestyle only group at 20%  compared to clomiphene and 
lifestyle of 12.2%, metformin plus lifestyle 14.4% and clomiphene and metformin plus 
lifestyle of 14.4% (Karimzadeh and Javedani 2010). These studies provide positive evidence 
supporting lifestyle intervention for reproductive outcomes in overweight women with 
PCOS. 
1.8 Evidence based clinical guidelines for management of Women with PCOS 
In response to the identification of PCOS as an area of clinical need, investigation into 
clinical guidelines according to best practice was commissioned by the Australian 
Government. In March 2011, the Evidence Based Clinical Guidelines for the management of 
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PCOS was produced by the PCOS Australian Alliance (PCOSAA) with the aim of mapping a 
plan to improve health outcomes in women with PCOS. The key areas of clinical need were 
identified as a) the assessment of PCOS; b) assessment of emotional wellbeing; c) 
management of lifestyle and d) management of infertility (AAPCOS 2011). These areas of 
clinical need were reiterated in a positional paper following the third ESHRE sponsored 
workshop on PCOS (ESHRE 2012). Knowledge gaps for clinical management of PCOS 
included the sources of psychological morbidity in women PCOS, determinants of 
participation and compliance in lifestyle intervention and the effects of lifestyle intervention 
on primary health outcomes including live birth outcomes (ESHRE 2012).  
Lifestyle and self-help interventions to assist with self-management of chronic disease 
frequently include complementary and alternative medicines (CAM). Although CAM was not 
mentioned specifically in the Australian evidence based guidelines it is known that women 
of reproductive age are frequent users of CM (Smith, Bateson et al. 2013). This thesis 
examined the use of self-help practices and complementary and alternative medicine (CAM) 
by women with PCOS and focuses on the role naturopathy (nutritional supplements and 
herbal medicine) may offer to women with PCOS. The following sections provide further 
justification for investigating herbal medicine and nutritional supplements in PCOS. 
1.9 Naturopathy 
Naturopathy is a distinct, western, whole CAM system defined by philosophy and principles 
based on the healing power of nature (Vis medicatrix naturae) (WHO 2010, Wardle and 
Oberg 2011). Naturopaths aim to maximise the body’s innate self-healing capacity by 
promoting optimal health and treatment of disease through personal responsibility, 
education and natural treatment of the whole person (NCCAM 2009, WHO 2010).  
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Naturopathic treatment strategies for women with PCOS aim to optimise the health and 
well-being of women through the treatment of signs and symptoms and through 
incorporation of interactive general factors into the case analysis (Kasim-Karakas and Mishra 
2009, Bargiota and Diamanti-Kandarakis 2012). Treatment strategies may include 
counselling, hydrotherapy, lifestyle practices, dietary and physical activity, herbal medicine 
and nutritional supplements (NCCAM 2009). Nutritional supplements and herbal medicine 
are widely recognised as integral to naturopathic practice, and have the potential to offer a 
clinically useful adjunctive to current conventional treatment approaches. Information 
about nutritional supplementation and western herbal medicine may also provide 
meaningful information for women with PCOS due to possible high acceptability and self-
administration potential.  
The rationale for naturopathic nutritional supplementation (vitamins and minerals) is based 
on three principles; 1. the paired role of nutrients integral to optimal health and potential to 
positively influence pathological process, 2. insufficient dietary intake of nutrients, and 3. 
pharmako-nutrient interactions (Wieland, Manheimer et al. 2011). In PCOS, specific 
nutrients may be indicated if they have an integral role in the prevention of disease or in 
healthy glucose metabolism, steroidogenesis, hormone function, metabolism and excretion, 
reduce inflammation or improve mental health. Individual nutrients include B group 
vitamins, vitamin D, magnesium, calcium and the micronutrients zinc and chromium (Sarris 
and Wardle 2010).  
Consumption of diets that are energy dense (associated with increased BMI) may lack 
certain vitamins and minerals essential for homoeostasis (Kant and Graubard 2005, Fulgoni, 
Keast et al. 2011). Negative effects on nutritional status may occur due to administration of 
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pharmaceuticals prescribed for management of PCOS. For example a common side effect of 
Metformin is reduced gastrointestinal absorption of vitamin B12 (Bouchoucha, Uzzan et al. 
2011). Supplementation of B12 at alternative administrative times to metformin may be 
required to maintain concentrations required for healthy function. Vitamin B12 has an 
essential role the prevention of anaemia and for healthy nervous system and brain function 
(Whitney EN 1996) and supplementation may prevent secondary complications in PCOS 
caused by pharmaceutical administration in combination with nutritionally deficient diets. 
1.10 Naturopathic herbal medicine 
Naturopathic (western) herbal medicine includes an eclectic mix of plants from various 
countries and cultures. Plants, cultivated or wild grown, are harvested, dried and processed 
to produce herbal medicine extracts. Chemical constituents from various parts of plants 
(roots, branches, stems, bark, leaves, flowers and seeds) are extracted using ethanol. Herbal 
extracts may be in liquid form or dried and processed to produce herbal tablets. The 
chemical composition of herbal extracts may be subject to a range of influences including 
the conditions in which the plant grew, season of harvest, parasites on plants, herbicides, 
the concentration of ethanol and additives (Mills and Bone 2000). Contents of herbal 
extracts are screened and standardised against benchmarked international plant signature 
profiles to confirm the identity of the plant and chemical composition of the extract 
(Bensoussan, Lee et al. 2015). 
Herbal formulae for women with PCOS may include herbs that have direct actions in the 
female reproductive system and in addition herbs with actions in other body systems such 
as the central nervous, adrenal, digestive, hepatic and biliary systems. Selection of individual 
herbal extracts is determined by the pathological profile of PCOS and an individual’s disease 
 34 
 
experience (Kasim-Karakas and Mishra 2009, Bargiota and Diamanti-Kandarakis 2012, 
Tippens, Oberg et al. 2012, Wardle, Lui et al. 2012, Steel, Wardle et al. 2014).  
The management of PCOS using single western herbal medicine has been explored in 
England (Grant 2010); Turkey (Akdoğan, Tamer et al. 2007); America (Kudolo, Wang et al. 
2006, Wang, Anderson et al. 2007);  Italy (Armanini, Castello et al. 2007) and Iran (Shahin, 
Ismail et al. 2008, Kamel 2013, Shahin and Mohammed 2014). Clinical effects include 
androgen lowering effects for Mentha spicata (spearmint tea) (Grant 2010) and Glycyrrhiza 
glabra (liquorice) (Armanini, Mattarello et al. 2004, Armanini, Castello et al. 2007), insulin 
sensitising effects for Cinnamomum cassia (cinnamon) (Wang JG 2007) and Ginkgo biloba 
(ginkgo)(Kudolo, Wang et al. 2006) and Grifola frondosa (miatake mushroom) (Konno, 
Tortorelis et al. 2001, Jui-Tung, Tominaga et al. 2010). Evidence for naturopathic herbal 
formulae is scant. There is one RCT examining pre-menopausal women and reproductive 
endocrinology following treatment with a naturopathic herbal formula designed to increase 
hepatic metabolism of steroid hormones (Greenlee, Atkinson et al. 2007). This thesis will 
examine the evidence for herbal medicine extracts and investigate the effectiveness of a 
naturopathic herbal formula for menstrual regularity in women with PCOS. 
However despite the potential for herbal medicine and nutritional supplements in PCOS, 
there are no surveys describing the use of CAM by women with PCOS. Surveys among 
groups of women with similar clinical or demographic characteristics to women with PCOS 
(attending fertility clinics) indicated that between 23-66% were regular users of CAM 
(Coulson and Jenkins 2005, Stankiewicz, Smith et al. 2007, Schaffir, McGee et al. 2009, 
Shannon, El Saigh et al. 2010). In a study examining women attending a women’s primary 
health clinic (n=221), 83% had used CAM in previous twelve months (Smith, Bateson et al. 
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2013).  Determinants for CAM use by women include university education and employed on 
higher than average incomes, with private health insurance (Xue C 2007, Adams, Lui et al. 
2009, Smith, Eisenberg et al. 2010, Frawley, Adams et al. 2013).  However other studies 
have demonstrated that CAM use is not limited to the ‘worried well’. The longitudinal 
survey of women in Australia showed that CAM use was more likely by women in living in 
non-urban areas, who had experienced major illness and were limited by their health. 
Findings were consistent in all aged cohorts including young women (18-23 years, 
n=14,779). The authors found that that CAM use was also more likely if conventional 
treatment had proven ineffective or was not desirable (Adams, Sibbritt et al. 2003).  
Many reasons were found for women utilising CAM treatments, including the desire to take 
an active role in medical care and an attraction to a holistic treatment approach (Smith, 
Eisenberg et al. 2010, Weiss, Harris et al. 2011, Smith, Bateson et al. 2013). Qualitative 
research in Australia has explored the motivations for infertile women consulting CAM 
practitioners, with the main themes found to include; to maintain wellbeing, enhance 
fertility potential and due to a positive relationship achieved with CAM practitioners, which 
was apparently not always attainable with orthodox providers (Rayner, McLachlan et al. 
2009).  
Although women with similar characteristics to women with PCOS utilise CAM therapies, 
there is a need to explore if CAM is used by women with PCOS and its relationship with 
lifestyle and self-management. This thesis will examine the use of CAM and lifestyle self-
management by women with PCOS, their attitudes towards safety and/or effectiveness.  
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1.11 Summary 
There is a gap in the clinical management of women with PCOS. International consensus 
emphasises a multidisciplinary approach due to the complexity of the disease (AAPCOS 
2011, ESHRE 2012). First line intervention is lifestyle changes and pharmaceuticals may be 
prescribed to target symptomatology. However contraindications for pharmaceuticals are 
common amongst women with PCOS (ESHRE 2012), some only moderately effective  (ESHRE 
2012) whilst others are associated with  non-serious adverse events (Legro, Barnhart et al. 
2007, ESHRE 2012, Tang, Lord et al. 2012). In addition women with PCOS are reportedly not 
satisfied with pharmaceutical management of their symptoms (Sills, Perloe et al. 2001). The 
evidence for lifestyle intervention is limited by methodological shortcomings with high 
dropout rates found in many studies (Moran, Hutchison et al. 2011, Moran 2013) and the 
most effective dietary and exercise practices for women with PCOS are not yet known 
(AAPCOS 2011, Moran 2013). In addition there are limited data available for lifestyle 
intervention for reproductive outcomes (Moran, Hutchison et al. 2011).   
Naturopathy is a western type of complementary medicine that exploits the self-healing 
capacity of the body using a holistic approach and treatments derived from the natural 
environment. Naturopathy may have high acceptability for use by women with PCOS. 
Nutritional supplementation may improve symptoms associated with PCOS by promoting 
healthy function and reducing the complicating effects of nutritional deficiencies on 
pathology. Herbal medicines may illicit therapeutic effects in the reproductive endocrine 
system and glucose metabolism and improve general health and well-being. Herbal 
medicine may be an effective adjunct to lifestyle intervention for women with PCOS by 
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improving menstrual regularity, hormone concentration, reproductive function, 
anthropometric features, psychological health and quality of life. Herbal medicine may 
improve compliance with lifestyle intervention. Naturopathic herbal medicine may cause 
serious and non- serious adverse reactions. 
1.12 Thesis outline 
This thesis examined the role of naturopathy for the management of women with PCOS 
through four discrete studies. The objective was to answer the following research questions. 
1. Is complementary and alternative (CAM) medicine being used by women with PCOS and if 
so what are women’s experiences? What is the prevalence of use for diet and exercise by 
women with PCOS? What are women’s attitudes towards self-help practices and CAM?  
2. What is the clinical evidence from RCTs for nutritional supplements and herbal medicines 
in PCOS? 
3. What is the pre-clinical and clinical evidence of reproductive endocrinological effects from 
herbal medicines in women with oligo/amenorrhoea, hyperandrogenism and PCOS?  
4. Does the addition of herbal medicine to lifestyle intervention compared to lifestyle 
intervention alone improve menstrual regularity in overweight women with PCOS?  
 There are six chapters to this thesis. Chapter two is the systematic review of RCTs for 
nutritional supplements and herbal medicine; Chapter three is the review of pre-clinical and 
clinical studies for reproductive endocrinological effects of herbal medicines; Chapter four is 
the survey of women with PCOS and Chapter five is the RCT investigating a herbal treatment 
developed for investigation in addition to lifestyle intervention for 122 overweight women 
with PCOS. Chapter six discusses the four studies, the strengths and limitations of the thesis, 
implications of the findings of the studies followed by the thesis conclusion. 
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Chapter 2: Herbal medicine and nutritional supplement effects on polycystic ovary syndrome (PCOS); a systematic review  
2.1 Introduction 
This chapter presents the methods, results and discussion from a systematic review 
examining the effects of herbal medicine and nutritional supplements on polycystic ovary 
syndrome (PCOS). The objectives of this review were to assess the safety and effectiveness 
of western herbal medicine and nutritional supplements to improve menstrual regularity in 
women with PCOS. Secondary outcomes included hyperandrogenism, reproductive, 
anthropometric and metabolic factors.  
2.2 Methods 
2.2.1 Criteria for study inclusion 
Types of studies 
Randomised controlled trials (RCT’s) that compared herbal medicine or nutritional 
supplements to: 
• placebo  
• active controls including pharmaceuticals, herbal medicines or nutritional 
supplements.  
• usual care including lifestyle advice according to the evidence based guidelines, 
pharmaceutical intervention or surgery. Lifestyle intervention may be structured 
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exercise programs alone or in combination with special diets aimed to improve 
symptoms associated with PCOS.  
Cross-over trials were included in this review for completeness but only data from the first 
phase were included in meta-analyses.  
Types of participants 
Studies including women of reproductive age (post menarche and premenopausal), with 
clinician verified  diagnosis of PCOS. The criteria for the diagnosis of PCOS was made 
according to the Rotterdam Criteria (2003), (ESHRE 2004) or the National Institutes for 
Health (NIH) (Azziz, Carmina et al. 2009).  
The exclusion criteria included women presenting with conditions similar to PCOS, but not 
due to PCOS such as congenital adrenal hyperplasia, androgen-secreting tumours and 
Cushing’s syndrome. 
Types of interventions 
A naturopathic herbal medicine or nutritional supplement intervention. Naturopathic 
intervention was defined as herbal medicine in a single or compound preparation and/or 
tablets containing vitamins, minerals or dietary derived molecules designed to improve 
symptoms associated with PCOS and not medically prescribed for conditions of deficiency 
(Wieland, Manheimer et al. 2011).  Herbal infusions (teas) investigated for therapeutic 
effects in PCOS were included. Other naturopathic treatment components included 
naturopathic lifestyle counselling, including dietary and exercise advice provided in a 
naturopathic setting such as a naturopathic clinic or during the course of professional 
consultation.  
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Types of outcome measures 
Primary outcome measures 
Menstrual regularity and time to menstruation. 
Secondary outcome measures 
1. Hyperandrogenism: androgens (free and total testosterone and androstenidione), free 
androgen index (FAI), and sex hormone binding globulin (SHBG), hirsutism using the 
Ferriman Gallwey Score. 
2. Reproductive including: ovarian volume measured using ultrasound; number of ovarian 
cysts or immature follicles (2-9mm in diameter), presence of a mature follicle or corpus 
luteum, number of menstruations, number of luteal weeks relative to total number of trial 
weeks, ovulation regularity, number of participants who ovulated or failed to ovulate, 
number of ovulations, number of days to ovulation and surrogate markers for ovulation 
(conception, miscarriage and pregnancy rates), FSH and LH serum concentration and ratio. 
3. Anthropometric factors: body mass index (BMI); bodyweight; waist circumference (cm) 
and waist to hip ratio (W:H). 
4. Metabolic factors: oral glucose tolerance tests (OGTT); fasting glucose and insulin, insulin 
resistance and insulin sensitivity. 
5. PCOS associated risk factors: blood lipid concentration (cholesterol, triglycerides, high and 
low density lipoproteins (HDL and LDL) and inflammation (C-reactive protein (CRP) and 
homocysteine).  
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6. Quality of life and anxiety and depression.  
7. Adverse events including mild and serious adverse events. 
2.2.2 Search methods  
All published and unpublished randomised controlled trials (RCTs) comparing herbal 
medicine and/or nutritional supplements with active controls, usual care or placebo, in 
English language, were sought using the following strategy. 
1. Electronic searches  
During May-August 2014 we searched the following electronic databases for studies in all 
languages using the following databases. Cochrane central register of controlled trials 
(CENTRAL), the Cochrane Library, MEDLINE ovidSP, CINAHL (1936 to present), SciVerse, 
EMBASE, PubMed (from the date of inception to July2014) (Appendix 1). 
We used the key words CONTAINS OR title CONTAINS; ‘PCOS’, ‘Polycystic Ovary Syndrome’, 
‘oligomenorrhoea’, ‘amenorrhoea’, ‘menstrual disorders’, ‘menses’, ‘menstrual cyclicity’, 
‘oligo-ovulation’, ‘anovulation’, ‘ovulation’, ‘ovarian cysts’, ‘hyperandrogenism’, ‘hirsutism’, 
‘acanthosis nigrans’, ‘acne’, ‘insulin sensitivity’, ‘insulin resistance’, ‘glucose metabolism’, 
‘ovulation’, ‘fertility’, and ‘infertility’ 
AND  
Keywords CONTAINS OR title CONTAINS; ‘herbal medicine’, ‘botanical medicine’, ‘alternative 
medicine’, ‘nutritional supplements’, ‘phytotherapy’, ‘vitamin supplements’, ‘mineral 
supplements’, ‘naturopathy’, ‘natural management’, ’vitamin’, ’nutrient’.  
AND 
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Keyword CONTAINS and title CONTAINS; ‘randomised controlled trial’, ‘RCT’, ‘clinical trial’. 
We searched the Register of Controlled Trials (http://controlled-trials.com/mrct) and the 
National Institute of Health Clinical Register (http://clinicaltrials.gov) 
Searching other resources. 
Hand searches:  
1. relevant text books and other texts for PCOS or polycystic ovary syndrome and 
naturopathy, herbal medicine or nutritional supplements to locate other potential 
eligible studies; and  
2. references of reviews and systematic reviews and other grey literature from 
professional journals. 
2.2.3 Data collection and analysis 
Selection of studies 
The study selection was carried out by two review authors (SA and CAS). Titles and abstracts 
of studies were screened by SA and CAS. The full texts were retrieved and independently 
assessed for inclusion potential. Disagreements were resolved through discussion and 
consensus and disputes resolved with a third person (JA). 
Data extraction and management 
A data extraction form was designed (Appendix 2) and data extracted independently by two 
authors (CAS and SA). For studies meeting the inclusion criteria the following information 
was extracted; location of the study, study methodology, source of funding, inclusion and 
exclusion criteria, patient characteristics, nature of interventions, competing interests and 
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measures of assessment.  Extracted data were entered into RevMan version 5.3 software 
(2012) (Cochrane 2012).  
2.2.4 Assessment of risk of bias in included studies  
The risk of bias according to the Cochrane risk of bias (sequence generation and allocation 
concealment), performance bias (blinding for participants and researchers), detection bias 
(blinding of the outcome assessment), attrition bias (missing data and intention to treat 
analyses), reporting bias (objective reporting of all outcomes) and other areas of potential 
bias including factors unique to particular settings or research designs (Higgins 2015). Two 
authors (SA, CAS) assessed these six domains with any disagreements resolved by consensus 
or by discussion with a third author (JA). A summary describing the overall risk of bias in 
each study is presented in Table 1. 
2.2.5 Assessment of heterogeneity 
Studies were considered for their clinical and methodological heterogeneity.  Data were   
visually inspected for overlap of the confidence intervals for individual studies. If there was 
poor overlap, this was suggestive of statistical heterogeneity and T², I² and Chi² statistics 
were examined in the meta-analysis. We regarded heterogeneity as substantial if I² was 
greater than 70% or there was a low P value (less than 0.10) in the Chi² test for 
heterogeneity. If heterogeneity was substantial it was assumed that variability may be due 
to factors other than sampling variation (different participants) and results incorporating 
random effects rather fixed effects were presented. 
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2.2.6 Data synthesis 
Data management and analysis were conducted using Review Manager (RevMan) 5.3 
(Cochrane 2012). Where possible dichotomous data were combined using a fixed-effect 
model and expressed as relative ratios (RR) with corresponding 95% confidence intervals 
(CIs). Normally distributed continuous data, were expressed as weighted mean differences 
(WMD) and as standardised weighted mean differences (SMD) if outcomes were 
conceptually the same but measured differently. If distributions of data were skewed and 
results reported as the median and range, with non-parametric tests of significance, the 
results were excluded from the meta- analysis. Androgen units of measure reported as nano 
grams per decilitre (ng/dL) or pictograms per millilitre (pg/ml) were converted to nanomoles 
per litre (nmol/l) for comparison, and the MD was calculated. Cholesterol and triglyceride 
units of measure reported as milligrams per decilitre (mg/dL) were converted to millimoles 
per litre (mmol/l) for comparison and the MD was calculated. 
Subgroup analysis and assessment of heterogeneity 
In the case of substantial heterogeneity (I2 > 70%) and where data were available, the 
authors endeavoured to use pre-defined sub-group analysis and sensitivity analysis. Sub-
group analysis was based on the following: 
1. Variation in the components of naturopathic intervention including single herbal 
extracts verses complex herbal extracts; herbal medicine alone verses nutritional 
supplements alone.  
2. Variation in the dose of naturopathic intervention including homoeopathic herbal 
preparations versus ethanol extractions versus water infusions (teas) and water 
decoctions. Tablet preparations versus liquid extractions.  
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3. Duration of intervention; short, 2-4 weeks; medium, 4 weeks to 6 months; long > 6 
months. 
Sub group analyses were not conducted if less than five studies were available. 
Sensitivity analysis 
We planned to perform sensitivity analysis on the results a priori, to look at the possible 
contribution of methodological bias, a) trials described as high risk versus low risk of bias; b) 
excluding studies with outliers and c) use of alternative imputation strategies.  Sensitivity 
analyses were not conducted if data were unavailable due to too few studies. 
2.3 Results 
 
A total of 93 records were identified through the electronic and manual search. Following 
initial screening of the title and abstract, 43 articles were retrieved for detailed evaluation 
(Figure 2.1). Nineteen full text articles were excluded as they did not meet the inclusion 
criteria (Appendix 3). Following detailed evaluation of 24 full text studies by CS, SA and JA a 
further six studies were excluded due to not meeting the inclusion criteria (Rizk, Bedaiwy et 
al. 2005, Schachter, Raziel et al. 2007, Genazzani, Lanzoni et al. 2008, Papaleo, Unfer et al. 
2009, Ciotta, Stracquadanio et al. 2011, Kalgaonkar, Almario et al. 2011). 
2.3.1 Included studies 
Design 
 
Eighteen randomised controlled trials met the inclusion criteria (Nestler, Jakubowicz et al. 
1999, Iuorno, Jakubowicz et al. 2002, Gerli, Mignosa et al. 2003, Kilicdag, Bagis et al. 2005, 
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Lucidi 2005, Chan, Koo et al. 2006, Gerli, Papaleo et al. 2007, Wang, Anderson et al. 2007, 
Costantino, Minozzi et al. 2009, Cussons, Watts et al. 2009, Rashidi, Haghollahi et al. 2009, 
Grant 2010, Vargas, Almario et al. 2011, Ardabili, Gargari et al. 2012, Dona, Sabbadin et al. 
2012, Mohammadi, Rafraf et al. 2012, Artini, Di Berardino et al. 2013, Shahin and 
Mohammed 2014). A total of 1109 participants were included and the sample sizes ranged 
from 10 to 283. The studies were conducted at university hospitals or clinical research 
centres in America (Lucidi 2005, Wang, Anderson et al. 2007, Vargas, Almario et al. 2011), 
Australia (Cussons, Watts et al. 2009), Egypt (Shahin and Mohammed 2014), Hong Kong 
(Chan, Koo et al. 2006), Iran (Rashidi, Haghollahi et al. 2009, Ardabili, Gargari et al. 2012, 
Mohammadi, Rafraf et al. 2012), Italy (Gerli, Mignosa et al. 2003, Gerli, Papaleo et al. 2007, 
Costantino, Minozzi et al. 2009, Dona, Sabbadin et al. 2012, Artini, Di Berardino et al. 2013) 
Turkey (Kilicdag, Bagis et al. 2005), United Kingdom (Grant 2010)  and Venezuela (Nestler, 
Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 2002).  
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Figure 2.1 Flow diagram of study inclusion or exclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
90 records identified through 
database search (NDS)   
 
 18 trials included in synthesis including 9 
trials in meta-analysis due to non-
significant heterogeneity of results 
 
24 full texts were examined for 
eligibility by SA and CS and SA and JA  
43 records whose full texts were 
assessed for eligibility by CS and SA 
together 
 48 records excluded as they did not 
meet study design criteria 
 91 records were screened (NDS) 
 91 records after duplicates were 
removed (NDS) 
 
 3 records identified through 
searching of bibliographies (NDS) 
 
 19 full-text articles excluded:  2 were 
not randomised controlled trials, 9 did 
not include the primary outcome 
measures and 8 did not examine 
naturopathic herbal and/or nutritional 
supplements 
 
6 full text articles were excluded: 3 
did not report on the primary 
outcome, 1 the control group was 
not identified, 1 was not truly 
randomised and 1 included different 
diagnostic criteria for PCOS 
(polycystic ovaries on ultrasound 
only). 
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2.3.2 Participants 
Characteristics of included studies 
Four studies restricted the age of participants to less than 35 years (Gerli, Mignosa et al. 
2003, Gerli, Papaleo et al. 2007, Grant 2010, Mohammadi, Rafraf et al. 2012). Five studies 
included overweight participants (overweight defined as BMI more than 25) (Nestler, 
Jakubowicz et al. 1999, Chan, Koo et al. 2006, Cussons, Watts et al. 2009, Vargas, Almario et 
al. 2011, Mohammadi, Rafraf et al. 2012), and two studies included women of normal 
bodyweight defined as BMI less than 25 (Iuorno, Jakubowicz et al. 2002, Dona, Sabbadin et 
al. 2012).  
Exclusion characteristics of studies  
Twelve studies excluded participants in the presence of diseases presenting similar but not 
due to PCOS. Other causes of hyperandrogenism and oligo/amenorrhoea were specified as 
adrenal and/or other endocrine disease (Kilicdag, Bagis et al. 2005) and serum prolactin 
(PRL) outside normal parameters (range 5–25 ng/ml or 0-500nmol/l) (Iuorno, Jakubowicz et 
al. 2002, Gerli, Mignosa et al. 2003, Chan, Koo et al. 2006, Gerli, Papaleo et al. 2007, Wang, 
Anderson et al. 2007, Cussons, Watts et al. 2009, Rashidi, Haghollahi et al. 2009, Vargas, 
Almario et al. 2011, Ardabili, Gargari et al. 2012, Mohammadi, Rafraf et al. 2012, Artini, Di 
Berardino et al. 2013). Seven studies specified additional exclusion criteria for women with 
hypo or hyper thyroid function (Iuorno, Jakubowicz et al. 2002, Gerli, Mignosa et al. 2003, 
Gerli, Papaleo et al. 2007, Wang, Anderson et al. 2007, Rashidi, Haghollahi et al. 2009, 
Mohammadi, Rafraf et al. 2012) and liver disease (Ardabili, Gargari et al. 2012, Mohammadi, 
Rafraf et al. 2012).  
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2.3.3 Interventions  
The intervention administration periods ranged from thirty days (Grant 2010) to seven 
months (Shahin and Mohammed 2014). Twelve treatments were administered over 6-12 
weeks (Nestler, Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 2002, Kilicdag, Bagis et al. 
2005, Chan, Koo et al. 2006, Wang, Anderson et al. 2007, Cussons, Watts et al. 2009, 
Rashidi, Haghollahi et al. 2009, Vargas, Almario et al. 2011, Ardabili, Gargari et al. 2012, 
Dona, Sabbadin et al. 2012, Mohammadi, Rafraf et al. 2012, Artini, Di Berardino et al. 2013). 
Four studies reported durations of three to four months (Gerli, Mignosa et al. 2003, Lucidi 
2005, Gerli, Papaleo et al. 2007, Costantino, Minozzi et al. 2009). (Table 1 and Table 2) 
Nutritional supplements 
One study investigated B complex vitamin supplements plus the pharmaceutical 
hypoglycaemic agent Metformin (Kilicdag, Bagis et al. 2005). Seven studies investigated 
inositol, of which five investigated myo-inositol at various doses including 200mg per day 
(Gerli, Mignosa et al. 2003), 1.2g per day (Nestler, Jakubowicz et al. 1999, Dona, Sabbadin et 
al. 2012), 2g in combination with folic acid 200mcg per day (Gerli, Papaleo et al. 2007, Artini, 
Di Berardino et al. 2013) and 4g combined with folic acid 400mcg per day (Costantino, 
Minozzi et al. 2009). The isomer of inositol chiro-inositol was investigated in two studies 
(Nestler, Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 2002). Vitamin D was investigated 
in two studies, one at the dose of 50,000 international units (IU) every twenty days (Ardabili, 
Gargari et al. 2012), and another in combination with calcium (Rashidi, Haghollahi et al. 
2009). One study investigated chromium (Lucidi 2005), and three studies investigated 
omega three essential fatty acids in the form of fish oil (Cussons, Watts et al. 2009, Vargas, 
Almario et al. 2011, Mohammadi, Rafraf et al. 2012). Specified standardised quantities of 
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the triglycerides eicosapentaenoic and docosahexaenoic acid (EPA and DHA) were 
administered at the respective doses of 258mg and 242mg per day (Vargas, Almario et al. 
2011), 720mg and 480mg per day (Mohammadi, Rafraf et al. 2012) and 1080mg and 
2240mg per day (Cussons, Watts et al. 2009). Table 2.1. 
Table 2.1.Interventions: Nutritional supplements  
 
 
nutritional 
supplements 
reference Dose control duration 
Omega 3 
fish oils 
Cussons A J; Watts GF; 
Mori TA; Stuckey BGA. 
2009 (Cussons, Watts 
et al. 2009) 
4000mg per day  
EPA 675mg 
DHA 1400mg 
(Ocean nutrition® by Halifax, 
Nova Scotia, Canada) 
Placebo  
Olive oil 4000mg 
(Cardinal Health  
Australia, Vic 
Australia) 
8 weeks 
Mohammadi E; Rafraf 
M; Farzadi L; Asghari-
Jafarabadi M; Sabour 
S. 2012 (Mohammadi, 
Rafraf et al. 2012) 
4000mg  
EPA 720mg 
DHA 480mg 
(by Good Health Company, 
USA) 
Placebo 
liquid paraffin 2000mg 
in four capsules 
(Zihravi Pharma, Iran) 
8 weeks 
Vargas LM; Almario 
RU; Buchan W; Kim, K; 
Karakas SE. 2011 
(Vargas, Almario et al. 
2011) 
 
3500mg 
EPA: 2450mg 
DHA: 1210mg 
(Nordic Naturals Watsonville, 
California)  
Placebo 
soybean oil 
3500mg(Nordic 
Naturals, Watsonville 
California) 
6 weeks 
Chromium Lucidi SR; Thyer AC; 
Easton CA; 
Holden AEC; 
Schenken RS; 
Brzyski RG. 2009 
(Lucidi 2005) 
Chromium picolinate 200mcg Placebo (type or 
manufacturer was not 
reported) 
16 weeks 
Vitamin D Ardibilli HR; Gargari 
BG; Farzadi L. 2012 
(Ardabili, Gargari et al. 
2012) 
Vitamin D 50,000 per 20 days 
(D-vitin® by Zahravi Pharma 
Iran) 
Placebo  
Identical appearance 
and packaging, type 
not specified. 
(Zihravi Pharma, Iran) 
16 weeks 
Vitamin D 
plus Calcium  
Rashidi R; Haghollahi F; 
Shariat M; Zayerii F. 
2009 (Rashidi, 
Haghollahi et al. 2009) 
Calcium 1000mg + vitamin D 
400mcg 
(Cal D tablets by Tehran 
Derou, Iran) 
Metformin 1500mg 12 weeks  
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Table 2.1 continued. Interventions: Nutritional supplements 
Nutritional 
supplements 
Reference Dose Control Duration 
Vitamin B 
complex 
Kilicdag EB; Bagis T; Tarim 
E; Aslan E; Erkanli S; 
Simsek E; 
Haydardedeoglu B; and 
Kuscu E.2005 (Kilicdag, 
Bagis et al. 2005) 
B1: 500mg 
B6: 500mg  
B12: 2000mcg (Apikobal® by 
Santa Farma Turkey) + 
Metformin (Glugophage® by 
Merke, Turkey) 1700mg/day 
Metformin (Glucophage® 
by Merke Turkey) 
1700mg/day 
12 weeks 
Inositol 
(vitamin B8) 
Artini PG; Di Berardino 
OM; Papini F; Genazzani 
AD; Simi G; Ruggiero M; 
Cela V. 2013 (Artini, Di 
Berardino et al. 2013) 
Inositol 2g and folic acid 
200mg  
(Inofert® by Italpharmaco) 
plus folic acid 200mcg 
Folic acid 200mg 12 weeks 
Costantino D: Minozzi G; 
Minozzi F; Guaraldi C. 
2009(Costantino, Minozzi 
et al. 2009) 
Inositol 4g + folic acid 
400mcg 
(Inofolic®) 
Folic acid 400mcg 
(Fertifol®) 
12-16 weeks 
Dona G; Sabbadin C; Fiore 
C; Bragadin M; Giorgino 
FL; Ragazzi E; Clari G; 
Bordin L; Armanini D. 
2012(Dona, Sabbadin et 
al. 2012) 
Inositol 1200mg/day 
as powder, pre-dosed 
presented in sachets 
dissolved in water 
(manufacturer not reported) 
Placebo 
(matched powder type or 
manufacturer not 
reported) 
12 weeks 
Gerli M; Mignosa; Di 
Renzo GC. 2003 (Gerli, 
Mignosa et al. 2003) 
Inositol 200mg (Gestosan®) Placebo matched to 
Gestosan®. (Type or 
manufacturer not 
reported) 
 
20 weeks 
Gerli E; Papaleo A; Ferrari 
GC; Di Renzo GC. 2007 
(Gerli, Papaleo et al. 
2007) 
Inositol 4g + folic acid 
400mcg 
(Inofolic®) 
Folic acid 400mcg 20 weeks 
Iuorno MJ; Jakubowicz 
DJ; Baillargeon JP; Dillon 
P; Gunn RD; Allan G; 
Nestler JE 2002 (Iuorno, 
Jakubowicz et al. 2002) 
Inositol (chiro) 600mg 
(INS-1 by Insmed 
pharmaceuticals, Richmond, 
Virginia, USA) 
Placebo  
(type or manufacturer 
not reported) 
6-8 weeks 
Nestler JE; 
Jakubowcz DJ; 
Reamer P; Gunn R; Allan 
G. 1999 (Nestler, 
Jakubowicz et al. 1999) 
Inositol 1200mg labelled 
according to subject number 
(INS-1 by Insmed 
pharmaceuticals, Richmond, 
Virginia, USA) 
Placebo  
Labelled and packaged at 
the same time as inositol. 
Placebo type not 
reported (by Insmed 
pharmaceuticals USA). 
6-8 weeks 
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Herbal medicines 
Four studies investigated herbal medicines including Cimicifuga racemosa (Klimadynon®) 
which was studied in combination with usual pharmaceutical care (Shahin and Mohammed 
2014). Other herbal medicines included Cinnamomum cassia (Integria nutriceuticals®) 
(Wang, Anderson et al. 2007); Mentha spicata in the form of two cups of herbal tea per day 
(Grant 2010) and Camellia sinensis, dehydrated and powdered and presented in the form of 
capsules (Chan, Koo et al. 2006) Table 2.2. 
Table 2.2. Interventions: naturopathic herbal medicine 
 
 
Herbal medicine and 
reference 
Dose Control Duration 
Camellia sinensis  
 
Chan CW; Marcel Koo 
MWL; Ng EHY; Tang OS; 
Yeung WSB, Ho P-C. 2006  
(Chan, Koo et al. 2006) 
 
Camellia sinensis tea infused 
in boiled water for 30 mins, 
freeze dried and 
encapsulated. 
Epigallocatechin (EGCG) 
standardised to 373.92mg ± 
20.57 equivalent to 1.5 cups of 
tea 
Placebo capsules 
Identical in appearance. 
Type or manufacturer not 
specified  
90 days 
Cimicifuga racemosa  
 
Shahin AY; Mohammed SA. 
2014  
(Shahin and Mohammed 
2014) 
120mg (Klimadynon®) plus 
clomiphene, trigger and 
progesterone 
supplementation  
Clomiphene, 150mg per day 
administered on menstrual 
cycle days three to seven, a 
trigger injection (HMG) and 
progesterone support 
(50mcg per day for two days 
following trigger injection). 
Three 
alternate 
menstrual 
cycles  
Cinnamomum cassia  
Wang JG; Anderson RA; 
Graham GM; Chu MC 2007 
(Wang, Anderson et al. 
2007) 
1000mg cinnamon extract 
(Integrity Nutriceuticals, 
Sarasota, Florida USA) 
Placebo 
Type or manufacturer were 
not reported 
8 weeks 
Mentha spicata  
Grant, P. 2009  
(Grant 2010) 
Tea bags standardised content 
of dried Mentha spicata 
leaves. Uniform instructions 
for preparation provided to 
participants 
Chamomile tea uniform  
preparation instructions 
provided to test and control 
groups 
30 days 
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2.3.4 Controls 
Control groups received either placebo or active comparisons. Eleven studies used a placebo 
control (Nestler, Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 2002, Gerli, Mignosa et al. 
2003, Lucidi 2005, Chan, Koo et al. 2006, Wang, Anderson et al. 2007, Cussons, Watts et al. 
2009, Vargas, Almario et al. 2011, Ardabili, Gargari et al. 2012, Dona, Sabbadin et al. 2012, 
Mohammadi, Rafraf et al. 2012). Seven studies included an active control including vitamins 
(Gerli, Papaleo et al. 2007, Costantino, Minozzi et al. 2009, Artini, Di Berardino et al. 2013),  
herbal medicines with different biological effects to the intervention (Grant 2010) or 
pharmaceutical controls including Metformin (Kilicdag, Bagis et al. 2005, Rashidi, Haghollahi 
et al. 2009) and Clomiphene citrate. (Shahin and Mohammed 2014). 
2.3.5 Outcomes 
Two studies reported on the primary outcome menstrual regularity (Chan, Koo et al. 2006, 
Rashidi, Haghollahi et al. 2009). Seven studies reported on other secondary menstrual cycle 
characteristics including ovulation rates (Nestler, Jakubowicz et al. 1999, Costantino, 
Minozzi et al. 2009), time to ovulation (Shahin and Mohammed 2014), number of ovulatory 
cycles during the trial period (Iuorno, Jakubowicz et al. 2002, Lucidi 2005) and ratio of luteal 
phase weeks relative to the number of weeks in the trial (Gerli, Mignosa et al. 2003, Gerli, 
Papaleo et al. 2007). One trial reported on polycystic ovaries using ultrasound (Shahin and 
Mohammed 2014). 
Ten trials reported on the outcomes of biochemical hyperandrogenism including 
testosterone concentration   (Nestler, Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 
2002, Lucidi 2005, Grant 2010, Vargas, Almario et al. 2011, Dona, Sabbadin et al. 2012, 
Artini, Di Berardino et al. 2013) and sex hormone binding globulin (SHBG) (Nestler, 
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Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 2002, Chan, Koo et al. 2006, Costantino, 
Minozzi et al. 2009, Cussons, Watts et al. 2009, Vargas, Almario et al. 2011) and five trials 
reported on concentration of the androgen androstenidione (Nestler, Jakubowicz et al. 
1999, Iuorno, Jakubowicz et al. 2002, Chan, Koo et al. 2006, Costantino, Minozzi et al. 2009, 
Dona, Sabbadin et al. 2012). Two trials reported the free androgen index (FAI) (Chan, Koo et 
al. 2006, Cussons, Watts et al. 2009). One trial reported on the outcomes of clinical 
hyperandrogenism using the Ferriman Gallwey score to measure degree of hirsutism and 
the dermatology quality of life index for health related quality of life, with reference to 
cutaneous manifestations (Grant 2010).  Four trials reported on follicle stimulating and 
luteinising hormone concentration (Lucidi 2005, Wang, Anderson et al. 2007, Grant 2010, 
Artini, Di Berardino et al. 2013). Two studies reported on pregnancy rates (Rashidi, 
Haghollahi et al. 2009, Shahin and Mohammed 2014) and one on miscarriage rates (Shahin 
and Mohammed 2014). 
Fifteen trials reported metabolic characteristics including concentrations of glucose and 
insulin following fasting for at least eight hours (Nestler, Jakubowicz et al. 1999, Iuorno, 
Jakubowicz et al. 2002, Gerli, Mignosa et al. 2003, Kilicdag, Bagis et al. 2005, Lucidi 2005, 
Chan, Koo et al. 2006, Gerli, Papaleo et al. 2007, Wang, Anderson et al. 2007, Costantino, 
Minozzi et al. 2009, Cussons, Watts et al. 2009, Vargas, Almario et al. 2011, Ardabili, Gargari 
et al. 2012, Dona, Sabbadin et al. 2012, Mohammadi, Rafraf et al. 2012, Artini, Di Berardino 
et al. 2013). Six trials reported anthropometric outcomes of participants (Gerli, Mignosa et 
al. 2003, Kilicdag, Bagis et al. 2005, Chan, Koo et al. 2006, Gerli, Papaleo et al. 2007, Wang, 
Anderson et al. 2007, Mohammadi, Rafraf et al. 2012). 
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2.3.6 Risk of bias for included studies 
All studies were assessed as having some risk of bias. The risk of bias assessment was 
impacted by the incomplete or poor reporting by most trial authors and the consequential 
risks of bias were assessed (Figures 3.2 and 3.3). 
Allocation 
Risk of selection bias was assessed as unclear in five studies due to insufficient reporting 
about methods for generating the randomisation sequence (Nestler, Jakubowicz et al. 1999, 
Costantino, Minozzi et al. 2009, Cussons, Watts et al. 2009, Vargas, Almario et al. 2011, 
Mohammadi, Rafraf et al. 2012) (Figure 3).  Thirteen studies were rated at low risk for 
generation of the randomisation sequence, and used computer generated randomisation 
sequences.  
Four studies were assessed as low risk and having no selection bias due to allocation 
concealment and randomisation sequences being concealed from participants and key 
personnel prior to randomisation through the use of sealed envelopes (Kilicdag, Bagis et al. 
2005, Chan, Koo et al. 2006, Artini, Di Berardino et al. 2013, Shahin and Mohammed 2014). 
Descriptions of concealment of group of assignment were insufficiently reported in fourteen 
studies. 
Blinding 
The blinding of participants and clinicians was adequately described and assessed as low risk 
for bias in six studies (Nestler, Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 2002, 
Kilicdag, Bagis et al. 2005, Lucidi 2005, Cussons, Watts et al. 2009, Rashidi, Haghollahi et al. 
2009). Nine studies were assessed as having an unclear risk due to insufficient information 
provided by authors where a description of the trial design was reported as blinded or 
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double-blinded, but blinding was not described in detail. (Gerli, Mignosa et al. 2003, Chan, 
Koo et al. 2006, Gerli, Papaleo et al. 2007, Wang, Anderson et al. 2007, Costantino, Minozzi 
et al. 2009, Grant 2010, Ardabili, Gargari et al. 2012, Dona, Sabbadin et al. 2012, 
Mohammadi, Rafraf et al. 2012). Three studies were assessed as high risk for bias due to 
participants and clinicians knowledge of the intervention (Vargas, Almario et al. 2011, Artini, 
Di Berardino et al. 2013, Shahin and Mohammed 2014).   
Incomplete outcome data 
Overall attrition was reported as low for twelve studies, with seven reporting no attrition 
(Nestler, Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 2002, Costantino, Minozzi et al. 
2009, Cussons, Watts et al. 2009, Rashidi, Haghollahi et al. 2009, Dona, Sabbadin et al. 2012, 
Artini, Di Berardino et al. 2013) and five reporting low attrition (Kilicdag, Bagis et al. 2005, 
Chan, Koo et al. 2006, Grant 2010, Ardabili, Gargari et al. 2012, Mohammadi, Rafraf et al. 
2012). Rates ranged between 2.5% (Grant 2010) and 12.5% (Kilicdag, Bagis et al. 2005). Of 
the five with low attrition, one included all data in ITT analyses (Chan, Koo et al. 2006). The 
remaining four studies analysed data per-protocol only (Kilicdag, Bagis et al. 2005, Grant 
2010, Ardabili, Gargari et al. 2012, Dona, Sabbadin et al. 2012).  
Three studies were determined to be at high risk for attrition bias (Gerli, Mignosa et al. 
2003, Gerli, Papaleo et al. 2007, Vargas, Almario et al. 2011). Two studies were found at 
high risk of bias due to over 30% dropouts in the test group only (Gerli, Mignosa et al. 2003, 
Gerli, Papaleo et al. 2007). Three studies were judged as unclear risk for attrition bias (Lucidi 
2005, Wang, Anderson et al. 2007, Shahin and Mohammed 2014).   
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Selective reporting 
The study protocol was available for one study only (Dona, Sabbadin et al. 2012) and was 
subsequently judged as having low risk for reporting bias with all of the pre-specified 
outcomes presented. Study protocols were not available for seventeen studies, however 
fourteen reported on primary outcomes and secondary outcomes of interest for women 
with PCOS which were  pre-specified in  the methods sections of texts (Nestler, Jakubowicz 
et al. 1999, Iuorno, Jakubowicz et al. 2002, Lucidi 2005, Chan, Koo et al. 2006, Wang, 
Anderson et al. 2007, Costantino, Minozzi et al. 2009, Cussons, Watts et al. 2009, Rashidi, 
Haghollahi et al. 2009, Grant 2010, Vargas, Almario et al. 2011, Ardabili, Gargari et al. 2012, 
Mohammadi, Rafraf et al. 2012, Artini, Di Berardino et al. 2013, Shahin and Mohammed 
2014). These were judged as having an unclear risk for reporting bias due to insufficient 
information available to permit the judgement of risks for reporting bias. Three studies were 
determined to be at high risk for reporting bias (Gerli, Mignosa et al. 2003, Kilicdag, Bagis et 
al. 2005, Gerli, Papaleo et al. 2007). 
Other sources of bias 
One study was assessed as being at low risk for other sources of bias (Grant 2010). Seven 
studies were assessed as having an unclear risk due to being underpowered and at risk of 
type one errors (Nestler, Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 2002, Wang, 
Anderson et al. 2007, Cussons, Watts et al. 2009, Rashidi, Haghollahi et al. 2009, Ardabili, 
Gargari et al. 2012, Dona, Sabbadin et al. 2012). Ten studies were at high risk for other 
sources of bias. Seven of those were judged to be at risk due to baseline imbalances. Two 
studies did not report the effect of high attrition (over 30%) on baseline menstrual 
characteristics in the test and control groups (Gerli, Mignosa et al. 2003, Gerli, Papaleo et al. 
2007). Two studies provided limited data on important baseline characteristics (Kilicdag, 
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Bagis et al. 2005, Lucidi 2005). One study period was judged as insufficient for the 
investigated outcomes as ovulation rates were assessed for oligomenorrhoeic women at six 
weeks (Costantino, Minozzi et al. 2009). Another potential source of bias identified was 
unaccounted factors confounding outcomes including participant’s dietary intake during the 
investigation of omega 3 fish oils (Vargas, Almario et al. 2011). One study used invalid 
criteria for the assessment of miscarriage rates determined per menstrual cycle rather than 
per pregnancy (Shahin and Mohammed 2014).  
 
Figure 2.2. Risk of bias graph: review authors' judgements about each risk of bias item 
presented as percentages across all included studies.  
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Figure 2.3. Risk of bias summary: review authors' judgements about each risk of bias item for each 
included study. 
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2.3.7 Effects of interventions 
This review included 18 trials and complete data for 1,119 women.  Data from two trials 
were not included in analyses. One used a cross-over trial design and first phase outcomes 
were not reported (Cussons, Watts et al. 2009), the other study reported outcomes as the 
median rather than the mean (Chan, Koo et al. 2006) and data were not comparable. Where 
data could not be included in a meta-analysis a narrative reporting of the findings was 
described. 
Nutritional supplements for PCOS 
 
Five nutritional supplements were investigated for PCOS; Calcium plus vitamin D, B complex 
vitamins, inositol (vitamin B8), chromium, vitamin D and omega three fish oils. 
Calcium plus vitamin D  
Primary outcome 
One trial (40 women) reported on calcium plus vitamin D compared with metformin for the 
primary outcome (Rashidi, Haghollahi et al. 2009). There was no evidence of an effect from 
calcium plus vitamin D compared to metformin for menstrual regularity (Table 4). Calcium 
plus vitamin D supplements and controls (metformin) increased the proportion of women 
with regular menstrual cycles within groups from 0% to 30% and from 10% to 35% 
respectively, however differences between groups were not significant.  
Secondary outcomes 
Rashidi and colleagues reported on the number ovarian cysts defined as immature follicles 
(diameter 5-9mm), pregnancy rates for calcium plus vitamin D against metformin (Rashidi, 
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Haghollahi et al. 2009) (Table2.3). No significant effect was found for ovarian cysts. There 
was no evidence of a treatment effect reported for pregnancy between groups. 
 Table 2.3. Calcium plus vitamin D versus Metformin in PCOS 
 Treatment 
n (number of 
effects)/N 
Control 
n (number 
of effects)/N 
Relative risk 95% CI P value 
Menstrual 
regularity 
 
6/20 7/18 0.77 0.32 to 1.87 0.57 
Number of 
ovarian cysts* 
0/20 1/20  0.33  
 
0.01 to 7.72 0.49 
Pregnancy 0/20 0/20 0 Not estimable Not estimable 
*Ovarian cysts were defined as immature follicles (diameters of 5-9mm) measured on ultrasound 
 
Vitamin B complex 
Primary outcome 
One study investigated B complex vitamins plus metformin compared with metformin 
alone, for 32 women with PCOS for regular menstrual cycles (Kilicdag, Bagis et al. 2005). 
Results were reported as ‘women taking Metformin’ between group differences were not 
reported. No data were available for B complex vitamins on menstrual regularity.  
Secondary outcomes 
Four secondary outcomes for vitamin B complex plus metformin were reported (32 women, 
18 in the treatment group and 14 controls). No significant effects were found for;  
• pregnancy rates (RR 0.16, 95% CI 0.01 to 3.05, p=0.22) 
• waist to hip ratio (MD -0.3, 95% CI -0.45 to 0.39, p=0.89) 
• HOMA-IR (MD -0.27, 95% CI -1.38 to 0.84, p=0.63) 
• adverse events (RR 0.16 95% CI 0.01 to 3.05, p=0.22). 
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Inositol (vitamin B 8) 
Primary outcome 
No trials reported on the primary outcome menstrual regularity for inositol versus placebo 
or active controls.  
Secondary outcomes 
Significant benefits were found for inositol versus placebo and active controls for the 
secondary outcomes of hyperandrogenism and reproductive characteristics (Table 2.4). 
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Table 2.4. Inositol for hyperandrogenism and reproduction  
 Treatment 
n* (number of 
effects)/N 
Control 
n* (number of 
effects)/N 
Number of RCTs 
Heterogeneity  
(I2, p value) 
Treatment effect 
MD or RR 
95% CI p value 
Hyperandrogenism 
Free testosterone  
nmol/l 
55 51 3 
0%, p=0.94 
MD -0.02  
 
 -0.10 to 0.06 0.62 
Total testosterone  
nmol/l 
73 59 4 
32%, p=0.0009 
MD 0.98 
 
 -1.37 to -0.60 <0.00001 
Androstenidione  
nmol/l 
73 59 4 
0%, p=1.0 
MD 3.59  -4.62 to -2.55 <0.00001 
Sex hormone binding globulin 
(SHBG) nmol/l 
55 67 2 
0%, 0.50 
MD 40.67  25.83 to 55.50 <0.00001 
Reproduction 
Number of days to ovulation  
(number of days) 
181 194 2 
0%, p=0.90 
MD 17.7 -31.4 to -4.1 0.01 
Ratio of luteal week to total trial 
luteal weeks: total trial weeks 
166/697 
 
140/1000 2 
0%, p=0.90 
RR 1.7 1.39 to 2.08 <0.0001 
Number of ovulations 25/32 8/32 2 
0%, p=0.95 
RR 3.13 1.68 to 5.83 0.0003 
Number of women who did not 
ovulate 
16/181 34/194 2 
0%, p=0.95 
RR 0.5 0.29 to 0.86 0.01 
Pregnancy  18/71 6/63 3 
0%, p=0.95 
RR 2.78 1.19 to 6.5 0.02 
Live births 8/25 3/25 1 RR 2.67 0.80 to 8.90 0.11 
FSH mIU/l 25 25 1 MD 1.4 -1.63 to -1.17 0.001 
LH mIU/l 25 25 1 MD 3.5 -4.9 to -2.1 0.001 
FSH:LH ratio 25 25 1 MD 0.4 -0.68 to -0.12 0.006 
* calculated for dichotomous outcomes only 
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Hyperandrogenism; analyses of a subgroup of studies with placebo controls (and without 
significant heterogeneity) revealed significant difference between groups for the reduction 
of total testosterone, (Nestler, Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 2002, Dona, 
Sabbadin et al. 2012). Significant reductions for androstenidione (Nestler, Jakubowicz et al. 
1999, Iuorno, Jakubowicz et al. 2002, Costantino, Minozzi et al. 2009, Dona, Sabbadin et al. 
2012) and increased SHBG was additionally found for inositol against placebo (90 women) 
(Figure 2.4). 
Figure 2.4. Forest plot comparison inositol versus placebo for total testosterone. 
 
No significant treatment effect was found for free testosterone (Nestler, Jakubowicz et al. 
1999, Iuorno, Jakubowicz et al. 2002, Costantino, Minozzi et al. 2009). 
Reproduction; significant changes in ovulation were found for inositol. Outcomes included 
the number of days to ovulation (MD 17.7 days, 95% CI -31.4 to -4.1, p=0.01) (Gerli, Mignosa 
et al. 2003, Gerli, Papaleo et al. 2007), the ratio of luteal weeks to total trial weeks (total 
trial weeks 1697) (RR 1.7 luteal weeks, 95% CI 1.29 to 2.08, p<0.0001) (Gerli, Mignosa et al. 
2003, Gerli, Papaleo et al. 2007), the number of  ovulations during the trial period (RR 3.13, 
95% CI 1.68 to 5.83, p=0.0003) (Nestler, Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 
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2002)  and the number of women who did not ovulate (RR 0.5, 95% CI 0.29 to 0.86, p=0.01) 
(Gerli, Mignosa et al. 2003, Gerli, Papaleo et al. 2007) (Table 5). 
Follicle stimulating hormone and luteinising hormone were significantly improved with 
inositol compared to controls (MD 1.4, 95% CI -1.63 to – 1.17, p=0.001 and MD 3.5, 95% CI -
4.9 to -2.1, p=0.001 for FSH and LH respectively) (Artini, Di Berardino et al. 2013). Meta 
analyses of three studies (134 women) demonstrated pregnancy rates were significantly 
higher for women taking inositol compared to controls (RR 2.78, 95% CI 1.19 to 6.5, p=0.02). 
Two trials reported on a subgroup of women wanting to conceive (84 women) (Gerli, 
Mignosa et al. 2003, Gerli, Papaleo et al. 2007)  and a third trial included women preparing 
to undergo medically assisted fertility treatment (50 women) (Artini, Di Berardino et al. 
2013). Live birth rates were investigated in one trial (Artini, Di Berardino et al. 2013). There 
was a non-significant difference (RR 2.67, 95% 0.80 to 8.90, p=0.11) in live birth rates with 
eight live births out of twenty five women (32%) reported in the inositol group compared 
with three live births (out of twenty five) (12%) for women  for the taking folic acid alone. 
Significant benefits were found for the secondary outcomes anthropometric characteristics, 
metabolic hormones and risk factors (Table2.5).
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 Table 2.5. Inositol for anthropometric characteristics, metabolic hormones and risk factors. 
 
 
Treatment group 
N 
Control group  
n 
Number of RCTs 
Heterogeneity  
(I2 , p value) 
Treatment effect 
MD  
95% CI p value 
Anthropometric 
BMI* 18 8 1 
 
-1.10 -1.47 to -0.73 0.64 
57 57 3 
I2 31%, p=0.24 
0.40 -0.07 to -0.86 0.86 
Waist to hip ratio 32 32 2 
0%, p=0.32 
-0.02 -0.03 to -0.01 0.01 
Metabolic hormones       
Fasting glucose 73 59 4 
0%, P=0.52 
1.17 -1.72 to – 0.63 <0.0001 
Fasting insulin  µU/ml 73 59 4 
18%, p=0.30 
2.7 -3.9 to -1.5 <0.0001 
HOMA-IR** 
 
25 25 1 
 
-1.30 -1.60 to -1.00 <0.00001 
18 8 1 -0.60 -0.89 to – 0.30 <0.0001 
Risk factors 
Cholesterol mmol/l 32 32 2 
27%, p=0.24 
0.56 -1.07 to -0.04 0.04 
Triglycerides mg/dL 32 32 2 
8%, p=0.30 
31.6 -61.1 to -2.0 0.04 
HDLmg/dL 22 22 1 0 -4.73 to 4.73 1.0 
LDL mg/dL 22 22 1 2.0 13.7- 9.7 0.74 
* four trials with significant heterogeneity (I2 89%, p<0.0001) following analyses incorporating random effects, therefore not combined. 
** two trials with significant heterogeneity (I2 91% p-0.0009) following analyses incorporating random effects, therefore not combined. 
 
 67 
 
Anthropometric characteristics: Significant effects were found for waist to hip ratio and 
mixed results were found for inositol with BMI in four trials (Nestler, Jakubowicz et al. 1999, 
Iuorno, Jakubowicz et al. 2002, Dona, Sabbadin et al. 2012, Artini, Di Berardino et al. 2013). 
(Table 2.5). Significant heterogeneity prevented meta-analysis (I2=89%, p<0.00001), 
however exclusion of one study by Dona and colleagues provided non-significant 
heterogeneity and subgroup meta analyses. Whilst Dona and colleagues (Dona, Sabbadin et 
al. 2012) demonstrated significant improvements in BMI for inositol (MD-1.10, 95% CI -1.47 
to -0.73, p<0.00001), Nestler and colleagues (Nestler, Jakubowicz et al. 1999) and Artini and 
colleagues (Artini, Di Berardino et al. 2013) found no significant difference between groups 
for BMI (p=0.47 and p=0.64 respectively) and Iuorno and colleagues (Iuorno, Jakubowicz et 
al. 2002) found significantly increased BMI for women taking inositol compared to controls 
(MD 0.7, 95% CI 0.08 to 1.32, p=0.03). Meta analyses showed non-significant increments in 
BMI. The high heterogeneity in these studies maybe explained clinically with variable 
duration of treatment doses of six weeks treatment in one study (Nestler, Jakubowicz et al. 
1999, Iuorno, Jakubowicz et al. 2002) compared to twelve in the other (Dona, Sabbadin et 
al. 2012, Artini, Di Berardino et al. 2013). 
Metabolic hormones: significant benefits were found for fasting glucose (Nestler, 
Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 2002, Costantino, Minozzi et al. 2009, 
Dona, Sabbadin et al. 2012), fasting insulin (Nestler, Jakubowicz et al. 1999, Iuorno, 
Jakubowicz et al. 2002, Costantino, Minozzi et al. 2009, Dona, Sabbadin et al. 2012) and 
reduced insulin resistance (HOMA-IR) (Dona, Sabbadin et al. 2012, Artini, Di Berardino et al. 
2013). Significant heterogeneity was found for the two trials investigating inositol for 
HOMA-IR. This was primarily due to trial methodologies and variable risks of bias.  
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Significant benefits were found for risk factors including total cholesterol (Nestler, 
Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 2002) and triglycerides (Nestler, 
Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 2002) however no significant treatment 
effect was found for HDL (Nestler, Jakubowicz et al. 1999) or LDL cholesterol (Nestler, 
Jakubowicz et al. 1999). No trials examined inositol for inflammation. 
Two trials (64 women) reported on adverse events for inositol (n=32) (Nestler, Jakubowicz 
et al. 1999, Iuorno, Jakubowicz et al. 2002). No side effects or adverse events were found for 
inositol against placebo. No studies reported on inositol for quality of life.  
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Chromium supplements 
Primary outcome 
One small pilot study reported on chromium against placebo in ten women with PCOS 
(Lucidi 2005). The primary outcome, menstrual regularity was not investigated. 
Secondary outcomes 
Five secondary outcomes were reported for chromium compared with placebo (Table 
2.6).No significant treatment effects were found for any outcome however there was a 
trend for reduced triglycerides. No adverse events reported for either chromium or placebo. 
Table 2.6. Chromium for secondary outcomes in PCOS. 
 Treatment group 
n (N = 10) 
Control group 
n (N = 10) 
Number of 
RCTs 
MD 95% CI P value 
Hyperandrogenism 
free testosterone  6 4 1 6.5 -13.2 to 26.2 0.52 
total testosterone  6 4 1 0.22 -1.05 to 1.49 0.74 
Reproduction 
Ovulation 6 4 1 0.44 0.08 to 2.37 0.34 
FSH 6 4 1 -2.10 5.09 to 0.89 0.17 
LH 6 4 1 -2.6 10.35 to 5.15 0.51 
Metabolic hormones 
Fasting glucose 6 4 1 6.5 -5.99 to 18.99 0.31 
Fasting insulin 6 4 1 25.8 -6.56 to 58.16 0.12 
Risk factors 
Total cholesterol  6 4 1 0.58 -4.96 to 6.12 0.84 
Triglycerides 6 4 1 45.8 2.30 to 93.9 0.06 
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Vitamin D 
Primary outcome 
One RCT examined vitamin D supplements compared with a placebo in 50 women (24 in the 
test group and 26 controls) with PCOS (Ardabili, Gargari et al. 2012). The primary outcome 
was not investigated. 
Secondary outcomes 
No significant treatment effect was found for vitamin D compared with placebo for 
metabolic hormones including fasting glucose (MD 2.14, 95% CI-9.01 to 4.73, p = 0.54), 
fasting insulin (MD 3.36, 95% CI -0.81 to 7.53, p=0.11), insulin resistance (HOMA-IR; MD 
0.75, 95% CI -0.38 to 1.88, p=0.19) or insulin sensitivity using the QUICKI index (MD 0.01, 
95% CI -0.03 to 0.02, p=0.60) (Ardabili, Gargari et al. 2012). 
Omega three fish oils 
Primary outcome 
The primary outcome was not reported in two RCTs examining omega three fish oils in 95 
women (Vargas, Almario et al. 2011, Mohammadi, Rafraf et al. 2012).  
Secondary outcomes 
A significant positive treatment effect was found for the risk marker total cholesterol for 
omega three fish oils in women receiving fish oils compared to placebo controls (MD -0.49, 
95% CI -0.62 to -0.35, p<0.0001) (Vargas, Almario et al. 2011, Mohammadi, Rafraf et al. 
2012) (Table2.7 and Figure 2.5). 
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Table 2.7. Omega three fish oils for secondary outcomes in PCOS. 
 Treatment 
group 
n 
Control  
group  
n 
Number of RCTs 
Heterogeneity  
(I2 , p value) 
Treatment 
effect 
MD 
95% CI p value 
Hyperandrogenism 
Free testosterone  
nmol/l 
17 17 1 -0.20  
 
 -0.84 to 0.44 0.54 
Sex hormone binding 
globulin (SHBG) nmol/l 
17 17 1 0.37  0.31 to 1.05 0.29 
Anthropometric 
BMI** 30 31 1* 
 
-0.20 
 
-1.77 to 1.37 0.80 
17 17 1* 3.30 2.12 to 4.48 <0.0001 
Waist to hip ratio 30 31 1 
 
0.0 -0.02 to 0.02 1.0 
Metabolic hormones 
Fasting glucose*** 30 31 1* 
 
-0.39 -0.66 to -0.12 0.004 
17 17 1* 0.33 0.26 to 0.40 <0.0001 
Fasting insulin  µU/ml 47 48 2 
0%, p=0.56 
 
1.37 -2.88 to -0.15 0.08 
HOMA-IR**** 30 31 1* 
 
0.60 -1.08 to -0.12 0.02 
17 17 1* 1.23 0.86 to 1.60 <0.00001 
Risk factors 
Cholesterol mmol/l 47 48 2 
0%, p=0.85 
-0.49 -0.62 to-0.35 <0.0001 
Triglycerides mg/dL***** 30 31 1* 
 
-0.90 -14.47 to 12.67 0.90 
17 17 1* -22.10 -32.03 to -12.17 <0.0001 
HDLmg/dL****** 30 31 1* 
 
0.02 -0.05 to 0.09 0.60 
17 17 1* -0.11 -0.22 to -0.00 0.04 
LDL mg/dL******* 30 31 1* 
 
-0.39 -0.79 to -0.02 0.04 
17 17 1* 0.88 0.72 to 1.04 <0.0001 
Inflammation C reactive 
protein 
30 31 1 0.03 -0.47 to 0.43 0.88 
* significant heterogeneity of studies and data not pooled for meta analyses only  
** heterogeneity following random effects analyses ** I2 95%, p=0.0005;***98%, P<0.0001; ****97%, p<0.0001; *****84%, p=0.01; 
******74%, p=0.05; *******97%, p<0.0001 
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Figure 2.5. Meta-analyses omega three fish oils for cholesterol in women with PCOS 
 
No evidence of a positive treatment effect was found for free testosterone or SHBG (Vargas, 
Almario et al. 2011), waist to hip ratio (Mohammadi, Rafraf et al. 2012) or for inflammation 
(c-reactive protein) (Mohammadi, Rafraf et al. 2012). Findings were mixed for some 
secondary outcomes including triglycerides, HDL and LDL (Vargas, Almario et al. 2011, 
Mohammadi, Rafraf et al. 2012), BMI (Vargas, Almario et al. 2011, Mohammadi, Rafraf et al. 
2012), fasting glucose and insulin resistance (Vargas, Almario et al. 2011, Mohammadi, 
Rafraf et al. 2012). Random rather than fixed effects were estimated however significant 
heterogeneity persisted and prevented meta-analyses. Heterogeneity was likely due to the 
dose of omega three as women in one trial received treatment of 3.5 grams (EPA 258mg 
and DHA 242mg) for six weeks (Vargas, Almario et al. 2011) which was substantially less 
than the other trial where women received 4 grams (EPA 720mg and DHA 480mg) over eight 
weeks. Significant positive effects were found for women taking the higher dose for fasting 
glucose (MD 0.39, 95% CI -0.66 to -0.12, p=0.004), insulin resistance (MD 0.60, 95% CI -1.08 
to -0.12, p=0.02) and reduced LDLs (MD 0.39, 95% CI -0.79 to -0.02, p=0.04) (Mohammadi, 
Rafraf et al. 2012) (Table 7).  
Evidence for significantly lowered triglycerides (0.85, 95%CI 0.73 to 0.99, p=0.002) was 
found in one study investigating omega three fish oils against placebo (25 women) (Cussons, 
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Watts et al. 2009). However, the trial employed a cross-over design without reporting first 
phase outcomes and data were not included in the present analyses. Differences between 
groups were not significant for the following outcomes testosterone, SHBG, free androgen 
index, BMI, waist to hip ratio, glucose, insulin, cholesterol, LDL, HDL, and c reactive protein. 
Significant differences were found for women with fatty liver disease (associated with PCOS) 
taking omega three fish oils compared to controls for triglycerides (p=0.012), insulin 
(p=0.048) and HOMA-IR (p=0.021).  No studies reported on reproductive outcomes, quality 
of life or adverse effects for omega three fish oils. 
Herbal medicines for PCOS 
Outcomes for PCOS were reported for four herbal medicines; Camellia sinensis (green tea), 
Cimicifuga racemosa (black cohosh), Cinnamomum cassia (cinnamon) and Mentha spicata 
(spearmint).  
Camellia sinensis. 
Primary outcome 
One trial reported on Camellia sinensis capsules compared with placebo for the menstrual 
regularity (Chan, Koo et al. 2006). Chan and colleagues (2006) investigated the proportion of 
amenorrheic women for Camellia sinensis compared to a placebo over a three month period 
(34 women) (Chan, Koo et al. 2006). (Table 2.8) Although the difference for the proportion 
of amenorrheic participants was reduced by 66.6% for green tea compared to controls of 
25%, the relative risk between groups was not significant (p=0.19). 
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Table 2.8. Camellia sinensis for menstrual regularity 
 Treatment 
n (number 
of 
effects)/N 
Control 
n (number 
of 
effects)/N 
Number of 
RCTs 
RR 95% CI P value 
Number of 
amenorrheic 
women 
6/14 8/14 1 0.44 0.13 to 1.48 0.19 
 
Secondary outcomes 
One trial reported on Camellia sinensis for secondary outcomes however data were 
presented as median differences and the interquartile range and analysed for changes over 
time. Consequently data were not suitable for inclusion in analyses in this review (Chan, Koo 
et al. 2006). No significant differences in median values over time were found for 34 women 
taking Camellia sinensis or placebo for testosterone, SHBG, FAI, androstenidione, FSH, LH, 
BMI, waist to hip ratio, insulin, glucose, cholesterol, triglycerides HDL or LDL.  
Cimicifuga racemosa 
Primary outcome  
The primary outcome of menstrual regularity was not reported in one study for Cimicifuga 
racemosa in addition to usual care (clomiphene, a trigger injection and progesterone 
supplementation) compared to usual care alone for 194 women with associated  infertility 
(Shahin and Mohammed 2014). 
Secondary outcomes 
A significant treatment effect was found for Cimicifuga racemosa and reproductive 
secondary outcomes (Shahin and Mohammed 2014) (Table 2.9). The secondary outcomes of 
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hyperandrogenism, metabolic hormones, anthropometric characteristics, risk markers, 
quality of life or adverse effects (other than miscarriage) were not reported.  
Table 2.9. Cimicifuga racemosa for secondary outcomes. 
 Treatment 
n* (number 
of effects)/N 
Control 
n* (number of 
effects)/N 
Number of 
RCTs 
 
Treatment effect 
MD or RR 
95% CI p value 
Reproduction 
Number of days to ovulation  
(number of days) 
96 98 1 
 
MD -3 -3.51 to -2.49 <0.00001 
Pregnancy  33/96 17/98 1 RR 1.98 1.19 to 3.31 <0.009 
FSH mIU/l 96 98 1 MD 0.40 0.22 to 0.58 <0.00001 
LH mIU/l 96 98 1 MD -2.30 -2.55 to -2.05 <0.00001 
Miscarriage 6/33 5/17 1 RR 0.62 0.22 to 1.74 0.36 
n* calculated for dichotomous outcomes only 
 
 
Cinnamomum cassia 
Primary outcome 
The primary outcome was not reported in one small RCT for Cinnamomum cassia compared 
with placebo (Wang, Anderson et al. 2007). 
Secondary outcomes 
A single study reported on metabolic hormones following treatment with Cinnamomum 
Cassia compared to placebo (Wang, Anderson et al. 2007). Wang and colleagues reported 
significant changes over time for Cinnamomum cassia for fasting glucose, insulin resistance 
(HOMA-IR) and insulin sensitivity (QUICKI) however the primary data were not reported and 
differences between groups could not be examined.  
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Mentha spicata 
Primary outcome 
One trial reported on Mentha spicata for women with PCOS. The primary outcome was not 
reported (Grant 2010). 
Secondary outcomes 
A significant treatment effect was found for Mentha spicata for reductions in total 
testosterone in 41 women (Grant 2010). Mentha spicata tea compared to Matricaria 
recutita (chamomile) tea demonstrated significant reductions in total testosterone over 30 
days (MD 0.18, 95% CI -0.34 to -0.02, p=0.03). No significant treatment effects were found 
for free testosterone, hirsutism (Ferriman Gallwey score) or the dermatology index quality 
of life assessment (Table 2.10).  
Table 2.10. Mentha spicata for secondary outcomes 
 Treatment 
n 
Control 
n 
Number of RCTs 
Heterogeneity  
(I2 , p value) 
Treatment 
effect 
MD  
95% CI p value 
Hyperandrogenism 
Free testosterone  
nmol/l 
21 20 1 
 
0.85  
 
 -3.41 to 1.71 0.52 
Total testosterone  
nmol/l 
21 20 1 
 
0.18 
 
 -0.34 to -0.02, 0.03 
Ferriman Gallwey score 21 20 1 0.00 -4.71 to 4.71 1 
Quality of life 
Dermatology quality of 
life index (DQoLI) 
21 20 1 4 -8.35 to 0.35 0.07 
* number of effects reported for dichotomous outcomes only 
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2.4 Discussion 
 
This systematic review included 18 randomised controlled trials of 1,109 women with PCOS. 
Six nutritional supplements and four herbal medicines were investigated and meta-analyses 
were reported for inositol (vitamin B8) and omega three fish oils. Menstrual regularity was 
not significantly improved for women taking any nutritional supplement or herbal medicine. 
However hyperandrogenism, time to ovulation, ovulation rates, reproductive and metabolic 
hormones, waist to hip ratio, cholesterol and triglycerides were significantly improved by 
inositol, and total cholesterol was significantly lowered by omega three fish oils compared 
to controls. Evidence from single herbal/nutritional supplementation studies was presented 
for improved total testosterone in women with PCOS for herbal tea Mentha spicata 
(spearmint) and improved ovulation, pregnancy rates and gonadotropin hormones for the 
herbal medicine Cimicifuga racemosa.  
This review provides some support for a therapeutic role of inositol. Significant effects for 
inositol versus placebo were demonstrated for the treatment of hyperandrogenism (total 
testosterone, increased SHBG and androstenidione), oligo-ovulation (number of women 
who ovulated), anthropometric characteristics (waist to hip ratio), metabolic hormones 
(fasting insulin and fasting glucose) and secondary risk markers (cholesterol and 
triglycerides) in six meta-analyses. Significant treatment effects for inositol verses active 
controls (folic acid) for were found for reproductive outcomes (number of days to ovulation, 
the number of luteal weeks relative to total trial weeks, the number of women who failed to 
ovulate and pregnancy rates).  
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Inositol is a non-essential B group vitamin (vitamin B8). Humans naturally synthesise two to 
three grams of inositol per day from glucose-6-phosphate in the kidneys (Parthasarathy, 
Ratnam et al. 2006). In addition, bioavailable inositol is found in fatty foods as part of 
lecithin (eggs, meat, fish and organ meats (brain and liver)). Inositol has both hydrophilic 
and hydrophobic characteristics and is involved in a range of biological roles that exploit its 
bipolarity (Mehta and Sen 2005). Inositol is a structural component of cell membranes and is 
essential for cell membrane signalling functions including those involving neurological 
signalling in the brain, second messenger systems and insulin signal transduction. Impaired 
insulin signalling in skeletal muscle and adipose tissue has a pathogenic role in conditions of 
insulin resistance (Dunaif and Book 1997, Larner 2002). It has been proposed that ovarian 
theca cells of women with PCOS remain sensitive to insulin despite insulin resistance, and 
theca cell androgen production continues through an alternative insulin signal transduction 
system (Nestler, Jakubowicz et al. 1998).  Evidence from a range of doses suggests 
therapeutic supplementation with inositol may improve metabolic profile in women with 
PCOS in addition to reduced biochemical hyperandrogenism and improved ovulation and 
pregnancy rates. However, only one small study included in this review examined live birth 
rates and no significant improvements were found compared to controls. As healthy, live 
birth outcomes is the primary goal of all interventions for women with PCOS seeking 
treatment for infertility there is a need for more research in light of the potential benefits 
demonstrated for inositol for other aspects of PCOS.  
BMI outcomes for inositol were mixed. One study demonstrated significant improvements 
for 600mg of inositol per day over twelve weeks compared to placebo (Dona, Sabbadin et al. 
2012) and two trials found no differences between groups over six to eight weeks (Nestler, 
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Jakubowicz et al. 1999, Iuorno, Jakubowicz et al. 2002). Non-significant findings however 
may have been due to the lower dosage of the treatment with insufficient time to 
demonstrate significant changes for this outcome.   
The findings of this review differ with the systematic review of hypoglycaemic interventions 
for women with PCOS (Tang, Lord et al. 2012). Tang and colleagues (2012) found no 
significant treatment effect for inositol against placebo for testosterone, fasting glucose, 
fasting insulin and blood lipids, however only one study was included in analyses (44 
women) (Nestler, Jakubowicz et al. 1999). Two RCTs were included in analyses for ovulation 
rate (327 women) (Nestler, Jakubowicz et al. 1999, Gerli, Papaleo et al. 2007) and the 
authors found no reliable treatment effects due to wide confidence interval and significant 
study heterogeneity (OR 5.38, 95% CI 0.70 to 41.31, I2 81%). The differences of findings 
between the two systematic reviews may be explained by the variable study inclusion 
criteria and the number of studies included in analyses. Tang and colleagues specified the d-
chiro isomer form of inositol against placebo or no treatment and included only two RCTs in 
meta-analyses for one outcome and only one RCT for analyses of four outcomes. The 
present review included seven RCTs investigating two isometric forms of inositol (d chiro 
and myo inositol) against placebo and active controls in analyses of fifteen outcomes.  This 
present review included more RCTs, contributed more data for analyses and added 
substance to findings for inositol.  
Findings for inositol for total testosterone, reproductive outcomes (pregnancy rates), fasting 
glucose and insulin were comparable to findings for metformin (against placebo or no 
treatment). Tang and colleagues (2012) found pregnancy rates for metformin were 
improved for non-obese women (OR 2.35, 95% CI 1.44 to 3.82, I2=72%, four studies, 413 
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women) (Tang, Lord et al. 2012). Pregnancy rates for inositol were comparable (OR1 3.62, 
95% CI 1.29 to 10.16, three studies, I2=0%, 134 women), however the wide confidence 
intervals for inositol suggest the estimation of effect sizes in studies was imprecise and 
these current pregnancy rates for inositol have limited utility in clinical settings. Fasting 
insulin outcomes were comparable for inositol and metformin in non-obese and obese 
women with PCOS. Analyses revealed similar mean differences over similar study durations 
with analyses of inositol showing narrower confidence intervals and less heterogeneity of 
studies compared metformin. The substantially fewer number of studies for inositol 
however implied that further data may impact on findings of inositol for fasting insulin.   
Adverse reactions of nausea and vomiting were significant for women taking metformin 
compared to placebo controls (Tang, Lord et al. 2012). Three studies (73 women) were 
included in meta-analyses (I2=0%). Women taking metformin were nearly four times more 
likely to experience nausea and vomiting (OR 3.91, 0.98 to 15.64, p=0.05). Although further 
evidence is needed to confirm the low rate of adverse effects for inositol in PCOS, risks for B 
group vitamins are generally reported as low (Timbo, Ross et al. 2006) and other 
investigations into high dose inositol for diabetes have reported no side effects (Arendrup, 
Gregersen et al. 1989). In light of the high rates of unpleasant gastrointestinal effects of 
metformin and the potential clinical effectiveness of inositol, investigations examining 
adverse effects are important to support the rationale behind inositol as possible alternative 
pharmaceutical treatment for women with PCOS.  
Findings for lowered cholesterol for omega three fish oils were comparable to treatment 
with metformin. The mean difference for metformin (compared to placebo or no treatment) 
                                                          
1 Relative risk (RR) was converted to odds ratio (OR) for comparison. 
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was -0.14nmol/l, (95% CI -0.14 to 0.02, ten RCTs, 563 women, I2=62%) and for omega three 
fish oils (compared to placebo), -0.49nmol/l (95% CI -0.62 to -0.35 two studies, 95 women I2-
0%). Less heterogeneity of studies and narrower confidence intervals for omega three fish 
oils suggests that findings for omega three fish oils may be more effective treatment than 
metformin for reducing this risk marker in women with PCOS. Anti-inflammatory effects of 
omega three fish oils shown in studies investigating cardiovascular and other chronic 
diseases  (Rangel-Huerta, Aguilera et al. 2012) suggests this nutrient may offer additional 
clinical benefits for women with PCOS. Insufficient evidence was found for reduced 
inflammatory markers in this review however more investigations are needed to assess of 
the clinical value of omega three fish oils for women with PCOS.  
This review found no single nutritional supplement or herbal medicine significantly 
improved the primary outcome however only two small studies investigated menstrual 
regularity (Chan, Koo et al. 2006, Rashidi, Haghollahi et al. 2009). Chan (2006) and 
colleagues found a treatment effect in a sub-analysis investigating Camellia sinensis with a 
lower proportion of amenorrheic women at twelve weeks for women taking Camellia 
sinensis compared to placebo controls however differences between groups were not 
significant (Chan, Koo et al. 2006). Findings were limited by the small sample size (only 14 
women) and the study was underpowered for secondary outcomes (number of amenorrheic 
women).   
2.4.1 Quality of studies 
Studies included in this review were of variable methodological quality. Many studies 
examined small sample sizes over short time frames. Studies that investigated inositol for 
hyperandrogenism, anthropometry, metabolic hormones and risk factors were found to 
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have better methodological quality compared to studies investigating inositol for 
reproductive outcomes. Although data were suitable for meta-analyses for a range of 
outcomes, individual studies investigating reproductive outcomes were at high risks of bias 
due to high attrition in the intervention arms of studies, insufficient reporting and due to 
other risks of bias.   
Findings for omega three fish oils were limited by the inclusion of studies at high risk of 
performance, attrition and other sources of bias. Eighty seven per cent of meta-analyses 
findings were attributed to an open label study in which 19% of participants in the 
treatment group dropped out compared to 5% in the control arm. Data were analysed using 
per protocol data only. Various other sources of bias included unaccounted dietary intake of 
omega three essential fatty acids during the trial period.  
The quality of evidence in this review was limited by the small number of nutritional 
supplements and herbal medicine interventions for possible use in PCOS. Methodological 
weaknesses lead to the exclusion of many studies. Of the studies included, risks of bias were 
assessed as most often unclear with ten studies assessed as having high risk for bias in one 
to three characteristics. Most risks of bias were due to small under-powered trials and 
insufficient reporting. Further research using rigorous methods is needed to corroborate the 
findings of this systematic review. 
2.4.2 Potential biases in the review 
A narrow inclusion criteria of only RCTs that examined the three diagnostic features of 
PCOS; menstrual regularity, hyperandrogenism or polycystic ovaries on ultrasound were 
included in this review. Several studies were excluded based on their investigation of 
surrogate PCOS markers including metabolic hormones and fertility outcomes. Further 
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reviews primarily focused on other clinical outcomes such as fertility, anthropometric or 
psychological features may provide further meta-analyses and strengthen the findings from 
single studies.  
Evidence from 18 RCTs included in this review suggests that women with PCOS may benefit 
from nutritional supplements (inositol and omega three fish oils) and two herbal medicines 
(Mentha spicata and Cimicifuga racemosa). However vitamin D, vitamin B complex, calcium, 
and chromium and Camellia sinensis, Cimicifuga racemosa, Cinnamomum cassia and 
Mentha spicata were each represented by only single studies and this review was unable to 
accurately assess the treatment potential or risks for women with PCOS. Given the range of 
nutritional supplements and herbal medicines that are recommended in the literature 
(Kasim-Karakas and Mishra 2009, Raja-Khan, Stener-Victorin et al. 2011)  for women with 
PCOS, this systematic review provided an inventory of higher quality evidence for some 
nutritional supplements and herbal medicines and highlights the absence of strong 
supportive evidence for nutritional supplements and herbal medicines. 
The English language of the searched data-bases and the studies included in this review 
limited the inclusion of non-English language research and indexations. Herbal medicine has 
a high prevalence of use amongst non-English speaking cultures and this review was limited 
by its omission of non-English language research and databases.  
Information from this review and a second literature review (Chapter 3) partially informed 
the design of the intervention for the randomised controlled trial reported in Chapter five. 
Further discussions of the contribution to the design of the intervention in the RCT (Chapter 
5) and the implications from this review are presented in chapter 6. The evidence base for 
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the effects for herbal medicines for the treatment of menstrual irregularity, 
hyperandrogenism and PCOS is subsequently examined in Chapter 3. 
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Chapter 3:  The physiological effects for naturopathic herbal medicine in oligo/amenorrhoea hyperandrogenism and polycystic ovary syndrome (PCOS)
  
3.1 Introduction  
 
This chapter presents a review of the literature for the reproductive endocrinological effects 
of herbal medicines for oligo/amenorrhoea, hyperandrogenism and polycystic ovary 
syndrome (PCOS). The aim of this review was to synthesise evidence from laboratory and 
clinical studies to explain the mechanisms of effect for herbal medicine extracts. Scientific 
studies examining the effects of herbal medicines using cell culture and animal models were 
compared with clinical studies for proof-of-concept effects. This literature review was used 
to develop an intervention for the clinical trial presented in Chapter five. The research 
questions were: 
1. What is the scientific evidence for the effects of herbal medicine in 
oligo/amenorrhoea, hyperandrogenism and polycystic ovary syndrome? 
2. Is there corroborative clinical evidence?  
3. What herbal medicines should be selected for investigation in a RCT investigating 
herbal medicine plus lifestyle for menstrual regularity in overweight women with 
PCOS?  
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This chapter formed the basis of an article published in the Journal of Alternative and 
Complementary Medicine, indexed by BioMed Central in December 2014 (Arentz, Abbott et 
al. 2014) (Appendix 4). 
2.2 Methods 
 
3.2.1 Definitions of the conditions 
We used the following definitions. PCOS according to the Rotterdam diagnostic criteria, 
specified by the presence of two out of three features; oligo/amenorrhoea, 
hyperandrogenism and polycystic ovaries on ultrasound (ESHRE 2004). Associated endocrine 
features included elevated LH (Legro, Zaino et al. 2007), which may be associated with 
infertility (p=0.0003) (Conway, Honour et al. 1989) and metabolic derangements including 
elevated fasting glucose, insulin and insulin resistance and insulin insensitivity (ESHRE 2012).  
Oligomenorrhoea was defined as menstrual cycle length that regularly extended beyond 35 
days (day one being the first day of menses). Amenorrhoea was defined as no menstrual 
period for three months and not due to other causes including pregnancy (Norman, Dewailly 
et al. 2007). This review was focussed on hypothalamic, pituitary and ovarian causes of 
menstrual irregularity with associated elevated prolactin and arrested folliculogenesis 
typically observed in polycystic ovaries. Hyperprolactinaemia is usually considered a unique 
cause for oligo/amenorrhoea, however in the present case it was included due to the 
potential co-existence for elevated prolactin and PCOS (Luciano, Chapler et al. 1984, 
Conway, Honour et al. 1989), and to incorporate holistic treatment principles and the 
possible association between elevated prolactin and cardiovascular risk markers in women 
with PCOS (Glintborg, Altinok et al. 2014). 
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Hyperandrogenism was defined as clinical or biochemically excessive androgens. Clinical 
markers included hirsutism (measured using the modified Ferriman Gallwey score (Ferriman 
and Gallwey 1961)), and acne or alopecia. Biochemical indications include elevated plasma 
concentration of androgens, reduced concentration of sex hormone binding globulin (SHBG) 
and elevated free androgen index (FAI).  
3.2.2 Search protocol 
Two searches were conducted. The first was sensitive and aimed to capture all pre-clinical 
studies explaining the reproductive endocrine effects of whole herbal extracts in PCOS or 
associated oligo/amenorrhoea and hyperandrogenism. The second search was specific and 
sought only clinical studies investigating herbal medicines revealed during the first search 
(for which a mechanism of effect had been demonstrated). An additional search was carried 
out on a case by case basis for pre-clinical evidence for herbal medicines identified during 
the second search, but not included in the results of the first search. Clinical studies were 
excluded based on the absence of evidence for a mechanism of effect for the whole herbal 
extract in reproductive endocrinology associated with PCOS, oligo/amenorrhoea and 
hyperandrogenism. We used this approach to gather evidence for specific herbal medicines 
with both pre-clinical and clinical data supporting a consistent mechanism of effect and to 
inform treatment decisions of women with PCOS. 
The first search revealed ten herbal medicines that informed the search terms of the second 
search. These were Cimicifuga racemosa, Cinnamomum cassia, Curcuma longa, Glycyrrhiza 
spp., Matricaria chamomilla, Mentha piperita, Paeonia lactiflora, Silybum marianum, 
Tribulus terrestris and Vitex agnus-castus. Herbal medicines with a demonstrated 
mechanism of effect were entered as key terms in the second search. 
 88 
 
We searched the following electronic databases:  the Cochrane Library, MEDLINE ovidSP, 
CINAHL (1936 to present), SciVerse, EMBASE, PubMed, from the date of database inception 
to June 2014. In addition, we manually searched bibliographies of review articles.  
Key terms for the first search included: title or abstract CONTAINS ‘herbal medicine’ OR 
‘herbal extract*’ OR ‘phytotherapy’ OR ‘botanical’ AND title or abstract CONTAINS 
‘androgen*’ OR ‘oestrogen*’OR ‘follicle stimulating hormone’ OR ‘luteinising hormone’ OR 
‘prolactin’ OR ‘insulin’ OR ‘glucose’ OR ‘polycystic ‘ovar*’. Search terms for the second 
search included the following key words in the title or abstract, CONTAINS; ‘menstrual 
irregularity’ OR ‘oligomenorrhoea’ OR ‘amenorrhoea’ OR ‘hyperandrogenism’ OR ‘hirsutism’ 
OR ‘acne’, OR ‘polycystic ovary syndrome’ OR ‘PCOS’ OR ‘polycystic ovar*’ OR ‘oligo-
ovulation’ OR ‘anovulation’ OR ‘fertility’ OR ‘infertility’ OR ‘pregnancy’ AND ten herbal 
medicines identified from the laboratory search;  ‘Cimicifuga racemosa’ OR ‘Cinnamomum 
cassia’ OR ‘Curcuma longa’ OR ‘Glycyrrhiza ’ OR Matricaria chamomilla OR ‘Mentha piperita’ 
OR ‘Paeonia lactiflora’ OR ‘Silybum marianum’ OR  ‘Tribulus terrestris’ OR   ‘Vitex agnus-
castus’ . Truncation was used to capture plural key words and synonyms, and acronyms 
were used for some hormones (FSH and LH).  
3.2.3 Study inclusion criteria 
Our laboratory search included investigations into the effects of herbal medicine using 
computer models, cell cultures, animals with PCOS induced with oestradiol valerate and 
androgens and sterilised and ovariectomised rats.  We excluded laboratory studies which 
commenced using isolated chemicals not directly extracted from crude herbal medicines 
and studies examining androgen effects in male animals. 
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Our second search for clinical trials was performed without language restriction and 
included randomised controlled trials, non-randomised, open label and single arm clinical 
trials.  We included clinical studies investigating commercially available herbal extracts and 
investigations that compared the effectiveness of herbal medicine with pharmaceuticals. 
We excluded clinical studies investigating herbal medicines with unrelated outcomes 
(including pre-menstrual syndrome, endometriosis and mastalgia) and clinical studies 
examining complex herbal formulas without demonstration of a mechanism of effect for the 
complex formula. We compared data from laboratory and animal studies with the outcomes 
of clinical trials. Clinical studies were assessed for risks of bias at study and outcome levels 
with risks summarised, tabulated (Table 1 and 2) and presented in contextual narrative.  
3.3 Results 
3.3.1 Characteristics of the studies 
Laboratory studies 
Our search identified 33 laboratory (pre-clinical) studies (Figure 3.1). Eighteen studies met 
the inclusion criteria, nine reported on receptor binding assays or ovarian or pituitary (brain) 
cell cultures, (Jarry, Harnischfeger et al. 1985, Sliutz, Speiser et al. 1993, Meier, Berger et al. 
2000, Zierau, Bodinet et al. 2002, Jarry, Spengler et al. 2003, Wuttke, Jarry et al. 2003, Sun, 
Imai et al. 2004, Jarry, Spengler et al. 2006, Jarry, Leonhardt et al. 2009) and nine used an 
animal experimental model with hormone assays and/or post-mortem examination of 
ovarian, uterine and brain histology, (Takeuchi 1989, Duker 1991, Lee, Pak et al. 2003, 
Seidlova-Wuttke, Hesse et al. 2003, Ibrahim, Shalaby et al. 2008, Martino-Andrade, Morais 
et al. 2010, Esfandiari, Dehghan et al. 2011, Dehghan, Esfandiari et al. 2012, Heibashy, 
Mazen et al. 2013) [45-53] (Table 3.1).   
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Fifteen studies were excluded for the following reasons; investigation of effects in male 
animals (n=4) and investigations which commenced with constituents that were isolated 
from herbal medicines (n=5). Six studies were excluded due to no clinical evidence found 
(n=6) (Appendix 5).  
Clinical studies  
Following the electronic and manual searches of bibliographies, forty six clinical studies 
were identified for inclusion/exclusion assessment (Figure 1). A pre-requisite for the 
inclusion of clinical studies was identified laboratory evidence explaining the mechanism of 
effect in reproductive endocrinology. Fifteen met the inclusion criteria (Milanov, Maleeva et 
al. 1981, Yaginuma 1982, Tabakova P 1984, Milewicz 1993, Takahashi and Kitao 1994, 
Gerhard 1998, Bergmann 2000, Ushiroyama 2001, Armanini, Mattarello et al. 2004, Kilicdag, 
Tarim et al. 2004, Armanini, Castello et al. 2007, Wang JG 2007, Shahin, Ismail et al. 2008, 
Kamel 2013, Shahin and Mohammed 2014). Eight were randomised controlled trials (RCTs) 
including 762 women (Milewicz 1993, Gerhard 1998, Bergmann 2000, Kilicdag, Tarim et al. 
2004, Wang JG 2007, Shahin, Ismail et al. 2008, Kamel 2013, Shahin and Mohammed 2014). 
(Table 2). Thirty one studies were excluded for the following reasons; investigation of 
isolated herbal chemicals (n=3); inclusion of male subjects (n=4); no pre-clinical evidence 
(n=11) and conditions different to those specified (n=13) (Appendix 5). 
Excluded studies 
Details of studies that were excluded from this review were presented in Appendix 5. 
Excluded studies investigating herbal medicines with clinical evidence but no preclinical 
evidence were provided in appendix 5, table 1. Herbal medicines with preclinical evidence 
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Figure 3.1. Flow chart included and excluded preclinical and clinical studies. 
 
 
 
  
Records identified through 
database searching 
(n = 66) 
 
 
 
Additional records identified 
through bibliography searches 
(n = 14) 
Records after one duplicate removed  
(n = 79) 
Records screened 
n = 79 
(Pre-clinical studies n = 33 
Clinical studies n = 46) 
 
 
Full-text articles assessed for 
eligibility 
(Preclinical studies n=26 
Clinical studies n= 39) 
 
 
Pre-clinical full-text studies excluded 
(total 8) for the following reasons; no 
clinical evidence (n=6), investigation of 
isolated herbal chemicals (n=2).  
Clinical full-text studies excluded (total 
24) for the following reasons; outcomes 
other than oligo/amenorrhoea, 
hyperandrogenism or PCOS (n= 13); no 
pre-clinical evidence (n= 11). 
Studies included in review 
synthesis 
(Pre-clinical studies n = 18 
Clinical studies n=15) 
 
 
Pre-clinical studies excluded (total 7) for 
the following reasons; investigation of 
effects in male animals (n=4) and study 
commenced with isolated herbal 
chemicals (n=3).  
Clinical studies excluded (total 7) for the 
following reasons; investigated isolated 
herbal chemicals (n = 3), including male 
subjects (n=4). 
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but no clinical evidence were detailed in appendix 5, table 2 and studies investigating 
chemicals isolated from herbal extracts were presented in appendix 5, table 3. 
Commercial preparations 
Seven RCTs examined commercially produced herbal medicine extracts. These were Vitex 
agnus-castus in the form of Strontan®(Milewicz 1993), Mastodynon®(Gerhard 1998), Phyto 
Hypophyson®(Bergmann 2000) and Agnacaston®(Kilicdag, Tarim et al. 2004) and Cimicifuga 
racemosa in the form of Klimadynon®(Shahin, Ismail et al. 2008, Kamel 2013, Shahin and 
Mohammed 2014) (Table 3.2).  
Combined herbal preparations 
Complex herbal preparations were investigated in two laboratory based studies (Lee, Pak et 
al. 2003, Sun, Imai et al. 2004). This was because laboratory findings were substantiated in 
clinical trials for therapeutic effects in oligo/amenorrhoea, hyperandrogenism and/or PCOS. 
The combination of Paeonia lactiflora and Cinnamomum cassia in the formulation Unkei-to, 
were tested in one laboratory based study (Sun, Imai et al. 2004), with effects corroborated 
by one clinical trial (Ushiroyama 2001). Two TCM herbal formulae Changbudodam-Tang and 
Yongdamsagan-Tang with the single common ingredient Glycyrrhiza glabra were compared 
for effectiveness in the polycystic ovaries of animals (Lee, Pak et al. 2003). Two clinical 
studies substantiated the effects for Glycyrrhiza glabra in PCOS and hyperandrogenism 
(Armanini, Mattarello et al. 2004, Armanini, Castello et al. 2007). 
3.3.2 Herbal medicines with effects in oligo/amenorrhoea, hyperandrogenism 
and PCOS 
The results of preclinical studies and clinical studies have been summarised together for six 
herbal medicines (Tables 3.1 and 3.2).  
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Table 3.1. Summary of evidence for the physiological effects of six herbal medicines in oligo/amenorrhoea, hyperandrogenism and PCOS.  
Herbal medicine  
Botanic name 
Herbal extract 
Evidence Physiological effects in menstrual irregularity (oligo/amenorrhoea), 
hyperandrogenism and/or PCOS. Pre-clinical in vitro and in vivo  
 
Clinical RCTs  
(detailed in Table 2) 
Vitex agnus-
castus 
 
Ethanol extracts  
 
Strontan®,  
Mastodynon®  
Phyto-
hypophyson® 
Agnucaston® 
 
Eight studies investigated gonadotropic hormone concentration effects of Vitex agnus-castus.  
1. Investigation for equivalence of dopaminergic effects for Vitex agnus-castus and the 
pharmaceutical Lisuride using rat pituitary cell cultures (basal and stimulated cells) (Sliutz, Speiser 
et al. 1993). 
2. Brain (calf, guinea pig and rats) receptor tissue cultures including DA2, histamine and 5HT 
transporters. Radio ligand and super-fusion experiments (Meier, Berger et al. 2000). 
3. Three investigations found affinity for Vitex agnus-castus and β oestrogen receptors (Jarry, 
Spengler et al. 2003, Wuttke, Jarry et al. 2003, Jarry, Spengler et al. 2006). 
4. Using recombinant human dopamine (DA2) receptor proteins (Jarry, Spengler et al. 2006).  
5. The affinity of Vitex agnus-castus extract (with and without fatty acids) for human µ opioid 
receptor cells cloned and transfected into hamster ovary cells (Webster, Lu et al. 2006). 
6. The endocrine effects for Vitex agnus-castus were investigated in normal and ovariectomised 
rats (Ibrahim, Shalaby et al. 2008). 
7. Corpus striatum membrane including D2 receptors to assess the inhibitory properties of Vitex 
agnus-castus on prolactin, FSH and LH (Jarry, Leonhardt et al. 2009).  
 
Three RCTs 
demonstrated 
effectiveness for Vitex 
agnus-castus for 
oligo/amenorrhoea 
and PCOS (Milewicz 
1993, Gerhard 1998, 
Bergmann 2000) 
 
One RCT 
demonstrated 
equivalence for 
Bromocriptine and 
Vitex agnus-castus 
(Kilicdag, Tarim et al. 
2004).  
1.Lowered prolactin due to dopaminergic effects(Sliutz, Speiser et al. 
1993, Meier, Berger et al. 2000, Kilicdag, Tarim et al. 2004, Jarry, 
Leonhardt et al. 2009) 
2.No change for serum prolactin (Milewicz 1993) 
3.FSH no change (Jarry, Leonhardt et al. 2009)  
4.LH no change (Jarry, Leonhardt et al. 2009)  
5.LH lowered (Ibrahim, Shalaby et al. 2008)  
6.Bound with β oestrogen receptors(Jarry, Spengler et al. 2003, 
Wuttke, Jarry et al. 2003, Jarry, Spengler et al. 2006)   
7.Increased serum oestradiol (Milewicz 1993) 
8.Increased serum progesterone (Bergmann 2000, Ibrahim, Shalaby et 
al. 2008) 
9.Improved pregnancy rates (Gerhard 1998, Bergmann 2000)  
Cimicifuga 
racemosa 
 
Ethanol extract 
 
Klimadynon® 
Four laboratory studies investigated pituitary oestrogen receptor binding and gonadotropin 
concentrations following exposure to Cimicifuga racemosa. 
1.  One study investigated a constituent flavonoid of Cimicifuga racemosa, discovered during the 
course of the study for reduction for LH in ovariectomised rats(Jarry, Harnischfeger et al. 1985) 
2. Oestrogen receptor binding affinity for Cimicifuga racemosa was studied using pituitary cell 
cultures from ovariectomised rats. This study followed a clinical study demonstrating significantly 
lowered LH in post-menopausal women following administration of Cimicifuga racemosa (2 mg for 
two months) against placebo control (n=110) (Duker 1991) 
3. Binding affinity for oestrogen receptors (ERα) for Cimicifuga racemosa examined using MCF7 cell 
cultures (Zierau, Bodinet et al. 2002) 
4. Chronic and acute dosage effects of Cimicifuga racemosa and oestradiol on oestrogen receptors, 
gene expression, uterine and bone tissue of ovariectomised rats (Seidlova-Wuttke, Hesse et al. 
2003) 
Three RCTs 
demonstrated  fertility 
effects for Cimicifuga 
racemosa in women 
with PCOS (Shahin, 
Ismail et al. 2008, 
Kamel 2013, Shahin 
and Mohammed 
2014)  
1. Bound with α oestrogen receptors (Zierau, Bodinet et al. 2002) in 
the pituitary and reduced LH secretion (Duker 1991, Seidlova-Wuttke, 
Hesse et al. 2003, Shahin and Mohammed 2014). 
2.Increased luteal progesterone concentration (Shahin, Ismail et al. 
2008, Kamel 2013, Shahin and Mohammed 2014)    
3. Improved endometrial thickness for infertile women with PCOS 
(Shahin, Ismail et al. 2008, Kamel 2013, Shahin and Mohammed 2014). 
4.Lowerd LH in women with PCOS (Shahin, Ismail et al. 2008, Kamel 
2013, Shahin and Mohammed 2014)   
5.Improved FSH:LH ratio for women with PCOS (Kamel 2013) 
6.Limited anti-oestrogen effects when used in combination with 
Clomiphene citrate for women with PCOS (Shahin, Ismail et al. 2008, 
Shahin and Mohammed 2014) 
Cinnamon cassia 
 
Aqueous extract  
(animal study) 
Ethanol 
extraction 
(Human trial) 
 
One animal study compared the effectiveness of Cinnamomum cassia with metformin against 
controls in rats with PCOS. Hormone concentration was measured at 15 and 30 days (Heibashy, 
Mazen et al. 2013) 
One pilot RCT 
demonstrated positive 
effects for metabolic 
parameter’s (HOMO 
and QUICKI) for 
Cinnamomum cassia 
in overweight women 
with PCOS (Wang JG 
2007) 
1. Equivalence for metformin for reduced testosterone in PCOS 
(Heibashy, Mazen et al. 2013) 
2. Equivalence for metformin for reduced LH in PCOS(Heibashy, Mazen 
et al. 2013) 
3. Equivalence for metformin for reduced LH in PCOS (Heibashy, 
Mazen et al. 2013) 
4  Equivalence for metformin for reduced insulin resistance (Heibashy, 
Mazen et al. 2013) 
5. Improved metabolic profile for overweight women with PCOS 
(Wang JG 2007)  
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Table 3.1 continued 
Herbal medicine  
Botanic name 
Herbal extract 
 
Evidence 
 
Physiological effects in oligo/amenorrhoea, hyperandrogenism 
and/or PCOS Pre-clinical in vitro and in vivo Data from clinical studies (non RCTs) 
Tribulus terrestris 
 
Ethanol extracts 
Three animal studies investigated the effects of 
Tribulus terrestris, two for polycystic ovaries and one 
on oestrogen sensitive tissues in rats. 
1. One study examined the oestrogenic effects of 
Tribulus terrestris on uterine and vaginal tissue of 
ovariectomised rats (Martino-Andrade, Morais et al. 
2010). 
2. Two studies investigated the ovulation rates, 
number of corpus luteum and follicle characteristics 
in rats with polycystic ovaries following exposure to 
various doses of Tribulus terrestris (Esfandiari, 
Dehghan et al. 2011, Dehghan, Esfandiari et al. 2012). 
 
Two clinical studies 
1. Pre and post serum hormone concentration for FSH, LH, 
testosterone and oestradiol at 8am and 12 pm during the early 
menstrual cycle (follicular phase) in 8 healthy women. Intervention 
consisted of Tribulus Terrestris 250 mg per day over five days. 
Results showed significant increase in FSH and rise in LH (not 
significant), an increase in oestradiol and no change in testosterone 
concentration (Milanov, Maleeva et al. 1981). 
2. Equivalence for Tribulus terrestris and three ovulation induction 
pharmaceuticals for ovulation induction in women with 
oligo/anovulation infertility (n=148) (Tabakova P 1984). 
1. Ovulation induction in polycystic ovaries (Esfandiari, Dehghan et al. 
2011, Dehghan, Esfandiari et al. 2012). 
2. No oestrogenic effects in female reproductive tissues (Martino-
Andrade, Morais et al. 2010). 
3. Increased FSH in healthy women (Milanov, Maleeva et al. 1981). 
4 .Equivalence for ovulation induction for Tribulus Terrestris and 
Clomiphene for women with oligo/anovulation infertility (Tabakova P 
1984). 
Glycyrrhiza glabra  
(European liquorice) 
Glycyrrhiza uralensis 
(Chinese liquorice) 
 
Ethanol extract  
 
Aqueous extract used in  
two pre-clinical studies  
Two preclinical studies investigated the effects of 
Glycyrrhiza spp. for steroid hormone concentration 
and in polycystic ovaries. 
1. Steroid hormone concentration in sterilised and 
oophrectomised rats following exposure to 
Glycyrrhiza spp. (kanzo) (Takeuchi 1989). 
2. Morphological features of polycystic ovaries of rats 
following exposure to two Chinese herbal compounds 
with only Glycyrrhiza spp. as a common ingredient 
(Lee, Pak et al. 2003).  
Two clinical trials 
1. Single arm clinical trial investigating serum androgen 
concentration in healthy women aged 22-26, (n=9) following 
administration of Glycyrrhiza spp. 7grams per day (Armanini, 
Mattarello et al. 2004). 
2. Single arm clinical trial including women with PCOS (n=32) taking 
Spirinolactone (Armanini, Castello et al. 2007). 
1. Increased aromatisation of testosterone to 17 beta oestradiol 
shown by reduced testosterone  and increased oestradiol (dose 
dependent) (Takeuchi 1989). 
2. Reduced free and total testosterone (Takeuchi 1989). 
3. Reduced serum androgens in healthy women (Armanini, Mattarello 
et al. 2004). 
4. Reduced androgen flare for women with PCOS using the anti-
androgen pharmaceutical Spirinolactone (Armanini, Castello et al. 
2007). 
5.Improved ovulation rates in polycystic ovaries (Lee, Pak et al. 2003). 
Paeonia lactiflora in 
combination with 
Glycyrrhiza spp.  
 
Aqueous extract 
Shakuyaku- 
kanzo-to (TJ-68) 
One laboratory study examined the effects for the 
combination Paeonia lactiflora and Glycyrrhiza 
uralensis on testosterone, oestradiol, FSH and LH in 
sterilised female rats (Takeuchi 1989).  
Two single arm clinical trials examined androgen concentrations 
Following treatment with Paeonia lactiflora and Glycyrrhiza 
uralensis in the Chinese herbal combination Shakuyaku-kanzo-to. 
One included infertile oligomenorrhoeic women with 
hyperandrogenism (n=8) (Yaginuma 1982) and the other included 
women with oligo/amenorrhoea and PCOS (n=34) (Takahashi and 
Kitao 1994). 
1. Reduced total and free testosterone (Takeuchi 1989, Takahashi and 
Kitao 1994) 58 .  
2.Increaed SHBG (Takahashi and Kitao 1994). 
3.Reduced LH (Takeuchi 1989). 
4.Reduced LH:FSH ratio (Takahashi and Kitao 1994). 
5. Oestradiol slight increase (not significant)(Takeuchi 1989). 
6. Improved ovulation in women with PCOS (Yaginuma 1982). 
Paeonia lactiflora in 
combination with 
Cinnamomum cassia  
 
Aqueous extract Unkei-to 
Paeonia lactiflora and Cinnamomum cassia 
combination was investigated for steroid hormonal 
effects on cultured human granulosa cells (obtained 
from women undergoing IVF). Cells were incubated 
with different doses for 48 hours (Sun, Imai et al. 
2004).  
One clinical trial investigated the effects of Paeonia lactiflora and 
Cinnamomum cassia combination (Unkei-to) (Ushiroyama 2001). 
This single arm study included amenorrheic women aged 17-29 
years (n=157) with a sub group of women with hyper-functioning 
oligo/amenorrhoea (n=42). Ovulation occurred in 61.3% of primary 
amenorrheic women and in 27.3% of secondary amenorrheic 
women following two months of treatment (Ushiroyama 2001). 
1.Increased granulosa production of oestradiol (Sun, Imai et al. 2004). 
2.Increased granulosa production of  
progesterone (Sun, Imai et al. 2004). 
3.Reduced LH in oligo/amenorrhoea (Ushiroyama 2001). 
4. Improved ovulation rates in  
oligo/amenorrhoea (Ushiroyama 2001). 
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Table 3.2. Summary of Randomised Controlled Trials for five herbal medicines in oligo/amenorrhoea, hyperandrogenism and PCOS. 
Authors and 
year of 
publication  
Study design 
and duration 
Subjects Intervention Outcome measures Results and level of significance Comments 
Kilicdag 2004 
(Kilicdag, 
Tarim et al. 
2004) 
 
RCT 
comparative 
effectiveness 
design.  
Treatment for 
3 months. 
Eighty women, 40 
with 
hyperprolactin-
aemia, 40 with 
cyclical mastalgia.  
Herbal extract Vitex agnus-
castus 40mg in the 
commercial preparation 
Agnucaston® by Biomeks, 
Germany.   
1 tablet per day. 
Bromocriptine in the form 
of Parlodel produced by 
Novartis, Turkey, 2.5mg 
twice daily. 
Serum prolactin 
concentration on days 
5-8 of the menstrual 
cycle. 
Normal range 
25.2mIU/l - 628.5 
mIU/l. 
Mean prolactin concentration before and after 
for women treted with Vitex agnus-castus; 
946mIU/L (± 173.5) to 529mIU/l (± 279.7), 
p<0.01. 
Women treated with Bromocriptine; 885.0 mIU/l 
(± 177.5) to 472.68mIU/L (± 265.6), p< 0.01. 
Equivalence demonstrated for Vitex agnus-
castus and Bromocriptine for prolactin reduction 
(P = 0.96). 
All participants completed the trial.  
Adverse reactions; zero reported in 
V. agnus-castus group; 12.5% of 
participants reported adverse 
reactions in the Bromocriptine 
group (nausea and vomiting). 
Limitations: small sample size with 2 
sub-groups. Insufficiently powered 
to correctly identify the effects; 377 
participants were required (±5%, 
95% confidence). 
Gerhard I, 
Patek A, et al 
1998 
(Gerhard 
1998)  
RCT, double 
blind, placebo 
controlled 
design. 
Three 
months. 
Follow up and 
at 2 years 
 
 
 
Ninety-six women 
with fertility 
disorders and 
confirmed 
infertility (2 
years).   
Secondary 
amenorrhoea, 
n=38; luteal 
insufficiency, 
n=31; idiopathic 
infertility, n=27.  
 
 
 
 
 
 
 
Vitex agnus-castus 32.4 
mg/d in the commercial 
preparation Mastodynon® 
liquid extract produced by 
Bionorica, Germany. 
30 drops per day over 3 
months. 
Mastodynon® additionally 
contains herbal extracts of 
Caulophyllum thalictroides, 
Lilium majus, Cyclamen, 
Ignatia and Iris.  
No evidence that additional 
therapeutic agents affect 
prolactin concentration. 
Spontaneous 
menstruation, luteal 
phase length, serum 
hormone 
concentrations and 
pregnancy rates. 
Hormonal data from 32 
cases. In the third 
treatment month 66 
complete data sets 
were available.  
Reasons were as 
follows; 4 due to drug 
reactions and 15 due to 
pregnancy. 
Four withdrew for 
unknown reasons. 
Non-significant improvement in clinical 
parameters in 57.6% of women in treatment 
group versus 36.0% in placebo group, P = 0.069. 
In a subgroup of women with luteal insufficiency 
(n=21) there were significant improvements in 
clinical parameters in the treatment group 
compared to placebo (p = 0.02).  
15 women conceived in the treatment group 
compared to 8 in placebo group in the first 3 
months (while women were treated).  
All pregnant women were withdrawn from the 
study. 
4 women had miscarriages, all in the active arm. 
After 2 years there were 21 more pregnancies 
with 2 miscarriages – evenly spread over active 
and placebo groups. 
 
Numbers too small for statistical 
significance in clinical outcomes.  
Preparation ‘Mastodynon’ contains 
Vitex agnus-castus plus other herbal 
extracts which may have influenced 
outcome measures.  
Inconsistencies in data assessment 
include the recommendation for 
treatment with Mastodynon over 3-
6 months yet it was tested for 3 
months.  
Women with infertility were 
included in this study however data 
from women who conceived were 
excluded. This may have led to an 
underestimation of treatment effect 
(type 1 error).  
 
 
 96 
 
Table 3.2 continued. 
Authors and 
year of 
publication  
Study 
design and 
duration 
Subjects Intervention Outcome measures Results and level of significance Comments 
Bergmann J, Luft 
B, et al. 2000 
[62] 
RCT, double 
blind, 
placebo 
controlled.  
Three 
months or 
three 
menstrual 
cycles. 
 
Women with fertility 
disorders, (n=67).  
Two sub-groups.  
1.oligomenorrhoea, n=37  
2. amenorrhoea n=30  
Oligomenorrhoea group:  
Treatment n=17. Placebo n= 
20. 
Amenorrhoea group.  
Treatment n=16. Placebo 
n=14. 
Herbal extract  
Phyto-Hypophyson® 
by Steril-Pharma 
GmbH Herrsching, 
Germany; contains 
Vitex agnus-castus 
plus Chelledonium 
majus and Silybum 
marianum (St Mary’s 
thistle) in 
homeopathic form. 
Additional herbal 
extracts have 
reported activity in 
hepatic function. 
There are no reports 
for direct 
reproductive effects. 
150 drops per day 
(7.5 ml per day). 
Primary outcome for 
participants with 
amenorrhoea: at least one 
spontaneous menses. 
For progesterone <1 ng/mL: 
an increase to >5 ng/mL at 
the end of 3rd cycle 
For oligomenorrhoea:  
Shortened menstrual cycle 
of at least 4 days. 
Earlier ovulation of at least 
3 days. 
For anovulatory 
oligomenorrhoea: Mid 
luteal progesterone  
increase (>50% 5-10 days 
before menstruation 
Secondary clinical 
outcomes, pregnancy rates 
and take home baby rates. 
Oligomenorrhoeic subgroup - clinical 
outcomes were significantly improved in 
the treatment arm at 82% compared to 
45% in placebo arm P = 0.02. 
When the amenorrheic group were 
included in analysis, differences were not 
significant p=0.19.  
Mid luteal progesterone concentration in 
oligomenorrhoeic sub-group was 
significantly higher than the placebo group 
p = 0.05 
At 6 months following conclusion of 
treatment, the take home baby rate with 
treatment was 18.7% compared to 6.4% in 
placebo group. Not statistically significant. 
 
Diagnosis for anovulatory amenorrhoea is 
not well described.  
Non-statistically significant take home baby 
rates were complicated by insufficient 
sample size. 366 patients are required to 
have a 95% chance, as significant at the 5% 
level, an increase in take home baby rates 
from 6% in the placebo group to 18% in the 
experimental group. 
The authors conclude that this preparation 
may be useful if given 3-6 months, yet they 
only tested for 3 months. 
Milewicz A, 
Gejdel E, et al 
1993 (Milewicz 
and Jedrzejuk 
2006). 
Randomised 
placebo 
controlled, 
double 
blind, trial. 
Three 
months. 
 
 
52 women with latent 
hyperprolactinaemia and 
luteal phase defects. 
Participants stratified for 
cycle length, height (cm) and 
weight (kgs) and randomised. 
Baseline differences between 
arms were not significant 
p=0.63, p=0.48 and p =0.37 
respectively. 
37 complete case reports:  
Treatment arm n=17, placebo 
n=20. 
Vitex agnus-castus 
extract 20mg in the 
commercial 
preparation of 
Strotan® Hersteller: 
Pharma Stroschein 
GmbH, Hamburg, 
Germany.   
1 capsule per day or 
placebo. 
Serum prolactin 
concentration at 15 and 30 
minutes following intra 
venous TRH (200mcg) 
stimulation. 
Luteal phase length, 
number of days. 
Measurements on 
menstrual cycle days 5 to 8 
and 20 for FSH, LH, 
oestradiol, progesterone, 
DHEAs, thyroid stimulating 
hormone (TSH), T3, T4, 
testosterone.   
No significant changes in prolactin before 
and after in either group. 
Length (number of days) of the luteal 
phase before and after; treatment group 
3.4 (± 5.0) to 10.5 (± 4.3) (p<0.01), placebo 
3.4 (± 5.1) to 5.5 (± 5.2), p= 0.22.  
Mid luteal (day 20) serum progesterone 
concentration before and after; treatment 
arm 2.46 (± 0.70) to 9.69 (± 6.34), p<0.001. 
Placebo 1.99 (± 0.65) to 2.34 (± 0.59) 
p=0.08. 
Mid-cycle oestradiol; treatment arm 131.6 
(± 25.0) to 151.6 (± 25.4), p<0.05. Placebo: 
119.5 (± 26.0) to 131.1 (± 33.2) p=0.22. 
Pregnancies in treatment group n=2. 
Limitations; missing data. Data from 37 out 
of 52 included in analyses. Data from nine 
women were not included due to the 
presence of luteinised, unruptured follicles. 
Six women did not present for further 
investigation. 
No description of the distribution of missing 
data. Potential imbalance between groups 
may have over-exaggerated the treatment 
effect.  
Intention to treat analysis was not 
performed. 
Unaccounted baseline characteristics include 
medications, fertility status, duration may 
have influenced outcomes. 
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Table 3.2 continued. 
Authors and 
year of 
publication  
Study 
design and 
duration 
Subjects Intervention Outcome measures Results and level of significance Comments 
Shahin 2008 
(Shahin, 
Ismail et al. 
2008) 
RCT 
comparative 
effectivenes
s design.  
One 
menstrual 
cycle. 
 
 
Women with un-
explained infertility 
and recurrent 
clomiphene 
resistance aged less 
than 35 years 
(n=147). 
Anovulatory 
participants were 
excluded (n=28). 
Anovulation was 
diagnosed by serum 
oestradiol < 
200ng/ml and 
absence of a 
dominant ovarian 
follicle on day 9 of 
the menstrual cycle. 
Complete data sets 
available for 119 
women. 
All women received Clomiphene 
citrate (clomiphene) 150mg on 
menstrual cycle days 3-7. A 
randomised group also took 
additional Cimicifuga racemosa 
20mg per day on days 1-12. 
Cimicifuga racemosa described as 
‘phytoestrogens’ was provided in 
the commercial preparation 
Klimadynon®, manufactured by 
Norica in Germany.   A trigger 
injection (human chorionic 
gonadotropin, 10 000 IU) and 
timed intercourse was 
recommended when a dominant 
follicle > 17mm was observed. 
Pregnancy rate measured as 
increasing serum human 
chorionic gonadotropin (HCG) 
over two days. 
Clinical pregnancy defined as 
detection of gestational sac 
with embryonic heart-beat.  
Endometrial thickness 
measured by ultrasound 
concurrent with follicle 
maturation monitoring. 
Number of days to ovulation 
(trigger injection). 
Serum concentration for FSH 
oestradiol and LH. Luteal 
progesterone measured on 
days 21-23 of the menstrual 
cycle. 
Miscarriage and multiple 
pregnancy rates. 
Pregnancy rate in clomiphene alone group 
were 20.3%. For women in the clomiphene 
plus Cimicifuga racemosa group, the 
pregnancy rate was 43.3% (P<0.01). 
Clinical pregnancy rate in the combination 
group was 36.7% versus 13.6% in the 
clomiphene alone group (P<0.01). 
Endometrial thickness in combination group 
was 8.9 (±1.4) versus 7.5 (± 1.3) (p<0.001). 
Days to ovulation in clomiphene alone group 
was 13.0 ±1.1 and in the clomiphene plus 
Cimicifuga racemosa group 14.2 ±1.3 (n.s.). 
Luteal progesterone  peak (ng/ml) in 
combination group was 13.3 (± 3.1) versus 
9.3 (± 2.0) in clomiphene alone  
group (p<0.01). 
All other hormone measures were not 
significantly different. 
 
Limitations; No baseline 
characteristics for other 
causes of infertility. 
Confounding factors 
include current male 
fertility status which may 
have influenced 
outcomes.  
 There was no 
description of the 
distribution of excluded 
(anovulatory) 
participants between 
groups. Removal of 
anovulation data may 
have influenced 
outcomes.   
 
 
Kamel 2013 
(Kamel 2013) 
RCT 
comparative 
effectivenes
s design. 
Three 
menstrual 
cycles.  
 
Women aged 21-27 
with PCOS and 
associated primary 
or secondary 
infertility. (n=100).   
Group one (n=50) 
received.  
One menstrual 
cycle.  
 
Group 1Cimicifuga racemosa 
extract , 20 mg twice daily days 2-
12 of menstrual cycle. Klimadynon® 
by Bionorica, Neumarkt i.d. OBF 
Germany (n=50). 
Group 2. Clomiphene citrate 
(clomiphene) 100mg daily for days 
2-7 of menstrual cycle. (n=50). 
Trigger injection (Human chorionic 
gonadotropin Pregnyl) and timed 
intercourse recommended when 
dominant follicle (>18mm) was 
observed. 
Serum measurements during 
follicular phase for FSH, LH and 
FSH:LH ratio. Mid luteal 
progesterone. Ultrasound 
observation of endometrial 
thickness.  
Pregnancy rates including twin 
pregnancies. 
Adverse events including 
hyperstimulation. 
Positive outcomes for Cimicifuga racemosa 
compared to clomiphene for reduced day 2-
5; LH (p=0.007) and improved FSH to LH ratio 
(p=0.06), mid luteal progesterone (p=0.01), 
endometrial thickness (p=0.01). Pregnancy 
rates were higher in the Cimicifuga racemosa 
group (7/50 compared to 4/50) but not 
statistically significant (p=0.1). 
Adverse events (4 women) and twin 
pregnancy’s (two women). No significant 
differences for adverse events between 
groups.  
No detail for diagnostic 
criteria for PCOS. 
Confounding fertility 
factors not described. 
Drop-out reasons were 
not reported seven in 
Cimicifuga racemosa 
group and four in 
clomiphene group.   
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Table 3.2 continued. 
Authors and 
year of 
publication  
Study 
design and 
duration 
Subjects Intervention Outcome measures Results and level of significance Comments 
Shahin 2014 
(Shahin and 
Mohammed 
2014) 
RCT 
comparative 
effectivenes
s design.  
Three 
menstrual 
cycles each 
separated 
by two 
months of 
no 
treatment. 
Women with PCOS and 
infertility, n=194. 
Randomisation of 206 
women. Endpoint data 
Treatment arm n=96, 
control n= 98. 
No significant differences 
between groups were 
found at baseline for 
demographics, age, BMI, 
primary and secondary 
infertility and duration of 
infertility (months).  
 
All participants 
received 
pharmaceutical 
ovulation 
induction 
(Clomiphene 
citrate 150mg on 
days 3-7 of cycle); 
trigger injection 
(HCG 10000IU 
Pregnyl), timed 
intercourse and 
progesterone 
support (oral 
micronized 
progesterone). A 
randomly 
selected group 
additional took 
Cimicifuga 
racemosa 120mg 
per day 
(Klimadynon®)   
Primary outcomes 
pregnancy rates. 
Secondary outcomes: 1. 
Number of days to 
ovulation (trigger 
injection). Follicular 
maturation monitored 
by ultrasound. 
2. Endometrial 
thickness monitored by 
ultrasound.  
3. Serum hormones 
during follicular phase 
oestradiol, LH and FSH. 
Luteal progesterone 
measured day 21-23 of 
the cycle. 
4. Pregnancy outcomes 
and early miscarriage. 
Pregnancy rates for clomiphene alone group were 33 
out of 192 cycles (17.2%) for the clomiphene plus 
Cimicifuga racemosa group 71 out of 204 cycles 
(34.8%) (P<0.01).  
 
Number of days to trigger injection 15 (±1.7) for the 
clomiphene alone group and 12.0 (±1.9) for women 
in the clomiphene plus Cimicifuga racemosa group 
(p=0.01)  
 
Endometrial thickness in the clomiphene alone 
group was 8.5mm (±1.9) compared to 12.9 (±2.3) in 
the clomiphene plus Cimicifuga racemosa group 
(p<0.01). 
 
Serum LH was 8.0 (±0.9) in the clomiphene group 
and 5.7 (±0.9) in the clomiphene plus Cimicifuga 
racemosa group (p<0.01). Oestradiol was 228.3 
(±30.2) in the clomiphene alone group and 299.5 
(±38.9) in the clomiphene plus Cimicifuga racemosa 
group (p=0.01)  
Miscarriages were 5 out of 192 cycles in the 
clomiphene group and 6 out of 204 cycles in the 
clomiphene plus Cimicifuga racemosa group (n.s.). 
The miscarriage rate per pregnancy 
for the clomiphene alone group was 
5 out of 33 (15.2%) and 6 out of 71 
(8.5%) in the clomiphene plus 
Cimicifuga racemosa group. 
 
This study examined the 
effectiveness of clomiphene alone 
and when Cimicifuga racemosa was 
added. It doesn’t explain the effects 
of the intervention, including the 
placebo effect of taking the extra 
tablet. However the outcomes were 
objective markers (serum 
concentration of hormones) and less 
at risk of placebo effects.  
 
Twelve were excluded due to failure 
to respond (treatment group n=7, 
control n=5). 
Wang et al 
2007 (Wang 
JG 2007) 
RCT Double 
blinded, 
placebo 
controlled 
(pilot). 
Eight weeks. 
 
 
 
 
Overweight women with 
oligo/amenorrhoea and 
polycystic ovaries on 
ultrasound (n=15). 
Mean body mass index 
28.8+1.3 kg/m2 
Mean age 31.1+ 2.0 
years. 
Comparisons with normal 
weight women. 
Cinnamomum 
cassia extracts 
333mg (Integrity 
Nutraceuticals 
International 
Sarasota, Florida) 
or placebo.  
One tablet three 
times per day. 
Primary outcomes: 
Insulin resistance and 
sensitivity. 
Secondary outcomes 
oestradiol and 
testosterone 
concentration. 
Body mass index (BMI) 
Body weight and 
ovulation.  
Adverse events. 
Over time improved insulin sensitivity (QUICKI) (0.35 
to 0.38, 7.7%,p < 0.03) and insulin resistance 
(HOMO-IR) (2.57 to 1.43 , 44.5% p < 0.03) 
significantly improved for women in treatment 
group. No change for women taking placebo. 
No change in either group for BMI, testosterone and 
oestradiol. 
Differences between Cinnamomum cassia group and 
normal weight and ovulatory controls were not 
significant. (P<0.17).  
No reported adverse reactions. 
Small pilot study, the authors report 
that larger studies are required to 
confirm findings. Small sample size 
may explain non-significant 
comparison with normal weight and 
ovulating women. 
Reproductive outcomes were 
unchanged in this study however the 
duration of the study was 
insufficient to demonstrate 
reproductive changes. 
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Vitex agnus-castus 
Vitex agnus-castus contains a variety of compounds which bound to dopamine type 2 (DA-2) 
receptors (in the brain), reduce cyclic adenosine mono phase (cAMP) and lowered prolactin 
secretion (Table 3.1). This was demonstrated in studies using recombinant DA-2 receptor 
proteins, and basal and stimulated rat pituitary cell cultures (Sliutz, Speiser et al. 1993, 
Meier, Berger et al. 2000, Jarry, Spengler et al. 2006, Jarry, Leonhardt et al. 2009). Prolactin 
lowering effects were found in normal and ovariectomised rats (Ibrahim, Shalaby et al. 
2008). Additional agonistic opiate effects were observed in studies using human opiate 
receptors cell cultures (Meier, Berger et al. 2000, Webster, Lu et al. 2006). 
Clinical equivalence for prolactin lowering effects of Vitex agnus-castus (Agnucaston® 40mg 
per day) and the pharmaceutical Bromocriptine (Parlodel® 5mg per day) was found in one 
study including 40 women with hyperprolactinaemia (Kilicdag, Tarim et al. 2004). Mean 
concentrations for prolactin following three months treatment with Vitex agnus-castus  
were significantly reduced from 946mIU/l (±173) to 529mIU/l (±297) (p<0.001). 
Comparatively, mean prolactin concentration in the Bromocriptine group was significantly 
reduced from 885mIU/l (±178) to 473mIU/l (±266) (p<0.001) demonstrating that both 
treatments were effective treatment for women with hyperprolactinaemia (normal 
reference range 25-628mIU/l). The mean difference in prolactin reduction of the two groups 
was not significant (p = 0.96) (Table 3.2).  
Positive effects for Vitex agnus-castus in oligo/amenorrhoea and infertility was 
demonstrated in three placebo controlled RCTs (Milewicz 1993, Gerhard 1998, Bergmann 
2000) (Table 3.2). In a study including women with menstrual irregularity and infertility 
(n=96), menstrual cyclicity was significantly improved for women treated with Vitex agnus-
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castus (Mastodynon® 30 drops per day for three months) compared to placebo (p=0.023) 
(Milewicz 1993). Another study, including women with sub fertility (n=67), showed 
improved menstrual cyclicity for a sub-group of women with oligomenorrhoea following 
treatment with Vitex agnus-castus (Phyto-Hypophyson® 7.5ml per day) compared to 
placebo, (p=0.023) (Gerhard 1998). A third study including women with 
hyperprolactinaemia (n=37) demonstrated improved menstrual cyclicity by an increased 
average number of luteal days from 3.4 days (±5.0) to 10.5 days (±4.3) (p<0.005) following 
treatment with Vitex agnus-castus (Strotan® 20 mg per day) for three months. The placebo 
group reported average number of days in the luteal phase was 3.4 (±5.1) at baseline and 
5.5 (±5.2) at three months, which was not significant (p=0.22) (Bergmann 2000). 
Methodological shortcomings for all three studies included not reporting baseline 
characteristics for subgroups and small sample sizes; however clinical outcomes 
demonstrated physiological effects consistent with laboratory and animal findings.  
Cimicifuga racemosa 
Cimicifuga racemosa was found to lower LH in two laboratory studies both examining cell 
cultures from ovariectomised rats (Duker 1991, Seidlova-Wuttke, Hesse et al. 2003). The 
mechanism occurred through competitive inhibition of oestrogen following the selective 
binding of oestrogen receptors (ERα) on the hypothalamus and pituitary (Seidlova-Wuttke, 
Hesse et al. 2003) (Table 3.1). An earlier study found contrary results for reduction of LH, 
however this study investigated an isolated flavonoid and suggested that other constituents 
may be active (Jarry, Harnischfeger et al. 1985).  
Three RCTs corroborate the positive fertility effects for Cimicifuga racemosa when added to 
and compared alone with clomiphene citrate (clomiphene) (Shahin, Ismail et al. 2008, Kamel 
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2013, Shahin and Mohammed 2014) (Table 3.2). Outcomes were reported for 441 women 
and showed improved pregnancy rates when Cimicifuga racemosa was added to 
clomiphene during one menstrual cycle. In one RCT including 147 women with PCOS, 
pregnancy rates were 43.3% for the group receiving combined therapy (clomiphene 150mg 
plus Cimicifuga racemosa 20mg per day (Klimadynon®) compared to 20.3% for women 
receiving clomiphene alone (Shahin, Ismail et al. 2008). In another study using similar 
methodology, significantly higher pregnancy rates were found for women on clomiphene 
therapy taking added Cimicifuga racemosa compared to women taking clomiphene alone, 
34.8%  and 17.2% (p<0.01) respectively (Shahin and Mohammed 2014). 
Another study included 100 women with PCOS and infertility (n=100) compared Cimicifuga 
racemosa (Klimadynon®) and clomiphene over three months for hormone concentrations 
and pregnancy rates. Pregnancy rates were higher in the women in taking Cimicifuga 
racemosa compared to clomiphene, 14% and 8% respectively; however differences were 
not statistically significant.  This study found significant effects for lowered luteinising 
hormone for women with PCOS receiving Cimicifuga racemosa compared to clomiphene  
(p=0.007) (Kamel 2013). Findings from clinical studies concur with laboratory and animal 
studies; however potential risks for bias include performance and collection bias due to lack 
of blinding (Table 3.2). 
Tribulus terrestris 
Two laboratory based RCT’s examined the effects of Tribulus Terrestris in rats with 
polycystic ovaries induced with oestradiol valerate (Esfandiari, Dehghan et al. 2011, 
Dehghan, Esfandiari et al. 2012) (Table 1). Both studies demonstrated significantly improved 
ovulation rates for animals treated with two doses of Tribulus terrestris extracts compared 
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to controls. Although the endocrinological effects were not described in either study, 
another study examined the effects of Tribulus terrestris on uterine and vaginal tissue of 
ovariectomised rats and found no direct oestrogenic effects (Martino-Andrade, Morais et al. 
2010). 
A prospective, observational clinical trial examined the endocrine effects of Tribulus 
terrestris 750mg per day, over five days in eight healthy women (aged 28-45) (Milanov, 
Maleeva et al. 1981). (Table 3.1) A significant increase in mean serum FSH concentration 
from 11mIU/ml before treatment to 17.75mIU/ml following treatment (P<0.001) was 
demonstrated. Pre-treatment FSH levels returned following cessation of treatment. 
Combined with the findings of Martino-Andrade and colleagues (2010) the endocrine effects 
of Tribulus terrestris were likely to be due to effects on the pituitary rather than the ovary 
(Martino-Andrade, Morais et al. 2010). The clinical effects of Tribulus terrestris (Tribestan®) 
and pharmaceuticals were compared for ovulation induction in 148 women with 
oligo/anovular infertility, (Tabakova P 1984). Following three months treatment, ovulation 
rates were highest with epimestrol (74%), followed by Tribulus terrestris (60%), clomiphene 
(47%) and cyclofenil (24%).  
The evidence for Tribulus terrestris should however be interpreted with caution due to risks 
for bias in clinical studies. One study was uncontrolled with a small number of healthy 
participants (Milanov, Maleeva et al. 1981), the second study did not report baseline 
characteristics, methods for allocation to treatment groups and data were not statistically 
analysed, remains unpublished and unsubjected to peer review and may be at risk of 
reporting bias (Tabakova P 1984) (Table 3.1). 
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Glycyrrhiza spp. 
Androgen lowering effects for Glycyrrhiza spp. have been demonstrated in one laboratory 
study examining hormone concentration in female rats (Glycyrrhiza uralensis), (Takeuchi 
1989) and corroborated in two clinical trials, one including healthy women (Armanini, 
Mattarello et al. 2004) and the other including women with PCOS (Glycyrrhiza glabra) 
(Armanini, Castello et al. 2007) (Table 3.1). 
The animal study reported significantly reduced free and total testosterone and increased 
oestradiol in sterilised rats and no hormonal changes in oophorectomised rats. The authors 
conclude that the hormonal effects occurred primarily on the ovary via enhanced 
aromatisation of testosterone to 17-beta oestradiol. The investigators also observed 
significantly increased oestradiol. There were no changes to FSH or LH in androgen sterilised 
or oophorectomised rats (Takeuchi 1989) (Table 3.1).  Another pre-clinical study examined 
the effects of Glycyrrhiza uralensis on the morphological features of polycystic ovaries of 
rats using immunohistochemistry (Lee, Pak et al. 2003) (Table 3.1). This study demonstrated 
significantly increased ovulation rates by the number of corpus luteum in polycystic ovaries 
compared with controls. The authors propose that the mechanism of effect for Glycyrrhiza 
uralensis was competitive inhibition of oestrogen at oestrogen receptor sites, limiting the 
production of nerve growth factor (NGF), its neurotropic effects and inhibition of 
sympathetic neurological involvement in the pathogenesis of polycystic ovaries. 
A single arm clinical trial demonstrated reduced testosterone in healthy women aged 22-26 
years (n=9) over two menstrual cycles. Treatment with Glycyrrhiza glabra, 7 grams per day, 
reduced testosterone from 27.8 (±8.2) to 17.5 (±6.4), p<0.05  (Armanini, Mattarello et al. 
2004). Another single arm clinical trial investigated the effects of Glycyrrhiza glabra in 
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women with PCOS, (n=32). Glycyrrhiza glabra 3.5g per day was added to anti-androgen 
pharmaceutical treatment, Spirinolactone 100mg/day over two menstrual cycles. An 
unwanted side effect of Spirinolactone was the flare of androgens during the initial phase of 
treatment. This study demonstrated reduced concentrations of testosterone during the first 
four days of treatment at 103 ±29ng/d  in the Spirinolactone group compared to 91 ng/d 
(±19) when combined with Glycyrrhiza glabra (p<0.05) (Armanini, Castello et al. 2007). 
Consistent laboratory and clinical outcomes were demonstrated however limitations 
included design shortcomings (Table 3.1). Both clinical studies were open label 
observational design with small sample sizes and one included healthy participants. 
Rigorous studies are needed to confirm the androgen lowering effects of Glycyrrhiza spp. in 
hyperandrogenism and PCOS.  
Results for Glycyrrhiza Spp. (and indeed any herbal ingredient) were complicated in this case 
by the variation in herbal extraction processes and subsequent variability in chemical 
profiles of the herbal ingredients. The laboratory studies of the herbal material were based 
on aqueous extracts of crude material whilst the clinical studies were based on ethanol 
extracts. Despite variability in the herbal extraction methods, both laboratory and clinical 
studies demonstrated anti-androgenic effects, suggesting the main active constituents were 
hydrophilic and dissolved in water.  
Paeonia lactiflora and Glycyrrhiza glabra 
One laboratory study (Takeuchi 1989) and two clinical investigations provided evidence for 
the two herb combination, Glycyrrhiza uralensis and Paeonia lactiflora (Yaginuma 1982, 
Takahashi and Kitao 1994) (Table 3.1). An animal study found exposure to the herbal 
combination caused reductions in total testosterone, 202 pg/ml (±7.0), and 190.0 pg/ml 
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(±7.0) and free testosterone, 10.3 pg/ml (±0.5), and 10.7 pg/ml (± 0.4) for 90 and 180mg/kg 
doses respectively (Takeuchi 1989). There were no changes to report for FSH and LH in both 
sterilised and oophorectomised rats showing that the effect was likely to have occurred in 
the ovary. There was an insignificant increase in oestradiol. Although the authors propose 
that the androgen lowering mechanism for Paeonia lactiflora was through increased 
aromatase activity shown in a later study (not included in this review) (Takeuchi, Nishii et al. 
1991) this effect was not demonstrated in the present study (Takeuchi 1989) (Table 3.1).  
The findings for combined Paeonia lactiflora and Glycyrrhiza uralensis were supported in 
two open label clinical trials including women with PCOS (n=34) (Takahashi and Kitao 1994) 
and women with hyperandrogenism, oligo/amenorrhoea and infertility (n=8) (Yaginuma 
1982) (Table 3.1). Both trials examined the effects the preparation TJ-68, (equal parts 
Paeonia lactiflora and Glycyrrhiza uralensis), 75 grams per day for 24 weeks and 5-10 grams 
per day for 2-8 weeks respectively. In the trial including women with PCOS, mean serum 
testosterone was significantly reduced from 137.1 ng/dL (± 27.6) to 85.3 ng/dL (± 38) 
(P<0.001) (Takahashi and Kitao 1994). Similar effects were observed in women with 
oligomenorrhoea and hyperandrogenism and showed serum testosterone reduced from 50-
160ng/dL prior to treatment to less than 50ng/dL (Yaginuma 1982). However statistical 
significance was not reached due to the small sample size despite positive outcomes in 
seven out of eight participants.  
Paeonia lactiflora and Cinnamomum cassia 
Paeonia lactiflora combined with Cinnamomum cassia in a preparation called Unkei-to was 
investigated in an in-vitro study for ovarian production of 17-beta-oestradiol and 
progesterone (Sun, Imai et al. 2004) (Table 1). Granulosa cells obtained from women 
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undergoing IVF were examined for steroid hormone concentration following incubation with 
different doses of over 48 hours. Oestradiol was significantly increased (p<0.01) following 
exposure to doses of 0.3ug/ml of Unkei-to. Supporting clinical evidence was found in one 
clinical trial including 157 infertile women aged 17-29 years, including a subgroup of 42 
women with hyper-functioning (PCOS) oligo/amenorrhoea. Treatment with Unkei-to, 7.5 
grams per day for eight weeks demonstrated significant reductions of mean LH 
concentration in the PCOS sub-group from 49.7 (±15.3%). Ovulation was confirmed in 30 out 
of 42 oligo/amenorrheic women (52%) (Ushiroyama 2001). Limitations however include 
findings based on sub-group comparisons without description of subgroup baseline 
characteristics (other than oligomenorrhoea). Although the same aqueous extract 
intervention was investigated in pre-clinical and clinical studies, it contained additional 
herbal extracts for which clinical effects may have been attributable.  
 Cinnamomum cassia 
An animal study compared the effectiveness of Cinnamomum cassia and the pharmaceutical 
Metformin against no treatment on hormone concentration in rats with PCOS (Heibashy, 
Mazen et al. 2013) (Table 3.1). Significant improvements (p<0.05) for both interventions 
compared to controls were observed at 15 days for measures of testosterone ng/ml 
(Cinnamomum cassia 0.625 (±0.029), metformin 0.647 (± 0.027) and controls 0.747 
(±0.039)); LH ng/ml (Cinnamomum cassia 6.891 (± 0.221), metformin 6.873 (± 0.214) and 
controls 7.641 (±0.267)) and insulin resistance (HOMA-IR) (Cinnamomum cassia 8.772 (± 
0.196), metformin 7.067 (± 0.184) and controls 10.018 ( ± 0.217)) (Heibashy, Mazen et al. 
2013). The metabolic effects of Cinnamomum cassia in PCOS were demonstrated in 
overweight women with oligo/amenorrhoea and PCOS in a placebo controlled RCT (Wang JG 
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2007) (Table 3.2). Fifteen women were allocated to one of two groups; Cinnamomum cassia 
333mg per day or placebo, for eight weeks. Significant improvements in insulin sensitivity 
were noted in the treatment group compared to controls (p<0.03). However, although the 
RCT had low risks for bias, it was a pilot study primarily investigating feasibility. Outcomes 
were promising for metabolic profile in PCOS however the sample size was small and the 
authors recommended further studies. 
3.3.3 Summary of results 
This review includes 18 preclinical laboratory based studies and 15 clinical trials. Positive 
reproductive endocrine effects in oligo/amenorrhoea, hyperandrogenism and/or PCOS were 
found for six herbal medicines. The quality of evidence, as determined by the volume of pre-
clinical studies and the methodological quality of clinical trials, was highest for the herbal 
medicines Vitex agnus-castus, Cimicifuga racemosa and Cinnamomum cassia, for which 
there were laboratory and/or animal studies demonstrating endocrine mechanisms of 
action consistent with clinical outcomes shown in RCT’s with relatively low risks for bias. 
However, replicated RCT data was only found for one herbal medicine, Cimicifuga 
racemosa.  
Evidence for Tribulus terrestris, Glycyrrhiza spp. alone and in combination with Paeonia 
lactiflora and Paeonia lactiflora with Cinnamomum cassia was limited by the small volume 
of laboratory and animal studies, with only one to two studies found for each herb or herbal 
combination. There was supporting clinical data, however many were small single arm, open 
label studies measuring endocrine effects in healthy women. Evidence for these herbal 
medicines is preliminary and in an emergent phase. 
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3.4 Discussion 
This review synthesised the evidence for mechanisms of effect for herbal medicine in 
oligo/amenorrhoea, hyperandrogenism and PCOS. Pre-clinical and clinical studies provided 
consistent preliminary evidence that six herbal medicine extracts may have beneficial 
effects in women with oligo/amenorrhea, hyperandrogenism and PCOS. The quality of the 
evidence was of variable methodological quality and strongest for Vitex agnus-castus and 
Cimicifuga racemosa in the management of oligo/amenorrhea and infertility associated with 
PCOS; and Cinnamomum cassia for improving metabolic hormones in PCOS. Evidence for 
Tribulus terrestris, Glycyrrhiza spp. alone and in combination with Paeonia lactiflora and 
Paeonia lactiflora combined with Cinnamon cassia is promising but in an emergent phase. 
Laboratory, animal and clinical studies demonstrate that the herbal medicines Vitex agnus-
castus, Cimicifuga racemosa and Tribulus terrestris initiate endocrine effects in the pituitary 
as measured by lowered prolactin and LH and raised FSH. Four herbal medicines, Tribulus 
terrestris, Glycyrrhiza spp., (alone and in combination with Paeonia lactiflora), Paeonia 
lactiflora (in combination with Cinnamomum cassia) and Cinnamomum cassia demonstrated 
morphological changes in polycystic ovaries and steroidogenesis, including reduced ovarian 
volume and cysts, lowered androgens, improved insulin sensitivity and increased oestradiol.  
Clinical investigations found no adverse effects for the six herbal medicines included in this 
review (Tables 1 and 2). A comparative study investigating the pharmaceutical 
Bromocriptine and the herbal medicine Vitex agnus-castus found no side effects associated 
Vitex agnus-castus compared to 12.5% of participants taking Bromocriptine reporting 
nausea and vomiting (Kilicdag, Tarim et al. 2004). No studies comparing the effectiveness for 
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herbal medicines and the oral contraceptive pill in PCOS, oligo/amenorrhoea and 
hyperandrogenism were found. 
3.4.1 Strengths and weaknesses 
Preliminary evidence for equivalent treatment effects were found for the two 
pharmaceuticals and three herbal medicines. These were Bromocriptine, in the 
management of hyperprolactinaemia compared with Vitex agnus-castus and clomiphene for 
infertility and ovulation induction compared with Cimicifuga racemosa and Tribulus 
terrestris. Herbal medicine had positive adjunct effects with the pharmaceuticals 
Spirinolactone in the management of hyperandrogenism (Glycyrrhiza Spp.), and clomiphene 
for PCOS related infertility (Cimicifuga racemosa). It is important however to highlight that 
evidence was provided by a limited number of clinical studies, some with significant risks for 
bias; particularly Tribulus terrestris, Glycyrrhiza glabra alone and in combination with 
Paeonia lactiflora and Paeonia lactiflora in combination with Cinnamomum cassia. 
Naturopathic selection of herbal medicines for the management of PCOS often includes the 
combined prescription of Glycyrrhiza spp. and Paeonia lactiflora (Sarris and Wardle 2010, 
Trickey 2011). We found preliminary evidence for this combination for hyperandrogenism 
only, and the evidence was more robust for Glycyrrhiza spp. alone than when combined 
with Paeonia lactiflora. Comparatively, our findings for the combination of Paeonia lactiflora 
and Cinnamomum cassia demonstrated no change in androgen concentration, suggesting 
that the anti-androgen activity in the Glycyrrhiza spp. and Paeonia lactiflora combination 
more likely attributable to Glycyrrhiza spp. Findings may have been complicated by the 
aqueous extraction methods used in the Paeonia lactiflora and Cinnamomum cassia 
combination and the preclinical studies into the Glycyrrhiza spp and Paeonia lactiflora 
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combination and more is needed to examine the androgen lowering mechanisms of each 
herb and for the combinations. 
This review has some limitations. We used a methodological approach which was not 
consistent with traditional rationale for herbal selection. Our inclusion criteria for clinical 
studies were specific and relied upon our identification of herbal medicines with preclinical 
(laboratory based) evidence explaining the mechanisms of reproductive endocrinological 
effects in oligo/amenorrhoea, hyperandrogenism and PCOS. Clinical studies were excluded 
from this review due to the absence of evidence for whole herbal extracts. This was the case 
for Camellia sinensis (green tea) for which only one laboratory study investigated the effects 
of injecting epigallocatechin, a catechin found in green tea in animals (Kao, Hiipakka et al. 
2000). High quality clinical evidence for Camellia sinensis was not presented in this review 
due to the absence of pre-clinical data explaining the mechanism for effect for the whole 
herbal extract (Chan, Koo et al. 2006) (Appendix 5). Mentha spicata (spearmint) was another 
herbal medicine excluded from this review despite the availability of high quality clinical 
evidence demonstrating testosterone lowering effects in women with PCOS (Grant 2010). 
We found no laboratory evidence describing the mechanism of action for Mentha spicata in 
hyperandrogenism. Camilla sinensis and Mentha spicata are examples of herbal medicines 
excluded from this review due to not meeting the inclusion criteria.  The search strategy 
may have restricted access to studies due to limited search terms. We didn’t include 
alternative spelling of oestrogen and additional search terms for herbal medicine could have 
been included to increase sensitivity of the search.  
This study synthesised the evidence for reproductive endocrine effects for six herbal 
medicine extracts that may be used to inform evidence based treatment decisions for 
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herbal medicines to improve PCOS and associated oligo/amenorrhoea and 
hyperandrogenism. The findings add to the understanding for the mechanisms of action for 
herbal medicine for treatment of these common conditions.  
3.4.2 Rationale for the herbal formulae investigated in the randomised 
controlled trial 
Findings from this study informed the intervention in a RCT detailed in Chapter five. Four 
herbal medicines from this review were included in a new herbal treatment for 
investigation. These were Tribulus terrestris, Glycyrrhiza glabra, Paeonia lactiflora, and 
Cinnamomum cassia. Methods, results and discussion of the RCT are presented in detail in 
Chapter five. The next chapter, number four, presents methods, results and discussion from 
the survey of 493 women with PCOS and their use and attitudes towards complementary 
medicine and self-help measures. 
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Chapter 4:  A survey of the use of complementary medicine and self-help measures by women with polycystic ovary syndrome 
  
4.1 Introduction  
This chapter describes the design, results and discussion from a survey of women with 
polycystic ovary syndrome. The aim of this study is to describe the prevalence and patterns 
of use for self-care with a focus on the lifestyle interventions diet and exercise and to 
examine the use complementary medicine for the management of polycystic ovary 
syndrome (PCOS) by women with PCOS. Women’s opinions were sought in relation to their 
symptoms of concern and their views about effectiveness for dietary intervention, patterns 
of exercise practice and complementary medicines. Adverse reactions arising from 
complementary medicine use were also explored.   
The specific research questions studied wee:  
1. What is the current interest and prevalence of use for dietary and exercise 
interventions and for complementary medicines (CM) for the management of PCOS 
by women with PCOS?  
2. What are the patterns of use relating to diet, exercise and complementary 
medicines? 
3. What are women’s attitudes towards the use of diet and exercise interventions and 
complementary medicines including perceptions for effectiveness and adverse 
reactions for complementary medicines? 
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This section on use of complementary medicine of this chapter was published by the BioMed Central 
Journal of Alternative and Complementary medicine in December 2014 (Appendix 6). 
4.2 Methods  
4.2.1 Ethics approval 
The research protocol was approved by the University of Western Sydney, Human Research 
Ethics Committee (EC00314) in November 2011 (reference H9314) (Appendix 7). 
4.2.2 Overview of study design and participants 
An anonymous survey using a web based, self-complete questionnaire was used to explore 
the research questions with a population of women with PCOS.  Contact was made with two 
consumer groups of women with PCOS seeking health support as members of social 
networks. The first group self-selected following direct email to the members of a consumer 
support group, the Polycystic Ovary Syndrome Association of Australian (POSAA). The 
second sample self-selected by following a link to the survey posted on the web based social 
network site, Facebook and the University Research for PCOS Facebook group, 
www.uws.edu.au/pcosfacebook.  
Survey design 
The rationale for using a web based survey was based upon the following considerations. 
1)  It was anticipated that an electronic survey, administered via consumer support 
groups would be acceptable to women with PCOS due to their possible preference 
for anonymity (Sills, Perloe et al. 2001, Kral, Malekinejad et al. 2010). 
2) Previous research into the prevalence of internet usage by women with PCOS has 
demonstrated that they value peer support (Percy, Gibbs et al. 2009). They also 
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frequently seek on-line education about PCOS, and seek out acceptance and peer to 
peer support through virtual communities (Barnard, Ferriday et al. 2007, Castillo 
2008). 
Electronic web based surveys have several advantages and disadvantages over published 
and mailed surveys. There are significant efficiencies from use of electronic surveys 
including reduced financial costs (Watt 1999), increased speed of delivery and response, 
greater geographic reach, and minimised interviewer error (Sills and Song 2002). In addition, 
data are collected and collated systematically, in electronic format and subsequently 
analyses can proceed over shorter time frames with less manual data entry (Yun and 
Trumbo 2000). Electronic surveys are relatively environmentally friendly without the burden 
of using paper based stationary. Fewer personnel are also required to manually collect data 
(Cobanoglu, Warde et al. 2001). Importantly it has also been suggested that the quality of 
data may be improved with electronic surveys due to the anonymity of respondents and 
improved self-disclosure, and increased unsolicited contributions (Walsh, Kiesler et al. 1992, 
Smith, Smith et al. 2007). Completion rates have also been demonstrated to be higher for 
electronic surveys at 97.1% compared to completion rates for paper surveys of 81.8% 
(Denscombe 2006). 
Although an electronic survey was considered the most appropriate method to reach the 
study population based on the advantages described above, there are disadvantages 
associated with this method. These include the presence of hidden costs that are difficult to 
estimate (Yun and Trumbo 2000) and information technological support required by people 
with specialist knowledge (Umbach 2004). To overcome this disadvantage, technological 
support was provided by the web based survey company Survey Monkey, and information 
technology experts at the University of Western Sydney.   
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Survey samples derived from the web may also be at risk of diminished reliability due to 
uneven access to the internet and socio-demographic strata (McLaren and Zappala 2002, 
Willis and Tranter 2002). Results generated from electronic surveys are more prone to 
measurement errors due to computer equipment and sampling errors (Umbach 2004). 
Disparities in internet usage across socio-demographic groups include education, income, 
literacy (McLaren and Zappala 2002) and age (Willis and Tranter 2006) may limit the 
generalisability of findings from electronic surveys.  
4.2.3 The research instrument 
A 37 item questionnaire was designed specifically for this study. The questionnaire 
examined women‘s use of CM and self-help measures including dietary and exercise 
practices, rate and patterns of use for complementary medicine, sources of information, 
perceptions of effectiveness and safety and demographic features (Appendix 8).  
The survey consisted of six sections; cover letter, introduction, use of CM, diet, exercise and 
demographics with an inbuilt ability to skip sections if relevant. A ‘protest’ question was 
included to enable participants to report their non-use of CM, diet and/or exercise and to 
limit bias arising from item non-response. Other than the cover letter and introduction, each 
section consisted of closed questions with pull down menus, and check boxes with open 
questions at the conclusion of the use of CM, diet and exercise. Multiple response options 
were available for participants to indicate which signs and symptoms of PCOS they were 
experiencing, the types of self-help practices and complementary medicines used and any 
adverse reactions experienced. Single response options were available for questions relating 
to demographics, and questions on the topic of the frequency and duration and perceptions 
of self-help/CM effectiveness. A cover letter in the form of a participant information sheet 
 116 
 
(appendix 9) was attached to the questionnaire.  
Content of questionnaire (Appendix 8) 
1. Self- perceptions of general health and PCOS 
Items inquired about women’s general health and experience of PCOS including which signs 
and symptoms they experienced and how they managed PCOS. A five point Likert scale 
enabled single responses to report on frequency, this ranged from ‘always,’ ‘most of the 
time’, ‘some of the time’, ‘a little of the time’, ‘hardly any of the time’ to ‘not at all’.  
2. Complementary medicine 
The complementary medicine (CM) section asked questions about CM use, with CM 
classified as the use of ingestible CM (tablets, liquids or drinks) and consultations with 
complementary practitioners. Items enquired about motivations for use, sources of 
information, attitudes towards effectiveness and adverse reactions.  An eight point Likert 
scale was used to assess the frequency of use for ingestible CMs. Options included ‘daily’, ‘4-
6 times per week’, ‘1-3 times per week’, ‘fortnightly’, ‘monthly’, ‘as needed during the past 
twelve months’ and ‘none’. A three point Likert scale enabled women to report the severity 
of adverse reactions. Options included ‘temporary and continued to use CAM’, ‘temporary 
side effects that resolved when CAM was ceased’ and ‘unwanted side-effects continued 
after stopping the use of CAM’. Other questions enabled a yes or no response to a list of 
options with multiple answers permitted and an open option at the end. For example, ‘for 
what area of your health have you used or currently use complementary medicines?’ The 
checklist included ‘PCOS; increase energy; period pain; fertility; sleep; digestion; 
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constipation; acne; cold and flu prevention; stay healthy; depression; anxiety; general well-
being’ and an open question at the end requesting ‘other, please specify’. 
3. Dietary management 
Questions enquired about respondents’ dietary practices, aims and perceptions of 
effectiveness. Yes or no responses were provided for whether or not participants used diet 
to manage PCOS, types of diets tried and for perceptions of effectiveness for managing 
features of PCOS. A four point Likert scale was used to assess women’s views with achieving 
their health goals using diet with the option of ‘yes’, ‘partly’, ‘no’ and ‘don’t know’.  
4. Physical activity and exercise 
Questions related to types of exercise, intensity, frequency, duration, barriers and 
motivators and perceptions of effectiveness for exercise as part of self-care and symptom 
management. Participants were asked to respond to lists indicating the types of exercise 
practices, reasons for exercise and no exercise. If women exercised the frequency of 
vigorous and moderate exercise was indicated along a seven point Likert scale ranging from 
‘more than once per day’, ‘everyday’, 5-6 times per week’, ‘2-4 times per week’, ‘weekly’ 
‘once or twice per month’ and ‘I don’t do this type of exercise’. Moderate exercise was 
defined as physical activity which slightly increased heart and breathing rate with the 
individual still able to engage in conversation. Vigorous activity was defined as a noticeable 
increase in heart and breathing rate (puffing) and unable to engage in conversation. The 
duration of moderate and vigorous exercise were recorded on five point Likert scale ranging 
from ; ‘I don’t do physical activity’, ‘up to 15 minutes’, ‘up to 30 minutes’ ‘about one hour’ 
and ‘more than one hour’.   
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5. Participant characteristics 
The final section of the questionnaire included questions relating to demographics, including 
age, education, employment, private health insurance and country of birth.  
Questionnaire design features 
The design of the questionnaire took into consideration aspects of design to optimise the 
response rate and completion.  An introduction detailed the purpose of the research, 
revealing neutral affiliations (university based research group), describing the response 
burden in the introductory statement and ensuring the length of the questionnaire was not 
too long.  More generally the content of the questionnaire was developed according to 
salience or the importance and timeliness of topics of interest to women with PCOS, i.e. 
diet, exercise and CM (Cook, Heath et al. 2000, Sheehan 2001). The topic of complementary 
medicine was considered important due to increasing use by women in general, symptoms 
associated with PCOS were considered relevant due to high prevalence of reproductive and 
metabolic abnormality in self-selected groups of women with PCOS and treatment need 
(Legro, Urbanek et al. 2002) and due to the corresponding frustration women with PCOS 
have expressed in relation to the medical management of PCOS (Sills, Perloe et al. 2001). 
Completion of the survey required approximately 10-20 minutes. 
4.2.4 Pilot study 
The questionnaire was tested on a pilot sample of eight women with and without PCOS to 
review the applicability of study using the proposed procedures and protocol, and to 
identify and eliminate potential problems (Polgar 2008). Four women were recruited from 
the university. Additional pilot data were collected from four women with PCOS to assess 
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whether or not the items interested women with PCOS and to review whether data 
gathered represented the values of variables. The stability (internal consistency and 
correlation of items) was tested by overviewing responses and interviewing respondents 
and by manually checking accuracy between verbal and questionnaire responses. 
Grammatical and organisation features were made to the questionnaire based on findings 
from the pilot study. Two terms of language were changed to improve clarity; ‘irregular 
menstruation’ to ‘a late menstrual period’ and brackets placed after the term ‘improve body 
composition’ containing ‘example to build muscle.’ Another skip pattern was inserted 
between question 16 and question 20 to reduce response burden and to improve the 
accuracy of the item ‘the aim of altering dietary practices’.  
4.2.5 Participants 
The sample included members of community support groups for women with self-reported 
PCOS. There were no exclusion criteria for participation however women without access to 
the internet were excluded by default due to this being an internet based electronic survey. 
Non-members of Polycystic Ovary Syndrome Australian Alliance (POSAA) and Facebook 
were also excluded due to the availability of the survey on these two sites.  
Selection of participants  
Two recruitment strategies were employed for this study, targeted (Watters and Biernacki 
1989) and snowballing (Barnard, Ferriday et al. 2007, Bhutta 2012). Targeted recruitment 
was used to gain access to women with PCOS through the consumer support group POSAA. 
Targeted methodology aims to select samples that are relatively homogenous and consist 
primarily of subjects with characteristics that match the population characteristics. It was 
presumed that most members of POSAA had previously been medically diagnosed with 
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PCOS due to the financial commitment required for membership; however there was no 
way of confirming the diagnosis of PCOS of members due to privacy laws.   
Targeted selection has been used for recruiting populations that are difficult to reach (Kral, 
Malekinejad et al. 2010). The financial membership of POSAA includes women with PCOS 
seeking social support, information about research into PCOS and management of PCOS. 
Members of POSAA were specifically targeted due to their health condition and health 
consumer status which correlated with the investigated subject and goals of the study.  
The second sampling method employed a snowball technique using the social network site 
(SNS), Facebook. Referrals through Facebook groups were used to access women with PCOS 
who may not be accessible through POSAA. Snowball sampling is a chain referral method 
that provides access to hidden populations that are difficult to sample (Faugier and Sargeant 
1997, Heckathorn 2002, Penrod, Preston et al. 2003). A Facebook Group page provided a 
platform to legitimise and humanise the study, two factors shown to increase survey 
response rates, (Kittleson 2002, Dillman 2011) retention and response quality (Sánchez-
Fernández, Muñoz-Leiva et al. 2012). Affiliation with the university was used to describe the 
non-commercial interests of the research. This was achieved through the title of the 
Facebook group, the provision of the researcher’s university email address and reference to 
members of the researcher’s dissertation committee. Scholarly articles regarding PCOS were 
posted on the Facebook group page, and the researcher provided answers to anticipated 
questions and responded to additional questions. All posts included a photo of the 
researcher putting a human face on the project.  
Facebook was electronically searched for PCOS support groups that consisted of members 
of women seeking support and information about PCOS (Bhutta 2012). The administrators 
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of the following groups; Newcastle, Central Coast and Sydney PCOS Cysters (121 members); 
PCOS TTC (333 members); and PCOS Talk (2011 members) were contacted by email 
between February and May 2013. The researcher requested a link to the University 
Research Facebook Group be posted on their own group pages enabling members to access 
the University group page where they could become members and respond to the survey if 
they wished.  Referral posts to the survey on the Members of the University Research Group 
page occurred bimonthly between February 2013 and May 2013.  
The sampling approach used in this survey may have some disadvantages.  Limitations for 
self-selected samples include response representativeness and the risk for non-response 
bias (Cook, Heath et al. 2000, Yun and Trumbo 2000, Umbach 2004, Fan and Yan 2010). 
Convenient, self-selected samples may consist of a sub-set of heterogeneous respondents, 
selected to represent the population but different from the population, which limits the 
generalisability for findings for the study. This approach may lead to an over-representation 
of women self-selecting to participate in the survey. For example they could have more or 
less severe symptoms of PCOS. In the present case, methodological strategies to improve 
generalisability focussed on improving response rates (Cook, Heath et al. 2000, Sheehan 
2001, Sills and Song 2002, Fan and Yan 2010), using two  sources   for recruitment (POSAA 
and Facebook) (Yun and Trumbo 2000), and attempting to ensure that all members of 
POSAA were surveyed. 
Non-response bias was assessed using the continuum of resistance model.  (Boshuizen, Viet 
et al. 2006). The continuum of resistance is based on the theory that the more resistant a 
person is to participate in a survey, the more they resemble people who do not respond; 
late responders are viewed by proxy as non-responders due to similar characteristics. This 
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method of assessment was chosen due to the subject of investigation; the use of CM by 
women with PCOS, and due to the higher likelihood for early response by women who 
found the topics salient or interesting (Porter and Whitcomb 2005). The non-response to 
the survey by non-users highlights a risk for an overestimation for the use of diet, exercise 
and CAM by women with PCOS (Etter and Perneger 1997).  
Responses to the survey after the 12th of June 2013 and before the 25th of February 2014 
were classified as late. Late responders were compared for difference with early responders 
to assess the impact of non-response bias. Variables included age, symptoms associated 
with PCOS, prevalence for the use of diet, exercise and CM.  
To assess the potential for selection bias, the two samples (of POSAA and Facebook) were 
compared for similarities and differences.  This enabled evaluation of selection bias for each 
questionnaire and the assessment of generalisability of the study. 
4.2.6 Survey administration 
Two surveys, identical in content, were collected by Survey Monkey (Finley 2013). Survey 
Monkey is a web survey development, cloud based company founded in 1999 by Ryan 
Finley. Survey templates were provided for individual development, accessed through the 
unique uniform resource locator (URL) using Listserv software, which supports functions 
which makes returning the survey anonymous. Data was secured by password access for 
administrators and using several trust seal (antiviral and anti-spyware) applications 
including Norton, TRUSTe, McAfee and Better Business Bureau 
(https://www.surveymonkey.com/ 2013). Repeat responses were prevented by a tool on 
Survey Monkey which logs the Internet Protocol (IP) address of each respondent’s computer 
on which the survey was taken, and limits responses to one per computer. 
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The consumer group the Polycystic Ovary Syndrome Australian Alliance (POSAA) was 
approached by the researcher. POSAA is a land based organisation consisting of a volunteer 
group of Australian women with PCOS whose purpose is to offer support and provide 
information informed by experts (AAPCOS 2011), promote understanding and encourage 
research into PCOS. Permission to recruit study participants was provided by the 
association’s president, Veryan McAllister (president@posaa.asn.au) in November 2011. It 
was estimated that 100% of financial members possessed a viable email contact address. In 
November 2011, the association’s administrator sent an email to all members of POSAA 
containing a letter of invitation and an electronic link to the survey as an attachment. 
Respondents selected the link to commence the electronic survey. Two reminders were sent 
out in November 2012 and March 2013. 
A Facebook group was created by the researcher with the help of the information 
technology administrator at the University, and this was loaded onto the internet in January 
2012. Facebook is a horizontally organised electronic social network with a daily active user 
(DAU) rate of 665 million people, (Facebook 2013). Over 86% of 15 to 24 year old 
Australians reported the use of social network sites in 2010-2011 (ABS 2011). Facebook 
groups are virtual communities of choice, linking people with shared interests, attributes or 
causes.  Groups may be open (anyone can join and invite anyone else to join), closed (an 
administrator approves requests of non-members who desire to join the group) or secret 
(invitation only). The University Research PCOS Facebook group was designed for women 
with PCOS to learn more about the study and other research and to obtain research findings 
as they became available. An invitation to participate in the survey and a link to the survey 
was placed on the ‘wall’ of the Facebook group page. Wall postings occurred bi-monthly 
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between February 2012 and May 2013. It was estimated that a response rate of at least 70% 
from the financial membership of POSAA would diminish, but not eliminate non-response 
bias (Sheehan 2001). 
4.2.7 Sample size  
In November 2011 POSAA consisted of 258 members. A sample size derived from POSSA of 
at least 70% (186 respondents) was an estimate considered reasonable to achieve a 
sampling error rate less than five percent (Fowler 2013).  
It was difficult to calculate an appropriate response rate for a survey through Facebook 
groups due to the difficulty in defining the target population of all women with PCOS as 
members of Facebook. Although the membership number of each Facebook group is 
detailed on the groups’ page, there was no indication of the active status of members 
(Bhutta 2012). Inactive members did not receive wall postings or the invitation to 
participate in the research.  
4.2.8 Data analyses 
Responses were electronically downloaded onto the software program Excel and 
transferred to the statistical package, SPSS version 21.0 (IBM 2013) for analyses. All data 
were described and summarised. All variables were coded with independent categorical 
variables coded as contrasting variables. Categorical responses were reported as numbers, 
percentages and proportions with 95% confidence intervals. Relationships between 
variables were explored using Pearson’s correlation (two tail) for parametric data (age, signs 
and symptoms, frequency and duration of exercise and use of CM) and Spearman’s Rho 
correlations or Gamma co-efficient (collapsed less than six variables) for non-parametric 
measurements (demographic data, types of diets and exercise, type of CAM practitioner).  A 
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value of less than or equal to 0.05 was considered statistically significant. Binomial logistic 
regression was used to predict whether or not women’s perceptions of effectiveness for 
complementary medicine were associated with reasons for use.  
4.3 Results  
4.3.1 Response rate 
Four hundred and ninety three (493) women with PCOS responded to the survey. A 
response was received from 235 of 258 invited members of the consumer support group 
POSAA (response rate of 91.1%). One hundred and eighty two women responded prior to 
the 12th of June 2013 and the response rate excluding late responders (based on the 
continuum of resistance model), was of 70.5%.  Non-responders (n=23) included a small 
number of ‘friends of POSAA’ (n=9) whose primary role was to provide expert advice to the 
association. Other non-responders (n=14) may have included women who had not provided 
email contact details to POSAA or did not have access to the internet during the time of the 
survey. The valid response rate following the removal of the ‘friends of POSAA’ was 94.4% 
(235 responses from 249 valid members). 
An additional 311 women participated in the survey in response to snowballing using the 
University Research Facebook group page. Four hundred and thirty four (87.9%) subjects 
completed all parts of the survey, 262 (84.7%) from Facebook, 171 (93.5%) from POSAA with 
the remainder taking advantage of the skip patterns inserted into the electronic survey or 
completing only part of the survey.  
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4.3.2 Demographics: description of respondents 
The demographics of participants are presented in Table 4.1. The age of participants  ranged 
from  less than 17 years to greater  than  45 years, with the majority aged between 25 and 
34 years (237, 48.1%, ± 4.41, 95%CI). Most participants were born in Australia 302, (61.3% ± 
4.3, 95% CI), with nearly one quarter (121, 24.5% ± 2.08 95% CI) born overseas including 43 
born in the United States (8.7% ± 2.49, 95% CI), 23 born in the United Kingdom and Ireland, 
(4.7% ± 1.87, 95% CI) and 15 born in New Zealand (3.0% ± 1.51, 95% CI).  The majority of 
respondents had completed high school education (371, 87.5%, ± 3.15, 95% CI). Over 
seventy five percent (323, 76.2%, ± 4.05, 95% CI) had attained tertiary qualifications with 
221 respondents (44.8%, ± 4.39, 95% CI) holding a University degree. Most respondents 
were employed, with 194 (39.4% ± 4.31, 95% CI) in full-time employment, 103, (20.9%, ± 
3.59, 95% CI) in part-time employment and 38 (7.7%, ± 2.35 95% CI) self-employed. Sixty 
five percent (275, ± 4.55, 95% CI) of respondents had private health insurance. 
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Table 4.1. Demographic characteristics of survey participants.  
 Frequency 
N=493 
Valid %  95% CI 
Age    
17 or less 3 0.7 ± 0.79 
18-24 72 17.0 ± 3.58 
25-29 126 29.7 ± 4.35 
30-34 111 26.2 ± 4.19 
35-40 71 16.7 ± 3.55 
41-44 25 5.9 ± 2.24 
45+ 16 3.8 ± 1.82 
    
Education    
Complete high School     
Yes 371 87.5 ± 3.15 
No 48 11.3 ± 3.01 
Currently enrolled 5 1.2 ± 1.04 
    
Completed tertiary education    
Yes 323 76.2 ± 4.05 
No 55 13.0 ± 3.0 
Currently enrolled at a tertiary inst. 46 10.8 ± 2.95 
Total 493   
    
Qualification from TAFE 103 20.9 ± 3.59 
Private institution Diploma  70 14.2 ± 3.08 
University degree 221 44.8 ± 4.39 
    
Ethnicity- country of birth    
Australia 302 61.3 ± 4.3 
Other 121 24.5 ± 2.08 
    
Employment    
Home duties 117 23.7 ± 3.75 
Self-employed 38 7.7 ± 2.35 
Student 80 16.2 ± 3.25 
Employed part time 103 20.9 ± 3.59 
Employed full-time 194 39.4 ± 4.31 
Other 12  ± 1.35 
    
Private Health Insurance    
Yes 275 65 ± 4.55 
No 148 35 ± 4.55 
    
Footnote: 14% of data was missing 
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Study participants’ polycystic ovary syndrome signs and symptoms 
Multiple symptoms of PCOS were reported by women, symptoms frequently experienced  
were reported as all or most of the time (Table 4.2)  Over 75% of participant’s reported 
being over-weight, (357, 77.3% (±3.82, 95% CI). Over two thirds had a late menstrual period 
(304, 67.1%, ± 4.33, 95% CI) and hirsutism (327, 68.8%, ± 4.17, 95% CI). Over half reported 
infertility (248, 60.2%, ± 4.73, 95% CI) and insulin imbalances (251, 55.7% ± 4.58, 95% CI) 
and nearly half reported feeling depressed as a result of having PCOS (200, 44% ± 4.56, 95% 
CI). 
Table 4.2. Participant’s characteristics of PCOS 
 ‘All or most of the time’ 
N=493  
Valid % 95% CI 
Late menstrual period 303 69% ± 4.31 
Acne  238 51% ± 4.52 
Depression  199 45% ± 4.64 
Hirsutism  325 66% ± 4.20 
Overweight 355 78% ± 4.46 
Very overweight  221 51% ± 4.61 
Insulin imbalance   249 56% ± 4.63 
Infertility 264 53% ± 4.49 
Footnote: 11.4% of data were missing 
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The data were explored to identify any relationships between individual PCOS symptoms. 
Correlation (Pearson’s rho) of signs and symptoms are presented in Table 4.3. In this sample 
there was a strong positive association between women with a late menstrual period 
(oligo/amenorrhea) and those reporting insulin imbalance (p<0.001), being very overweight 
(p< 0.001) and infertility (p<0.001). There was a statistically significant association with 
women reporting oligo/amenorrhoea and hirsutism (p = 0.008) and overweight (p = 0.023). 
Data from women reporting hirsutism were strongly associated with depression (P<0.001), 
large hip to waist ratio (p<0.001) and overweight (p<0.001). The significant association of 
particular signs and symptoms of PCOS aligns with the concept of four phenotypes or 
presentations of women with PCOS.  
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Table 4.3. Associations between signs and symptoms 
  Oligo/amen Hirsute O’weight V. o’weight Insulin ↑ H:W Depressed Infertility 
Oligo/ 
amenorrhoea 
Pearsons r. 
Sig. (2-tailed) 
N 
1 
 
451 
.125** 
.008 
444 
.107* 
.023 
450 
.286** 
.000 
437 
.452** 
.000 
444 
.273** 
.000 
440 
.079 
.097 
443 
.450** 
.000 
419 
Hirsutism Pearsons r. 
Sig. (2-tailed) 
N 
.125** 
.008 
444 
1 
 
465 
.192** 
.000 
461 
.081 
.090 
442 
.069 
.146 
452 
.301** 
.000 
448 
.241** 
.000 
453 
.082 
.092 
426 
Overweight Pearsons r. 
Sig. (2-tailed) 
N 
.107* 
.023 
450 
.192** 
.000 
461 
1 
 
475 
.264** 
.000 
448 
.210** 
.000 
460 
.222** 
.000 
455 
-.013 
.781 
458 
.225** 
.000 
433 
Very 
overweight 
Pearsons r. 
Sig. (2-tailed) 
N 
.286** 
.000 
422 
.081 
.090 
442 
.264** 
.000 
448 
1 
 
450 
.441** 
.000 
442 
.228** 
.000 
440 
.019 
.690 
443 
.408** 
.000 
422 
Insulin Pearsons r. 
Sig. (2-tailed) 
N 
.452** 
.000 
444 
.069 
.146 
452 
.210** 
.000 
460 
.441** 
.000 
442 
1 
 
462 
.225** 
.000 
448 
.112* 
.018 
449 
.691** 
.000 
426 
 Hip 
circumference 
larger than 
waist 
circumference 
(↑ H:W) 
Pearsons r. 
Sig. (2-tailed) 
N 
.273** 
.000 
440 
.301** 
.000 
448 
.222** 
.000 
455 
.228** 
.000 
440 
.225** 
.000 
448 
1 
 
455 
.185** 
.000 
448 
.260** 
.000 
426 
Depression Pearsons r. 
Sig. (2-tailed) 
N 
.079 
.097 
443 
.241** 
.000 
453 
-.013 
.781 
458 
.019 
.690 
443 
.112* 
.018 
449 
.185** 
.000 
448 
1 
 
460 
.075 
.122 
427 
Infertility Pearsons r. 
Sig. (2-tailed) 
N 
.450** 
.000 
419 
.082 
.092 
426 
.225** 
.000 
433 
.408** 
.000 
422 
.691** 
.000 
426 
.260** 
.000 
426 
.075 
.122 
427 
1 
 
433 
**Correlation was significant at the 0.01 level (2-tailed) 
* Correlation was significant at the 0.05 level (2-tailed) 
Abbreviations: 
oligo; oligomenorrhoea 
O’weight; overweight 
V. O’weight; very overweight 
↑ H:W; increased hip circumference to waist circumference 
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Participants use of conventional medical therapies 
The respondents used various medical therapies to manage PCOS (Table 4.4). Over 65% (± 
4.21, 95% CI) had used the oral contraceptive pill, 62.7% (± 4.26, 95% CI) had used other 
pharmaceuticals including ovulation induction, hypoglycaemic and anti-androgen drugs. 
Medications used to stimulate the ovaries for in vitro fertilisation (IVF) were reported by 
11.8% (± 2.87, 95% CI) of respondents.  
Table 4.4. Medical interventions used by participants to manage PCOS. 
 Frequency 
(n=493) 
Valid %  
Oral contraceptive pill 322 65.3% 
Pharmaceuticals ovulation induction, anti-
androgens, hypoglycaemics, etc 
309 62.7% 
Ovarian stimulation as part of an IVF cycle 58 11.8% 
Surgery 49 9.9% 
No medical treatment 10 2% 
 
4.3.3 Lifestyle intervention 
Dietary practices 
Fifty seven percent (± 4.37, 95% CI) of women reported using diet specifically to manage 
symptoms associated with PCOS.  An additional eleven percent of respondents (± 2.76, 95% 
CI) reported altering their dietary intake during the previous five years for health reasons, 
(68.15 ± 4.11, 95% CI) (Table 4. 5).  
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Table 4.5. Dietary adjustment used by participants during the past five years. 
 Frequency 
(N=493) 
%  95% CI 
Yes I have adjusted my diet to manage or improve PCOS. 282 57.2 ± 4.37 
I eat a healthy diet but not specifically to manage or 
improve PCOS. 
54 11.0 ± 2.76 
I eat a healthy diet but for no particular reason. 70 14.2 ± 3.08 
No I have not adjusted my diet and I am not interested in 
diets. 
28 5.7 ± 2.05 
Footnote: 12% of data were missing  
Types of diets 
The most frequently used diet was the low glycaemic (GI) index diet (50.1%, ± 4.41 95% CI), 
followed by the low calorie diet (36.9%, ± 4.26, 95% CI), low carbohydrate diet (33.7%, ± 
4.17 95% CI) and a low fat diet (32.9%, ± 4.15 95% CI) (Table 4.6). The Lifescripts diet, which 
is recommended in the Evidence Based Guidelines for the Management of PCOS (AAPCOS 
2011), was reported by a small number of participants (23, 4.7%).  
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Table 4.6. Types of diets reported by survey participants. 
 Frequency 
(N = 493) 
%  95% CI 
Low glycaemic index (GI) 247 50.1% ± 4.41 
Low calorie 181 36.9% ± 4.26 
Low carbohydrate (CHO) 166 33.7% ± 4.17 
Low fat  162 32.9% ± 4.15 
High protein 127 25.8% ± 3.86 
Weight Watchers 124 25.2% ± 3.83 
Meal replacement 123 24.9% ± 3.82 
Protein powders 65 13.2% ± 2.99 
Very low calorie diet 58 11.8 ± 2.85 
Lite and Easy 56 11.4% ± 2.81 
CSIRO diet 54 11.0% ± 2.76 
Low allergy 50 10.1% ± 2.66 
Whole food diet 50 10.1% ± 2.66 
Lean cuisine 40 8.1% ± 2.41 
Low energy 32 6.5% ± 2.18 
Lifescripts diet 23 4.7% ± 1.87 
Others 83 16.6% ± 3.28 
Others included the liver detox, blood group diet, anti-candida, Jenny Craig, Optifast, Scarsdale, Tony 
Ferguson, mass attack, Michelle Bridges, and vegetarian diets. 
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Dietary aims 
Women were asked to indicate their reason for dieting. The majority of respondents (63.7%, 
± 4.24, 95% CI) reported modifying their diet with the aim to lose weight (Table 4.7). Other 
reasons included maintaining general health, (51.7%, ± 4.41 95% CI), to manage blood sugar 
levels (32.7%, ± 4.14 95% CI), to improve body composition (13.2%, ± 2.99 95% CI) and for 
social or religious reasons or other reasons.  
Table 4.7. Participant’s reasons for dieting. 
 Frequency 
(N=493) 
%  95% CI 
Lose weight (n=314) 314 63.7% ± 4.24 
General health (n=255) 255 51.7% ± 4.41 
Manage blood sugar balance (n=161) 161 32.7% ± 4.14 
Body composition (n=65) 65 13.2% ± 2.99 
Social or religious (n=32) 32 6.5% ± 2.18 
Other, fertility, insulin, mental health (n=26) 26 5.3% ± 1.98 
 
Perceptions of the achievement of health goals using diets 
Participants were asked whether or not they felt they had achieved their health goals using 
dietary changes. Over forty six percent (± 4.78, 95% CI, n=195) of women reported that 
dietary practices had contributed at least partly, to positive health changes. Over thirty 
three percent ( ± 4.5, 95% CI, n=140) reported they did not achieve their health goals 
relating to weight loss or positive health changes at all from dietary practices. A small 
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number of women (n=51) reported fully achieving their health goals using dietary practices 
(12.2%, ± 3.13, 95% CI).   
These data were analysed to examine associations between the five most frequently used 
diets plus the Lifescripts diet (recommended in the EBG) and achieving health goals. Two 
diets were found to be associated with women achieving their health goals. These were the 
low carbohydrate diet (p=0.001) and the high protein diet (p = 0.001). There was an 
interesting but non-significant (p = 0.076) association observed between the low GI diet and 
the achievement of health goals. There were no associations between the low calorie diet, 
the low fat diet and the Lifescripts diet and the achievement of health goals p = 0.747, 
p=0.807 and p=0.447 respectively.  
Exercise practice 
Most women, (73.1%, ± 4.2 95% CI, n=313) reported regular participation in moderate or 
vigorous exercise.  Sixty six women (13.4%) did not respond to the question. 
Types of exercise 
Women were engaged in a variety of different forms of exercise (n=305), the majority (79%, 
± 4.57, 95% CI) reported practicing two or more types. Over half of participants  (61.3%, ± 
3.13,  95% CI) were engaged in formal exercise including supervision provided by a personal 
trainer, participation in a team sport or attending a gymnasium and lifting weights, running, 
swimming, cycling or supervised classes. Over one third (37.5%, ± 4.27 95% CI) of women 
reported incidental activity as exercise. Other exercise included Pilates, dance, personal 
trainer, tennis and team sports (Table 4.8). 
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Table 4.8. Types of exercise reported by participants. 
 N=493 % 95% CI 
Incidental (busy lifestyle) 186 38% ± 4.27 
Brisk walking 162 33% ± 4.15 
Lifting weights 110 22% ± 3.67 
Running 88 18% ± 3.38 
Classes at the gym 75 15% ± 3.17 
Cycling  51 10% ± 2.68 
Swimming 49 10% ± 2.64 
Yoga practice 42 9% ± 2.46 
Dancing 40 8% ± 2.41 
Others  127 26% ± 3.86 
others included personal trainer, team sports tennis  
 
Participants’ reasons for exercise  
Most respondents reported multiple reasons for exercising, with 80% (± 4.45, 95% CI, 
n=342) using exercise to feel better in themselves, 75% (± 4.79, 95% CI, n=320) to induce 
weight loss and 60% (± 5.45, 95% CI) to prevent weight gain. Sixty percent of respondents (± 
5.45. 95% CI, n=256) were exercising specifically to manage their PCOS. Nearly all 
respondents, 94.8% (± 2.47, 95% CI, n=405), felt they would continue to exercise for the 
next twelve months (n=310).  
One hundred and fourteen participants reported not practicing any exercise (23.1%, ± 3.72 
95% CI). Reasons for not exercising included lack of time (n=109), felt embarrassed (n= 93), 
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and financial costs (n= 52). Fifty one respondents cited other reasons included feeing 
unmotivated (n=11), depressed (n=7), secondary pathology to being overweight including 
back pain and arthritis (n=12) (Figure 4.1). 
Figure 4.1. Reasons for not Exercising 
 
Intensity of exercise 
Most women reported participation in both moderate and vigorous exercise. Over 88% (± 
3.5 95% CI) of women were regularly engaged in moderate exercise, and nearly half (48.7% 
± 6.04 95% CI) in vigorous exercise. Only seven women reported not doing any moderate 
exercise at least once per month however 88 women (28.3% ± 4.67, 95% CI) were not 
engaged in any vigorous exercise at least once per month and 87 women were not engaged 
in any vigorous exercise at all.  
 
 
 
50.9% 
43.5% 
24.3% 23.8% 22.0% 
15.9% 
8.4% 7.0% 5.6% 5.1% 4.2% 2.3% 
Reasons for not exercising (n=213) 
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Frequency of exercise 
Most women who exercised participated in activities two to four times per week (n=132 
42.0% ± 5.46, 95% CI) (Table 4.9). 
Table 4.9. Participant’s reported frequency of exercise 
 Frequency 
(N=493) 
%  95% CI  
More than once per day 23 4.7% ± 1.87 
Everyday 67 13.6% ± 3.03 
5-6 times per week 56 11.4% ± 2.81 
2-4 times per week 132 26.8% ± 3.91 
Once per week 22 4.5% ± 1.83 
1-2 times per month 13 2.63% ± 1.41 
No exercise 114 23.1% ± 3.72 
Footnote: 13.4% of data were missing 
Duration of exercise sessions  
Just under 50% of women exercised moderately for 15-30 minutes per session (n= 146, 
46.1% ± 5.49, 95% CI) and just under 40% exercised vigorously for 30 – 60 minutes (n= 134, 
39.9% ± 5.44, 95% CI). 
Perceptions of the achievement of health goals using exercise  
Over half of respondents felt that they had partly achieved their health goals using exercise 
(n=166, 51.8%, ± 5.46 95% CI), and 7.8% (n=25, ± 2.93, 95% CI) felt they had achieved their 
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health goals with exercise. Nearly forty percent (39.4% ± 5.35 95% CI, n=127,) reported non 
achievement of health goals with exercise. 
Data were further examined to explore associations between the intensity, frequency and 
duration of exercise and the achievement of health goals.  A significant association was 
found between the frequency of exercise and the achievement of health goals  for women 
who moderately exercised for up to 60 minutes per session (p < 0.01), but sessions over 60 
minutes were not significantly associated with the achievement of health goals (p = 0.062). 
Vigorous exercise up to 60 minutes (p<0.01) and greater than 60 minutes per session was 
significantly associated with the achievement of health goals (p < 0.001). 
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4.3.4 Complementary medicine  
Use of CM by survey participants 
Participants were asked about their use of complementary medicine (CM). Seventy percent 
(n=304, 70.4% ± 4.3, 95% CI) of women reported using CM in the previous 12 months (Table 
4.10). Twelve percent did not answer this question.  
Table 4.10. Participant’s use of complementary medicine. 
Footnote: 12.4% of data were missing 
The most commonly used CAM products taken on a daily basis were nutritional 
supplements including vitamins, minerals and nutrients from food such as from fish (n =317, 
64.3% ± 4.23, 95% CI) (Table 4.11). Nearly half were using more than one type of CAM 
product (n= 232, 47.1%, ± 4.41, 95% CI). 
  
 Frequency 
(n=432) 
Valid %  95% CI 
Yes use of complementary medicine  304 70.4% ± 4.30 
No use of complementary medicine 128 29.6% ± 4.28 
 141 
 
Table 4.11. Types of complementary medicine taken by participants and frequency of use 
 Daily 
N=493 
Weekly 
N=493 
Monthly or 
as required 
Total use % 95% CI 
Nutritional supplements, including vitamins, 
minerals, nutrients from food such as fish oil. 
317 111 102 64.3 ± 4.23 
Herbal medicines including herbal tea tablets 
and liquids, Traditional Chinese Herbal 
Medicines and Indigenous medicine. 
138 55 98 36.7 ± 4.25 
Vitamins and/or minerals prescribed by a 
medical doctor 
62 10 37 12.8 ± 2.95 
Multiple forms of CAM products 137 70 25 47.1 ± 4.41 
Footnote: 35.7% of data were missing; 23.3% skiped CM section (no use) 12.4% did not 
respond to the question. 
 
Complementary practitioner visits 
Consultations with complementary practitioners in the previous twelve months were 
popular with nearly half of participants (n= 233, 47.3%, ± 4.41, 95% CI) (Table 4.12). CAM 
practitioners included acupuncturists, chiropractors, naturopaths, massage therapists and 
others. Women had also consulted medical doctors for acupuncture treatment or 
integrative medicine which was provided within the general medical setting (n=41, 8.3% ± 
3.13 95% CI). Over a quarter of women (n=136, 27.6% ± 3.95, 95% CI) consulted multiple 
CAM practitioners during the previous twelve months, usually an acupuncturist and 
naturopath (n=47) or an acupuncturist and chiropractor (n= 41).  
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Table 4.12. Consultations with complementary practitioners during the previous twelve 
months. 
Footnote: 39.4% of data was missing; 23.3% skiped CM section (no use), 16.1% did not 
respond. 
Reasons for using Complementary Medicine (CM) 
Many women were using CM to treat PCOS (n=199, 40.4%, ± 4.33, 95% CI) however the 
majority of participants were using CM to assist with improving more than one aspect of 
their health and wellbeing (n=277, 56.2%, ± 4.3895% CI) (Table 4.13). The most common 
reasons were to improve PCOS and improve general wellbeing (n=135, 44.4% ± 5.59 95% 
  Frequency 
N= 493 
%  95% CI 
CM practitioner use 233 47.3% ± 4.31 
Acupuncturist 88 17.8%  ± 3.38 
Chiropractor 103 20.9%  ± 3.59 
Homoeopath 34 6.9%  ± 2.24 
Kinesiologist 20 4.1%  ± 1.75 
Massage therapist  79 16.0%  ±3.24 
Medical doctor for acupuncture 14 2.8%  ± 1.46 
Medical doctor for integrative medicine 27 5.5%  ± 2.01 
Naturopath 118 23.9% ± 3.76 
Osteopath 41 8.3%  ± 2.44 
Reflexologist,  aromatherapist, iridologist 36 7.3%  ± 2.3 
No consultations with CAM practitioners 181 36.7%  ± 4.25 
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CI); to treat PCOS symptoms and infertility (n=102, 33.6%, ± 5.31, 95% CI) and treat PCOS 
and reduce depression (n=92, 30.3% ± 5.17 95% CI).  
Table 4.13 Participant’s reasons for using complementary medicine. 
 
Perceptions for the effectiveness for CM 
Many women using CM (n=304) indicated they found CM effective, and over one third of 
participants reported CM as being effective for more than one condition (n=114, 37.5% ± 
5.44, 95% CI) (Table 4.14). Conditions for which CM was perceived to be most effective 
included improved general well-being (n= 96, 31.6% ± 5.23, 95% CI), PCOS (n= 82, 27.0% 
±4.99, 95% CI), sleep (n=51, 16.8%± 4.2, 95% CI) and weight loss (n=48, 15.7% ± 4.09, 95% 
CI). Nearly one quarter (n=75, 24.7%, ± 4.85, 95% CI) felt that CM in conjunction with diet 
and exercise was effective management for PCOS and only 23 respondents (7.6%, ± 2.98, 
95% CI) felt that CM in conjunction with medical management was effective treatment for 
PCOS.  
 Frequency  N=493 % 95% CI 
PCOS 199 40.4% ± 4.33 
Infertility 102 20.7% ± 3.58 
Acne 65 13.2% ± 2.99 
Depression 91 18.5% ± 3.43 
Anxiety 79 16.0% ± 3.24 
Improve general wellbeing 134 27.2% ± 3.93 
More than one reason 227 46.0% ± 4.40 
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Table 4.14 Participant’s perceptions of CM effectiveness  
 Frequency n=304 % 95% CI 
Effective for PCOS  82 27.0% ± 5.99 
Effective for PCOS with diet and exercise 75 24.7% ± 4.85 
Effective for PCOS with medical management 23 7.6% ± 2.98 
Effective treatment for infertility 33 10.9% ± 3.5 
Effective for general wellbeing 96 31.6% ± 5.23 
Effective for sleep  51 16.8% ± 4.22 
Effective for weight loss 48 15.7% ± 4.09 
Effective for more than one aspect of health 115 37.5 ± 5.44 
Not effective  57 18.75% ± 4.39 
Footnote: 38.3% of data was missing; 23.3% skiped CM section (no use), 15% did not 
respond 
Perceptions for effectiveness of CM according to reasons for use 
The use of CM for specific health issues and perceptions of effectiveness were explored 
using Pearson’s correlation coefficient. Significant correlations were found between 
perceptions for effectiveness and using CM to treat PCOS (n=199, 40.8%, Pearson’s 
correlation coefficient (PCC) 4.64 p=0.001), infertility (n=102, 32.4%, PCC 3.84, p=0.001) and 
to improve wellbeing (n=134, 71.6%, PCC 4.04 p=0.001).  
A binomial logistic regression model was used to predict whether or not perceptions of 
effectiveness (dependent variables) were associated with reasons for use (covariates). A 
significant individual effect was found for using CM to treat PCOS and perceptions for 
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effectiveness of CM for PCOS (odds ratio (OR) 24.8, CI 11.1-55.3, p=0.0001); for using CM to 
treat infertility and perceptions of effectiveness for infertility, (OR 18.8, CI 7.9-44.8, p= 
0.0001) and for using CM to improve wellbeing and perceptions of effectiveness for 
improved wellbeing (OR 8.8, CI 5.2-14.9, p=0.0001).  
Adverse reactions and CM 
Participants were asked about any adverse reactions or negative experiences with their use 
of CM. Adverse reactions to nutritional and herbal supplements, traditional Chinese herbal 
medicine and acupuncture were reported by thirty seven participants (7.5%). Nine reactions 
were to vitamins, seven to fish oil supplements, six to Traditional Chinese Medicine 
including two to acupuncture, two to herbal teas and five to vitamin supplements 
prescribed by a medical practitioner.  
Eleven types of adverse reactions were reported, including lengthening of the menstrual 
cycle, other variation in the menstrual cycle, bowel habit changes, headaches, nausea 
and/or vomiting, skin rashes, sleep changes, increased heart-beat, increased sweating, 
anaphylaxis or other adverse reactions.  
Ten women reported variation in their menstrual cycle length, one respondent continued to 
take CM and menstrual regularity spontaneously returned.  Other types of menstrual cycle 
variation were reported by eight women, two continued to use CM with spontaneous 
resolution. Bowel changes were reported by 15 participants, four continued to use CM with 
spontaneous resolution. Headaches were reported by 16 women, five continued to use CM 
and headaches spontaneously resolved following cessation of CM.  Increased heart-beat 
was reported by ten women, one continued to use CM and heart beat spontaneously 
regulated. Nausea and vomiting was reported by six participants, one continued to use CM 
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and reported spontaneous resolution. Skin rashes were reported by four women. Sleep 
disturbances reported by nine women, two continued to use CM and sleep disturbances 
spontaneously resolved. Eight women reported increased sweating and four women had an 
anaphylactic reaction however one continued to use CM without ongoing symptoms. Most 
adverse reactions spontaneously resolved whilst continuing to use CM (n=20) or following 
the cessation of CM use (n= 55), however 15 adverse reactions reported by six women 
continued after ceasing use of CM (Table 4.15).  
Table 4.15. Adverse reactions to CM 
 Spontaneous 
resolution and 
continued use  
Spontaneous 
resolution following 
discontinued use  
Adverse reaction 
ongoing following 
discontinuation of CM 
Variation in menstrual cycle length 1 6 3 
Other variation in menstrual cycle 2 3 3 
Bowel changes 4 11 0 
Headaches 5 11 0 
Increased heart beat 1 7 2 
Nausea & vomiting 1 4 1 
Skin rashes 0 2 2 
Sleep disturbances 2 5 2 
Increased sweating 3 3 2 
Anaphylactic 1 3 0 
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Adverse reactions which were ongoing included menstrual cycle lengthening or variation 
reported by six respondents. Sleep disturbances, increased heart- beat, increased sweating 
and skin rashes were reported by two respondents. One respondent reported ongoing 
vomiting following the cessation of CM. 
Participant’s views on the advantages and disadvantages of CM 
Two hundred and fifty nine women (52.5%, ± 4.41 95% CI) indicated there were advantages 
for using CM. These included 157 (60.6% ± 5.95, 95% CI) identifying naturalness of CM, 120 
(46.3%± 6.07, 95% CI) the complementary nature of CM, 104 (40.2%, ± 5.97, 95% CI) the low 
risk of side effects, 81 (31.3%, ± 5.65, 95% CI) self-responsibility and 75 (29%, ± 5.52 95% CI) 
reported the holistic nature of CM. 
Disadvantages associated with CM were cited by 354 women (71.8%, ± 3.97 95% CI). These 
included CM being too expensive (n=187, 52.8%± 5.2, 95% CI), lack of research into CM 
(n=175, 49.4% ± 5.21 95% CI) and 163 women (46.0% ± 5.19, 95%CI) were not confident 
about the effectiveness of CM. Only 13.6% (± 3.57, 95% CI) felt that the inability to combine 
CM with pharmaceuticals was a disadvantage. Women’s open answer responses included 
the perception of ‘product driven’ advice and the difficulty in finding a reputable CM 
practitioner.  
Sources of information about CM 
Women were asked about where they obtained their information about CM. Information 
was sought from multiple sources.  Twenty two percent (± 4.12 95% CI) of respondents 
obtained information about CM through self-prescribing and/or from a CM practitioner, 
19% (± 3.9, 95% CI) from family and friends, 15% (± 3.55, 95% CI) from the internet and 11% 
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(± 3.11, 95% CI) from a medical practitioner. Other sources of information included 
magazines 5%, allied health providers, 3%, retail assistants 2% and television 1%.  
4.3.5 Assessment of non-response bias 
Non-response bias was assessed by comparing the characteristics of the early survey 
respondents with the late respondents using a continuum of resistance model. Early 
responders participated in the research between 15th November 2011 and 12th of June 
2013. Late responders participated in the research from the 20th June 2013 until the 25th of 
February 2014. Late responses were received from an additional 53 women. 
Non response bias could not be assessed for the Facebook group. Non-response bias for the 
POSAA group was assessed using a continuum of resistance model. Comparison between 
the early survey responses and the late responses demonstrated that the late responders 
displayed similar characteristics to early responders (Table 16). There were no significant 
differences for age, symptoms associated with PCOS and for prevalence of use for diet, 
exercise or complementary medicines.  
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Table 4.16. Comparison between early and late respondents in the POSAA group. 
 Early respondents (b) 
(n=182) 
Late respondents (a) 
(n=53) 
Difference % 
 
Age % 95% CI % 95% CI a – b % P value 
<17 years 0.7 ± 0.79 2.2 ± 3.95 1.5 0.086 
20-24 17.0 ± 3.58 17.8 ± 10.3 -0.8  
25-29 29.7 ± 4.35 22.2 ± 11.9 -7.5  
30-34 26.2 ± 4.19 40.0 ± 13.19 13.8  
35-40 16.7 ± 3.55 8.9 ± 7.66 -7.8  
41-44 5.9 ± 2.24 6.7 ± 6.71 -0.8  
>45 3.8 ± 1.82 2.2 ± 3.95 -1.6  
      
Education      
Finished high school 83.3 ± 5.42  80.6 ± 10.65 -4.2 0.497 
Tertiary education 71.0 ± 6.59 71.4 ± 12.17 -4.8 0.492 
      
PCOS signs and symptoms all or most of the time 
Late menstrual period 69.7 ± 6.68 68.5 ± 12.51 -1.2 0.815 
Hirsutism 67.8 ± 6.79 69.8 ±12.36  2 0.782 
Overweight 72.7 ± 6.47 74.5 ± 11.73 1.8 0.674 
Depression  47.1 ± 7.25 45.5 ±13.41 -1.6 0.842 
      
Prevalence of use        
Complementary medicine  69.8 ± 6.67 67.4 ± 12.62  -2.4 0.206 
Diet to manage PCOS 62.9 ± 7.02 63.6 ± 12.95 0.7 0.910 
Exercise vigorous or moderate 75.6 ± 6.24 76.1 ± 11.48 0.5 0.240 
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Demographic comparison between two samples 
There were no statistical differences between the groups for demographics, symptoms 
associated with PCOS, and the prevalence of use for diet exercise and CM (Table 4.17). 
Table 4.17. Demographic and clinical characteristics of partcipants from the two groups 
 POSAA sample  
(n=182) 
Facebook sample 
(n=311) 
P value 
 % 95% CI % 95% CI  
Demographics      
Age 25-29 years 31.6 ± 6.77 27.9 ± 4.98 0.588 
Finished high school 83.3 ± 5.42 87.9 ± 3.62 0.165 
Employment full time 53.1 ± 7.25 39.8 ± 5.44 0.543 
 
Symptoms associated with PCOS all or most of the time 
Late menstrual period 69.7 ± 6.68 61.1 ± 5.42 0.334 
Hirsutism 67.8 ± 6.79 66.2 ± 5.26 0.880 
Overweight all or most of the time 72.7 ± 6.47 80.4 ± 4.41 0.617 
Depression all or most of the time 47.1 7.25 45.2 ± 5.53 0.947 
      
Prevalence of use       
Complementary medicine 69.8 ± 6.67 70.6 ± 5.06 0.910 
Diet to manage PCOS 62.9 ± 7.02 65.7 ± 5.28 0.873 
Exercise vigorous or moderate 75.6 ± 6.24 71.3 ± 5.03 0.879 
 
Investigations into the reliability of findings demonstrate that there was no non-response 
bias for findings for this study and there were no significant differences between the two 
samples (derived from POSAA and Facebook).  
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4.3.6 Summary of key findings 
Overall the findings from this survey provide new insights into women with PCOS and their 
use of self-management interventions including diets, exercise and complementary 
medicine (CM). A high response rate was achieved for this survey with participants 
characterised as members of two consumer support groups. Diet, exercise and CM were 
widely used to assist with the management of PCOS symptoms and general wellbeing. 
Women indicated the primary aim of adopting lifestyle practices was to lose weight and 
manage their PCOS. Over 57% of participants reported use of diet and 73% were using 
exercise on a daily to biweekly basis for the previous twelve months, with most women 
using the low glycaemic index diet and exercising 2-4 times per week for 45-60 minutes per 
session. However less than 13% of respondents reported complete achieved their health 
goals using dietary and/or exercise practices.   
Participants had used a variety of diets. The diet most strongly associated with the 
achievement of health goals was the high protein diet. Seventy three percent reported 
moderate/vigorous exercise, 79% reported using two or more forms of exercise, 80% 
exercised to feel better in themselves but many other reasons were also given. Most 
women were exercising two to four times per week. One quarter did not exercise at all 
citing many reasons including lack of time, feelings of embarrassment and injury. Only 25 
(8%) women thought they had achieved their health goals using exercise, all of whom were 
engaged in regular, vigorous exercise. 
CM was utilised by over 70% of respondents with over 64% using nutritional supplements 
on a daily basis and over 47% consulting a CM practitioner within the previous twelve 
months.  CM was reportedly used to treat symptoms associated with PCOS and to improve 
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general wellbeing. Nearly 40% reported CM as effective for more than single symptoms and 
greater self-perceived effectiveness was found when CM was used to address specific health 
needs. Adverse reactions were reported by thirty seven women with nearly all 
spontaneously resolving following the cessation of CM use or continued use. Six women 
reported ongoing adverse reactions following the cessation of CM usually menstrual cycle 
variation. Women sourced information about CM from multiple sources usually self-
prescribing and from CM practitioners.  
4.4 Discussion  
 
This is the first study to report prevalence for the use of complementary medicines (CM) by 
two groups of women with PCOS and results show that these women are frequent users. 
Women with PCOS seek more than the management of symptoms associated with PCOS 
when using CM’s and that psychological health and well-being are important aspects of 
care. This confirms findings from other research demonstrating that improved quality of life 
and better health is associated with women’s use of CM (Coulson and Jenkins 2005, Rayner, 
McLachlan et al. 2009, Smith, Bateson et al. 2013). A range of complementary medicines 
were reportedly being used, most commonly nutritional and herbal supplements, with 
naturopaths, chiropractors and acupuncturists found to be the most popular CM 
practitioners. Other studies demonstrate women’s similar preferences for types of CM 
including Rayner et al and Smith et al where nutritional and herbal supplements were the 
most commonly reported CM (Rayner, Willis et al. 2011, Smith, Bateson et al. 2013). 
Preferences for types of CM practitioners were similarly found by Stankeiewicz et al for 
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women attending fertility clinics (Stankiewicz, Smith et al. 2007). These findings show that 
most women with PCOS perceive the effectiveness of CM as at least somewhat helpful. 
This study reported data for the first time for adverse events arising from complementary 
medicines used by women with PCOS. Whilst there is an increasing body of knowledge for 
potential adverse reactions and the use of complementary medicines in women’s health 
(Tiran 2003, Tiran 2012), much of the evidence is insufficient, contradictory or inconclusive 
(Kronenberg and Fugh-Berman 2002, Low Dog 2005). These data add to the evidence base 
showing that self-reported risks associated with complementary medicine are low at 7.5% 
compared with pharmaceutical management (Vincent 2001).  Over 45% of women reported 
gastro-intestinal side effects for the commonly prescribed insulin sensitising 
pharmaceutical, metformin (Tang, Glanville et al. 2006). Participants in this study indicated 
that one of their primary motivations for their use of CM included perceptions 
(appropriately or inappropriately) that prescribed medicines have more side-effects than 
CM. This finding is an important step in our understanding of women’s attitudes towards 
pharmaceutical management as   their converse positive perceptions towards CM  may at 
least partially explain women’s desire for treatment alternatives to birth control pills and 
fertility drugs (Sills, Perloe et al. 2001). Findings additionally highlight participant’s lack of 
appreciation for potential risks with concurrent use of CM and conventional medicine, 
which concurs findings from other studies (Smith, Bateson et al. 2013). Although 
mechanisms for adverse reactions have been presented for some complementary medicines 
(herbal medicines, nutritional supplements and acupuncture) in PCOS and in women’s 
health (Tiran 2003, Raja-Khan, Stener-Victorin et al. 2011) available data were severely 
limited and mostly theoretical. Our data show that women’s perceptions and reported 
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experiences of adverse reactions associated with CM are relatively low. Findings for adverse 
reactions in this study however should be interpreted with some caution. Although adverse 
reactions for CM are generally reported as low in the literature (Barnes 2003, MacLennan, 
Myers et al. 2006) and results here show similar findings, the effect of any reporting bias on 
this area of the study could not be clarified.   
This study adds to our understanding for the lack of adherence for dietary and exercise 
interventions for women with PCOS (Humphreys and Costarelli 2008). Current evidence 
based first-line treatment aims to manage the condition through lifestyle changes to 
prevent and treat obesity (Norman, Davies et al. 2002, AAPCOS 2011, Moran, Hutchison et 
al. 2011). These data demonstrate that despite engagement with dietary and exercise 
practices apparently extended beyond those recommended in the evidence based 
guidelines, perceptions for effectiveness were very low. In contrast, the current outcomes 
demonstrate women’s higher perception for effectiveness for CM, which was again higher 
when asked about effectiveness when used to treat aspects of PCOS. Perhaps if asked about 
specific areas of treatment for lifestyle intervention including but not limited to losing 
weight, perceptions for the effectiveness of diet and exercise may have been higher.  
Women’s self-perceived effectiveness for lifestyle interventions may have additionally been 
influenced by the absence (or presence) of professional and social support including 
professional lifestyle advice (Teixeira, Going et al. 2005, Moran, Pasqueli et al. 2009). One 
on one consultation with dietitians, exercise physiologists or personal trainers was not 
assessed in this study and further examination of the relationships between women’s 
satisfaction with lifestyle intervention and social and professional clinical support may 
highlight a potentiating influence. These results underline the urgent need for self-perceived 
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effective lifestyle interventions that emphasise the wide range of potential benefits and 
accommodate the cognitive needs of women with PCOS. 
It is unclear which dietary and exercise practices are optimal for women with PCOS (Huber-
Buchholz, Carey et al. 1999, Marsh 2010, Lamb, Johnstone et al. 2011, Kozica, Deeks et al. 
2012, Moran 2013). We found greater self-reported effectiveness for women consuming 
high protein, low carbohydrate diets and for women participating in vigorous exercise. This 
supports other findings showing psychological benefits for women with PCOS consuming 
high protein, low carbohydrate diets (Galletly, Moran et al. 2007). This research adds new 
information by describing the acceptability of high protein, low carbohydrate diets and 
exercise interventions by women with PCOS.  
4.4.1 Discussion of methodology 
One of the strengths of this study is that the results may be generalisable to women with 
PCOS. Women who responded to this survey were comparable to other researched 
populations of women with PCOS (Balen, Conway et al. 1995, Ching, Burke et al. 2007, 
Teede, Gibson-Helm et al. 2013). Most participants were of reproductive age, held tertiary 
qualifications, were employed, had private health insurance and were born in Australia. All 
of the participants reported signs and symptoms associated with PCOS with a large 
proportion, 77%, being overweight. The current sample reported higher prevalence for 
being overweight compared to other community samples of women with PCOS which 
ranged between 18 and 44% (Balen, Conway et al. 1995, Ching, Burke et al. 2007, Teede, 
Gibson-Helm et al. 2013), however the prevalence for obesity was less (51%) compared to 
other studies showing obesity prevalence as 60-64% (Azziz, Sanchez et al. 2004, Ching, 
Burke et al. 2007). This suggests that participants may have under-reported obesity. The 
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prevalence for hirsutism reported by women in our study (68%) was consistent with two 
other studies 66-72% (Balen, Conway et al. 1995, Azziz, Sanchez et al. 2004).  
The response rate for this survey was 71.3% (excluding late responders), and met our 
response target. Whilst this was lower than some other self-administered surveys of women 
with PCOS in face to face interviews,  (Guyatt, Weaver et al. 2004, McCook, Reame et al. 
2005), it  compared favourably with other mail out surveys  to women with PCOS (52%) 
(Ching, Burke et al. 2007). As well as obtaining a sufficient response rate, comparisons with 
late respondents determined the impact of non-response bias for the age, education, 
symptoms of PCOS and the main prevalence outcome variables.   A continuum of resistance 
model showed no statistically significant non-response bias for age, education, 
characteristics of PCOS and for the prevalence of use for diet, exercise and CM.  
Additional study strengths include the accessibility of this survey to a large number of 
women with PCOS in a non-clinical setting and not restricted by geographical location. This 
survey had capacity to reduce survey burden and skip sections if participants’ response was 
‘no use’ and high completion rates suggested that the methods were acceptable to women. 
The setting of the survey was congruent with the self-care location of dietary and exercise 
interventions. The anonymity by this study provided an opportunity for increased self-
disclosure of women with PCOS possibly discouraged with first line medical management 
(Walsh, Kiesler et al. 1992, Smith, Smith et al. 2007). These data are likely to reflect the 
authentic views of women with PCOS in the community.  
The sampling framework used in this study was acceptable to women as members of PCOS 
support groups. The targeted sampling methodology eventually appealed to nearly all of the 
members of POSAA. In relation to snowballing sampling used on Facebook, we found that 
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the number of responses exceeded the number of members in the University Facebook 
group.  This shows that invitations spread via members to PCOS support groups from whom 
referral was sought and suggests that recruitment of study participants through electronic 
social networks was acceptable to women with PCOS. However we were unable to directly 
assess non-response and selection bias for the Facebook group due to the sampling 
methodology.  Estimation for the impact of non-response bias for the Facebook group relies 
on the POSAA estimates as surrogate calculations and the similarities between samples. 
Participation in the current study indicated computer literacy and competence however 
generalisations from findings are limited to computer literate women with English language 
skills and some ethnic minority groups of women with PCOS may be under-represented. 
Limitations of the study include the exclusion of women unable to communicate in English.  
Our data may also be at risk of reporting bias. The possibility exists that some participants 
were not properly diagnosed with PCOS and the sample inappropriately inflated. However 
the characteristics of PCOS within the sample compared similarly with other community 
samples of women with a medical diagnosis of PCOS (March, Moore et al. 2010) which 
suggests that the respondents were properly diagnosed with PCOS. In addition the response 
rate was considered sufficiently large to mitigate this sampling bias effect.  
These findings may provide further insight into the motivators behind the use of CM by 
women with PCOS and further articulate the gap in the management of PCOS for lifestyle 
intervention for women with PCOS. The implications of these findings and the contribution 
of the study within the context of the thesis will be discussed in Chapter Six.    
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Chapter 5:   The addition of herbal medicine to a lifestyle intervention, for women with polycystic ovary syndrome: A Randomised Controlled Trial.  
 
5.1 Introduction  
This chapter presents the methods and results from a randomised controlled clinical trial for 
women with polycystic ovary syndrome (PCOS) conducted between August 2012 and August 
2014. The objective of this study was to evaluate the effectiveness and safety for five 
western herbal medicines in addition to lifestyle intervention for menstrual regularity in 
overweight women with PCOS. The primary hypothesis was:   
1. The addition of herbal medicine to lifestyle intervention (structured personalised 
exercise program and dietary advice), compared to a lifestyle alone, will improve 
menstrual regularity for overweight women with PCOS. 
Secondary hypotheses were: 
2. The addition of herbal medicine to a lifestyle intervention compared to lifestyle 
alone, in overweight women with PCOS, will improve: 
a) Reproductive and metabolic hormone concentrations during the 
follicular phase of the menstrual cycle.  
b) Anthropometric markers. 
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c) Conception rates, pregnancy and live birth outcomes. 
d) Quality of life and psychological morbidity. 
3. The use of five herbal medicines, by women with PCOS will not be associated 
with increased adverse reactions or adverse events compared with women 
receiving a lifestyle intervention alone.  
5.2 Methods  
5.2.1 Overview of study design 
A parallel randomised controlled trial using a pragmatic research design was used to test the 
hypotheses and to maximise translation of the research outcomes into everyday settings.  
Pragmatic trial methodology measures clinical effectiveness, and examines the potential 
benefit the treatment may produce in routine clinical practice (Rothwell 2005). In light of 
the frequent use of herbal medicine by women with PCOS and the absence of robust 
evidence, examination of the herbal medicine as it is delivered in the community was 
considered an appropriate research strategy due to its capacity to provide relevant answers 
to current questions of women and clinicians. Pragmatic RCT design has advantages over 
trials utilising RCT efficacy research design.  The main advantage is improved external 
validity (Sullivan and Goldmann 2011) which is achieved by reproducing conditions that the 
intervention will encounter in the real world. Pragmatic trials are characterised by broader 
eligibility criteria, a degree of flexibility for the administration of complex interventions and 
flexibility of practitioner expertise (Thorpe and Altman 2009). These factors contribute to 
the provision of outcomes that translate efficiently into real world settings, and directly 
meet the information needs of consumers, clinicians and policy makers (Sox and Greenfield 
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2009, Sullivan and Goldmann 2011). The rationale for using pragmatic research design in 
this study was based upon the following considerations. 
1. The research hypothesis examined the question “does herbal medicine work under 
usual circumstances” rather than “can herbal medicine work under ideal conditions”. 
The aim of this research was to ensure the findings were relevant to women with 
PCOS living in the community, to clinicians treating women with PCOS and to policy 
developers aiming to improve health outcomes for women with PCOS (Rothwell 
2005). Given the established high use of herbal medicines by women with PCOS 
(Arentz, Smith et al. 2014), clinical effectiveness was considered an appropriate next 
step to best meet the demand for ‘real world’ risks and benefits (Fønnebø, 
Grimsgaard et al. 2007). 
2. PCOS is a complex, heterogeneous condition with variable expression. A pragmatic 
research design permitted the inclusion of participants with any phenotypical 
presentation, and had greater applicability for women with PCOS in general, (Thorpe 
and Altman 2009, Witt 2009). 
3. Pragmatic research seeks measures of clinical effectiveness for complex 
interventions without disassembly of the interventions (Hotopf 2002). Herbal 
medicine is a complex intervention and pragmatic design enabled evaluation in its 
complete form as it is administered in self-care and naturopathic clinical practices. 
Outcome measures of effectiveness were relevant and easily transferable to health 
consumers, clinicians and policy makers (Thorpe and Altman 2009).  
4. The active control arm characteristic of pragmatic RCTs (Rothwell 2005) was 
anticipated to increase women’s engagement with the research, limit attrition and 
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maximise internal validity. 
However there are limitations to this design.  Firstly, this design limits findings to measures 
of comparative effectiveness rather examining the cause and effect relationship of 
interventions against placebo. In other words, the research did not primarily explain how 
the intervention worked and there was limited opportunity to explain the biological effects 
attributable to components of the intervention. Secondly pragmatic research design is a 
relatively new and there are limited empirical data to estimate sample sizes sufficient for 
significant effect sizes. Combined with the use of an active control arm pragmatic RCTs 
require relatively large sample sizes compared to efficacy studies. In the present case, 
participants were expected to improve based on the evidence for lifestyle intervention 
(dietary and exercise practices) for PCOS (Thomson and Brinkworth 2008, Thomson, Buckley 
et al. 2009, Marsh 2010, Teede 2011, Moran 2013).  
5.2.2 Ethics and registration 
The research protocol was approved by the University of Western Sydney, Human Research 
Ethics Committee in November 2011 (reference H9407) (Appendix 10) and by Family 
Planning New South Wales in April 2013 (reference R2012-09) (Appendix 11). The trial was 
registered at the Australian and New Zealand Clinical Trials Registry (ANZCTR) in January 
2012 (reference 12612000122853).  
A herbal tablet was developed for investigation. The Therapeutic Goods Administration 
(TGA), a division of the Department of Health in the Australian Federal Government was 
notified about the new herbal tablet via the clinical trial notification (CTN) scheme 
(Appendix 12). A risk analysis and statement presenting the levels of evidence for the 
therapeutic claims was attached to the notification (Appendix 13). The TGA listed the new 
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tablet, PCOS-1 product for investigation March 2012. Malpractice, product liability and 
public liability insurances for the trial were provided by UniMutual Pty Ltd, certificate 
number ULWSYD12. 
The intellectual property for the invented herbal medicine was claimed by the researcher, 
her supervisors and the University of Western Sydney. The manufacturer of the tablet 
Mediherb Australia, sponsored by Integria Healthcare Australia, retained the first rights to 
commercialisation of the product. 
5.2.3 Study design  
This study was a parallel prospective randomised controlled trial. Figure 5.1 outlines the 
main stages of the trial.  
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Figure 6.1 Flow chart outline of the clinical trial 
 
Informed consent 
Enrolment/baseline measures/diet/exercise/menstrual cycle 
   
Randomisation 
Lifestyle intervention plus herbal medicine  Lifestyle intervention program  
 
Blood tests Early follicular phase of the menstrual cycle (days 2-10)  
Compliance and adverse event injury check week 1 (phone or email) 
Herbal medicine consults 
week 4 & 8 phone, email 
or face to face 
Exercise program revised week 2, 4, 6, 8, & 10 (email) 
Compliance, adverse event and injury check  
week 4 and 8. Phone or email 
Outcome measurements week 12 (blood tests menstrual cycle (day 2-5) closest to week 12). 
Pregnancy and birth outcomes for women who conceived at 12 weeks of pregnancy and one month 
following estimated due date 
Figure 5.1.Overview of trial 
design 
Recruitment/screening 
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5.2.4 Strategies to minimise bias 
Randomisation 
Participants were randomised to one of two interventions; lifestyle alone or lifestyle 
intervention plus herbal medicine. An account with the web based online randomisation 
company Sealed Envelope, London, England was established and the University (University 
of Western Sydney (UWS)) purchased 150 password protected randomisations for this trial. 
The randomised sequences were computer generated by Sealed Envelope using random 
permuted blocks of 50 randomisations to ensure the balancing of the two groups.  
Following formal enrolment and baseline data collection, participants were stratified into 
one of three groups based on their BMI: group 1- BMI 24.5 to 29.9; group 2-BMI 30 to 33 or 
group 3- BMI over 33.1. The researcher logged onto the trial portal at Sealed Envelope using 
a mobile phone; https://www.sealedenvelope.com/simple-
randomiser/v1/trials/naturopathy-for-women-with-pcos; entered the trial password, 
participant’s study ID and BMI strata group. Sealed Envelope replied by email indicating 
participant assignment to either group one, lifestyle, or group two lifestyle plus herbal 
medicine.   
Allocation sequence and concealment 
The randomisation sequence was concealed through central computer randomisation. 
Allocation concealment was performed externally and unknown to the research team prior 
to the assignment of interventions. A randomisation sequence was requested from Sealed 
Envelope three months after completion of recruitment in March 2014 (Appendix 14).  
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Blinding 
Blinding occurred in one out of three domains. Participants and clinicians were aware of 
group assignment and therefore not blinded, however the test and control groups were 
concealed prior to data analyses. The data entry officer and study analyst were blind to 
group allocation the analyst was unblinded following the finalisation of data analyses. 
5.2.5 Participants 
The study population was women with polycystic ovary syndrome (PCOS). 
Participant inclusion criteria 
• 2Clinically verified medical diagnosis of  PCOS according to the Rotterdam Criteria 
(two of three of the following signs and symptoms 1. Polycystic ovaries on 
ultrasound; 2. Oligomenorrhoea or amenorrhoea; 3. Clinical or biochemical 
hyperandrogenism).  
• Overweight, body mass index2 (BMI) greater than or equal to 24.5. 
• Aged 18-44 years. 
• Not taking medically prescribed hormone therapy (including the oral contraceptive 
pill). 
                                                          
2 The Rotterdam criterion is the most widely used diagnostic tool for the diagnosis of PCOS 
in research ESHRE (2004). "Revised 2003 consensus on diagnostic criteria and long-term 
health risks associated with polycystic ovary syndrome." Fertility & Sterility 81(1): 19-25.  
BMI is the ratio of bodyweight in kilograms relative to height (metres) squared.  BMI was 
calculated using the formula BMI = body weight (kg)/height (metres) squared.  
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• Not taking medically prescribed pharmaceuticals to treat or manage depression. 
• Be able to read and write English, provide informed consent and permission to 
establish contact with individual medical care providers  
• Able to meet face to face with researchers on two occasions 
Participant exclusion criteria 
• BMI equal to or less than 24.4  
• Use of pharmaceutical hormone medications including the oral contraceptive pill  
• Use of antidepressant medications 
• Pregnant women  
• Aged less than 18 years or more than 44 years 
• No medical diagnoses of PCOS 
 
5.2.6 Trial protocol 
Participant recruitment 
The recruitment strategy included several approaches. The research was presented to the 
general community through health forums including the Women’s Health Forum sponsored 
by Campbelltown City Council, and through media releases including print sources organised 
by the media department of UWS and the researcher. Topical stories about the trial 
appeared in printed and online newspapers including the Newcastle Herald, the St George 
Leader, the Bankstown Canterbury Torch and Daily Life. Meetings with women’s health 
providers (FP NSW and NSW Women’s Health Clinics) and gynaecologists (Professor Jason 
Abbott (research supervisor) and Professor John Eden) encouraged referral of women with 
PCOS to the trial. The trial was advertised using posters (Appendix 15) placed at UWS 
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campus’, in private gynaecology and primary health care (FP NSW) clinics, through on-line 
media at Daily Life health and Fitness section (www.dailylife.com.au) and on the social 
network site, Facebook. A group page was established by the researcher 
www.uws.edu.au/pcosfacebook to inform women with PCOS about the trial and provide a 
platform for presentation of the trial results in due course.  
Women interested in participating were encouraged to contact the researcher by email or 
mobile phone. Initial screening took place and if suitable, an appointment was made and a 
participant information package emailed or mailed. The information package contained a 
cover letter and participant information sheet, (Appendix 16). Women were contacted 24 
hours prior to their appointment to confirm their understanding of the research and 
continued interest in participation. There were no financial or other non-health benefits 
offered to participants.  
The trial inclusion criterion of ‘overweight’ was confirmed by the researcher during the 
screening interview. Women were asked about their current BMI. If this information was 
not available, women were asked about their body weight in kilograms and height in metres 
or feet. Individual BMI’s were calculated during the screening interview by the researcher.  
Signed permission was sought to make contact with the woman’s doctor to confirm 
diagnosis of PCOS (according to the Rotterdam criteria), and to inform the doctor of their 
patient’s participation and request pathology history. These forms were returned by 
participants’ doctors to the National Institute of Complementary Medicine (NICM).  
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Trial entry 
Following an expression of interest, eligibility screening and agreement of a suitable 
meeting time and location, participants met the researcher and exercise physiologist for one 
to two hours.  Locations for meetings were sourced by the researcher and selected based on 
their convenience and suitability.  
Following confirmation of eligibility and obtaining of informed consent, baseline data were 
collected relating to the trial entry data form (Appendix 17). Data included participant’s 
socio-demographic characteristics, including ethnicity, education, occupation, postcode and 
personal relationship status. Participants provided a chronological account of their PCOS, 
whether or not they were trying to conceive and information about their medical history 
including previous pathology tests (blood tests, ultrasounds, surgical treatment or 
investigations). It was reiterated that the researcher would attempt to obtain copies of 
previous reports and results from their doctor and women were presented with the ‘letter 
to medical provider’ for signed permission. The measurement of anthropometric 
characteristics and blood pressure followed subjects recalling their social drug use, exercise 
behaviours for the previous six weeks and use of pharmaceutical management for PCOS 
including complementary therapies. 
The interview then moved to collecting health related quality of life data. Two 
questionnaires including the polycystic ovary syndrome questionnaire (PCOSQ) and the 
Depression, Anxiety and Stress Score (DASS 21) were administered (Appendix 18). 
Participants were advised about the general content of the questionnaire and its’ seeking of 
information about how they felt about current symptoms. Participants were reassured that 
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all information was confidential, and that it would take approximately 10-15 minutes to 
complete.  
Women were provided with a referral to a pathology collection centre for collection of 
blood at local pathology collection centres. Women were advised that the test was required 
to be taken on or between days two to five of their menstrual cycle (and individual date 
range specified if possible) and to take the test after not consuming any food or drinks other 
than water for eight hours. 
Participants were thanked for their interest and involvement, and provided with a 
‘Polycyster trial package’ including folded information sheets, important dates, pathology 
request forms, menstrual charts, LH tests and a pedometer. 
Withdrawal 
Participants could withdraw from the study at any time and for any reason. Further, this 
might be recommended by the research team in the event of adverse reactions or due to 
injury or pregnancy. In the event of injury, participants were referred to their GP or 
physiotherapist and withdrawn if the injury prevented exercise participation for more than 
two consecutive weeks. In the event of adverse reactions, participants were requested to 
consult their GP and were monitored by the research team daily for three days to observe 
progress. If the participant continued with the intervention and adverse effects resolved, 
the participant was not withdrawn from the trial. If reactions persisted following the 
cessation of intervention, participants were withdrawn from the trial.  
If pregnancy was suspected this was confirmed by a blood test (serum beta human chorionic 
gonadotropin (HCG) over 10mIU/l) and the participant was withdrawn from the trial, and 
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encouraged to continue with exercise (without increasing intensity) and eating a healthy 
diet. A face to face meeting was organised for data collection.  
In the event of withdrawal, the following protocol was followed. 
• Withdrawal and any reasons given were documented in the participant’s files. 
• Participants were asked to cease the intervention. 
• Participants withdrawn by the research team (due to injury, adverse effects or 
pregnancy) were followed up at appropriate intervals.  
• There was no follow-up for participants who withdrew themselves or ceased contact 
with the research team. 
• The participant was not replaced.  
• Withdrawing participant data was used in analyses based on intention-to-treat 
principles. 
5.2.7 Interventions 
The interventions were administered for twelve weeks. All participants were able to 
continue taking medications other than pharmaceutical hormones and antidepressant 
prescriptions. Medical practitioners were informed about their patient’s participation in this 
trial and participants were monitored for changes in prescribed medication dose. 
Lifestyle intervention  
The lifestyle intervention was based on recommendations in the Evidence Based Guidelines 
(EBG) for the management of PCOS, (AAPCOS 2011, Teede 2011). Chapter five; Lifestyle 
Management in PCOS, is summarised in algorithm three, ‘Lifestyle management for women 
with polycystic ovary syndrome’ (Appendix 19). Recommendations emphasise behaviours to 
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prevent increments in body weight and induce weight loss of 5-10% in overweight women 
and to maintain a BMI of 25 or less. Lifestyle intervention is recommended as first line 
treatment for the induction of ovulation for women wanting to conceive and to prevent 
complications associated with pregnancy and obesity. Exercise and dietary practices are 
central behavioural recommendations with specific dietary recommendations of a calorie 
controlled diet within a healthy food choice setting (Lifescripts diet (AFG 2014)) and exercise 
for at least 150 minutes per week including 90 minutes of aerobic activity (60-90% 
maximum heart rate) (AAPCOS 2011).  
Exercise  
An exercise program that consisted of 150 minutes of exercise per week including 90 
minutes of aerobic exercise (60-90% of maximum heart rate) was provided to all 
participants. The ‘exercise prescription’ was designed by exercise physiologist at UWS Lisa 
Vizza. It included body postures which applied resistance to large skeletal muscle groups 
(progressive resistance training) combined with aerobic activity (brisk walking on an incline, 
jogging, cycling, cross trainer, circuits at the gym, dancing etc.). A degree of flexibility was 
embedded into the program to accommodate individual ability and exercise preferences. 
Exercise sessions consisted of two parts, aerobic and resistance each estimated to take 20 to 
30 minutes. Participants were advised to exercise for at least 150 minutes per week. This 
was presented in terms of weekly time allocations for exercise for example one 60 minute 
session and two 45 minute sessions or three 30 minute sessions or three sessions of 50 
minutes each. The first exercise session was supervised by the exercise physiologist. 
Subsequent sessions were either supervised by the exercise physiologist, a trainer at a gym 
or self-administered at a location convenient to the participant. The intensity of an 
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individual’s exercise prescription increased at two weekly intervals to improve outcomes 
and compliance, (Thomson and Brinkworth 2008).   
Participants were introduced to the exercise intervention during the trial entry interview. 
The exercise physiologist screened participants for exercise safety using the pre-screening 
for exercise form (Appendix 20). A demonstration of exercises was performed by the 
exercise physiologist and participants were asked to repeat the exercises, whilst the exercise 
physiologist provided feedback regarding technique and assessed subjects exercise 
capability. Participants were presented with a pedometer and shown how to monitor their 
heart rate and monitor daily exercise activity.  The exercise physiologist made fortnightly 
contact with participants to provide exercises of increased intensity relative to the 
participants previous exercise prescription throughout the trial period. 
Diet 
Participants in each group received the same dietary recommendations based on the 
Australian Department of Health Lifescripts Dietary Program, recommended in the EBG for 
management of PCOS. Written information was provided outlining the calorie controlled 
Lifescripts diet included daily consumption of macro nutrients found in a range of food 
groups detailed in Appendix 21. Additional written information was provided to enable 
participants to identify foods with a low glycaemic index (GI). Although low GI foods were 
not referred to in the EBG or the Lifescripts diet evidence emerged during the early stages of 
the trial supporting dietary glycaemic control as best dietary practice for women with PCOS 
(Marsh 2010). Written information, recipes, menus suggestions and referrals to information 
based web sites enabled participants to access further information provided by the Human 
Nutrition Unit at the University of Sydney (Brand-Miller J 2012), (Appendix 22).  
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Participant’s recalled their usual daily food intake over the previous two weeks during the 
trial entry interview. Key components were recorded; daily intake of vegetables and fruit, 
type of diet and consumption of take-away fast food (with reference to the Lifescripts diet 
(Appendix 21)).    
5.2.8 Herbal medicine intervention 
The herbal medicine intervention consisted of two types of herbal medicine tablets and two 
consultations with naturopath Susan Arentz at weeks four and eight. Susan’s naturopathic 
qualifications and experience included an Advanced Diploma of Naturopathy (with botanical 
and nutritional medicine), a Bachelor of Health Science with Honours and continuous clinical 
practice experience since 1997. During the consultations women were assessed for 
symptomatic progression or amelioration and adverse effects.  
Selection of herbal medicines and rationale for two tablets  
Five herbal medicines were selected for investigation in this trial. These were Cinnamomum 
cassia, Glycyrrhiza glabra, Hypericum perforatum, Paeonia lactiflora and Tribulus terrestris. 
The selection of herbs was informed by the results of the literature reviews in Chapters two 
and three and based on naturopathic clinical reasoning and practice (Kasim-Karakas and 
Mishra 2009, Bargiota and Diamanti-Kandarakis 2012, Tippens, Oberg et al. 2012, Trickey 
2011, Sarris and Wardle 2010, Wardle, Lui et al. 2012, Steel, Wardle et al. 2014).  The whole 
clinical ‘picture’ typically observed in women with PCOS was incorporated into the decision 
process. Considerations included deficient hepatic function, fatigue and energy deficits, sub-
optimal digestive and elimination functions and chronic low grade inflammation and sleep 
disturbances.  
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Tribulus terrestris was included due to possible potentiating FSH efects (Milanov, Maleeva 
1981); Glycyrrhiza glabra and Paeonia lactiflora to reduce androgens (Yaginuma 1982, 
Takahashi and Kitao 1994, Armanini, Mattarello et al. 2004, Armanini, Castello et al. 2007); 
Cinnamon cassia was included to improve insulin sensitivity (Wang 2007) and Hypericum 
perforatum to reduce depression (Gaster and Holroyd 2000). Although there was no 
evidence for Hypericum perforatum specifically in women with PCOS, evidence from 
systematic reviews has demonstrated effectiveness for mood enhancing effects with a high 
safety profile in other cohorts, (Linde 1996, Kim 1999, Hübner 2001, Findling 2003, Simeon 
2005). It was anticipated that this herb may improve mood without causing serious adverse 
reactions or pharmacokinetic interactions in women not taking antidepressant 
pharmaceuticals or contraceptive pills (Whiskey, Werneke et al. 2001). 
Additional actions of the herbal medicines included digestive carminative properties 
(Glycyrrhiza glabra and Cinnamomum cassia), improved hepatic metabolism of androgens 
(Hypericum perforatum and Glycyrrhiza glabra) (Patki, von Moltke et al. 2003, Greenlee, 
Atkinson et al. 2007), anti-inflammatory actions (Glycyrrhiza glabra) (Asl and Hosseinzadeh 
2008) and improved sleep, mood and cognitive effects (Hypericum perforatum and Paeonia 
lactiflora) (Bone and Morgan 1996, Mills 2000, Greenlee, Atkinson et al. 2007, Linde, Berner 
et al. 2008, Wardle, Lui et al. 2012).  
Findings from Chapter two indicated that additional herbal extracts (Cimicifuga racemosa 
and Mentha spicata) and nutritional supplements (inositol and omega three fish oils) may 
have therapeutic potential for women with PCOS. These additional supplements were not 
included in the intervention due to added dosage requirements, including administration of 
herbs in the form of tea and additional tablets, and to limit the burden of the intervention 
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on study participants. Limited burden of the intervention was intended to mimic real world 
circumstances and women’s daily tablet intake capacity, align with pragmatic research 
principles (Rothwell 2005) and improve the translation of findings into clinical practice. The 
herbal selection was additionally rationalised for efficiency, intended to limit the economic 
costs of the intervention. 
There were two herbal medicine tablets administered during this investigation. Tablet one 
contained the combined herbal extracts of Glycyrrhiza glabra, Paeonia lactiflora, 
Cinnamomum cassia and Hypericum perforatum. Tablet two contained Tribulus terrestris. 
The herbal intervention was provided in separate tablets so that administration of Tribulus 
terrestris could be restricted to the pre-ovulatory phase of the menstrual cycle. Based on 
the evidence presented in Chapter Three it was proposed that Tribulus terrestris may induce 
ovulation in women through increased serum concentrations of FSH. With this effect in 
mind, administration of Tribulus terrestris was considered appropriate during pre-ovulatory 
phase of the menstrual cycle only. Women with amenorrhea (no menstrual period for the 
previous six months) were instructed to start taking tablet two on the day of trial entry for 
ten consecutive days. In cases of no ovulation or no menstrual period, women were asked 
to repeat the dose of tablet two.  
Manufacture and packaging 
The two herbal tablets were manufactured by Mediherb Australia and donated to the NICM 
by Integria Healthcare Australia Pty Ltd, 8 Clunies Ross Court, Eight Mile Plains, Queensland, 
Australia, 4113. Tablet one, PCOS-1, was manufactured specifically for the trial. Tablet two, 
Mediherb Tribulus Forte (M1445), was listed with the Australian Therapeutic Goods 
Administration product number 18507 (Appendix 23).  
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Herbal medicine tablet one, PCOS-1.  
A new herbal tablet PCOS-1 was manufactured in June 2012. The tablets each contained 
four herbal medicines in a combination invented by the principle investigator and her 
supervisors. The formulation was and remains subject to intellectual property claims, 
commercialisation and confidentiality agreements. The PCOS-1 formula is listed in Table 5.1.  
 Table 5.1 Intervention contents per tablet PCOS-1  
Herbal extract  
Common name 
Ratio of dried herb to 
 solvent (ethanol) 
Dried herb 
equivalent in 
extract (mg) 
% weight to 
weight per tablet 
Mg per tablet Biomarkers (analytes) 
Glycyrrhiza glabra root 
Liquorice 
7:1 
107.2 25% 750mg glycyrrhizic acid (aglycone of 
glycyrrhizin) 
eugenol (volatile oil) 
Paeonia lactiflora root 
White peony 
4:1 
187.5 25% 750mg paeoniflorin (triterpene 
glycoside) 
quercetin (aglycone) 
Cinnamomum cassia 
stem bark 
Cinnamon 
12.1 
62.5 25% 750mg cinamaldehyde (aldehyde) 
 
cinnamic acid (acid) 
 
Hypericum perforatum 
Flowering herb 
St John’s wort 
6:1 
125.0 25% 750mg hypericin 
(naphthodianthrone) 
hyperiforin (flavonoid) 
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The tablets were manufactured in accordance with good manufacture practice (GMP) 
standards specified by the Therapeutic Goods Administration (TGA) of the Australian 
Federal Government. Four herbal medicines with constituents extracted using variable 
rations of ethanol were mixed in equal proportions by weight and extracted in liquid 
ethanol solvent, spray dried, excipients added and tableted. Post manufacture chemical 
analysis and audit for pathogens confirmed the safety of the tablet for oral administration 
(Appendix 24). Two hundred and thirty bottles each containing 90 tablets labelled with the 
manufacturers batch number, were delivered to the researcher in August 2012.  
Storage of the herbal medicine tablets 
Bottles were securely stored in an air-conditioned room without natural light at NICM, 
(UWS). A tablet register was used to record the dispensing of tablets according to the date 
of dispensing (Appendix 25). 
Validation of herbal constituents and quantified active ingredients in PCOS-1 
Swastika Singh, a Bachelor of Medical Science Honours graduate at UWS analysed the 
contents of the new tablet, PCOS-1 (Singh 2013). The identity of herbal medicines and 
herbal biomarkers (analytes) were assessed for individual herbal medicines separated from 
the tablet as well as the herbal tablet in its complete form. Biomarkers used for quality 
control and chemical definition of the formula were selected using the Bioactivity Ranking 
Scale, (Appendix 26), which is standard procedure at NICM. The index was calculated 
according to analyte bioavailability, reported bioactivity, physiological action related to 
intended use and graded according to standardised concentration measures commercially 
available for most herbal analytes.  
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Specifically, the contents of the tablet were extracted by sonication in aqueous methanol 
70:30 (methanol:water). The characterisation and concentration of seven active ingredients 
using Ultra Performance Liquid Chromatography (UPLC), was carried out on a C18 column 
with a gradient mobile phase of 1% aqueous formic acid and acetonitrile. Liquid 
chromatography (LC) coupled with photo diode array (PDA) detection and electrospray 
ionization with tandem mass spectrometry (ES-MS/MS) confirmed the composition of the 
tablet. Herbal analytes were identified in concentrations comparable to benchmarked 
analyte concentration standards, consistent with therapeutic effects.  
Raw specimens of each herbal medicine were acquired from alternative sources (to 
Mediherb), subjected to the same analytical processes and presented chromatographically 
for comparisons.  Chromatographs of herbs isolated from the tablet and subsequently, 
herbs together as a formula, were overlayed with alternative specimen chromatographs, 
confirming the identity of the herbal medicines in the tablet and concentration of analytes. 
Results are presented in Table 5.2.   
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Table 5.2 Concentration of bioactive chemicals in herbal tablet PCOS-1. 
Herbal extract 
 
Biomarkers (analytes) Concentration of biomarkersa per tablet 
(Mean recovery mg/g-1  ± % RSD b) 
Glycyrrhiza glabra glycyrrhizic acid 
eugenol 
0.86 ± 3.86 
 
0.53 ± 3.56 
Paeonia lactiflora  paeoniflorin 
Quercetin 
0.18 ± 3.23 
 
0.63 ± 4.63 
Cinnamomum cassia  cinamaldehyde 
 
cinnamic acid 
0.60 ±6.02 
 
0.18 ± 1.69 
Hypericum perforatum  hypericin 1.25 ± 3.63 
a Analysis performed at the National Institute of Complementary Medicine, University of Western Sydney (Singh S 2013) 
bMean recovery ± % relative standard deviation (RSD) calculated from 5 replicate extractions and analysis 
 
 
Herbal medicine tablet Two – Mediherb Tribulus Forte (aerial parts) 
Tribulus Forte (aerial Parts) was (and continues to be) manufactured by Mediherb Australia 
with an established listing with the TGA of Australia (Appendix 23). Manufacture involved 
extraction of the aerial parts (branches, leaves, stems, flowers and seeds) of the plant 
Tribulus terrestris using liquid ethanol solvent at a ratio of 55:1. The extraction was then 
spray dried and excipients added to the powdered extract, tableted and coated. The 
contents of the second herbal tablet, PCOS-2, are presented in Table 5.3. 
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Table 5.3. Intervention contents tablet PCOS-2 Mediherb Tribulus Forte (aerial parts) 
 
 
Herbal medicine intervention labelling and daily dosage 
The dosage of the PCOS-1 tablet provided the equivalent dried herb dose of 2250mg per day 
for each herbal extract (Glycyrrhiza glabra, Paeonia lactiflora, Cinnamomum cassia and 
Hypericum perforatum). The dose of Tribulus terrestris provided equivalent dried herb 
dosage of 40.5g per day. The rationale for daily dosage of Glycyrrhiza glabra, Paeonia 
lactiflora and Cinnamomum cassia was based on the evidence detailed in Chapters Two and 
Three. The daily dosage of Hypericum perforatum was based on the data of a systematic 
review of the literature by Linde and colleagues (Linde, Berner and Kriston, 2008). Daily 
dosages were increased for use in overweight women in alignment with physiological 
effects based on milligrams per kilogram and naturopathic clinical practice standards (Mills, 
Bone 2000; Trickey 2011).  
In alignment with pragmatic research methods, the dispensing protocol was designed to 
reflect self-management and herbal medicine clinical practice. A label for each bottle was 
applied at the time of dispensing with the following details specified; the name of the tablet 
Herbal extract 
Part of the plant 
ratio of dried herb to solvent (ethanol) 
Dried herb 
equivalent (g) 
Extract per 
tablet (mg) 
Dried herb equivalent 
per tablet (g) 
Biomarkers (analytes) 
Tribulus terrestris  
aerial parts 13.5 g  
55:1  
13.5 245 13.5 furostanols 
calculated as 
protodioscin 45-54% 
Listed with the Therapeutic Goods Administration (TGA) of Australia number 185079 (Appendix 23) 
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as PCOS-1 or PCOS-2; date of dispensing; dosage instructions; study participants ID; the 
researcher’s name and contact details; instructions to store below 30°C; ‘for clinical trial use 
only’ and to ‘keep out of reach of children’. The dosage on bottles of PCOS-1 was ‘take three 
tablets per day with water’. The dosage of PCOS-2 was ‘take three tablets per day starting 
day five of your menstrual cycle (with the actual dates inserted if possible), for ten days in a 
row, up to day 14 of your menstrual cycle, (day 1 is the first day of your period)’. 
Participants were advised that the tablets could be taken in a format that suited them such 
as three tablets at once or one tablet three times per day, with or without food but most 
people felt more comfortable taking herbal tablets with food. Participants were provided 
with four bottles of labelled herbal medicine tablets and advised that the researcher would 
be in touch by phone or email at weeks four and eight.  
5.2.9 Study outcomes 
Outcome data was collected during the trial and at an interview twelve weeks from trial 
entry using the trial exit data collection form (Appendix 27). 
Primary endpoint  
• The mean percentage reduction in the number of days in the menstrual cycle at 
three months. 
Secondary study endpoints assessed at baseline and at three months. 
• Number of menstrual periods. 
• Percentage of women with normal menstrual cyclicity (21-34 days). 
• Serum concentration of the following hormones during the first and last menstrual 
cycle on or between days two to ten of the menstrual cycle assessed for: oestradiol, 
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follicle stimulating hormone (FSH), luteinising hormone (LH), and FSH and LH ratio,  
             testosterone, sex hormone binding globulin and free androgen index. 
• Anthropometric characteristics assessed by: body weight (kg) and BMI, waist and hip 
circumference (cm) and waist to hip ratio (W:H). 
• Serum metabolic hormone concentrations: fasting (eight hours) insulin and glucose, 
insulin sensitivity using Quantitative Insulin Sensitivity Check Index (QUICKI) (Katz, 
Nambi et al. 2000). 
• Health related quality of life assessed by: 
Polycystic ovary questionnaire (PCOSQ) and Depression, Anxiety and Stress Scale 
(DASS 21 short form). 
• Pregnancy at three months and birth outcomes assessed by: 
Serum measurements of β HCG over 10mIU/mol, ultrasound reports, antenatal 
screening and post natal reports one month following estimated due date. 
• Safety of the herbal medicine assessed by: 
Participant’s self-reporting adverse experiences, reactions or events at weeks 
four and eight 
5.2.10  Data collection protocols 
1. The number of days in the menstrual cycle  was calculated by observing the first day of 
menstrual blood flow as day one in the menstrual cycle with subsequent days numbered 
sequentially throughout the menstrual cycle until the next first day of the next menstrual 
period, which was observed as day one of the next menstrual cycle. The day before the first 
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day of the menstrual period was retrospectively noted as the last day in the previous 
menstrual cycle, calculated to represent the total number of days in the menstrual cycle.  
Participants were provided five copies of the menstrual diary charts (Appendix 28) and 20 
luteinising hormone (LH) ovulation detector tests. Women were shown web sites providing 
free menstrual cycle tracking services for use on iPhone and android mobile phones and 
devices as an additional method for recording day one of the menstrual cycle. Web sites 
included Fertility Friend and Period Tracker www.fertilityfriend.com  (FertilityFriend 2014).  
Explicit instructions were delivered in relation to day one of the menstrual cycle as ‘the first 
day of full menstrual blood flow’. Women were asked to record the date of this event in 
their menstrual diary’s and/or digital tracker. It was explained that this was the main 
outcome of the research. The menstrual cycle was explained to extend up to the next first 
day of the menstrual period. If more than forty days were observed between menstrual 
periods, participants were instructed to continue onto a new paper chart. Menstrual 
cyclicity was reviewed during the consultations at week four and eight. 
2. The number of menstrual periods in three months was determined from data collected by 
participants and recorded in the menstrual cycle diary on the day the menstrual period 
commenced. Data were collected at the trial exit interview. Participants were asked how 
certain they were of this date and could respond as a) sure, b) fairly sure or c) not sure at all. 
Participants who maintained a digital record of their cycle emailed a link to their menstrual 
calendar (Fertility Friend or Period Tracker) to the researcher. Files were downloaded, 
printed and inserted into the participants file. Baseline data (number of menstrual periods 
during previous six months) were halved at data entry for consistency with endpoint data 
reporting. 
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3. The percentage of women with normal menstrual cyclicity was determined as the 
Percentage of participants considered to have normal menstrual cycle length (mean number 
of menstrual cycle days ranged between 21 and 34 days). Twenty days or less and 35 days or 
more was considered a normal menstrual cycle length. 
4. Serum concentration of hormones were assessed using pathology tests Participants were 
requested to attend a pathology centre on or between days two and five of their menstrual 
cycle, after fasting for at least eight hours. All blood samples were collected by qualified 
phlebotomists employed by registered pathology company’s, Douglas Hanly Moir (DHM), 
Laverty Pathology (Sydney), Medilab (Canberra), Southern Pathology (Illawarra), Melbourne 
Pathology and St Vincent’s Pathology (Melbourne). Participants provided a specimen of 
blood collected in accordance with the statutory standards specified in the Australian 
Government requirements for medical pathology specimen collection (NPAAC 2013). 
Specimens were labelled and centrifuged at the collection centres prior to collection by a 
courier for delivery to the company’s laboratories. All specimens were analysed within 24 
hours of collection using automated or digital testing procedures. Laboratories were fully 
accredited with the National Association of Testing Authorities (NATA) and associated with 
the Royal College of Pathologists of Australasia (RCPA). These protocols met the 
requirements of the UWS Biosafety and Radiation Safety Guidelines.  
Serum concentration of FSH and LH were measured as international units per millilitre 
(IU/ml). Oestradiol and testosterone were measured as micromoles per litre (mmol/l) and 
SHBG measured as nanomoles per litre (nmol/l). Serum concentration of insulin was 
measured as micro units per litre (mU/l) and glucose was measured as micromoles per litre 
(mmol/l). An index used to assess insulin sensitivity, the Quantitative Insulin Sensitivity 
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Check Index (QUICKI) method was calculated using the following formula 1/(log(Io) + log Go), 
where Io was fasting insulin in mIU/ml and Go was fasting glucose levels in mg/dl (conversion 
from mmol/l to mg/dL): multiplied by 18.0. Hard copies of results were forwarded by post to 
the researcher at UWS. Copies of pathology reports were forwarded to participants and 
their medical providers.   
5. Body characteristics were measured as waist and hip circumference using a single vinyl 
tape measure, height by a metal tape measure and body weight using single analogue body 
weight scales.  
Body weight was measured consistently using the same calibrated clinical trial analogue 
bodyweight scales only. Participants were requested to remove shoes, bags, keys, phones 
and any other heavy items in pockets or items of clothing. The scales were placed on a flat, 
firm (tiled or wooden) floor surface and participants were asked to stand on scales. The 
researcher viewed the dial from one metre directly above (perpendicular) the scales and 
recorded weight in whole kilograms.  
Participant’s height was measured by asking the participant to remove shoes and stand 
against a wall, touching heels and shoulders, to look straight ahead and flatten the top of 
their head. Height was recorded as metres and two decimal places. 
Waist circumference was measured over a single layer of clothing. The tape measure was 
placed around the waist and moved to the narrowest horizontal point. The participant was 
asked to exhale. Measures were taken to the closest 0.5 cm. 
Hip circumference was measured over two items of clothing including underwear. The tape 
measure was placed around the participant’s buttocks and moved to a level, horizontal 
 186 
 
position encompassing the widest measurement. For some women this would be 
determined around buttocks for others it would be the widest abdominal region. Measures 
were taken to the closest 0.5 cm. Hip to waist ratio (H:W) was calculated as hip cm, divided 
by waist cm. 
6.  Measures of health related quality of life were assessed using the PCOSQ (Cronin, Guyatt 
et al. 1998) and depression, anxiety and stress from the short form of the depression, 
anxiety and stress scale (DASS) (Lovibond 1995).(Appendix 18). The questionnaire 
commenced with four questions about participants previous use and expectations for the 
effectiveness of the two interventions lifestyle (diet and exercise) and herbal medicine. 
The PCOSQ is a validated tool used to assess five domains of PCOS health related quality of 
life including body hair, infertility, bodyweight, menstrual problems and emotions (Cronin, 
Guyatt et al. 1998, Jones, Hall et al. 2008). Twenty six items (questions) associated with a 
seven point Likert scale that ranged from ‘all of the time’ to ‘none of the time’ were self-
reported by participants. Responses were scored one to seven so that higher scores 
indicated greater patient concern. The PCOSQ is conventionally scored so that lower scores 
denote a higher degree of patient concern. In the present case, the scores were inverted or 
reversed and the score of one represented optimal function and seven indicated worst 
function.  
Responses to certain questions in the PCOSQ provided outcomes for each domain with the 
number of questions ranging between four (infertility and menstrual problems) and eight 
(emotions). The range of scores for each domain were as follows; body hair, 5-35; infertility, 
5-28; bodyweight, 5-35; menstrual problems, 5-28 and emotions 5-56. Scores were added to 
produce an aggregate score for each domain and a total score ranging between 25 and 182.  
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The DASS 21 assessed three domains of emotional health during the previous two weeks; 
depression, anxiety and stress  (Lovibond 1995). Participants self- reported on twenty one 
items, yielding three scales of seven items each, scored on a four point Likert scale (0-3)  
ranging between ‘did not apply to me at all’ and ‘applied to me very much or most of the 
time’.  Aggregate scores for depression, anxiety and stress were calculated to range 
between zero and 21 with higher scores associated with greater depression, anxiety and/or 
stress. Mild depression was indicated as a score between 5-6; mild anxiety 4-5 and mild 
stress 8-9. Moderate scores for depression, anxiety and stress were 7-10, 6-7 and 10-12 
respectively. Severe depression scores were between 11-13, for anxiety 8-9 and for stress 
13-16. Higher scores (up to 21) were associated with extremely severe depression, anxiety 
and stress.  
The validity and reliability of the DASS 21 was exhibited through high convergent validity 
with other measures of anxiety and depression (Crawford, Garthwaite et al. 2009, Crawford, 
Cayley et al. 2011) and a factor structure consistent with the allocation of items to 
subcategories in both community and clinical samples (Antony, Bieling et al. 1998, Henry 
and Crawford 2005).  
7. Pregnancy rates, miscarriage and birth outcomes were measured following the receipt of 
pathology test results that reported serum concentrations of beta human chorionic 
gonadotropin (βHCG) over 10 international units per litre (IU/L), or the receipt of ultrasound 
report positively identifying uterine containment of embryonic heart-beat between weeks 
six to twenty gestation. Miscarriage and birth outcomes were self- reported. 
Timing of intercourse for conception was presented in detail for participants wanting to 
conceive. Women were instructed about the detection of ovulation through observation of 
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cervical mucus changes (Billings 1994) and through the use of LH ovulation urine tests. The 
ambiguity of results from the LH detector tests for women with PCOS was explained and 
stated that this was ‘another self-administered method of ovulation detection that may, or 
may not work in individual cases but worth trying because the information may be useful for 
them’.  
5.2.11  Evaluation of safety 
Adverse events  
This trial investigated herbal medicines for which there are known incidences of mild 
adverse events which may be experienced by some participants. These include nausea, 
bowel habit changes, skin rashes and headaches. Participants were questioned about their 
previous adverse reactions or experiences prior to enrolment into the trial. All participants 
were informed about the adverse events associated with herbal medicines in the Participant 
Information Brochure (Appendix 16) and advised to contact the researcher, their GP or 
health provider if they felt discomfort or side effects during the trial.  
Participants were closely monitored for potential adverse effects (Appendix 29). The 
researcher informed medical practitioners about their patient’s participation in the trial, 
fasting serum glucose and insulin concentrations were checked and clinical questions 
relating to signs and symptoms of hyper and/or hypoglycaemia (dizziness, sweating, light-
headedness, agitation, polyuria, and polydipsia) and hypertension (dizziness, headaches 
after waking, and agitation ) were asked at four weekly intervals.   
Adverse event definitions 
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The definitions, principles and procedures for adverse events (or experiences), adverse drug 
reactions (ADR) and unexpected adverse reactions were guided by the therapeutic goods 
administrations (TGA) reporting procedures specified in the Note for Guidance on Clinical 
Safety Data Management (CPMP/ICH/377/95) (TGA 2000). Adverse events were defined as 
any unfavourable and unintended find (for example an abnormal laboratory find), 
symptoms or disease temporally associated with the use of the medicine whether or not 
considered related to this medicine. Adverse drug reactions were defined as serious and 
unexpected reactions attributable to the herbal tablet. 
Adverse event management 
Participants who reported adverse events were assessed for severity and closely monitored. 
Women who reported mild adverse experiences including headache or increased bowel 
motions were advised that clinical experience has shown that these symptoms usually 
dissipate after 2-3 days. Women were encouraged to continue participation and contacted 
at 24 hour intervals to monitor progress. If symptoms lessened, women were advised to 
continue and monitored at weekly intervals for three weeks. If symptoms worsened, women 
were advised to cease medicines for seven days and to start taking again on a lower dose 
with increments every three days until the prescribed dose was reached (three tablets per 
day).  
Adverse event reporting 
All adverse reactions were addressed and recorded in individual participant records. All 
adverse events that required cessation of the intervention were reported to the UWS HREC 
within thirty days. For any serious or unexpected adverse drug reactions the ADRAC blue 
card (Report of Suspected Adverse Reaction to Drugs and Vaccines) was completed and 
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submitted to the TGA (www.tga.gov.au/adr/bluecard/pdf) within seven days (if life-
threatening) to fifteen days. This included reporting adverse events within a month and 
adverse drug reactions within a week to the approving ethics committees (UWS and FPA).  
5.2.12  Evaluation of compliance 
Compliance with the herbal medicine intervention was assessed at weeks four, eight and 
twelve as missed or reduced doses of the herbal tablets. Participants recorded their herbal 
tablet use in their menstrual diaries throughout the trial period and were asked to bring 
empty and partially empty bottles of PCOS-1 and PCOS-2 to the exit interview. Bottles were 
assessed for contents and number of remaining tablets recorded at week 12. 
Compliance with the lifestyle intervention was assessed by maintaining contact with the 
participants, by seeking feedback and by direct questioning at week 12. Women recorded 
their daily exercise duration in their menstrual diaries which was cross checked during the 
exit interview. Data included the number of weeks they completed the exercise program, 
the (average) number of days per week they exercised and the duration of exercise sessions.  
Compliance with the dietary intervention was assessed by qualitative questions about diet 
and food frequency. Participants recalled their dietary practices during the trial. Data 
collection was guided by the Lifescripts dietary sheet (Appendix 21). Women were asked if 
they had altered their dietary habits compared to pre-trial eating patterns. Participants 
recalled their typical daily intake for the number of servings of vegetables and fruit, foods 
containing fibre, weekly intake of red meat, poultry, fish, legumes and beans and their 
typical weekly intake of fast foods, (for example fried chicken, hamburgers etcetera) cakes, 
biscuits, pies and soft drinks. The use of qualitative questions over quantitative dietary 
assessment tools was intended to limit the trial burden on participants. Tools validated to 
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assess macronutrient and energy intake often require participants to measure food volume 
with scales at each meal and to respond fortnightly to questionnaires (Bountziouka, 
Bathrellou et al. 2012). Compliance with diet and exercise was compared with 
anthropometric outcomes to legitimise women’s self-reported behaviours. 
5.2.13  Sample size 
The minimal important clinical difference was determined a priori as a mean percentage 
reduction in the number of days in the menstrual cycle of 55% for the group receiving 
herbal medicine plus lifestyle intervention, compared with a reduction of number of days in 
the menstrual cycle by 30% in the group receiving only lifestyle intervention.  This was 
estimated pragmatically based on a few studies investigating similar outcomes in women 
with PCOS, using similar study design and showing statistically significant effect sizes for 
lifestyle interventions  (Hoeger, Kochman et al. 2004, Qublan, Yannakoula et al. 2007, 
Thomson and Brinkworth 2008). 
To achieve 80% power with 5% significance the minimum sample size of 61 subjects in each 
group or 122 study participants was the minimum requirement. Attrition was estimated at 
approximately 25% (Tang, Glenville et al. 2006, Stamets, Taylor et al. 2004) and the required 
sample size was calculated at 152 participants.  
5.2.14  Data entry, management and analyses 
Data were entered onto the electronic software program statistical package, SPSS version 
21.0 (IBM 2013) by an independent research assistant. There were no interim analyses. Data 
for all randomised participants were included using an intention to treat analyses (ITT). Data 
from participants who withdrew or were withdrawn were analysed according to their group 
of random assignment (Fisher, Dixon et al. 1990). Missing endpoint data were imputed with 
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the last observation carried forward method. Modified ITT analyses (post randomisation 
data excluded) were used to analyse secondary outcomes (Ten Have, Normand et al. 2008). 
Comparisons of the primary outcome following modified ITT analyses versus ITT for all 
randomised participants was used to assess risks for bias for favourable outcome reporting 
(Montedori, Bonacini et al. 2011). 
All data were described and summarised. Categorical variables were reported as 
frequencies and percentages and continuous variables as means and standard deviations 
(SD). Baseline characteristics between groups were compared for differences using chi 
square tests for categorical variables and independent t-tests for continuous variables. Data 
were assessed for normal distribution using a Kolmogorov Smirnov test prior to analyses. 
Log transformations were carried out on data not normally distributed (non-parametric) 
before analyses. Differences between groups at twelve weeks were analysed using Chi 
square tests for categorical data and independent t-tests for continuous data. Baseline and 
endpoint differences were measured between groups using independent t tests and within 
each group over twelve weeks using paired t-tests. Means, SD and 95% confidence intervals 
(CI) were reported for parametric and non-parametric data (if normally distributed or 
sample size over 30). Mean differences between groups were reported as the standard 
error of the mean, to describe the sample mean with reference to the population mean 
(with 95% probability). Non-parametric data (skewed distribution) with less than thirty 
observations were converted to their logarithmic value prior to statistical testing and back 
converted prior to reporting results. A p value less than 0.05 was estimated to be 
statistically significant.  
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Relationships between the primary outcome and secondary variables were examined using 
two-way analysis of variance (ANOVA) tests. The significance of association of secondary 
outcomes with the primary outcome, number of days in the menstrual cycle, (dependent 
variable) highlighted potential mechanisms of effect. Secondary outcomes were chosen 
based on their clinical relevance and included hormone concentrations, anthropometric 
characteristics and metabolic changes. 
The magnitude or the effect size of the intervention was estimated using Cohen’s d. Cohen’s 
d is a method for expressing the mean difference of change between the test and control 
groups in terms of standard deviations, compared with zero change using a standardised 
scale (Cohen 1992). Cohen’s d was calculated using the difference between the means of 
the test and control group, divided by the (pooled average) SD (Ellis 2009). Results were 
interpreted using standard interpretation methods according to the following scale; 0.8 (or 
eight tenths of a SD unit) was considered a large treatment effect; 0.5 (or half of a SD unit) 
was considered a moderate treatment effect size and 0.2 (or one fifth of a SD unit) was 
considered a small treatment effect size.  
To control for potential data entry errors, the files of ten participants (from the test and 
control groups) were randomly selected. Data were re-entered by an independent data 
entry research assistant. The primary outcome, anthropometric features and health related 
quality of life were analysed by measuring the difference over time within the test and 
control groups.  The location of outcomes was observed with reference to standard 
deviations of whole sample analyses. Data entry errors were not considered to have 
impacted upon the findings if results fell within standard deviations of the whole sample.   
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5.3 Results  
The first section of the results outlines the recruitment and the progression of participants 
throughout the trial period, followed by a presentation of baseline characteristics of 
participants and analysis of primary and secondary endpoints. 
5.3.1 Participants 
One hundred and eighty nine women were screened for eligibility following enquiries about 
participation in the trial. Enquiries were from women residing in; Tasmania, Western 
Australia and South Australia (n=7), Queensland (n=10), Victoria (n=13), Australian Capital 
Territory (ACT) (n=3) and in New South Wales (NSW) Hunter region (n=38), Illawarra region 
(n=9) and Greater Sydney area (n=109). Topical stories in newspapers generated the most 
enquiries about participation in the trial (n= 77). Forty eight enquiries were generated by 
web based advertisements and eleven enquiries were from women referred to the trial by 
medical providers. The remainder of enquiries were generated from community 
presentations, membership of the UWS PCOS Facebook group and through word of mouth. 
One hundred and twenty two women met the inclusion criteria and were enrolled into the 
study (Figure 2). Two participants had physical disabilities; one was restricted to movement 
using a wheelchair and another participant had significant hearing loss. Sixty seven women 
were excluded for the following reasons; location of residence not corresponding with 
recruitment locations (n=28); women taking the oral contraceptive pill or using hormonal 
tablets to induce menstrual periods (n=17); use of antidepressants (n=7), normal BMI (n=13) 
and aged less than 18 or more than 44 years (n=2).  
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Sixty women were randomly assigned to the test intervention group, herbal medicine plus 
lifestyle, and sixty two women were randomly assigned to the active control group, lifestyle 
intervention program. The progression of participants during the trial is presented in Figure 
5.2.   
5.3.2 Withdrawals and attrition 
Fourteen women or 11.5% of participants withdrew or were lost from the trial; eight were in 
the herbal medicine plus lifestyle intervention (test) group and six were in the lifestyle 
intervention alone (control) group. Rates of withdrawal were similar for each group. Two 
women allocated to the herbal medicine group were asked to withdraw due to adverse 
events associated with taking the herbal medicine intervention. Other reasons for attrition 
included loss of contact (n=6), changes in participant’s personal circumstances (n=5), leg 
injury (n=2) and self-withdrawal due to feeling incapable for participating in the exercise 
program (1). Changes in personal circumstances included travel overseas for extended 
period following death in family, separation from partner, increased family commitments, 
moved interstate for new job and enrolled in full-time study. The weeks at which drop out 
occurred included; one woman dropped out during week one (lifestyle intervention only 
group); eight women dropped out during week four (five allocated to the herbal medicine 
plus lifestyle group and three in the lifestyle intervention only group) and five women 
dropped out during week seven (three from the herbal medicine group and two from the 
lifestyle intervention only program). Two women who dropped out were trying to conceive, 
one allocated to each group. 
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Figure 5.2 Flow chart (CONSORT Diagram) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Women assessed for eligibility; 
(n = 189) 
 
 
 
Allocated to Herbal medicine + lifestyle intervention (n=60) 
Received intervention (n=60)                                                    
Did not receive intervention (n=0) 
Women excluded (n = 67). 
Not meeting inclusion criteria (n= 38) 
Refused to participate (n=0)  
Other reasons (lived interstate and 
not accessible) (n=28). 
Analysed (n=52) 
Excluded from analyses (n=0) 
Lifestyle intervention program alone (n=62) 
Received intervention (n=62) 
Did not receive intervention (n=0) 
Analysed (n=56) 
Excluded from analyses (n =0) 
Lost to follow-up (n=8)                  
Reasons; Changes in personal 
circumstances (n=4); lost contact (n=2) 
and withdrawn due to adverse effects 
(n=2). 
 
Lost to follow-up (n= 6).                       
Reasons; changes in personal circumstances 
(n=1); lost contact (n=2), injury (n=2) and 
felt apprehensive about exercise program 
(n=1). 
Randomised (n = 122) 
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5.3.3 Adverse reactions 
Two women were withdrawn from the trial due to adverse events; both were allocated to 
the herbal medicine plus lifestyle group. Physical symptoms were mild and resolved 
following cessation of taking the herbal tablets. One participant experienced flu-like 
symptoms, (headache, lethargy and joint pain) that were relieved following cessation of the 
herbal tablets. Recommencement of tablets was associated with the return of symptoms. 
Withdrawal of this participant occurred three weeks following randomisation.  
The second adverse event involved dysfunctional uterine bleeding. At week five, the 
participant’s menstrual period commenced and continued for 21 days. The participant was 
provided with a request for pathology testing, advised to cease taking the herbal tablets and 
to contact her general practitioner for assessment. Although serum concentration of 
oestradiol, progesterone, follicle stimulating hormone, luteinising hormones and fasting 
insulin and glucose were within normal ranges, the participant’s menstrual period continued 
for one week post cessation of the tablets. This participant was withdrawn from the trial at 
week six. Adverse events were reported to the human research ethics committee at UWS.  
5.3.4 Baseline characteristics of participants 
Of the 122 participants enrolled, all were aged between 18 and 43 years with an average 
age of 29.1 years (Table 5.4). Nineteen participants (15.6%) were aged 35 years or over. 
Most participants had finished high school (n=110, 90.2%) with 108 (88.5%) attaining 
tertiary qualifications. The most common highest-achieved level of education were 
undergraduate or post graduate qualifications, (n=64, 52.9%), followed by vocational skills 
training attained by 49 (40.2%) participants. Sixty six (53.3%) participants held full time 
employment, twenty one (17.2%), were in part-time employment and seventeen (13.9%) 
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were full time students. The majority of participants were Caucasian (n=82, 67.2%). Twenty 
four participants (19.7%) reported unknown ethnicity and the remainder of the group 
(n=16, 32.8%) reported descent other than Caucasian including Asian, Aboriginal or Torres 
Strait Islander, Polynesian and Maori descent.  
The relationship status of participant’s was mostly partnered; sixty participants (49.2%) 
were married and twenty one (17.2%) were living with a partner in a de facto relationship. 
Thirty four participants (27.9%) were single and seven participants reported being either 
being separated (5.7%) or divorced from their partner or ‘other’ marital status.  Differences 
in the demographic characteristics between groups were examined (Table 6.4). No 
differences between groups were found.  
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Table 5.4 Demographic characteristics at baseline 
Demographic characteristics Herbal medicine plus 
lifestyle intervention 
(n=60)  
n (per cent)  
Lifestyle 
intervention alone 
(n=62)  
n (per cent)  
p-value 
Age 
Mean age 
 (years, ± SD) 
29.23 (± 5.56) 28.97 (± 5.57) p=0.79* 
Aged 35 years or more  
 
11 (18.3) 8 (12.9) p= 0.41 
    
Ethnicity,  
Caucasian 39 (65.0) 43 (69.4) p = 0.14 
Asian 4 (6.7) 2 (3.2) 
Aboriginal TSI 5 (8.3) 0 (0) 
Polynesian 2 (3.3) 2 (3.2) 
Maori 1 (1.7) 0 (0) 
Unknown 9 (15.0) 15(24.2) 
 
Education  
High school 55 (91.7) 55 (88.7) p=0.58 
Tertiary qualifications 53 (49.1) 55 (50.9) p = 0.95 
 
Employment 
Full time 36 (60.0) 32 (51.6) p=0.49* 
Part time 10 (16.7) 11 (17.7) 
Student 5 (8.3) 12 (19.4) 
Home duties 6 (10.0) 5 (8.1) 
Casual employment part-time 3 (5.0) 2 (3.2) 
* Fishers exact test 
 
Menstrual cycle characteristics at baseline 
Most women reported long (over 35 days) and irregular menstrual cycles (n= 95, 77.9%) 
including nineteen women (15.6%) reporting amenorrhoea (180 days or more) (Table 5.5). 
Over eighty per cent (81.1%) reported surety in menstrual cycle dates. Women unsure of 
their cycle dates were amenorrheic and could estimate first day of their menstrual cycle 
dates.   
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Baseline differences for menstrual cyclicity and number of menstrual periods were not 
statistically significant between groups. Women assigned to the herbal medicine plus 
lifestyle intervention (n=60) reported mean menstrual cycle duration of 106.0 (± 123.0) days 
and women allocated to the lifestyle intervention only group (n=62) reported a mean 
menstrual cycle duration of 109.5 (± 148.0) days (p=0.889). The mean number of menstrual 
periods over the previous three months for women allocated to the test group was 1.67 (± 
1.0) and for women allocated to the lifestyle intervention only group, 1.82 (±0.98), 
(p=0.409). 
Table 5.5 Self-reported reproductive characteristics and history of test and control groups at 
baseline. 
Self-reported reproductive health 
characteristics 
Herbal medicine plus 
lifestyle intervention  (n=60) 
n (per cent)  
Lifestyle intervention 
alone (n=62) 
n (per cent) 
p-value 
Wanting to conceive during trial period 
 
36 (60.0) 36 (58.1) p = 0.828 
Time spent trying to conceive at date of 
trial entry; number of months*  
21.78 (28.20) 17.69 (15.05) p = 0.446 
Participants currently trying to conceive 
using pharmaceutical ovulation induction  
1 (1.7) 2 ( 3.2) p = 0.916 
Participants trying to conceive and using 
pharmaceutical insulin sensitisers ** 
11 (30.6) 11 (30.6) p = 9.16 
Reproductive history 
No prior conceptions  42 (70.0) 41 (66.1) p = 0.533 
Null parity  47 (78.3) 45 (72.6) p = 0.666 
Number of women previous live births  13 (21.7) 17 (27.4) 
Previous use of medical assistance  
In vitro fertilisation   3 (5.0) 2 (3.2) p = 0.48 
No use of medically assisted conception 
techniques  
10 (16.7) 9 (14.5) 
Previous pregnancy outcomes 
Previous miscarriage***   9 (15.0)** 10 (16.1)** p = 0.50 
Previous late pregnancy loss  
(week 20 or more)  
1 (1.7) 2 (3.2)  p =1.00 
* t test for difference between the means using independent samples significance of two tailed comparison 
** valid per cent 
*** miscarriage defined as loss of embryo or foetus up to the 20th week of pregnancy 
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There were no statistically significant baseline differences between the two groups for 
women with normal cyclicity oligomenorrhoea and amenorrhoea. Normal cyclicity was 
reported by eleven women (18.3%) in the test group and sixteen women (25.8%) in the 
control group. Oligomenorrhoea was reported by 40 women (66.7%) in the test group and 
36 (58.1%) in the control group and amenorrhoea was reported by nine women (15.0%) in 
the test group and ten women (16.1%) in the control group.  
Reproductive characteristics and history 
Overall there were seventy two women (59.0%) wanting to conceive. Most women wanting 
to conceive had been trying for longer than twelve months (n=39, 54.2%) and could be 
diagnosed with clinical infertility. These results included twenty women trying to conceive 
for more than two years, seven trying for more than four years and two women who had 
been trying to conceive for over ten years. Nineteen participants (15.6%) reported previous 
miscarriage and three reported late pregnancy loss. There were no statistical differences 
between the groups (Table 5.5).  
Reproductive hormone concentrations  
Serum concentrations for reproductive hormones were performed on subjects with regular 
and oligomenorrhoeic menstrual cycles during the follicular phase (day two to ten) of the 
menstrual cycle. Seventy women participated in baseline serum concentration tests 38 
(54.3%) women were assigned to the test group and 32 (45.7%) women in the control 
group. According to normal references ranges provided by the pathology laboratories, mean 
concentrations for oestradiol, FSH and LH were within normal ranges for reproductive aged 
women. However, the relative concentration of LH and FSH was elevated in both groups and 
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typically observed in women with PCOS. In the present case the FSH LH ratio was greater 
than one in 35.8% (valid percent) of subjects. There were no statistically significant 
differences between the test group (n=38) and control group (n=32) for FSH (IU/L) and LH 
(IU/L) concentration, p = 0.557 and p = 0.248, and the FSH:LH ratio p= 0.223. 
The mean testosterone concentrations and the free androgen index (FAI) indicated that the 
prevalence for biochemical hyperandrogenism for women who participated in blood tests 
(n=70) was 48%. The normal reference range for testosterone according to the pathology 
laboratories was 0.2- 1.8 nano moles per litre (nmol/l). In the present case, the mean 
concentration for testosterone was 1.84 nmol/l, (± 0.87). Thirty two women (47.8%) had 
testosterone levels over 1.79 nmol/l. The distribution of women with hyperandrogenism 
between the two groups was not significantly different 44% versus 52%.  
The normal reference range for the free androgen index (FAI) was indicated as 0.3-4.0%. The 
mean result for FAI in the sample was 7.92% (± 1.64). Sixteen women with elevated FAI 
were allocated to the test group (26.7%) and twelve to the control group (19.4%).  
There were no statistically significant differences between baseline average testosterone 
concentration (nmol/l), sex hormone binding globulin (SHBG) (nmol/l) and free androgen 
index (FAI) (%) for the test (n=40) and control group (n=37). Probability values for mean 
differences were testosterone, p = 0.589; SHBG, p = 0.203 and FAI, p = 0.370. Mean 
concentrations for oestradiol at baseline were not statistically different between the test 
and control groups (p=0.253). 
There were no statistically significant differences between groups at baseline for serum 
reproductive hormone concentrations, although the test group tended to have a higher 
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level of luteinising hormone relative to follicle stimulating hormone, higher testosterone 
and lower SHBG compared to controls group.  
Anthropometric characteristics  
Consistent with entry criteria for this trial, all participants were overweight however, 
participant’s average body mass index (BMI) was in the obese class two category at 34.66 (± 
6.987) (Govt 2005) (Table 6.6). Women’s average body weight in kilograms was 95.28 (± 
20.197) and average waist and hip circumferences in centimetres were 102.03 (± 15.353) 
and 121.00 (± 14.373) respectively. There were no significant differences between groups 
(Table 5.6). 
Table 5.6 Anthropometric characteristics at baseline 
Anthropometric measurements at 
baseline 
Herbal medicine plus lifestyle 
intervention (n=60) 
mean (SD)   
Lifestyle intervention 
alone (n=62) 
mean (SD)  
p-value 
Body weight, kilograms  94.2 (19.4) 97.3 (21.3) p = 0.260 
Body mass index (BMI) * 34.6 (7.2) 35.2 (6.8) p = 0.422 
Waist circumference (centimetres)  101.1 (13.3) 103.5 (17.1) p = 0.284 
Hip circumference  (centimetres)  120.3 (14.0) 121.7 (14.8) p =0.588 
Waist to hip ratio (H:W) ** 0.83 (0.1) 0.85 (0.1) p= 0.147 
* BMI = bodyweight (kg) divided by height (metres) squared. (BMI = w(kg)/height(m)2) 
** Waist to hip ratio = hip in (cm) divided by waist (cm). (Hip (cm)/waist (cm)) 
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Metabolic hormone concentration  
The average fasting glucose concentration for the women allocated to the herbal medicine 
plus lifestyle group was 5.066nmol/L (± 0.962) and for women in the lifestyle intervention 
only group, 5.107nmol/L (± 1.39) (p= 0.887). Average fasting insulin concentration was 
18.38mU/l (± 21.38) in the test group and 15.64mU/L (± 9.57) in the control group (p= 
0.529). The average insulin sensitivity according to QUICKI calculations was 0.33 (0.41) in the 
test group and 0.33 (0.34) in the control group (p=0.734). No differences were found 
between groups. 
The reference range according to the pathology laboratories indicated normal insulin 
sensitivity can be demonstrated by fasting insulin concentrations less than 10mU/L. Fasting 
insulin in the range of 10-14mU/L was suggestive of insulin resistance and levels over 
14mU/L in combination with QUICKI outcomes were consistent with the diagnosis of insulin 
resistance. In the present case, there were twenty nine participants with fasting insulin 
results greater than 14mU/L, fifteen (valid per cent 51.7%) in the test group and fourteen 
(valid per cent 48.3%) in the control group. Differences between groups were not significant 
(p = 5.72).Twenty nine participants were taking insulin sensitising pharmaceuticals 
(metformin) at baseline. There were no differences between groups (p=0.916). 
Lifestyle characteristics 
Women self-reported diet, exercise practices, use of complementary medicine and social 
drug use. Most women reported healthy lifestyle practices for diet and exercise. Seventy 
nine women (65%) reported consuming a diet with the aim to improve their PCOS or 
physical health, most often a healthy diet aligned with the recommendations in the 
 205 
 
Although there were more women in the test group consuming a low glycaemic index 
carbohydrate diet, there were no statistical differences for types of diets between the 
groups. Most women (n=71, 58.2%) participated in regular vigorous exercise and/or walking 
(n=109, 89.3%). Complementary medicine use was reported by 82 participants (67.2%). 
Twelve women smoked (9.8%) and seven women (5.7%) consumed more than moderate 
alcohol levels as per Australian Government standards (NH&MRC 2006). There were no 
significant differences between the groups for lifestyle habits including diet, exercise 
practices, complementary medicine use and social drug use (Table 5.7).  
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Table 5.7 Self-reported lifestyle characteristics at baseline 
Self-reported lifestyle 
characteristics 
Herbal medicine plus 
lifestyle intervention (n=60)  
n (per cent)  
Lifestyle intervention 
alone(n=62) 
n (per cent)  
p-value 
Prevalence of use for lifestyle intervention (diet and exercise) to treat PCOS 
Use of diet and exercise 43 (71.7) 46 (75.4) p = 0.57 
Self-reported dietary habits  
*Healthy diet  
 
15 (25) 17 ( 27.4) p = 2.71 
Low glycaemic index 
(GI) carbohydrates 
 
12 (20) 5 (8.1) 
High protein  
 
5 (8.3) 8 (12.9) 
Low carbohydrate  
 
5 (8.3) 7 (11.3) 
Low fat (n, per cent) 4 (6.7) 1 (1.6) 
Dietary practices not 
determined by health 
or PCOS  
 
19 (31.7) 24 (38.7) 
Self-reported exercise practices 
Engaged in regular 
vigorous exercise  
 
33 (55.0) 38 (61.3) p = 0.48 
Engaged in walking  
 
52 (86.7) 57 (91.9) p = 0.35 
Participants exercising 
more than 150 minutes 
per week  
39 (65.0) 38 (61.3) p = 0.59 
Self-reported use of complementary medicines 
Use of complementary 
medicines  
44 (73.3) 38 (61.3) p = 0.16 
Previous use of herbal 
medicine 
34 (54.8) 28 (45.2) p = 0.24 
Self-reported social drug use 
Participants who 
smoked cigarettes  
 
7 (11.7) 5 (8.1) p = 0.50 
**More than moderate 
alcohol consumption  
 
3 (8.6) 4 ( 11.1) p = 0.72 
*A healthy diet was defined according to the Lifescripts Dietary recommendations, (Appendix 21). 
**Moderate alcohol consumption was considered less than four standard alcoholic drinks, less than 
three times per week (NH&MRC 2006). 
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Health related quality of life (HRQoL) 
Women in this study reported that body-weight and infertility were the cause of greatest 
concern to them in relation to HRQoL. The mean baseline scores for the five domains, and 
percentage of maximum possible scores for the PCOSQ were; body-weight 29.2 (± 5.33), 
(82%); infertility 19.6 (± 6.56), (70%); menstrual problems 18.2 (± 5.01), (64%), emotions 
34.1 (± 9.28), (60%) and concerns about body hair 18.8 (± 9.26), (53%). PCOSQ scores at 
baseline for each group were not significantly different. Total scores for the test group was 
118.0 (± 21.9) compared to the control group 113.3 (± 24.5) (p =0.264). Domain scores were 
not significantly different either (Table 5.8). 
Table 5.8. Health related quality of life scores on the PCOSQ 
 
Scores for three domains relating to depression, anxiety and stress further indicated the 
poor quality of life for women with PCOS. The scores indicated that the average participant 
was experiencing moderate depression at 7.5 (± 5.5), moderate levels of anxiety at 6.0 (± 
Health related quality of life 
PCOSQ 
Herbal medicine plus 
lifestyle intervention 
(n=59) 
mean (SD) 
Lifestyle intervention 
alone (n=62) 
 mean (SD) 
 p-value 
Total PCOSQ score (26 – 182) 118.0 (21.91) 113.3 (24.46)  0.264 
Body hair (5-35) 19.3 (8.9) 18.2 (9.5) 0.51 
Infertility (5-28) 20.7 (6.4) 18.6 (6.6) 0.09 
Body weight (5-35) 30.1 (4.6) 28.4 (5.9) 0.08 
Menstrual problems (5-28) 17.8 (4.9) 18.6 (5.2) 0.42 
Emotions (5-56) 34.9 (9.5) 33.3 (9.1) 0.34 
The PCOSQ was scored with lower scores indicative of better health related quality of life. This is an inverted 
method compared to conventional scoring.  
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4.1) and moderate stress 10.1 (± 4.9). There were no significant differences found between 
the two groups for the domains of depression, anxiety or stress (Table 5.9). 
Table 5.9. Psychological characteristics according to the DASS 21 at baseline. 
 
Women’s expectations  
For the questions regarding expectations for lifestyle and herbal medicine interventions, 
most participants indicated that they felt positively towards both and expected that 
participation in the trial would improve their PCOS. Positive expectations were held for the 
effective of diet and exercise by fifty eight (96.7%, ± 4.5) women in the test group and fifty 
seven (95.0%, ± 5.51) in the control group, (p=1.0). Similarly, positive expectations towards  
herbal medicine in PCOS were reported by fifty eight women (96.7%, ± 4.5) in the test group 
and fifty six women (91.8%, ±6.89) in the control group,  (p = 0.23). 
Blood pressure  
The distribution of participants with pre-hypertensive systolic blood pressure was fifteen in 
test group and twenty in the control group (Table 5.10). The distribution of participants with 
stage one hypertension was five in the test group and six in the control group. There were 
no participants with systolic or diastolic blood pressure that exceeded 160mmHg or 
 Herbal medicine plus lifestyle 
intervention (n=59) 
mean (SD) 
Lifestyle intervention 
alone (n=62) 
mean (SD) 
p-value 
Depression 0-21  7.76 (5.22) 7.16 (5.76)  0.549 
Anxiety 0-21  6.22 (3.74) 5.73 (4.51) 0.514 
Stress 10.72 ( 4.59) 10.00 (5.22) 0.763 
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100mmHg respectively.  Differences between the groups were not statistically significant 
(p=0.558).  
Table 5.10 Blood pressure measurements at baseline. 
Blood pressure 
measurements (mmHg)at 
baseline 
Herbal medicine 
plus lifestyle 
intervention (n=60) 
Mean (SD) 
Lifestyle 
intervention alone 
(n=62)  
Mean (SD) 
Difference 
statistic, p-
value 
Systolic blood pressure   119.14  
(11.9) 
120.4  
(11.7) 
t = -0.461 
p = 0.646 
Diastolic blood pressure  75.1  
(13.7) 
75.8  
(14.4) 
t = -0.138 
p = 0.891 
 
In summary, there were no statistically significant differences between groups for menstrual 
characteristics, reproductive history, serum reproductive hormone concentration, 
anthropometric features, metabolic hormone concentration, lifestyle practices health 
related quality of life and blood pressure at baseline. 
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5.3.5 Effectiveness for herbal medicine plus lifestyle intervention for menstrual 
regularity 
Primary analyses were conducted using intention to treat analyses. In addition, a modified 
intention to treat analysis on the primary outcome including per-protocol data only was 
conducted due to the small number of evenly distributed withdrawals post randomisation 
(Appendix 30). Significant differences between groups at three months were observed for 
the number of days in the menstrual cycle, fasting insulin, body weight, BMI, waist 
circumference, health related quality of life, psychological morbidity and pregnancy rates.   
The primary outcome, percentage reduction of days in the menstrual cycle was significantly 
less for women in the herbal medicine plus lifestyle group compared to women undertaking 
lifestyle intervention alone. Between group analyses revealed that women in the herbal 
medicine plus lifestyle group had an average menstrual cycle length that was 32.9% (95% CI 
23.3 to 42.6, p<0.001) less than women in the control group (Table 5.11). The mean number 
of menstrual cycle days was reduced by 41.5 (95% CI, 19.9-63.0) days more than the  mean 
cycle lengths of women in the lifestyle intervention alone group, and was statistically 
significant (p<0.0001).  
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Table 5.11 Differences between the groups for the primary outcome 
Difference between 
groups 
Herbal 
medicine 
plus 
lifestyle 
mean  
(SD) 
(SE) 
Lifestyle 
intervention 
only  
mean  
(SD) 
(SE) 
 
Mean 
difference 
between 
groups 
mean  
(SD) 
(SE) 
P value 95% confidence 
interval  
Difference in the number of 
days in the menstrual cycle 
at three months  
-45.5 
(74.2) 
(9.6) 
-4.0 
(42.2) 
(5.4) 
 
41.5 
(120.4) 
(10.9) 
 
<0.0001 19.9 63.0 
Relative mean percent 
reduction in the number of 
days in the menstrual cycle 
% 
32.1 
(31.4) 
(4.1) 
0.9 
(21.7) 
(2.8) 
32.9 
(120.4) 
(4.9) 
<0.0001 23.3 42.6 
SD standard deviation of the sample mean 
SE standard error of the mean with reference to the population mean 
 
The Cohen’s effect size value was calculated as 0.7 or a moderate to high treatment effect 
size for the herbal medicine plus lifestyle intervention for reduced number of days in the 
menstrual cycle. 
A linear regression approach was used to determine the association of herbal medicine in 
addition to lifestyle intervention for the reduction of number of days in the menstrual cycle. 
The validity (normality and homoscedasticity) of the regression model was confirmed by the 
even distribution around zero for the residuals of the mean number of days in the menstrual 
cycle.   It was found that being assigned to the herbal medicine plus lifestyle group   
significantly predicted a mean reduction in the number of days of the menstrual cycle at 
three months. Results for changes in menstrual cycle length throughout the samples are 
presented in Figure 5.3. The numbers of days were scaled down from 1001 to 200 days to 
include the majority of participant’s graphic detail. 
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Figure 5.3 Number of days in the menstrual cycle 
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The change in the mean number of days was significantly reduced over time (p<0.001) for 
women within the test group from 106.0 to 62.2 days (43.8 days less, 95% CI, 24.1 to 63.5). 
Changes over time were not significant for the control group (1.5 days less, 95%CI -11.6 to 
14.5, p=0.46) (Table 5.12).  
Table 5.12 Changes in the number of days in the menstrual cycle at three months, within 
group comparisons. 
Number of days in the 
menstrual cycle at three 
months 
Baseline 
mean  
(SD) 
Endpoint  
mean  
(SD) 
Mean 
difference 
(SE) 
95% confidence 
interval 
P value 
Lifestyle program only 
(n=62) 
109.5 
(148.0) 
108.0 
(151.0) 
1.5 
(9.8) 
-11.6 14.5 0.824 
Herbal medicine plus 
lifestyle program 
(n=60) 
106.0 
(123.3) 
62.2 
(101.8) 
43.8 
(6.5) 
24.1 63.5 <0.001 
 
5.3.6 Secondary outcomes 
Number of menstrual periods during three months 
Participants in the herbal medicine plus lifestyle intervention group reported more 
menstrual periods during the three month trial period compared to the women in the 
lifestyle intervention only group. At three months, the average number of menstrual periods 
in the test group was 2.47 (± 0.92) which was 0.83 (± 0.48) more menstrual periods than 
women in the control group who reported 1.85 (±0.99). Differences between the two 
groups for numbers of menstrual periods were statistically significant p < 0.001. 
Proportion of women with amenorrhoea, oligomenorrhoea and normal menstrual cycles. 
At the end of three months, the proportion of women reporting normal menstrual cyclicity  
had significantly increased in the herbal medicine plus lifestyle group compared to the 
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control group (p<0.0001). Thirty three women (55.0%) reported normal menstrual cycles (20 
to 34 days). Comparatively, fifteen women (24.2%) reported normal cyclicity after three 
months in the control group. In addition, there were fewer amenorrheic women in the test 
group compared to controls at endpoint with three women (5.0%) in the test group 
reporting no menstrual periods compared to ten (16.1%) in the control group (p<0.0001).  
 Oligomenorrhoeic and amenorrheic data from each group were combined and compared 
with normal cycle length at endpoint (dichotomous data). The relative risk for developing a 
normal menstrual cycle length from an oligomenorrhoeic or amenorrheic cycle length was 
1.9 (95% CI 1.32-2.69) for women in taking the herbal medicine tablets (Table 5.13).  
Table 5.13 Participants with normal cyclicity, oligomenorrhoea and amenorrhoea within 
each group after three months. 
Menstrual 
cyclicity, 
normal, 
oligomenorrhoe
a and 
amenorrhoea 
Herbal medicine plus lifestyle 
intervention 
n=60 
Lifestyle intervention only 
n=62 
Difference 
 Baseline 
n, (%) 
Endpoint  
n, (%) 
Change 
from 
baseline 
n, (%) 
95% 
CI 
 
Baseline    
n, (%) 
Endpoint  
n, (%) 
Change 
from 
baseline  
n, (%) 
95% 
CI 
 
p 
value 
relative 
risk  
(95% CI) 
Menstrual cycle 
normal duration  
(20-34 days in 
menstrual cycle )  
11 
(18.3) 
33  
(55.0) 
+22 
(36.7) 
23.7
-
49.1 
16 
(25.8) 
15  
(24.2) 
-1 
(1.8) 
1.7-
5.3 
<0.001 1.9 
(1.32-
2.69) 
 
Menstrual cycle 
oligomenorrhoei
c (35-179 days in 
the menstrual 
cycle) 
40 
(66.7) 
24  
(40.0) 
-16 
(-26.6) 
22.0
-
47.2 
36 
(58.1) 
37  
(57.7) 
+1 
(7.1) 
0.4-
13.8 
Menstrual cycle 
amenorrheic  
(180 to 1001+ 
days in the 
menstrual cycle) 
9 
(15.0) 
3 
(5.5) 
-6 
(10.9) 
2.7-
19.1 
10  
(16.1) 
10  
(16.1) 
0 
(0) 
1.7-
5.3 
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Reproductive hormone concentrations 
Sixty four women provided blood samples for hormone analyses between days two and ten 
of the menstrual cycle at three months. The distribution of data for FSH, LH oestradiol, 
testosterone and free androgen index (FAI) was not normal and these variables were 
transformed into their logarithmic expression prior to analyses. Following examination of 
the graphical presentation of data, one outlier for the variable FSH (63.0mmol/L) was 
observed at endpoint. Data were cross-examined for explanations. It was found these data 
represented a participant aged 43 who had progressed into menopause. Considering that 
the diagnosis of menopause would not positively influence the primary outcome (increase 
rather than decrease the number of days in the menstrual cycle)  it was decided to re-enter 
the data so that it remained the highest result but with less difference compared to the 
second highest FSH result. This limited its influence on the regression line. There were no 
outliers for remaining variables.  There were no significant differences between groups 
however, the mean differences between the groups for reduced LH and improved FSH and 
LH ratio tended towards significance with the p values of 0.09 and 0.07 respectively (Table 
5.14).   
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Table 5.14. Mean difference in reproductive hormone concentration between groups 
Reproductive hormone 
concentration days 2-10 of the 
menstrual cycle  at three months 
Herbal 
medicine plus 
lifestyle 
(n=34) 
 
Lifestyle 
intervention 
program 
(n=30)  
 
Difference in changes between the two 
groups 
 
 mean (SD) mean (SD) Mean 
difference  
(SE) 
 
95% CI 
P value 
Follicle stimulating hormone  
(FSH) IU/L * 
0.51  
(1.9) 
0.91 
(1.9) 
0.16 
(0.5) 
-1.16 0.74 0.74 
Luteinising hormone (LH) IU/L * -2.71 
(6.3) 
0.86  
(3.2) 
1.71 
(1.0) 
-0.33  3.76 0.09 
FSH:LH ratio  - 0.16  
(0.329) 
-0.09  
(0.6) 
0.31 
(0.2) 
-0.65  0.03 0.07 
Oestradiol pmol/L * -31.84  
(214.8) 
-20.05  
(220.0) 
0.40 
(61.9) 
-124 -125 0.99 
Testosterone nmol/L * -0.38  
(1.2) 
-0.15  
(0.5) 
0.17 
(0.3) 
-0.32 - 0.67 0.49 
Sex hormone binding globulin  
nmol/L  
-2.66  
(15.9) 
0.16  
(10.4) 
36.44 
(28.4) 
-93.4  20.6 0.21 
Free androgen index %  0.54  
(3.1) 
0.21  
(2.4) 
1.77 
(3.7) 
-5.60 9.13 0.63 
*Log transformations were carried out on the data before analyses. 
 
There was a clinical improvement for biochemical hyperandrogenism in both groups. The 
endpoint testosterone was within the normal range for reproductive aged women (0.2-1.8 
nmol/l) at the end of the intervention however, this was not significantly different between 
groups (Table 5.14). 
Within group changes over time found significant reductions within the test group for 
luteinising hormone (p=0.017) (Figure 5.4) and FSH and LH ratio (p=0.002) (Table 5.15). 
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Figure 5.4. LH within groups over three months.  
 
 
 
 
 
 
 
 
 
 
 
8.78 
5.48 
6.90 
5.95 
0
1
2
3
4
5
6
7
8
9
10
Baseline At three months
Se
ru
m
 c
on
ce
nt
ra
tio
n 
of
 L
H 
IU
/L
 
Herbal medicine + lifestyle intervention Lifestyle intervention alone
p = 0.017 p = 0.12 
 218 
 
Table 5.15 Serum reproductive hormones within group changes from baseline  
 Herbal medicine plus lifestyle Lifestyle intervention only 
Serum hormone 
concentrations 
day 2-5 of the 
menstrual cycle  
Baseline 
(n=40) 
mean 
(SD) 
Endpoint 
(n=33) 
mean 
(SD) 
 
Mean 
difference 
(SD) 
p  
value 
95% 
CI 
Baseline 
(n=37) 
mean 
(SD) 
Endpoint 
(n=30) 
mean 
(SD) 
 
Mean 
difference 
(SD) 
p 
value 
95% 
CI 
Follicle 
stimulating 
hormone (FSH) 
IU/L * 
6.04  
(3.95) 
5.10  
(1.69) 
 
0.37 
(1.7) 
0.21 0.23-
0.98 
5.59 
(1.78) 
5.01 
(2.04) 
 
 
0.69 
(2.1) 
0.08 -0.08 
– 
1.45 
Luteinising 
hormone (LH) 
IU/L  * 
8.78 
(6.726) 
5.48  
(2.22) 
-2.71 
(6.3) 
0.02 0.92 
-4.23 
6.90  
(3.85) 
5.78  
(3.87) 
1.19  
(4.1) 
0.12 -0.34 
– 
2.72 
FSH:LH ratio  
 
1.49 
(1.00) 
0.92  
(0.39) 
-0.21 
(0.36) 
0.00 0.02 
–  -
0.53 
1.282 
(0.67) 
1.09 
(0.54) 
0.10 
(0.92) 
0.54 -0.23 
– 
0.25 
Oestradiol 
pmol/L * 
200.2 
(116.5) 
228.0 
(160.4) 
-17.7 
(201.2) 
0.68 -
104.
7- 
69.3 
165.96 
(102.95) 
192.9 
(176.7) 
-18.1 
(209.0) 
0.70 -
113.
2 – 
77.1 
Testosterone 
nmol/L * 
1.94  
(1.21) 
1.68 
(0.81) 
0.35 
(1.16) 
0.11 -0.08 
– 
0.78 
1.81 
(0.721) 
1.69 
(0.763) 
0.18 
(0.51) 
0.09 -0.03 
– 
0.38 
Sex hormone 
binding globulin 
nmol/L  
47.38 
(34.31) 
47.93 
(26.69) 
-2.3 
(24.1) 
0.61 -
11.4
8 – 
6.88 
78.63 
(138.42) 
41.86 
(21.95) 
4.29 
(20.4) 
0.34 -4.77 
– 
13.3
4 
Free androgen 
index % * 
9.19 
(15.39) 
6.53  
(8.10) 
3.37 
(16.14) 
0.29 -2.87 
– 
9.40 
6.20 
(8.024) 
5.48  
(4.86) 
1.5 (6.7) 0.31 -1.47 
– 
4.47 
* Log transformations were carried out on the data before analyses. Means and 95% CI were reported after results were 
back transformed. 
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Anthropometric outcomes 
At three months there were significantly greater improvements for the test group compared 
to controls in body weight (p<0.001), BMI (p<0.001) and waist circumference (p<0.001). 
Differences in change for hip to waist ratio were not significantly different between groups 
(Table 5.16). 
Table 5.16 Anthropometric characteristics between groups at three months 
Differences between groups 
for anthropometric changes.  
Herbal medicine 
plus lifestyle 
intervention 
(n=55) 
Lifestyle 
intervention only 
(n=58) 
Difference in change between groups 
 
mean (SD) 
 
mean (SD) mean difference  
(SE***) 
95% CI P value 
Body weight in kilograms -3.28  
(4.89) 
-0.10  
(3.48) 
3.18 
(0.79) 
1.6 4.8 <0.001 
Body mass index (BMI)* -1.26  
(1.7) 
-0.15  
(1.3) 
1.11  
(0.28) 
0.6  1.7 <0.001 
Waist circumference (cm)  
 
-4.8  
(5.3) 
-1.2 
(3.6) 
3.62 
(0.84) 
2.0  5.3 <0.001 
Waist to hip ratio (W:H)**  
 
-0.0002 
(0.04) 
-0.004  
(0.03) 
-0.004 
(0.001) 
-0.02 0.01 0.569 
* BMI = bodyweight (kg) divided by height (metres) squared. (BMI = w(kg)/height(m)2) 
** Waist to hip ratio = hip in (cm) divided by waist (cm). (Hip (cm)/waist (cm)) 
*** Standard error of the mean difference with reference to the population mean 
  
Within group changes were significantly improved for women in the herbal medicine plus 
lifestyle intervention for body weight (p<0.001), BMI (p<0.001) and waist circumference 
(p<0.001). Women assigned to lifestyle intervention alone demonstrated significant within 
group improvements for waist circumference (p=0.02) (Table 5.17). 
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Table 5.17 Anthropometric characteristics within groups at three months 
Anthropometric 
characteristics 
Herbal medicine plus lifestyle  
 
Lifestyle intervention only 
 Baseline 
(n=60) 
mean, 
(SD) 
Endpoint 
(n=55) 
mean, 
(SD) 
Mean 
difference 
(SD) 
p 
value 
95% 
CI 
Baseline 
(n=62) 
mean, 
(SD) 
 
Endpoint 
(n=58) 
mean, 
(SD) 
 
 
Mean 
difference 
(SD) 
 p 
value 
95% 
CI 
Body weight in 
kilograms 
 (mean, SD)  
94.2 
(18.9) 
90.9 
(19.1) 
-3.28 
(4.89) 
<0.001 1.96-
4.60 
97.3 
(21.3) 
97.4 
(22.1) 
-0.10 
(3.48) 
0.825 -
0.81-
1.1 
Body mass 
index (BMI) 
(mean, SD)* 
34.5 
(7.2) 
33.3 
(7.4) 
-1.26 
(1.7) 
<0.001 0.80 
– 
1.72 
35.16 
(6.8) 
35.03 
(7.1) 
-0.15 
(1.29) 
0.384 -0.19 
– 
0.50 
Waist 
circumference 
(cm)  
(mean, SD) 
101.1 
(13.3) 
96.3 
(13.7) 
-4.8 
(5.25) 
<0.001 3.38 
– 
6.22 
103.5 
(17.1) 
102.4 
(17.28) 
1.17 
(3.58) 
0.02 0.23- 
2.11 
Waist to hip 
ratio (W:H)  
(mean, SD)  
0.83 
(0.07) 
0.83 
(0.06) 
-0.0002 
(0.044) 
0.973 -0.01 
– 
0.01 
0.85 
(0.09) 
0.84 
(0.09) 
0.004 
(0.33) 
0.369 -
0.005 
– 
0.012 
* BMI = bodyweight (kg) divided by height (metres) squared. (BMI = w(kg)/height(m)2) 
** Waist to hip ratio = hip in (cm) divided by waist (cm). (Hip (cm)/waist (cm)) 
 
Serum metabolic hormone concentration 
Serum fasting insulin and glucose concentration and insulin sensitivity was assessed for fifty 
one subjects. Significantly improved outcomes was found for the test group compared to 
controls for fasting insulin (p=0.03). There were no differences between the two groups for 
fasting glucose and the QUICKI index at endpoint (Table 5.18).  
  
 221 
 
Table 5.18 serum metabolic hormone concentration between groups at three months 
Differences between groups fasting 
metabolic hormone concentrations 
Test group 
difference 
(n=26) 
 
Control group 
difference 
(n=25) 
 
Difference between 
groups 
 
P 
value 
 mean  
(SD) 
mean  
(SD) 
mean 
(SE) 
95% CI  
Fasting glucose nmol/L## -0.07  
(0.56) 
-0.02 
(0.50) 
0.51 
(0.15) 
-0.26 0.36 0.53 
Fasting insulin mU/L## 
 
-6.36  
(21.15) 
2.16 
(11.13) 
8.52 
(4.76) 
-1.04 18.09 0.03 
QUICKI## 0.02 
( 0.04) 
0.004  
(0.02) 
-0.007 
(0.009) 
0.03 0.01 0.15 
Quantitative Insulin Sensitivity Check Index (QUICKI) method = 1/(log(Io) + log Go).    
Io fasting insulin levels in mIU/ml 
Go fasting glucose levels in mg/dl (conversion from mmol/l to mg/dL: multiplied by 18.0  
##Log transformations were carried out on the data before analyses.  
 
No statistically significant within group differences were found  for fasting glucose, insulin or 
the QUICKI index at three months however a clinically significant difference was observed in 
the women taking the herbal medicine tablets. In this group the mean serum concentration 
for fasting insulin at three months was 14.7 which was in the ‘suggestive of insulin 
resistance’ category rather than within the category of diagnosis of insulin resistance 
(>14.9). The average fasting insulin concentration increased in the lifestyle intervention only 
group from 15.7 (±9.6) to 18.3 (±17.02) (Table 5.19). 
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Table 5.19. Metabolic hormone concentration within groups at three months 
Metabolic 
hormone 
concentrations 
after fasting for 
at least eight 
hours 
Herbal medicine plus lifestyle Lifestyle intervention only 
Baseline 
(n=40) 
mean 
(SD) 
Endpoint 
(n=26) 
mean 
 (SD) 
Mean 
difference 
(SD) 
p 
value 
95% 
CI 
Baseline 
(n=37) 
mean 
(SD) 
 
Endpoint 
(n=25)  
mean 
(SD) 
 
 
Mean 
difference 
(SD) 
 p 
value 
95% 
CI 
Fasting glucose 
nmol/L 
 
5.07  
(0.96) 
4.98  
(1.26) 
0.07  
(0.56) 
0.55 -0.16 
– 
0.29 
5.11 
(1.39) 
5.2  
(1.8) 
0.02 
(0.05) 
0.87 -0.20 
-0.23 
Fasting insulin 
mU/L 
 
18.4  
(21.4) 
14.7 (10.7) 6.4 
(21.2) 
0.14 -2.18 
– 
14.9 
15.7  
(9.6) 
18.3 
(17.02) 
2.16  
(11.13) 
0.34 -6.75  
-2.43 
*QUICKI## 0.33  
(0.41) 
0.34   
(0.03) 
0.01 
(0.04) 
0.16 -0.03 
-0.01 
0.33 
(0.034) 
0.33 
(0.04) 
0.01  
(0.04) 
0.48 -0.01 
– 
0.01 
*Quantitative Insulin Sensitivity Check Index (QUICKI) method = 1/(log(Io) + log Go).    
Io fasting insulin levels in mIU/ml 
Go fasting glucose levels in mg/dl (conversion from mmol/l to mg/dL: multiplied by 18.0  
##Log transformations were carried out on the data before analyses. 
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Health related quality of life (HRQoL) 
Women assigned to the herbal medicine plus lifestyle group reported significantly greater 
improvements in HRQOL compared to the lifestyle intervention only group. Comparative 
improvements were demonstrated for the total score of the PCOSQ (p<0.001) and for the 
domains of menstrual problems (p < 0.001), bodyweight (p = 0.001) and emotions (p = 
0.001) (Table 5.20).  
Table 5.20. Differences between groups for the PCOSQ at three months 
PCOSQ Test group 
difference 
(n=54)  
 
Control 
group 
difference 
(n=55) 
 
Difference between groups 
 
PCOSQ mean  
(SD) 
mean  
(SD) 
mean 
(SE) 
95% CI P value 
PCOSQ 
 
-33.55  
(25.88) 
-4.43  
(22.23) 
29.12 
(4.78) 
19.6  38.6 <0.001 
Body hair (5-35) 4.8 
(5.9) 
1.3 
(4.8) 
2.01 
(1.79) 
-5.6 1.5 0.248 
Infertility (5-28) 6.7 
(6.3) 
1.7  
(3.8) 
2.2 
(5.19) 
-5.2 0.1 0.059 
Body weight (5-35) 8.6  
(7.6) 
2.3  
(6.4) 
5.1 
(8.1) 
-8.1 -2.2 0.001 
Menstrual problems (5-28) 5.5  
(4.4) 
1.2  
(3.7) 
4.6 
(6.5) 
-6.5 -2.6 <0.001 
Emotions (5-56) 12.3  
(8.5) 
 
2.5  
(8.4) 
7.7 
(11.9) 
-11.9 -3.4 0.001 
The PCOSQ was scored with lower scores indicative of better health related quality of life. This is the reverse 
of conventional scoring. 
 
Within group changes demonstrated that HRQoL improved statistically for women taking 
the herbal medicine tablets in all five domains of PCOS concerns over time (P<0.001). 
Women allocated to the lifestyle intervention group reported statistically significant 
improvements in four domains; body weight (p = 0.01), infertility (p = 0.02), menstrual 
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problems (p = 0.02) and emotions (p = 0.04) but concerns about body hair and the total 
PCOSQ score were not significantly different following the three month study period (Table 
5.21). 
Table 5.21 PCOSQ within group changes at three months  
Health related 
quality of life 
PCOSQ 
Herbal medicine plus lifestyle 
 
Lifestyle intervention only 
 
Baseline 
(n=60) 
mean 
(SD) 
Endpoint 
(n=54) 
Mean 
(SD) 
 
Mean 
difference 
(SD) 
p 
value 
95% 
CI 
Baseline 
(n=62) 
mean 
(SD) 
 
Endpoint 
(n=58) 
Mean 
(SD) 
 
Mean 
difference 
(SD) 
P 
value 
95% CI 
PCOSQ (26-182) 118.03 
(21.91) 
85.05 
(32.39) 
33.6 
(25.9) 
<0.001 26.3-
40.8 
113.29 
(24.46) 
107.75 
(31.45) 
5.6  
(22.6) 
0.161 
 
-1.82 – 
10.69 
Body hair (5-35) 19.3 
(8.9) 
14.8 (9.2) 4.8 
(5.9) 
<0.001 -5.6-
1.5 
18.2  
(9.5) 
16.9  
(9.6) 
1.3 
(4.8) 
0.06 -0.004-
2.6 
Infertility (5-28) 20.7 
(6.4) 
14.3 (7.1) 6.7 
(6.3) 
<0.001 -5.2-
0.1 
18.6  
(6.6) 
16.9  
(6.8) 
1.7  
(3.8) 
0.001 0.70-
2.76 
Body weight (5-
35) 
30.1 
(4.6) 
21.5 (8.7) 8.6  
(7.6) 
<0.001 -8.1- 
-2.2 
28.4  
(5.9) 
26.6  
(7.0) 
2.3  
(6.4) 
0.01 0.6-4.0 
Menstrual 
problems (5-28) 
17.8 
(4.9) 
12.2 (5.0) 5.5  
(4.4) 
<0.001 -6.5- 
-2.6 
18.6  
(5.2) 
16.7  
(5.0) 
1.2  
(3.7) 
0.02 0.21-
2.23 
Emotions (5-56) 34.9 
(9.5) 
23.1 
(10.1) 
12.3  
(8.5) 
 
<0.001 -11.9 
- -3.4 
33.3  
(9.1) 
30.7 
(11.7) 
2.5  
(8.4) 
0.04 0.2-4.8 
The PCOSQ was scored with lower scores indicative of better health related quality of life. This is the reverse for 
conventional scoring. 
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Differences between groups for depression, anxiety and stress were significant, with 
participants in the group taking the herbal medicine tablets reporting less depression, 
anxiety and stress compared to controls (Table 5.22). 
Table 5.22 Anxiety, depression and stress between groups at three months  
DASS scores  Test group 
difference 
(n=54) 
 
Control group 
difference 
(n=55) 
 
Difference between the test and 
control  groups 
 
Mean differences in scores for the test 
and control groups baseline to 
endpoint  
mean  
(SD) 
mean  
(SD) 
Mean  
difference 
(SE) 
95% CI P value 
Depression 0-21  
(mean, SD) 
4.74 
(4.65) 
0.54 
(5.03) 
3.90 
(0.93) 
2.05 5.75 <0.001 
Anxiety 0-21  
(mean, SD) 
3.87 
(3.77) 
0.53 
(3.46) 
3.34 
(0.69) 
1.97 4.71 <0.001 
Stress  
(mean, SD) 
5.019 
(4.684) 
0.86 
(4.39) 
4.16 
(0.87) 
2.43 5.89 <0.001 
 
Within group changes over time for anxiety, depression and stress significantly improved for 
women in the test group at three months from being in the moderated range for all three 
domains into the normal reference range (depression 0-4, anxiety 0-3 and stress 0-7). The 
scores of women in the control group however, remained within the moderate range for 
depression and stress (7-10, and 10-12 respectively) and in the mild range for anxiety (4-5). 
Although there were within group improvements in anxiety and stress for women assigned 
to the lifestyle intervention group they were not statistically significant and exacerbation 
was demonstrated for depression with scores at three months (7.44, ±5.89) greater than 
baseline scores (7.16, ±5.76) (Table 5.23).  
 226 
 
Table 5.23 Anxiety, depression and stress within groups at three months  
 
The effectiveness of taking the herbal tablets with lifestyle intervention compared to the 
lifestyle program alone for the PCOSQ and DASS21 was examined using a linear regression 
approach. Baseline values were inserted as co-variants. Results showed an average 
reduction in the scores of the PCOSQ of 28.6 points (95% CI, 19.0 -38.18) for women taking 
the herbal plus lifestyle intervention. The effectiveness for herbal medicine plus lifestyle on 
the DASS 21 was also analysed. The addition of herbal tablets effectively lowered mean 
depression scores by 3.5 points (95% CI, 1.9-4.9); mean anxiety scores by 3.2 points (95% CI, 
1.9– 4.7) and mean stress scores by 4.2 points (95% CI, 2.76-5.73) compared to women 
engaged in the lifestyle intervention program only. 
 
 
 
 
DASS21 Herbal medicine plus lifestyle 
 
Lifestyle intervention only 
 
Baseline 
(n=60) 
mean 
(SD) 
 
Endpoint 
(n=54) 
mean 
(SD) 
 
p value 95% CI Baseline 
(n=62) 
mean 
(SD) 
 
Endpoint 
(n=58) 
mean 
(SD) 
 
P value 95% CI 
Depression 0-21  
 
7.76 
(5.22) 
3.50 
(3.8) 
<0.001 3.46 – 6.02 7.16 
(5.76) 
7.44 
(5.89) 
0.22 -0.52-2.20 
Anxiety 0-21  
 
6.22 
(3.74) 
2.52 
(2.95) 
<0.001 2.84 – 4.90 5.73 
(4.51) 
5.40 
(4.85) 
0.26 -0.41 – 1.46 
Stress 0-21 
 
10.72 
(4.59) 
5.13 
(3.82) 
<0.001 3.72 – 6.32 10.00 
(5.22) 
9.46 
(5.27) 
0.15 -0.32-2.03 
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Conception, pregnancy and birth outcomes 
Conception rates were significantly higher in the test group where 11/34 (32%) of women 
who wanted to conceive did compared with 3/36 (8%) in the control group (p=0.01). 
Overall, 70 of 122 (57.4%) women wanted to conceive (34 in the test group and 36 in the 
control group) and there were 14 pregnancies in the sample (14/122 17.1%) of which 78.6% 
were women allocated to the herbal medicine plus lifestyle group. These results 
demonstrated that the likelihood of conception for women wanting to conceive in the 
herbal medicine group was 3.88 (95% CI 1.18-12.73) times greater than women assigned to 
the lifestyle only group.  
Pregnant women miscarried at similar rates in the test and control groups at approximately 
one in three (test group 4/11, 36.4%, control group 1/3 33%, p=0.2). Seven out of eleven 
pregnancies led to the live birth of a healthy baby in the herbal medicine group and two out 
of three pregnancies lead to the birth of a live healthy baby in the lifestyle intervention only 
group.  The live birth rate was not statistically different between the groups (test group 
34/7, control group 36/2, p=0.06). Twenty two percent of women in the herbal medicine 
group gave birth to a healthy baby compared to 5.6% of women in the lifestyle only group 
(Table 5.24). 
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Table 5.24 Conception, pregnancy and birth outcomes between groups for women wanting 
to conceive. 
Conception, pregnancy and birth 
outcomes for women wanting to 
conceive 
Herbal medicine plus lifestyle 
intervention 
(n=34) 
Lifestyle intervention program  
(n=36) 
P value 
 N % 
(95% CI) 
relative risk  
(95% CI) 
N % 
(95% CI) 
Relative risk 
(95% CI) 
 
Positive pregnancy result 11 32.4* 
(16.7-
48.1) 
 
3.87  
(1.14-13.13) 
3 8.3* 
-0.7-
17.3 
0.74  
(0.57-0.95) 
0.01*** 
Miscarried before week 12 4 36.4** 
(8.0-
64.8) 
1.0  
(0.59-1.8) 
1 33.3** 
(-20.0-
86.6) 
0.9  
(0.11-7.63) 
 0.20* 
Live birth following completion of 
trial 
7 21.9 
(8.0-
35.8) 
3.7 
(0.8-16.6) 
2 5.5 (-
2.0-
13.0) 
0.84  
(0.7-1.0) 
0.06* 
* valid percent and risk ratio calculated for women trying to conceive n=34 each group. 
**Valid percent  and risk ratio calculated for women who conceived 
*** Fishers exact test two sided test for significance 
 
5.3.7 Predictive variables  
 There was a significant effect of reduced luteinising hormone concentration on the number 
of days in the menstrual cycle (F (1, 62) = 13.7, n=64, p<0.001). Fasting insulin was not found 
to be a significant predictor for the number of days in the menstrual cycle (F (1, 24) = 0.391, 
n= 51, p = 0.99) and nor was BMI (F (1,110) =0.62, n=113, p = 0.43) (Appendix 31). 
 
5.3.8 Adverse event exploration - Blood pressure 
There were no adverse events reported in relation to changes in blood pressure. Women 
within the herbal medicine group had significantly lower systolic and diastolic blood 
pressure following three months treatment (P<0.001) (Table 5.25).  
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Table 5.25 Blood pressure within group comparisons at three months 
 
5.3.9 Lifestyle practices during the trial. 
Women self-reported their lifestyle practices throughout the trial (Table 6.24). There were 
no significant differences between the groups for exercise duration. There were however 
significant improvements for the control group for dietary practices (P<0.001) with 
increased adoption of a low GI diet. Most participants in the trial reported improved lifestyle 
habits with reference to the EBG for the management of PCOS. Eighty nine participants 
reported more than 150 minutes of exercise per week at the end of the trial compared to 
seventy participants at baseline which was statistically significant (p=0.03) (Table 5.26). 
  
Blood 
pressure 
Herbal medicine plus lifestyle 
 
Lifestyle intervention only 
 
Baseline 
(n=60) 
mean 
(SD) 
 
Endpoint 
(n=51) 
mean  
(SD) 
 
Mean 
difference 
(SD) 
p 
value 
95% 
CI 
Baseline 
(n=62) 
mean 
(SD) 
 
Endpoint 
(n=57) 
mean 
(SD) 
 
Mean 
difference 
(SD) 
p 
value 
95% 
CI 
Systolic blood 
pressure 
mmHg 
 
119.3 
(11.9) 
113.8 
(11.8) 
5.5 
(9.1) 
<0.001 3.0-
8.1 
120.4 
(11.7) 
119.0 
(10.2) 
1.5 
(8.4) 
0.19 0.8-
3.7 
Diastolic 
blood 
pressure 
mmHg 
 
75.1 
(13.7) 
68.6  
(8.5) 
6.6 
(9.5) 
<0.001 3.9-
9.2 
75.8 
(14.4) 
75.1  
(12.1) 
0.7 
(10.9) 
0.65 2.2-
3.6 
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Table 5.26 Self-reported lifestyle practices within group comparisons over time 
 
Self-reported lifestyle 
practices 
Herbal medicine plus lifestyle (n=60) Lifestyle intervention only (n=62) 
 Baseline 
n,  (%)  
Endpoint  
n, (%) 
P value Baseline  
n, (%) 
Endpoint  
n,  (%) 
P value 
Exercise practices 
Exercise more than 
150 minutes per week 
35 (58.3) 43 (71) 0.10 35 (56.5) 46 (74.2) 0.19 
Dietary practices 
Healthy diet 14 (23) 15 (25) 0.09 16 (25) 16 (25.8) <0.001 
Low glycaemic index 9 (15) 17 (28.3) 5 (8.1) 12 (24.2) 
Low carbohydrate 4 (6.7) 1 (1.6) 71 (1.2) 2 (3.2) 
High protein 5 (8.3) 17 (28.3) 8 (12.9) 14 (22.5) 
Low fat 4 (6.7) 1 (1.6) 1 (1.6) 0 (0) 
No health conscious 
dietary practices 
18 (30) 3 (5) 21 (33.8) 14 (22.5) 
 
  
 231 
 
5.4 Discussion  
This randomised controlled trial (RCT) demonstrated the positive therapeutic impact of 
adding five herbal medicines  to a lifestyle program compared to lifestyle intervention alone 
for overweight women with PCOS. Herbal medicine plus lifestyle produced a significant 
reduction in the number of days of the menstrual cycle, and provided a moderate to large 
treatment effect on menstrual cyclicity (oligo/amenorrhoea). The null hypothesis was 
rejected with less than 5% type I error rate.  Other statistical and clinically significant 
improvements to women’s physical and emotional wellbeing were found for women taking 
the herbal medicine tablets plus lifestyle compared to controls. These outcomes included 
body weight, BMI, waist circumference, fasting insulin, conception rates, quality of life and 
blood pressure. The study also showed important significant reductions to women’s 
depression, anxiety and stress. Interesting observations included significantly reduced 
serum luteinising hormone (LH) in the test group over three months and improved live birth 
rates for women in the test group compared to controls. Although this study was not 
powered for sub-group analyses (number of women who participated in blood tests and 
number who conceived), results for these variables were promising. 
This study adds new information by demonstrating improvements for menstrual regulation 
for a new combination of herbal medicines in overweight women with PCOS. The selection 
of herbal medicines was based on the results of the literature reviews and naturopathic 
herbal combining principles and this study confirms the contribution of this approach to 
significant positive outcomes and low adverse reactions. The herbal selection was based on 
their potential to improve reproductive endocrinology in PCOS, and tailored to the wider 
presentation of women with PCOS.  The herbal treatment strategy was aimed to address the 
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pathological endocrine profile of PCOS, and to improve women’s well-being and general 
physical and emotional health. These additional effects may have improved participant’s 
compliance with the lifestyle program and enhanced the menstrual cycle effectiveness of 
the interventions. 
Positive menstrual cyclicity effects for herbal medicines have been demonstrated in two 
other RCTs (Bergmann 2000, Shahin and Mohammed 2014). Bergmann and colleagues 
(2000) demonstrated improvements for the herbal complex formulae Phyto-hypophyson 
(Vitex agnus-castus plus homoeopathic preparations of Cheledonium majus and Silybum 
marianum) compared to placebo for 67 women with fertility disorders. Significant 
improvements were observed in women with baseline oligomenorrhoea (82% versus 45%, 
p=0.01). However comparisons of outcomes were limited due to the unclear diagnosis of 
PCOS (Bergmann 2000). It was not possible to assess whether or not oligomenorrhoea was 
associated with PCOS or due to other causes. Shahin and colleagues (2014) demonstrated 
the significantly reduced number of days to ovulation when Cimicifuga racemosa was added 
to Clomiphene citrate (clomiphene) compared to clomiphene alone, for 194 women with 
PCOS related infertility (p=0.01) (Shahin and Mohammed 2014). Endocrine findings included 
significantly reduced LH for women taking the additional Cimicifuga racemosa (5.7IU/ml ± 
0.9 versus 8.0 IU/ml ±0.9, p<0.01) which suggested that the mechanism of herbal effect was 
related to reduced LH. Another RCT also demonstrated significantly reduced LH for women 
who took Cimicifuga racemosa alone compared with women who took clomiphene, 
(3.45IU/ml ±0.14 versus 4.55IU/ml ±0.16, p = 0.007) in 100 women with PCOS related 
infertility (Kamel 2013). Findings from the present RCT add weight to the LH lowering effects 
of herbal medicines due significant reductions observed in the test group over time however 
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further investigation is needed. Cimicifuga racemosa was not included in the the present 
herbal formulation and whilst lowered LH may be a mechanism of herbal effect of 
Glycorrhizza glabra, Paeonia lactiflora and Cinnamon cassia (Takeuchi 1989, Ushiroyama 
2001, Heibashy, Mazen et al. 2013) several other factors may have contributed to the 
reproductive outcomes. Anthropometric changes, relative hormone concentrations,  altered 
hepatic function; reduced inflammation, compliance with the lifestyle intervention and 
improved well-being are all possible contenders. Findings here suggest LH as a key marker 
for the mechanism of effect however the research did not seek to find the effects of the 
interventions and further research is needed.  
The herbal medicine plus lifestyle intervention here compared favourably for menstrual 
regulation in women with PCOS and the pharmaceutical interventions metformin and the 
oral contraceptive pill Diane nova (ethinyl oestradiol 35µg and cyproterone acetate 2mg) 
(Morin-Papunen, Vauhkonen et al 2000). A RCT including 35 obese (BMI ≥27) women with 
PCOS demonstrated mean reductions in for the number of days between menstrual periods 
for metformin of 24.8% (24.3/98.1 days, p<0.05) with significant improvements in waist to 
hip ratio and fasting insulin. Diane nova was shown to be more efficient at menstrual cycle 
regulation with mean reductions of 68.0% (59.6/87.6 days p<0.05), but no significant impact 
on anthropometric or metabolic outcomes. For comparison the herbal medicine plus 
lifestyle here demonstrated mean percentage menstrual cycle reductions of 41.3% 
(43.8/106.0 days, p<0.001) with significant improvements in anthropometric and metabolic 
improvements. In addition significant improvements were found for a cardiovascular risk 
marker hypertension which suggested a potential alternative treatment to the oral 
contraceptive pill for menstrual regulation for overweight women with PCOS. The oral 
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contraceptive pill has been shown to increase blood pressure and cardiovascular disease in 
young women (Costello, Shrestha et. al. 2007, Hickson, Miles 2011). 
This is the first RCT of herbal medicine plus lifestyle intervention to demonstrate statistical 
and clinically significant anthropometric improvements compared to lifestyle alone for 
overweight women with PCOS. Many of the participants at baseline represented ‘class two 
obesity’ and the severe risk of obesity related health conditions, (Govt 2005). At the end of 
the trial, the anthropometric improvements for participants in the test group clinically 
improved and were placed the obesity class one category and at moderate risk for 
developing obesity related health complications. Anthropometric improvements 
corresponded with significantly reduced blood pressure in the test group. The relationship 
between anthropometry and cardiovascular risk factors were not examined in this RCT and 
more research with additional risk marker outcomes is needed to clarify relationships 
between loss of body weight and the effects of the herbal intervention. 
 This study also demonstrated significant improvements for lifestyle intervention for health 
related quality of life and psychological morbidity. Whilst other RCTs have shown 
improvements from lifestyle interventions improving quality of life outcomes and for 
depression (Thomson, Buckley et al. 2010), this study demonstrated significant 
improvements following the addition of herbal medicine and, for the first time, benefits for 
women’s anxiety and stress. Women’s positive attitudes towards psychological assessment 
(demonstrated by high response rates) suggested that the DASS 21 was an accepted method 
of psychological screening and assessment for women with PCOS and may inform the future 
research into validated tools of assessment (ESHRE 2012). Previous studies have 
demonstrated construct validity, internal consistency and reliability of the DASS21, (Henry, 
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Crawford 2005), and this instrument may provide accurate assessment of women’s 
correlated dysphoria and sadness, physiological arousal and fear and states of tension and 
stress respectively. 
Twenty two percent of women in the test group delivered a live healthy baby compared to 
6% of women engaged in lifestyle intervention alone. These results using herbal medicine 
compared favourably to pharmaceutical treatment. This includes live birth outcomes for 
women prescribed clomiphene where live births have been reported for 15-21% of the 
study population (Legro, Barnhart et al. 2007, Zain, Jamaluddin et al. 2009) and metformin 
where outcomes resulting in a live birth were smaller (7.1-7.9%)  (Legro, Barnhart et al. 
2007, Zain, Jamaluddin et al. 2009). However this study was small with wide confidence 
intervals and was not sufficiently powered to demonstrate statistical significance for women 
wanting to conceive.  
Study results confirm the positive role of herbal medicine for abnormal menstrual cyclicity in 
PCOS, and refute previous findings demonstrating high rates of side effects. The five herbal 
medicines investigated in the present study were well tolerated by participants with only 
3.3% of women reporting adverse events. In a RCT comparing the herbal medicine Stachys 
Lavandulifolia and the pharmaceutical agent medroxyprogesterone acetate for abnormal 
uterine bleeding in PCOS, equivalent effectiveness was demonstrated for normalised 
menstrual cycle patterns, however higher rates of adverse events were reported for the 
herbal medicine (Jalilian, Modarresi et al. 2013). The three month study conducted by 
Jalilian and colleagues of 66 women with PCOS investigated the dried aerial parts of Stachys 
lavandulifolia, (5g (standardised flavonoid content of 3.15mg per dose), infused in 100 ml of 
boiled water and taken three times per day) compared with the pharmaceutical agent 
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medroxyprogesterone (10mg per day, taken on menstrual cycle days 10-24). The abnormal 
uterine bleeding index was reduced from 2.5 (95%CI 0.3-40.2) to 0.7 (95% CI 0.0-12.1) for 
women taking Stachys lavandulifolia (p<0.001) and from 2.7 (95% CI 0.6-48.0) to 1.1 (95% CI 
0.1-18.3) for women taking medroxyprogesterone acetate (p<0.001). Although there were 
no statistical differences between the interventions at three months (p= 0.248), side effects 
(abdominal cramps and bloating) were greater for the herbal intervention (45.5% compared 
to 24.2%) compared to medroxyprogesterone acetate (Jalilian, Modarresi et al. 2013).    
The selection of the herbal medicine Stachys lavandulifolia was based on traditional use and 
its content of the flavone, apigenin. Although few side effects have been previously 
reported for Stachys lavandulifolia, (Rabbani, Sajjadi et al. 2003) nearly half of participants 
taking the herbal medicine experienced abdominal cramps and bloating. These adverse 
events may have been due to the high dose needed for the therapeutic effect of the single 
flavonoid constituent (apigenin), (Mills 2000) and the incidental high dose of additional 
constituents found within the whole herbal extract. Additional chemical ingredients of 
Stachys lavandulifolia include iridoid glycosides (Delazar, Delnavazi et al. 2011), which may 
act as intermediaries in alkaloid biosynthesis (Mills 2000) and negatively affect enteric 
nervous system function. In addition, several volatile oils were included (Javidnia, Mojab et 
al. 2010) for example, pinene which as an antimicrobial, may have destabilised enteric micro 
flora ecology. The high dose of iridoid glycosides and volatile oils in addition to the single 
hypothesised flavonoid, apigenin may have adversely affected the safety profile of Stachys 
lavandulifolia.  
Women in this trial reported substantially fewer adverse reactions compared to 
pharmaceutical interventions clomiphene and metformin for the treatment of PCOS. 
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Adverse events for the herbal medicine and lifestyle intervention in the present study were 
few and starkly contrasted with the frequently reported adverse effects women reported 
for clomiphene and metformin (Legro, Barnhart et al. 2007). Unwanted symptoms for 
clomiphene (n=209) included abdominal pain reported by 52.6% of women, diarrhoea 
23.0%, nausea 39.2%, hot flushes 27.8%, headaches 44% and mood swings 15.3%. Adverse 
effects for women taking metformin (n=208) included abdominal pain 59.1%, diarrhoea 
64.9%, nausea 61.5%, vomiting 29.8%, headaches 42.3% and mood swings 17.2%. There 
were four serious adverse events reported for clomiphene and metformin including one 
death. In the present case, non-serious adverse effects for the herbal medicine were 
reported by two participants (3.3%) and included flu like symptoms and abnormal uterine 
bleeding. There were no adverse effects reported for the lifestyle only group and no serious 
adverse events during the trial. These findings suggest that this combination of herbal 
medicines added to lifestyle intervention may present an effective alternative to fertility 
drugs for treatment of infertility for overweight women with PCOS with greater 
acceptability due to substantially reduced unwanted side effects. This research provides 
preliminary findings that indicate lifestyle intervention is more effective for several 
outcomes following the addition of a five herbal medicine combination, without causing 
significant adverse effects. It informs future research investigating the effects of herbal 
medicine plus lifestyle on conception rates and live birth outcomes 
Contrary to the previously reported adverse reaction for Glycyrrhiza glabra, it was found 
that at doses prescribed in the trial protocol there was no evidence to suggest an increased 
risk for hypertension. However it is plausible that antihypertensive outcomes may be 
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associated with reduced anxiety and stress and improved anthropometry, of which both of 
these endpoints significantly improved within the test group compared to controls.  
Lifestyle intervention, weight loss and menstrual cyclicity 
Menstrual cycle improvements for lifestyle intervention in overweight women with PCOS 
are consistently associated with loss of body weight (Thomson and Brinkworth 2008, 
AAPCOS 2011, Moran 2013).  A RCT by Thompson and colleagues (2008) demonstrated 
significantly menstrual improvement from a 20 week lifestyle intervention (hypocaloric diet 
versus diet plus aerobic and diet plus resistance exercise) on the number of days in the 
menstrual cycle in PCOS among 94 women (Thomson and Brinkworth 2008). A subgroup 
analyses of oligomenorrhoeic women (n=53) found a mean reduction in menstrual cycle 
length of 13.8 days (49.6 days (±25.0) to 32.7days (± 4.3)). Greater menstrual cycle 
improvements were significantly associated with larger amounts of weight loss (p<0.001) 
(Thomson and Brinkworth 2008).  Similarly Tang and colleagues (2006) found that minimal 
body weight loss in obese women with PCOS (following treatment with metformin and 
lifestyle advice) significantly correlated with improved menstrual cyclicity (Tang, Glanville et 
al. 2006). This present study did not produce any significant weight loss or menstrual cycle 
benefits for women allocated to lifestyle intervention alone. Three factors may have 
contributed to these findings. These were; a) the format of the lifestyle intervention, b) 
participant’s compliance with the lifestyle intervention and c), women’s awareness of group 
of assignment.   
The lifestyle intervention program was developed in accordance with the evidence based 
guidelines for the management of PCOS (AAPCOS 2011) and based on effective 
interventions with minimal professional contact (Tang, Glanville et al. 2006) determined by 
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pragmatic RCT design. Although there is little evidence for any lifestyle intervention 
composition being optimal for overweight women with PCOS (Moran 2009, Thomson and 
Brinkworth 2008), outcomes from the control group suggested that dietary advice provided 
by a dietician (Moran, Noakes et al. 2003, Moran, Brinkworth et al. 2006, Thomson and 
Brinkworth 2008, Marsh 2010) is a characteristic of effective lifestyle intervention programs 
for weight loss associated menstrual cycle improvements in overweight women with 
PCOS.The menstrual cycle outcomes for women in the control group aligned more closely 
with studies investigating lifestyle programs as an exercise only form of lifestyle intervention 
(Hoeger, Kochman et al. 2004).  
Compliance with lifestyle intervention may have complicated the outcomes in the present 
study. Participation in the lifestyle program was self-reported and at some risk of reporting 
bias. Significantly improved anthropometric findings for women in the test group suggested 
disparities between groups for engagement with the lifestyle intervention. However, waist 
circumference was significantly reduced over the trial period for women in both groups, 
confirming positive lifestyle engagement for women in the control group. These findings 
were complicated by the structure of the lifestyle intervention which included progressive 
resistance training (PRT) exercises or weight lifting. Resistance exercises can lead to changes 
in body composition by increasing muscle mass relative to adipose (fat) tissue, a primary 
goal of lifestyle intervention for women with PCOS. However muscle mass has greater 
density and causes increments in body weight. This may explain the limited weight loss 
despite significantly improved hip to waist ratio for women in the control group. Although 
physical changes resultant to altered energy intake and expenditure were demonstrated in 
both groups (verifying positive self-reported compliance) the degree and extent of 
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engagement was not formally measured. Future research design should include validated 
lifestyle intervention assessment to control for the degree of lifestyle engagement and 
positive effects of anthropometric improvements on reproductive outcomes in overweight 
women with PCOS. 
  
Women’s knowledge of group of assignment may have contaminated the lifestyle program 
through altered motivation and engagement. Women’s expectation of a positive treatment 
effect for lifestyle intervention has been shown to significantly predict successful weight loss 
(Teixeira, Going et al. 2005) and it is reasonable to presume trial participants may have 
anticipated positive treatment effects from taking the herbal tablets. Despite self-reported 
equally positive attitudes towards both the herbal medicine and lifestyle interventions at 
trial entry and exit, women’s awareness of group allocation may have altered levels of 
engagement with lifestyle intervention. Other contaminating factors may have included the 
peer support that developed during the trial. The membership of the Facebook group page 
included trial participants and non-participants who frequently shared PCOS experiences 
and expressed empathy and support. Other studies investigating overweight women have 
demonstrated positive engagement in research in association with peer support, (Clark, 
Ledger et al. 1995) such as in group therapy. Further research utilising blinding techniques is 
needed to minimise women’s cognitive expectations and influences on trial outcomes. 
5.4.1  Strengths and weaknesses 
This study had many methodological strengths. It was an appropriately designed RCT to 
answer the clinical question. It successfully investigated effectiveness and safety for herbal 
medicines for a broad range of clinical, biochemical and mental health outcomes in a 
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community-based cohort of overweight women with PCOS (Sox and Greenfield 2009). The 
recruitment success indicated the research was attractive to women with targets achieved 
within a limited time frame and with limited resources. The randomisation produced no 
evidence of selection bias and the inclusion of women with a broad range of demographic, 
degree of overweight and PCOS characteristics indicates that findings from this study are 
likely to generalise well to women with PCOS in the community. Significant improvements in 
the primary outcome supported by significant biochemical changes were observed over a 
relatively short time frame.  Sufficient power, low attrition and intention to treat analyses 
added strength to the internal validity of the findings. Attrition of 11.5% was low compared 
to other similar RCTs investigating lifestyle with attrition rates of 33% (Stamets, Taylor et al. 
2004), 37.7% (Moran, Noakes et al. 2003), 39% (Hoeger, Kochman et al. 2004), 49% (Marsh 
2010) and 52.9% (Thomson and Brinkworth 2008). The high retention of participants was 
likely due to the desires of women with PCOS for research based information about 
complementary medicines and treatment options alternative to birth control pills or fertility 
drugs (Sills, Perloe et al. 2001, Arentz, Smith et al. 2014). Transparent quality control of the 
herbal intervention was achieved through independent verification of the herbal identity 
and contents. High compliance with the interventions suggested that the herbal medicine 
and the lifestyle programs were well tolerated and acceptable to women with PCOS.  
This study had some methodological shortcomings. Pragmatic research is a relatively new 
framework of RCT design and there is limited empirical information explaining some of the 
‘real world’ characteristics on effect size (Chalkidou, Tunis et al. 2012). The lack of blinding 
for example could have influenced the estimated treatment effect size and confounded the 
outcomes particularly for the subjective outcomes, although objectively measured 
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outcomes were less likely to be at high risk of performance bias (Wood, Egger et al. 2008). 
Although the expectations of treatment were reportedly not different between groups, and  
there was no significant difference between groups for key health behaviours (diet and 
exercise), women and assessors’ knowledge of the group of assignment may have 
influenced the effects of the of the treatment (Zwarenstein, Treweek et al. 2008).  There 
was also limited opportunity to control for non-specific effects that occurred within the trial 
that may not be attributable to the herbal medicine or the lifestyle intervention. This was a 
preliminary RCT that appropriately utilised pragmatic research design to answer the 
research question about clinical effectiveness intended to satisfy the initial information 
needs of health consumers with established high prevalence of use and clinicians with an 
insufficient evidence base (Fønnebø and Launsø 2009). Research is now needed to examine 
the discrete effects of components of the herbal intervention and to examine the 
relationships between the herbal medicine and lifestyle intervention. The positive impact of 
reduced body weight on reproductive, metabolic and psychological outcomes in overweight 
women with PCOS was a likely contributor to the positive outcomes observed in this trial. 
Further research differentiating the effects of the herbal medicine and reduced body weight 
may further explain the mechanism of the herbal medicine separately to the effects of 
improved bodyweight. This would be best achieved using efficacy RCT design (double 
blinded placebo controlled) to explain the factors of the intervention that may have 
influenced the outcomes and to validate the size of the treatment effects.  
The social support that became an incidental part of the trial may have contaminated the 
intervention and provided women with additional benefits or detriments. Other research 
has demonstrated the positive impact of social support on reproductive outcomes in 
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overweight women attending fertility clinics (Clark, Ledger et al. 1995) and more research is 
needed to examine social support as part of interventions on clinical outcomes in 
overweight women with PCOS. Social support may influence attrition rates in other studies 
investigating lifestyle interventions. 
Approximately one third of participants concurrently used metformin during the trial. Rates 
of use decreased (non-significantly) in both groups and more research is needed to examine 
the effects of herbal and lifestyle intervention on pharmaceutical use. Outcomes including 
serum concentration of metformin over time, fasting insulin and adverse effects may 
provide valuable information regarding women’s concurrent use of herbal medicine, 
lifestyle intervention and metformin.  
Generalisability of findings was restricted to English speaking women. There is considerable 
variation in the ethnic presentation of PCOS with a higher prevalence in some ethnic groups 
(ESHRE 2012). Future research that includes women of diverse ethnic and language groups 
would increase the generalisability of findings to a wider range of ethnic groups. 
This trial has provided much needed evidence for the additive effectiveness and safety of 
herbal medicine to lifestyle intervention in overweight women with PCOS. These data 
provide consumers, clinicians and researchers with information about management of 
women with a wide range of PCOS characteristics in a real world setting. Although future 
research is needed to explain the effects of herbal medicine and examine the incidental 
aspects of real world circumstances, this current study is the first to inform the use of 
naturopathically combined herbal medicine in conjunction with lifestyle changes.  
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The contribution of this study within the context of other findings presented in previous 
chapters will be discussed and concluded in the next Chapter, number 6. 
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Chapter 6:  Discussion, conclusion and recommendations for future research.  
 
 
This thesis examines the use of self-help practices and complementary medicine use by 
women with PCOS and focused on the role naturopathy may offer women with PCOS. The 
research themes incorporate the perspectives of women with PCOS with orientation 
towards strengthening the evidence base and informing clinical decisions. Evidence is 
provided from four studies supporting the therapeutic role of naturopathic nutritional 
supplements and herbal medicines. 
The survey of women with PCOS highlighted frequent use of complementary medicine and 
identified key motives and important clinical gaps explaining why these therapies are being 
used and what naturopathy offers to women. Evidence from pre-clinical and clinical studies 
found consistent evidence of physiological effects for six herbal medicines and the 
systematic review of RCTs found beneficial effects for inositol and omega three fish oil 
supplements and two herbal medicines (Mentha spicata and Cimicifuga racemosa) for a 
range of clinical outcomes in PCOS with effect sizes of inositol and omega three fish oils 
comparable to pharmaceutical agents (metformin) and with substantially fewer side effects. 
The RCT demonstrated significantly enhanced menstrual regularity for lifestyle intervention 
following the addition of a naturopathically formulated herbal combination in overweight 
women with PCOS. Additional important outcomes included significant reproductive, 
anthropometric and psychological benefits and low rates of unpleasant side effects and 
non-exacerbation of risk factors.  
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The identified frequent use of nutritional supplements and herbal medicine by women with 
PCOS coupled with the evidence of clinical effectiveness and low rates of adverse events, 
suggests that naturopathy may play an important role in support of women’s improved 
health and well-being. This chapter summarises the findings, presents the strengths and 
limitations of the thesis, the implications of the findings and future research needs.  
6.1 The research answers 
Women’s use of CAM 
The investigation into use and attitudes towards complementary medicine and self-help 
measures (diet and exercise) of women with PCOS successfully recruited 493 participants 
(91.1% survey response rate from POSAA) and confirmed frequent use of nutritional 
supplements and herbal medicines with over 70% of women reporting daily use during the 
previous twelve months (Arentz, Smith et al. 2014). Women were found to use diet and 
exercise with similar frequency, (82% and 73% respectively) however participants reported 
relatively low perceptions of the effectiveness for using diet (12%) and exercise (8%) to 
achieve their goals of weight loss and reduce PCOS symptoms. The survey highlighted that 
women sought management for many symptoms associated with PCOS and emphasised a 
particular need to address their psychological health and well-being. The adverse reactions 
from CAM (in general) were reported by a minority of women (12%) and concurrent use 
with pharmaceuticals highlighted the need for further research. 
Evidence for nutritional supplements and herbal medicines in PCOS 
In spite of high use of nutritional supplements and herbal medicines, the evidence from 
RCTs for women with PCOS was limited to only two nutritional supplements (inositol and 
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omega three fish oils) and two herbal medicines (Mentha spicata and Cimicifuga racemosa). 
The systematic review assessed 18 RCTs (1109 women) for clinical effectiveness and safety 
and significant benefits were demonstrated for inositol (vitamin B8) in seven studies (563 
women) for hyperandrogenism, reproductive outcomes (ovulation and pregnancy rates), 
waist to hip ratio, metabolic hormones and reduced cardiovascular risk markers. Small but 
still significant effectiveness was found for omega three fish oils in three studies (120 
women) for reduced total cholesterol in women with PCOS. Treatment effect sizes of 
inositol on total testosterone, reproductive outcomes (including pregnancy rates), fasting 
glucose and insulin and of omega three fish oils on cholesterol were similar to those of 
metformin and with substantially fewer non-serious adverse effects (Tang, Lord et al. 2012).  
The review of physiological effects of herbal medicine found consistent evidence of positive 
reproductive endocrinological changes from both pre-clinical and clinical studies for six 
herbal medicines for menstrual regulation, hyperandrogenism and PCOS. Herbal extracts of 
Cimicifuga racemosa, Cinnamomum cassia, Glycyrrhiza glabra, Paeonia lactiflora, Tribulus 
terrestris and Vitex agnus-castus produced beneficial reproductive endocrine and ovarian 
morphological changes consistent with improved symptomatology of PCOS (Arentz, Abbott 
et al. 2014). Endocrine effects included lowered luteinising hormone (LH) (Cimicifuga 
racemosa and Paeonia lactiflora); increased follicle stimulating hormone (FSH) (Tribulus 
terrestris), lowered androgens (Glycyrrhiza glabra alone and in combination with Paeonia 
lactiflora), and improved metabolic hormone profile (Cinnamon cassia). Evidence from this 
investigation informed the rationale for the herbal intervention investigated in the RCT.  A 
new herbal medicine treatment that included five herbal medicines was developed for 
investigation. 
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The research question; ‘Does the addition of herbal medicine to lifestyle intervention 
compared to lifestyle intervention alone improve menstrual regularity in overweight women 
with PCOS?’ was answered using a pragmatically designed RCT. One hundred and twenty 
two women with medically diagnosed PCOS (Rotterdam criteria (ESHRE 2004) were 
successfully recruited from the community. This study provided evidence that the addition 
of five herbal medicines to lifestyle intervention may significantly improve menstrual 
regularity, fasting insulin, anthropometric characteristics, conception rates, health related 
quality of life and depression, anxiety and stress compared to lifestyle intervention alone.  
Beneficial outcomes for psychological comorbidities provided evidence for women’s 
improved health related quality of life and psychology, which is an area of clinical need 
identified by experts, clinicians and by women with PCOS. This is the first RCT to 
demonstrate improved live birth outcomes for five herbal medicines in women with PCOS. 
The live birth rate of 22% in the test group compared favourably with pharmaceutical 
interventions (clomiphene 15-21% and Metformin 7.1-7.9%) (Legro, Barnhart et al. 2007, 
Zain, Jamaluddin et al. 2009) and adverse effects of the herbal medicine were substantially 
lower (3.3%) than reported for clomiphene (52.6% abdominal pain (Legro, Barnhart et al. 
2007)) and metformin (64.9% diarrhoea (Legro, Barnhart et al. 2007), OR 4.27, (95% CI 2.40 
to 7.59) for gastrointestinal disturbances (Tang, Lord et al. 2012). These outcomes suggest 
that herbal medicine in addition to lifestyle intervention may present an effective 
alternative treatment option to fertility pharmaceuticals, a treatment desire expressed by 
99% of 657 surveyed women with PCOS (Sills, Perloe et al. 2001).  
This study contributed much needed evidence to the small volume of evidence for 
naturopathic complex herbal formulations combined to treat pathology and to improve 
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general health and well-being. Herbal extracts were selected to address endocrine 
pathology associated with PCOS and incorporated naturopathic principles to treat disease 
and concurrently improve well-being. Low adverse effect findings in the RCT provided 
supportive evidence for the use of combinations of herbal medicines that may mitigate 
adverse effects and provide concurrent effective treatments. This study found that 
administration of the Glycyrrhiza glabra extract (7:1, 2.25g per day for three months) as 
component in herbal formula did not increase blood pressure in an at risk sample of 
overweight women with PCOS.  
6.2 Strengths and weaknesses 
This thesis provides new clinical evidence addressing the research and clinical gaps for the 
management of PCOS using nutritional and herbal supplements. The survey established 
women’s frequent use of naturopathic interventions and the RCT data provided high quality 
evidence of the beneficial role of naturopathic herbal medicine in addition to lifestyle 
intervention compared to lifestyle alone for effective management of PCOS. The pragmatic 
design enabled evaluation of a complex naturopathic intervention as it is delivered in a 
naturopathic clinical setting (Fønnebø, Grimsgaard et al. 2007) and aligned with government 
initiatives to increase the volume of clinical evidence relevant to patients and their clinicians 
(Zwarenstein, Treweek et al. 2008, Sox and Greenfield 2009, Chalkidou, Tunis et al. 2012). 
The design frame appropriately answered the research question and findings are likely to 
translate efficiently into real word settings, providing new evidence relevant to women with 
PCOS living in the community.  Attrition was relatively low compared to other investigations 
of lifestyle intervention (Moran, Hutchison et al. 2011, Moran 2013). Low attrition, sufficient 
power and intention to treat analyses were methodological strengths that supported the 
 250 
 
rigour and validity of the findings. A significant association was found between the primary 
outcome and reduced LH. This contrasted with other findings for lifestyle intervention 
where positive effects were attributed to improved anthropometry (Moran, Hutchison et al. 
2011). It appeared possible that there were stand-alone reproductive endocrine effects for 
the new herbal combination that contributed to the positive outcomes.  
It is important to recognise however that the RCT did not examine the mechanisms of 
treatment effect of the interventions. Whilst the review of pre-clinical and clinical literature 
(Chapter three) explained the effects of herbal medicine in oligo/amenorrhoea, 
hyperandrogenism and PCOS, and the RCT provided supportive evidence for the significant 
clinical effectiveness, the mechanisms of the herbal intervention effect were not examined 
in the RCT. Possible biological endocrine effects may have included reduced LH due to the 
LH lowering effects of Paeonia lactiflora and Cinnamomum cassia which were demonstrated 
in the mechanistic review and the RCT. However Tribulus terrestris was found to increase 
FSH in the mechanistic review and was not evaluated in conjunction with herbal 
administration (blood tests on day two to five of the menstrual cycle and Tribulus terresand 
tris administered on days five to fourteen) in the RCT. Outcomes in the RCT may have been 
secondary to weight loss or improved psychological profile and stronger engagement with 
lifestyle intervention in the test group.  
The lifestyle intervention alone was able to produce significant improvements in body size 
(reduced waist to hip ratio). This anthropometric imrovements did not translate to 
menstrual cyclicity and highlighted the important inclusion of weight loss as a treatment 
goal for lifestyle intervention for overweight women with PCOS. The herbal medicine 
appeared to enhance the effectiveness of the lifestyle intervention producing significant 
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improvements for menstrual regularity, anthropometry, fasting insulin, quality of life, 
psychological profile and pregnancy outcomes. This may have been due to secondary effects 
of the herbal medicine including increased hepatic metabolism of hormones, improved 
mood or sleep patterns, reduced inflammation or better digestive, absorption and 
elimination functions. The trial provided results of clinical effectiveness for a complex 
naturopathic intervention in addition to lifestyle intervention compared to lifestyle 
intervention alone, and may inform further investigations into the mechanisms of biological 
effects of components and interactions for both of the interventions.  
The research strategy to evaluate the effectiveness of an intervention prior to examining the 
effects of the intervention contrasts with pharmacological research order but aligned with 
research strategies developed for investigation of complementary medicines (Fønnebø, 
Grimsgaard et al. 2007). The order of research priority was driven by the established 
frequent use of herbal supplements by women with PCOS in the absence of evidence for 
safety and effectiveness. Research that initially answered these questions was considered 
salient to health consumers and clinicians and provided direction to future examinations 
into how and what parts of the intervention worked.    
This research presents a comprehensive evaluation of a naturopathic intervention based on 
an evidence based approach that may enhance the naturopathic management for women 
with PCOS. The intervention drew upon the current best evidence, combined naturopathic 
expertise and incorporated values and treatment expectations of women with PCOS 
(Sackett, Rosenberg et al. 1996) without competing with naturopathic  philosophy or 
diminishing the potential synergistic effects of the complex intervention (Wardle, Adams et 
al. 2013). The research process aligned with the goals of the naturopathic research agenda 
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by investigating a condition with a high burden of suffering, interventions with the most 
potential for effectiveness and by developing research methods for investigation of whole 
naturopathic programs, in this case herbal formulations (Standish, Calabrese et al. 2006). 
The design features of the pragmatic RCT paralleled naturopathic complex intervention 
philosophy and the methods may inform future RCT investigations of complex naturopathic 
interventions seeking to explain clinical effectiveness for other complex diseases. This thesis 
was inhibited by the absence of validated instruments available for the adequate evaluation 
of important naturopathic outcomes such as vitality and well-being. Consequently this thesis 
adds limited evidence for complete naturopathic care of women with PCOS.  
Other limitations were the generalisability of findings from the survey and RCT to Australian 
English speaking women and the restriction of studies published in English in the Systematic 
Review. Findings for the survey and the RCT may vary with inclusion of diverse language 
women and the systematic review with the inclusion of RCTs published in languages other 
than English, particularly those from countries with high use of herbal medicine such as 
Europe, China and India. Naturopathic herbal medicine is eclectic and broadly utilises herbal 
medicines from many countries and cultures. Broader language inclusion may have provided 
different outcomes. 
6.3 Implications of findings 
There were four primary implications for the findings of this thesis. The first was clinical 
evidence for the management of women with PCOS using naturopathic interventions with 
probable high acceptance amongst women, second was new evidence for contribution to 
the evidence based guidelines for the management of women with PCOS, third the 
development of an evidence based framework for the investigation of naturopathic 
 253 
 
interventions informed by naturopathic practice and fourth, the dissemination of evidence 
through consumer support groups to inform the self-care treatment decisions of women 
with PCOS and promote judicious self-care nutritional and herbal supplement selections. 
Clinical management 
This thesis provided evidence that may inform evidence-based multidisciplinary clinical 
teams caring for women with PCOS. Findings from the RCT, the systematic review and the 
evidence for the effects of herbal medicine indicate important clinically relevant findings 
that some nutritional supplements and herbal medicines may be effective treatment with 
limited adverse effects for women with PCOS. This preliminary research added to the 
evidence base for women seeking alternatives to pharmaceutical management and at least 
partially explains the safety for herbal medicines for consideration during clinical decision 
making. Outcomes from this thesis may facilitate dialogue between women and their 
conventional medical providers regarding their supplement and herbal use and support 
evidence based treatment selection. 
 Evidence based guidelines for the management of PCOS 
The systematic review provided some evidence for inositol and omega three fish oils, and 
Mentha spicata tea and Cimicifuga racemosa for the treatment of symptoms associated 
with PCOS. It also highlighted an insufficient evidence base and the absence of findings of 
effectiveness for many supplements. The findings of the systematic review may contribute 
new information to the evidence based clinical guidelines for the management of women 
with PCOS (AAPCOS 2011). The systematic review provided some evidence of benefits for 
non-pharmacological first-line management of PCOS with potential grading for 
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hyperandrogenism (inositol and Mentha spicata), reproduction (inositol and Cimicifuga 
racemosa) and reduced cholesterol (omega three fish oils) with lower levels of evidence  
(NHMRC 2104).  
An evidence-based framework for the assessment of naturopathy 
This thesis highlighted the positive contribution of naturopathically informed evidence 
based evaluation for naturopathic management of women with PCOS. The complex 
intervention and philosophy of naturopathy was supported by the pragmatic RCT design and 
evidence based medicine was shown to refine the naturopathic treatment protocol. The 
intervention in the RCT drew upon an evidence basis of effects and safety, incorporated 
naturopathic expertise related to selection of herbal medicines based on traditional use and 
included women’s individual needs and values in the development of the naturopathic 
treatment strategy. The RCT demonstrated a single naturopathic modality, herbal medicine 
in conjunction with lifestyle intervention produced broad health benefits for a complex 
woman’s health condition. Naturopathic treatment plans may be confined to one type of 
intervention potentially limiting the supplement burden of naturopathic treatment for 
women with PCOS. The herbal intervention provided an evidence based treatment as the 
foundation of more complex individualised naturopathic treatment plans, a desired 
treatment approach described by complementary medicine consumers (Wardle, Adams et 
al. 2010).  The evidence framework additionally identified limitations of herbal and 
nutritional interventions and areas of research need and is likely to support transparent 
naturopathic treatment decisions.  
This thesis presents valuable evidence in support of the collaborative practices between 
naturopaths and gynaecologists. The development of evidence based naturopathic practice 
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provides language and cross disciplinary education and defines naturopathic treatment 
goals aligned with goals of conventional health professionals. This may support integrative 
education and complementary rather than alternative naturopathic practices and women’s 
supplement use.  
Judicious use of supplements by women with PCOS 
This thesis highlighted women’s need for transparent research based information to inform 
their self-care treatment decisions. The current Australian regulatory framework enables 
the natural supplement industry to make health claims without any evidence of 
effectiveness or safety and various supplements are recommended to women with PCOS. 
This thesis identified nutritional supplements and herbal medicines with some evidence in 
PCOS and provides relatively transparent information to women about the treatment 
effectiveness, the limitations and safety. Dissemination of findings through consumer 
support groups may better inform women’s judicial use of nutritional supplements and 
herbal medicines.  
 6.4 Future research  
To date there has been an absence of high quality research examining naturopathy in 
women with PCOS. This thesis identified a number of nutritional and herbal interventions 
and provides new evidence to inform future research. Research is now needed to better 
understand the mechanisms by which the interventions caused the effectiveness 
demonstrated in the RCT. Double blind, placebo controlled trial design would provide the 
most appropriate method to examine the effects of herbal medicine intervention and 
independent mediators such reduced body weight. Areas of further investigation include 
effects of the herbal medicine combination on reproductive endocrinology in PCOS including 
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Tribulus terrestris on FSH and combined Paeonia lactiflora and Cinnamomum cassia on LH 
both of which may better explain the menstrual regulation effectiveness of the herbal 
medicine combination. Furthermore, explanations of the effects of the interventions 
components may provide insight into the interactive effects of herbal medicines, lifestyle 
interventions and pharmaceuticals.   
An interesting observation was the live birth outcomes for women taking the herbal 
medicine and lifestyle intervention. These outcomes were comparable with first line 
pharmaceutical treatment (clomiphene), but with reduced incidence of non-serious adverse 
effects. Findings for herbal medicine supported the possibility of effective non-
pharmacological treatment for infertility for women with anovulatory infertility with 
reduced treatment burden for herbal medicine use compared to pharmaceutical 
management. Further research that directly compares clomiphene and the herbal 
combination plus lifestyle interventions for the treatment of infertility, live births outcomes, 
adverse effects, tolerance, acceptability and costs is needed to inform women’s and 
clinicians decisions for treatment of infertility.  
Safety data for nutritional supplements and herbal medicines in pregnancy is urgently 
needed. This thesis found nutritional supplements and herbal medicines may offer potential 
treatment for infertility in women with PCOS, and it is possible that women could continue 
taking the herbal intervention once pregnant. This thesis did not examine safety in 
pregnancy however in light of the positive evidence found for inositol, omega three fish oils, 
Cimicifuga racemosa, Tribulus terrestris, Glycyrrhiza glabra, Paeonia lactiflora, 
Cinnamomum cassia and Hypericum perforatum, safety data are urgently needed.  
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Another interesting observation was significantly reduced blood pressure for women taking 
the herbal medicine combination and menstrual regulation effects comparable with the oral 
contraceptive pill (Diane nova) (Morin-Papunen,Vauhkonen 2000). Further investigation into 
the effects of herbal medicine plus lifestyle intervention on cardiovascular risk markers in 
overweight women with PCOS and direct comparisons with oral contraceptive pills is 
warranted due to the possible moderately effective and safer treatment (Diamanti-
Kandarakis, Baillargeon et al. 2003).  
The review of the traditional herbal medicine literature of cultures (in languages other than 
English) with long term herbal medicine use in pregnancy may reveal some evidence of 
safety or risks for herbal medicines. Additional evaluation of herbal extracts using variable 
solvents would be important to provide valid safety information for naturopathic extracts.  
Epidemiological evidence may provide some evidence of safety for nutritional and herbal 
medicine however prospective animal studies examining herbal and supplement risk may 
provide outcomes of greater relevance due to the potential to observe biological effects. 
Dosages aligned with appropriate human doses (by weight) would improve the 
transferability of findings from animal studies to humans.  
More research is needed to validate the findings of the RCT in women of diverse ethnicity. 
Participants in the RCT were English speakers living in urban and regional areas of Australia. 
Further research examining women of diverse ethnicity in other settings is needed to 
evaluate the influence of ethnicity and the setting on the findings. Some ethnic groups have 
higher prevalence of PCOS phenotypes and further research including different ethnic 
groups would improve the generalisability of the findings in this thesis.  
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The evidence for the herbal medicines Cimicifuga racemosa in PCOS may be strengthened 
by additional reproductive outcomes specified in the systematic review. The review of pre-
clinical and clinical data were strongest for this herbal medicine and some RCTs examining 
its effectiveness for treatment of PCOS associated infertility did not meet the inclusion 
criteria of the systematic review. Additional specified reproductive outcomes may enable 
the inclusion of herbal medicines specifically used to manage PCOS for infertility, and better 
inform the evidence based guidelines for the non-pharmacological management of 
infertility and provide further relevant clinical evidence. 
Given that women with PCOS seek more than the management of symptoms, more detailed 
descriptions of ‘health’ are needed to fully understand the complete health needs of women 
with PCOS. Research that explores the various dimensions of health unique to women with 
PCOS may lead to the development of management strategies that incorporate women’s 
health desires as well as their health needs which is important due to the lifelong nature of 
PCOS and commitment behaviours required for effective prevention. From this research it 
would appear that women’s health decisions were driven by their anticipation of health 
improvements and not only by the effective prevention or treatment of disease. This 
suggests that treatment interventions that provide better health may improve motivation, 
compliance and outcomes. Further research is needed to develop of an objective validated 
tool to measure the well-being effects women claim from naturopathy. Development of 
valid instruments to assess health and well-being would be best explored using a qualitative 
inductive research approaches to generate women’s authentic dimensions of health 
followed by quantitative approaches the measure change over time. 
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6.5 Conclusion 
In conclusion this thesis confirms the frequent use of natural health supplements by women 
with PCOS and women’s treatment desires for improved well-being in addition to symptom 
management. The two literature reviews identified RCT evidence for nutritional and herbal 
supplements and consistent data for the physiological effects of six herbal medicine extracts 
in pre-clinical and clinical studies. These findings informed the development of a new herbal 
combination for investigation in a clinical trial and added to evidence based naturopathic 
management of women with PCOS. The frequent use of herbal medicine provided rationale 
for conducting a pragmatically designed RCT to examine effectiveness and safety in 
overweight women with PCOS. The RCT presented a treatment addition that significantly 
enhanced the effectiveness of lifestyle intervention (according to the evidence based 
guidelines) for a broad range of PCOS characteristics. Substantially fewer side effects were 
observed compared to the pharmaceuticals metformin and Clomiphene citrate. Menstrual 
regulation effects of the herbal medicine plus lifestyle were superior to metformin and 
comparable, although not as efficient as the oral contraceptive pill Diane nova (ethinyl 
oestradiol 35µg and cyproterone acetate 2mg). The observation of reduced blood pressure 
suggested a higher level of safety for the herbal combination plus lifestyle compared to 
Diane nova in women at high risk of cardiovascular disease. These outcomes inform 
clinicians and women with PCOS about the strengths and limitations of non-pharmacological 
management.   
This thesis describes the potential therapeutic impact of naturopathy for the management 
of women with PCOS. It represents the initial steps towards building a stronger evidence 
base for naturopathic care of women with PCOS and gives insight into important clinical 
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gaps of medical management and the potential role of nutritional supplements and herbal 
medicines to meet the self-identified health needs of women. This thesis contributes to the 
basis for the therapeutic role of naturopathy in the management of women with PCOS. 
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Appendix 1 
Search terms used for the systematic review of RCT evidence for nutritional 
supplements and herbal medicines 
 
PCOS; polycystic ovary syndrome; Polycystic Ovary Syndrome; ovarian cysts; hyperandrogenism; 
hirsutism; acanthosis nigrans; acne; oligomenorrhoea; amenorrhoea; oligo-ovulation; anovulation 
menstrual disorders; menstrual; ovulation; fertility;  
AND 
alternative medicine; integrative medicine; complementary medicine; naturopathy; natural; herbal 
medicine; botanical medicine; phytomedicine; phytotherapy; herbs; nutritional supplements; dietary 
supplements; vitamin supplements; mineral supplements; vitamin; nutrient;  
AND 
randomised controlled trial; RCT; clinical trial 
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Appendix 2 
Systematic Review Data Extraction Template 
Review title: Naturopathic herbal medicine and nutritional intervention effects in women with 
polycystic ovary syndrome (PCOS). 
 
Review ID: CAM in PCOS 
 
Study ID: 
 
Reference ID: 
 
Person extracting data: 
 
Date of data extraction: 
  
  
Title: 
 
 
Author(s): 
Reference: 
 
Journal: 
Year: Volume: Pages: 
 
Study design 
Type of study design (RCT; block randomisation; stratified randomisation; multi-arm; 
comparative effectiveness; etc):  
Unit of randomisation:  
Exclusion criteria of trials; any one of the following please indicate  
• Quasi randomised trials 
• Trials if unable to ascertain if truly randomised please liaise with SA if this requires follow up. 
• <18 years, > 50years 
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Participants and setting 
 
Describe setting:  
• Country of study: 
• Language of publication: 
• Setting: 
• Total study duration: 
 
Inclusion criteria (participants): Women with PCOS diagnosed according to the Rotterdam criteria or 
the National Institute for Health criteria. The Rotterdam criterion for the diagnosis of PCOS specifies at 
least two of the following three features 1. Polycystic ovaries viewed on ultrasound; 2. Oligomenorrhoea 
(menstrual cycle length frequently more than 35 days) or secondary amenorrhoea (no menses for six 
months or more); 3. Hyperandrogenism, either clinical or biochemical. NIH Criteria for diagnosis of 
PCOS specifies two of the following features; 1. Hyperandrogenism (either clinical or biochemical); 2. 
Polycystic ovaries on ultrasound and/or oligo/amenorrhoea. 
Intervention  
Frequency and Dose: 
Type of control:  
Comparison: 
Outcomes 
 
  
Outcomes: One of the following primary outcomes needs to be reported: 
Reproductive outcomes; oligo/amenorrhoea, polycystic ovaries on ultrasound, hyperandrogenism 
(clinical or biochemical). 
Metabolic hormones (HOMA-IR, QUICKI, GTT, fasting insulin and glucose). 
Quality of life (QOL) using the polycystic ovary syndrome questionnaire (PCOSQ) 
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Study methods 
Risk of bias 
 
  
Adequate sequence 
generation  
 
Was the allocation 
sequence adequately 
generated? 
 
 
 
Was the allocation sequence adequately generated?             Yes / Unclear / No 
Yes (low risk of bias) 
No (high risk of bias) 
Unclear (uncertain risk of bias) 
Criteria for judgement 
Adequate (yes- low risk for bias) 
Computer generated sequence 
Random number tables  
Lot drawing 
Coin tossing 
Shuffling cards 
Throwing dice 
Inadequate (no – high risk for bias)  
Case number 
Date of birth 
Date of admission 
Alternation 
OR     NOT STATED                                                         
Allocation concealment 
Was allocation 
concealment adequate? 
 
Was allocation concealment adequate?                               Yes / Unclear / No 
Describe the method used to conceal the random allocation sequence in as 
much detail as possible as state confidence in which the allocation sequence 
was adequately concealed until interventions were assigned.  
Criteria for judgement 
Adequate (low risk of bias) 
Central randomisation, Coded boxes, Envelopes:   Sealed / Opaque   Sequentially 
numbered 
Inadequate (high risk of bias) 
Open allocation sequence, Procedures based on inadequate generation, 
Unclear (uncertain risk of bias)     
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Blinding 
Was knowledge of the 
allocated intervention 
adequately prevented 
during the study? 
 
Was knowledge of the allocated intervention adequately prevented during the 
study? 
Participant:               Yes / Unclear / No  
Clinician:             Yes / Unclear / No  
Outcome assessor :                                                         Yes / Unclear / No  
Describe:  
Criteria for a judgement of ‘YES’ (i.e. low risk of bias). 
Anyone of the following: 
• No blinding, but the review authors judge that the outcome and the outcome 
measurement are not likely to be influenced by lack of blinding; 
• Blinding of participants and key study personnel ensured, and unlikely that 
the blinding could have been broken; 
• Either participants and key study personnel were not blinded, but outcome 
assessment was blinded and the non-blinding of others unlikely to introduce 
bias. 
Criteria for the judgment of ‘NO’ (i.e. high risk of bias). 
Any one of the following: 
• No blinding or incomplete blinding, and the outcome or outcome 
measurement is likely to be influenced by lack of blinding; 
• Blinding of key study participants and personnel attempted, but likely that the 
blinding could have been broken; 
• Either participants or some key study personnel were not blinded, and the 
non blinding or others likely to introduce bias. 
Criteria for the judgment of "UNCLEAR" (uncertain risk of bias) 
Any one of the following: 
• Insufficient information to permit judgment of "yes" or "No"; 
• The study did not address this outcome.                                                                
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Incomplete outcome  
data addressed  
 
Were complete outcome 
data adequately 
addressed? 
 
 
Were complete outcome data adequately addressed? 
                                                                              
Describe any loss of participants to follow-up at each  
data collection point:                                                             Yes / Unclear / No              
Describe any exclusion of participants after  
randomisation:                                                                      Yes / Unclear / No 
Was the analysis intention to treat?  
If not has the data been able to be re-included?                  Yes / Unclear / No 
Criteria for a judgment of ‘YES’ (i.e. low risk of bias). 
Anyone of the following: 
• No missing data; 
• Reasons for missing outcome data unlikely to be related to true outcome (for 
survival data, censoring unlikely to be introducing bias); 
• Missing outcome data balanced in numbers across intervention groups, with 
similar reasons for missing data across groups; 
• For dichotomous outcome data, the proportion of missing outcomes 
compared with observed event risk not enough to have clinically relevant 
impact on the intervention effect estimate; 
• For continuous outcome data, plausible effect size (difference in means or 
standardized difference in means) among missing outcomes not enough to 
have a clinically relevant impact on observed effect size; 
• Missing data have been imputed using appropriate methods. 
Criteria for the judgment of ‘NO’ (i.e. high risk of bias). 
Any one of the following: 
• Reason for missing outcome data likely to be related to true outcome, with 
either imbalance in numbers or reasons for missing data across intervention 
groups; 
• For dichotomous outcome data, the proportion of missing outcomes 
compared with observed event risk enough to induce clinically relevant bias 
in the intervention effect estimate; 
• For continuous outcome data, plausible effect size (difference in means or 
standardised difference in means) among missing outcomes enough to have 
a clinically relevant impact on observed effect size; 
• "As treated" analysis done with substantial departure of the intervention 
received from that assigned at randomisation; 
• Potentially inappropriate application of simple imputation. 
Criteria for the judgment of "UNCLEAR" (uncertain risk of bias) 
Any one of the following: 
• Insufficient reporting of attrition/exclusions to permit judgement of "Yes" or 
"No" (e.g. number randomised not stated, no reasons for missing data 
provided); 
• The study did not address this outcome.                                                       
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Free of selective 
reporting bias 
Are reports of study free 
of suggestions of 
selective reporting bias?  
 
 
 Are reports of study free of suggestions of selective reporting bias? 
Yes / Unclear / No                                                                                       
Describe:                                                                                   
Criteria for a judgment of ‘YES’ (i.e. low risk of bias). 
Anyone of the following: 
The study protocol is available and all the study's pre-specifies (primary and 
secondary) outcomes that are of interest in the review have been reported in the pre-
specified way; 
The study protocol is not available but it is clear that the published reports include all 
expected outcomes, including those that were pre-specified (convincing test of this 
nature may be uncommon); 
 
Criteria for the judgment of ‘NO’ (i.e. high risk of bias). 
Any one of the following: 
Not all of the study's pre-specified primary outcomes have been reported; 
One or more primary outcomes is reported using measurements, analysis methods 
or subsets of the data (subscales) that were not pre-specified; 
One or more reported primary outcomes were not pre-specified (unless clear 
justification for their reporting is provided, such as an unexpected adverse effect); 
• One or more outcomes of interest in the review are reported incompletely so 
that they cannot be entered be entered in a meta-analysis; 
• The study report fails to include results for a key outcome that would be 
expected to have been reported for such a study. 
Criteria for the judgment of "UNCLEAR" (uncertain risk of bias) 
Insufficient information to permit judgment of "yes" or "No". It is likely that the 
majority of studies will fall into this category.     
 
Free of other bias 
 
Was the study apparently 
free of other problems 
that could put it at high 
risk of bias? 
 
Was the study apparently free of other problems that could put it at high risk 
of bias?                                                                                           Yes / Unclear / No 
If the study was stopped early, explain the reasons: 
Describe any baseline imbalance:  
Describe any differential diagnosis:  
 
Criteria for a judgment of ‘YES’ (i.e. low risk of bias). 
The study appears free of other sources of bias. 
Criteria for the judgment of ‘NO’ (i.e. high risk of bias). 
There is at least one important risk of bias. For example, the study: 
• Had a potential source of bias related to the specific design used; or 
• Stopped early due to some data-dependent process (including a formal-
stopping rule); or 
• Had extreme baseline imbalance; or 
• Has been claimed to have been fraudulent; or 
• Had some other problem. 
Criteria for the judgment of "UNCLEAR" (uncertain risk of bias) 
There may be a risk of bias, but there is either: 
• Insufficient information to assess whether an important risk of bias exists; or 
• Insufficient rationale or evidence that an identified problem will introduce bias. 
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Additional information requested 
Outcomes for main analysis 
   
Outcome Measures (Continuous data)    
      Total number of participants in study =  
Intervention group  
Total no. in study =        
Control group 
Total no. in study =  
total mean SD total mean SD 
  Primary outcomes       
1 Menstrual cycle characteristics (clinical); menstrual 
regularity, spontaneous menses, time to menstruation 
(number of days), number of menstruations.  
      
2 Number of ovarian cysts on ultrasound. Ovarian volume 
measured using ultrasound. 
      
3 
 
Androgens biochemical; free and total serum 
concentration for androgens (testosterone and 
androstenidione), free androgen index (FAI) and sex 
hormone binding globulin (SHBG).  
      
4 Androgens clinical; hirsutism using the Ferriman 
Gallwey Score (0-36). 
      
5 Quality of life outcomes. Polycystic ovary syndrome 
questionnaire (PCOSQ). 
      
6 Metabolic factors. Fasting (8-12 hours) plasma glucose 
and insulin levels. Oral glucose tolerance tests (OGTT). 
Plasma glucose following glucose challenge test (GCT).  
Homeostasis model assessment of insulin resistance 
(HOMA-IR). QUICKI assessment of insulin sensitivity. 
 
      
 
Was an intention to treat analysis mentioned?   Yes/no 
Was an intention to treat analysis undertaken Yes/no 
Flow diagram           
Potentially eligible     n= 
Excluded before  
randomisation           n= 
Number randomised in each group 
Experiment        n= 
Control         n= 
Post randomised exclusions  
Experiment        n= 
Control         n= 
No. analysed            
Experiment        n= 
Control         n= 
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Secondary 
      
9 Anthropometric factors. Body mass index (BMI), waist 
circumference (cm) and waist to hip ratio (W:H). 
      
10 Surrogate markers for PCOS. Serum follicle stimulating 
hormone (FSH) and luteinising hormone (LH). FSH: LH 
ratio during the follicular phase of the menstrual cycle.  
      
11 Serum lipids, cholesterol, high density lipoprotein 
(HDL), low density lipoprotein (LDL), triglycerides. 
      
12 Inflammatory markers, c-reactive protein interleukin 2, 
18, antinuclear antibodies (ANA) 
      
13 Serum anti-mullerian hormone (AMH)       
14 Serum progesterone on day 21       
15 Ovulation tests luteinising hormone (LH) detector urine 
tests (OPK). 
      
16 Adverse events.       
17 Validated assessments for quality of life including 
depression and anxiety scores, the depression and 
anxiety score (DAS), hospital anxiety and depression 
score (HADS). 
      
18 Pregnancy, miscarriage, live birth.       
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Outcome Measures (dichotomous data)     Total number of participants in study = 101 
Intervention group  
total no. in study =  
Comparison group 
Total no. in study =  
events Total events total 
  Primary:      
1 Number of ovarian cysts on ultrasound. Ovarian volume 
measured using ultrasound.  
    
2 Menstrual cycle characteristics (clinical); menstrual 
regularity, ovulation regularity, spontaneous menses, 
time to menstruation (number of days), number of 
menstruations. 
    
3 
 
Androgens biochemical; free and total serum 
concentration for androgens (testosterone and 
androstenidione), free androgen index (FAI) and sex 
hormone binding globulin (SHBG).  
    
4 Androgens clinical; hirsutism using the Ferriman 
Gallwey Score (0-36). 
    
5 Quality of life outcomes. Polycystic ovary syndrome 
questionnaire (PCOSQ). 
    
6 Metabolic factors. Fasting (8-12 hours) plasma glucose 
and insulin levels. Oral glucose tolerance tests (OGTT). 
Plasma glucose following glucose challenge test (GCT).  
Homeostasis model assessment of insulin resistance 
(HOMA-IR). QUICKI assessment of insulin sensitivity. 
    
 
 
 
Secondary 
    
8 Anthropometric factors. Body mass index (BMI), waist 
circumference (cm) and waist to hip ratio (W:H). 
    
9 Surrogate markers of PCOS. Serum follicle stimulating 
hormone (FSH) and luteinising hormone (LH) ratio 
during the early follicular phase of the menstrual cycle.  
    
10 Serum lipids, cholesterol, high density lipoprotein 
(HDL), low density lipoprotein (LDL), triglycerides. 
    
11 Inflammatory markers, c-reactive protein interleukin 2, 
18, antinuclear antibodies (ANA) 
    
12 Pregnancy, miscarriage, live birth.     
13 Serum progesterone on day 21     
14 Ovulation tests luteinising hormone (LH) detector urine 
tests (OPK). 
    
15 Adverse events.     
16 Validated assessments for quality of life including 
depression and anxiety scores, the depression and 
anxiety score (DAS), hospital anxiety and depression 
score (HADS). 
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Very brief summary of study authors main findings/conclusions: 
 
Exclusion after data extraction 
 
Reasons for exclusion: (study design? participants? interventions/ outcomes? attrition? bias?) 
 
 
Dates: 
Date entered into RevMan and by whom? 
Date checked and by whom? 
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Appendix 3 
Systematic review, trials excluded following screening  
Author year Reason  Further 
details 
1. Akdogan, M., M. N. Tamer, E. Cure, M. C. Cure, B. K. Koroglu and N. Delibas (2007). 
"Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women 
with hirsutism." Phytotherapy Research 21(5): 444-447. 
Not an RCT  
2. Akdoğan, Tamer et al. 2007 Duplicate   
3. Armanini, D., M. J. Mattarello, C. Fiore, G. Bonanni, C. Scaroni, P. Sartorato and M. 
Palermo (2004). "Licorice reduces serum testosterone in healthy women." Steroids 
69(11-12): 763-766. 
Healthy 
participants 
 
4. Baillargeon, J.-P., M. J. Iuorno, D. J. Jakubowicz, T. Apridonidze, N. He and J. E. 
Nestler (2004). "Metformin therapy increases insulin-stimulated release of D-chiro-
inositol-containing inositolphosphoglycan mediator in women with polycystic ovary 
syndrome." Journal of Clinical Endocrinology & Metabolism 89(1): 242-249. 
Not 
randomised 
Not related 
to research 
question 
5. Baillargeon, J. P., E. Diamanti-Kandarakis, R. E. Ostlund, Jr., T. Apridonidze, M. J. 
Iuorno and J. E. Nestler (2006). "Altered D-chiro-inositol urinary clearance in women 
with polycystic ovary syndrome." Diabetes Care 29(2): 300-305.  
Not 
randomised 
Compared with 
healthy 
women 
Didn’t relate 
to the 
research 
question 
6. Bloomgarden, Z. T., W. Futterweit and L. Poretsky (2001). "Use of insulin-
sensitizing agents in patients with polycystic ovary syndrome." Endocrine Practice 
7(4): 279-286. 
Review  
7. Ehling, D. (2013). "Integrative techniques using acupuncture, Chinese herbal 
medicine, diet, and supplements for polycystic ovary syndrome: a case report." 
Journal Of Integrative Medicine 11(6): 422-427. 
Case report  
8. Elisabeth, W. (2011). "Vitamin D-associated polymorphisms are related to insulin 
resistance and vitamin D deficiency in polycystic ovary syndrome." European Journal 
of Endocrinology 164(5): 741-749. 
Genetic 
outcomes 
 
9. Escobar-Morreale, H. F. and M. Luque-Ramirez (2011). "Role of androgen-
mediated enhancement of erythropoiesis in the increased body iron stores of 
patients with polycystic ovary syndrome." Fertility & Sterility 95(5): 1730-
1735.e1731. 
Case 
controlled 
study 
 
Fenkci, S. M., V. Fenkci, O. Oztekin, S. Rota and N. Karagenc (2008). "Serum total L-
carnitine levels in non-obese women with polycystic ovary syndrome." Human 
Reproduction 23(7): 1602-1606. 
Not an RCT  
Firouzabadi, R., A. Aflatoonian, S. Modarresi, L. Sekhavat and S. MohammadTaheri 
(2012). "Therapeutic effects of calcium & vitamin D supplementation in women with 
PCOS." Complementary Therapies in Clinical Practice 18(2): 85-88. 
Case control  
Genazzani, A. D., A. Prati, S. Santagni, F. Ricchieri, E. Chierchia, E. Rattighieri, A. 
Campedelli, T. Simoncini and P. G. Artini (2012). "Differential insulin response to 
myo-inositol administration in obese polycystic ovary syndrome patients." 
Gynecological Endocrinology 28(12): 969-973. 
Investigation 
of dosage 
 
Hoch, A. Z., S. L. Lynch, J. W. Jurva, J. E. Schimke and D. D. Gutterman (2010). "Folic 
acid supplementation improves vascular function in amenorrheic runners." Clinical 
Journal of Sport Medicine 20(3): 205-210. 
Not PCOS or 
similar 
 
Igarashi, M. (1976). "Augmentative effect of ascorbic acid upon induction of human 
ovulation in clomiphene-ineffective anovulatory women." International journal of 
fertility 22(3): 168-173. 
Not 
randomised 
 
Insenser, M., R. Montes-Nieto, M. Murri and H. F. Escobar-Morreale (2013). 
"Proteomic and metabolomic approaches to the study of polycystic ovary 
syndrome." Molecular & Cellular Endocrinology 370(1-2): 65-77. 
In vitro study  
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Kasim-Karakas, S. E., R. U. Almario, L. Gregory, R. Wong, H. Todd and B. L. Lasley 
(2004). "Metabolic and endocrine effects of a polyunsaturated fatty acid-rich diet in 
polycystic ovary syndrome." Journal of Clinical Endocrinology & Metabolism 89(2): 
615-620. 
Not 
randomised 
 
Kaya, C., S. D. Cengiz and H. Satıroğlu (2009). "Obesity and insulin resistance 
associated with lower plasma vitamin B12 in PCOS." Reproductive BioMedicine 
Online (Reproductive Healthcare Limited) 19(5): 721-726. 
Not 
randomised 
intervention 
trial 
 
Kotsa, K., M. P. Yavropoulou, O. Anastasiou and J. G. Yovos (2009). "Role of vitamin D 
treatment in glucose metabolism in polycystic ovary syndrome." Fertility & Sterility 
92(3): 1053-1058. 
Observational 
study 
 
Krul-Poel, Y. H. M., C. Snackey, Y. Louwers, P. Lips, C. B. Lambalk, J. S. E. Laven and S. 
Simsek (2013). "The role of vitamin D in metabolic disturbances in polycystic ovary 
syndrome: a systematic review." European Journal of Endocrinology 169(6): 853-865. 
Review vitamin 
D in PCOS 
 
Kuek, S., W.-j. Wang and S.-q. Gui (2011). "Efficacy of Chinese patent medicine Tian 
Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled 
trial." Zhong Xi Yi Jie He Xue Bao = Journal Of Chinese Integrative Medicine 9(9): 965-
972. 
Duplicate  
Lee, J. C., S. C. Pak, S. H. Lee, S. C. Lim, Y. H. Bai, C. S. Jin, J. S. Kim, C. S. Na, C. S. Bae, 
K. S. Oh and B. C. Choi (2003). "The effect of herbal medicine on nerve growth factor 
in estradiol valerate-induced polycystic ovaries in rats." The American Journal Of 
Chinese Medicine 31(6): 885-895. 
In vivo (rat) 
study 
 
Lerchbaum, E., A. Giuliani, H. J. Gruber, T. R. Pieber and B. Obermayer-Pietsch 
(2012). "Adult-type hypolactasia and calcium intake in polycystic ovary syndrome." 
Clinical Endocrinology 77(6): 834-843. 
Case control  
Li, H. W. R., R. E. Brereton, R. A. Anderson, A. M. Wallace and C. K. M. Ho (2011). 
"Vitamin D deficiency is common and associated with metabolic risk factors in 
patients with polycystic ovary syndrome." Metabolism 60(10): 1475-1481. 
Observational 
study 
 
Luque-Ramirez, M., F. Alvarez-Blasco, M. Alpanes and H. F. Escobar-Morreale (2011). 
"Role of decreased circulating hepcidin concentrations in the iron excess of women 
with the polycystic ovary syndrome." Journal of Clinical Endocrinology & Metabolism 
96(3): 846-852. 
Case control  
Luque-Ramirez, M., F. Alvarez-Blasco, J. I. Botella-Carretero, R. Sanchon, J. L. San 
Millan and H. F. Escobar-Morreale (2007). "Increased body iron stores of obese 
women with polycystic ovary syndrome are a consequence of insulin resistance and 
hyperinsulinism and are not a result of reduced menstrual losses." Diabetes Care 
30(9): 2309-2313. 
Pharmaceutical 
intervention 
 
Minozzi, M., D. Costantino, C. Guaraldi and V. Unfer (2011). "The effect of a 
combination therapy with myo-inositol and a combined oral contraceptive pill versus 
a combined oral contraceptive pill alone on metabolic, endocrine, and clinical 
parameters in polycystic ovary syndrome." Gynecological Endocrinology 27(11): 920-
924. 
Not 
randomised 
 
Minozzi, M., G. D'Andrea and V. Unfer (2008). "Treatment of hirsutism with myo-
inositol: a prospective clinical study." Reproductive Biomedicine Online 17(4): 579-
582. 
observational  
Nestler, J. E., E. R. Reilly, K. I. Cheang, L. M. Bachmann and R. W. Downs, Jr. (2012). 
"A pilot study: effects of decreasing serum insulin with diazoxide on vitamin D levels 
in obese women with polycystic ovary syndrome." Transactions of the American 
Clinical & Climatological Association 123: 209-219; discussion 219-220. 
Case 
controlled 
 
Ngo, D. T. M., W. P. Chan, S. Rajendran, T. Heresztyn, A. Amarasekera, A. L. Sverdlov, 
P. D. O’Loughlin, H. A. Morris, Y. Y. Chirkov, R. J. Norman and J. D. Horowitz (2011). 
"Determinants of insulin responsiveness in young women: Impact of polycystic 
ovarian syndrome, nitric oxide, and vitamin D." Nitric Oxide 25(3): 326-330. 
Case matched  
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Nordio, M. and E. Proietti (2012). "The combined therapy with myo-inositol and D-
chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients 
compared to myo-inositol supplementation alone." European Review for Medical & 
Pharmacological Sciences 16(5): 575-581. 
Not 
randomised 
 
Ott, J., L. Wattar, C. Kurz, R. Seemann, J. C. Huber, K. Mayerhofer and E. Vytiska-
Binstorfer (2012). "Parameters for calcium metabolism in women with polycystic 
ovary syndrome who undergo clomiphene citrate stimulation: a prospective cohort 
study." European Journal of Endocrinology 166(5): 897-902. 
Cohort study  
Pal, L., A. Berry, L. Coraluzzi, E. Kustan, C. Danton, J. Shaw and H. Taylor (2012). 
"Therapeutic implications of vitamin D and calcium in overweight women with 
polycystic ovary syndrome." Gynecological Endocrinology 28(12): 965-968. 
Open label   
Papaleo, E., V. Unfer, J. P. Baillargeon, L. De Santis, F. Fusi, C. Brigante, G. Marelli, I. 
Cino, A. Redaelli and A. Ferrari (2007). "Myo-inositol in patients with polycystic ovary 
syndrome: a novel method for ovulation induction." Gynecological Endocrinology 
23(12): 700-703. 
Not 
randomised 
 
Phelan, N., A. O'Connor, T. Kyaw Tun, N. Correia, G. Boran, H. M. Roche and J. Gibney 
(2011). "Hormonal and metabolic effects of polyunsaturated fatty acids in young 
women with polycystic ovary syndrome: results from a cross-sectional analysis and a 
randomized, placebo-controlled, crossover trial." American Journal of Clinical 
Nutrition 93(3): 652-662. 
Cross sectional  
Rezvanfar, M. A., M. A. Rezvanfar, A. Ahmadi, H. A. Shojaei-Saadi, M. Baeeri and M. 
Abdollahi (2012). "Molecular mechanisms of a novel selenium-based complementary 
medicine which confers protection against hyperandrogenism-induced polycystic 
ovary." Theriogenology 78(3): 620-631. 
In vivo (rats) 
study 
 
Sakai, A., Z. Kondo, K. Kamei, S. Izumi and K. Sumi (1999). "Induction of ovulation by 
Sairei-to for polycystic ovary syndrome patients." Endocrine Journal 46(1): 217-220. 
TCM  
Santos, B. R., L. P. Mascarenhas, F. Satler, M. C. Boguszewski and P. M. Spritzer 
(2012). "Vitamin D receptor gene polymorphisms and sex steroid secretion in girls 
with precocious pubarche in Southern Brazil: a pilot study." Journal of 
Endocrinological Investigation 35(8): 725-729. 
Genetic study 
not 
randomised 
 
Selimoglu, H., C. Duran, S. Kiyici, C. Ersoy, M. Guclu, G. Ozkaya, E. Tuncel, E. Erturk 
and S. Imamoglu (2010). "The effect of vitamin D replacement therapy on insulin 
resistance and androgen levels in women with polycystic ovary syndrome." Journal 
of Endocrinological Investigation 33(4): 234-238. 
Not 
randomised 
 
Sharifi, F., S. Mazloomi, R. Hajihosseini and S. Mazloomzadeh (2012). "Serum 
magnesium concentrations in polycystic ovary syndrome and its association with 
insulin resistance." Gynecological Endocrinology 28(1): 7-11. 
Cross sectional 
not 
randomised 
 
Sohrabvand, F., M. Shirazi, M. Shariat and F. Mahdiyin (2013). "Serum zinc level in 
infertile women with and without polycystic ovary syndrome: a comparative study. 
(English)." Tehran University Medical Journal 71(3): 157-163. 
Comparative 
study 
 
Takahashi, K. and M. Kitao (1994). "Effect of TJ-68 (shakuyaku-kanzo-to) on 
polycystic ovarian disease." International Journal Of Fertility And Menopausal 
Studies 39(2): 69-76. 
Not 
randomised 
 
Takahashi, K., K. Yoshino, T. Shirai, A. Nishigaki, Y. Araki and M. Kitao (1988). "Effect 
of a traditional herbal medicine (shakuyaku-kanzo-to) on testosterone secretion in 
patients with polycystic ovary syndrome detected by ultrasound." Nihon Sanka 
Fujinka Gakkai Zasshi 40(6): 789-792. 
Not RCT  
Thomson, R. L., S. Spedding, G. D. Brinkworth, M. Noakes and J. D. Buckley (2013). 
"Seasonal effects on vitamin D status influence outcomes of lifestyle intervention in 
overweight and obese women with polycystic ovary syndrome." Fertility & Sterility 
99(6): 1779-1785. 
Cohort study  
Thomson, R. L., S. Spedding and J. D. Buckley (2012). "Vitamin D in the aetiology and 
management of polycystic ovary syndrome." Clinical Endocrinology 77(3): 343-350. 
Review  
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Thys-Jacobs, S., D. Donovan, A. Papadopoulos, P. Sarrel and J. P. Bilezikian (1999). 
"Vitamin D and calcium dysregulation in the polycystic ovarian syndrome." Steroids 
64(6): 430-435. 
Not a clinical 
trial 
 
Velija-Ašimi, Z. (2014). "Evaluation of the association of vitamin D deficiency with 
gona-dotropins and sex hormone in obese and non-obese women with polycystic 
ovary syndrome." Procjena povezanosti nedostatka vitamina D s gonadotropnim i 
spolnim hormonima u pretilih i žena koje nisu pretile sa sindromom policističnih 
jajnika. 11(1): 170-176. 
Not 
randomised 
 
Vigerust, N. F., P. Bohov, B. Bjorndal, R. Seifert, O. Nygard, A. Svardal, D. Glintborg, R. 
K. Berge and M. Gaster (2012). "Free carnitine and acylcarnitines inobese patients 
with polycystic ovary syndrome and effects ofpioglitazone treatment." Fertility & 
Sterility 98(6): 1620-1626.e1621. 
Case 
controlled 
 
Villeneuve, M. C., R. E. Ostlund, Jr. and J. P. Baillargeon (2009). "Hyperinsulinemia is 
closely related to low urinary clearance of D-chiro-inositol in men with a wide range 
of insulin sensitivity." Metabolism: Clinical & Experimental 58(1): 62-68. 
Cross sectional  
Wehr, E., T. R. Pieber and B. Obermayer-Pietsch (2011). "Effect of vitamin D3 
treatment on glucose metabolism and menstrual frequency in polycystic ovary 
syndrome women: a pilot study." Journal of Endocrinological Investigation 34(10): 
757-763. 
Not 
randomised 
 
Wehr, E., S. Pilz, N. Schweighofer, A. Giuliani, D. Kopera, T. R. Pieber and B. 
Obermayer-Pietsch (2009). "Association of hypovitaminosis D with metabolic 
disturbances in polycystic ovary syndrome." European Journal of Endocrinology 
161(4): 575-582. 
Association 
study 
 
Wickenheisser, J. K., V. L. Nelson-DeGrave, K. L. Hendricks, R. S. Legro, J. F. Strauss, 
3rd and J. M. McAllister (2005). "Retinoids and retinol differentially regulate steroid 
biosynthesis in ovarian theca cells isolated from normal cycling women and women 
with polycystic ovary syndrome." Journal of Clinical Endocrinology & Metabolism 
90(8): 4858-4865. 
In vitro study  
Yildizhan, R., M. Kurdoglu, E. Adali, A. Kolusari, B. Yildizhan, H. Sahin and M. Kamaci 
(2009). "Serum 25-hydroxyvitamin D concentrations in obese and non-obese women 
with polycystic ovary syndrome." Archives of Gynecology & Obstetrics 280(4): 559-
563. 
Not RCT  
Zacche, M. M., L. Caputo, S. Filippis, G. Zacche, M. Dindelli and A. Ferrari (2009). 
"Efficacy of myo-inositol in the treatment of cutaneous disorders in young women 
with polycystic ovary syndrome." Gynecological Endocrinology 25(8): 508-513. 
Not 
randomised 
 
Zhang, J., T. Li, L. Zhou, L. Tang, L. Xu, T. Wu and D. C. Lim (2010). "Chinese herbal 
medicine for subfertile women with polycystic ovarian syndrome." The Cochrane 
Database Of Systematic Reviews(9): CD007535. 
Review  
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Appendix 5 
Studies excluded from this review. 
The aim of this review was to synthesise the pre-clinical and clinical evidence explaining the mechanism of effect for herbal medicines in PCOS and associated 
oligo/amenorrhoea and hyperandrogenism. Clinical studies investigating herbal medicines were excluded  based on the absence of evidence for a mechanism of effect in 
oligo/amenorrhoea, hyperandrogenism and PCOS (Table 1) absence of clinical data corroborating  mechanism of effects (Table 2)or investigation of incomplete herbal 
extracts (isolated herbal chemicals) (Table 3). 
Table 1. Herbal medicines for which there was clinical evidence for effect but no pre-clinical evidence demonstrating mechanism of effect and/or evidence for the specified 
clinical conditions. 
Herbal medicine Clinical evidence (or potential) for PCOS and associated oligo/amenorrhoea or hyperandrogenism Reason for non-inclusion – insufficient pre-clinical evidence for 
mechanism of effects for whole herbal extract 
Camellia sinensis  
(green tea) 
Hormone concentration in obese women with PCOS 
Chan C C,Koo MW, Ng EH, Tang OS,  Yeung WS and Ho PC. (2006)."Effects of Chinese green tea on 
weight, and hormonal and biochemical profiles in obese patients with polycystic ovary syndrome; a 
randomized placebo-controlled trial." Journal of the Society for Gynecologic Investigation 13(1): 63-
68. 
Isolated constituent (epigallocatechin gallate 1) examined (Kao, 
Hiipakka et al. 2000). No evidence found for effects for whole 
herbal extract in PCOS, oligo/amenorrhoea and 
hyperandrogenism. 
Mentha spicata 
(spearmint tea) 
Lowered testosterone in women with PCOS  
Akdoğan M, Tamer MN,  Cüre E, Cüre MC, Köroğlu BK and Delibaş N.(2007). "Effect of spearmint 
(Mentha spicata Labiatae) teas on androgen levels in women with hirsutism." Phytotherapy 
Research 21(5): 444-447.  
Grant, P. (2010). "Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian 
syndrome. A randomized controlled trial." Phytotherapy Research 24(2): 186-188. 
No evidence for mechanism of effect found for PCOS, 
oligo/amenorrhoea or hyperandrogenism. 
Ginkgo Biloba 
(ginkgo) 
Metabolic hormone management in type two diabetes  
Kudolo G B, Wang W, Javors M and Blodgett J (2006). "The effect of the ingestion of Ginkgo biloba 
extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic 
subjects--A double blind placebo-controlled, crossover study." Clinical Nutrition 25(4): 606-616. 
No evidence for mechanism of effect in PCOS, oligo/amenorrhoea 
or hyperandrogenism found. 
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Appendix 5 Table 1 continued 
Herbal medicine Clinical evidence (or potential) for PCOS and associated oligo/amenorrhoea or hyperandrogenism Reason for non-inclusion – insufficient pre-clinical 
evidence for mechanism of effects for whole herbal 
extract 
Grifola frondosa 
(miatake mushroom) 
Ovulation rates in PCOS 
Chen JT, Tominaga, K, Sato Y, Anzai H and Matsuoka R. (2010). "Maitake mushroom (Grifola frondosa) extract 
induces ovulation in patients with polycystic ovary syndrome: a possible monotherapy and a combination 
therapy after failure with first-line clomiphene citrate." The Journal of Alternative and Complementary 
Medicine 16(12): 1295-1299. 
No evidence for mechanism of effect in PCOS, 
oligo/amenorrhoea or PCOS revealed. 
Linum usitatissimum 
(flax seed) 
Menstrual regulation and hormonal concentration in post-menopausal women. 
Frische EJ, Hutchins AM, Martini MC, Thomas W and Slavin JL (2003). "Effect of flaxseed and wheat bran on 
serum hormones and lignan excretion in premenopausal women." Journal of the American College of Nutrition 
22(6): 550-554. 
Hutchins AM, Martini MC, Olson BA, Thomas W and Slavin JL (2001). "Flaxseed consumption influences 
endogenous hormone concentrations in postmenopausal women." Nutrition and cancer 39(1): 58-65.  
Lampe J, Martini M, Kurzer K, Adlercreutz H and Slavin J. (1994). "Urinary lignan and isoflavonoid excretion in 
premenopausal women consuming flaxseed powder." The American journal of clinical nutrition 60(1): 122-128. 
Phipps WR, Martini MC, Lampe JW, Slavin JL, Kurzer MS (1993). "Effect of flax seed ingestion on the menstrual 
cycle." The Journal of Clinical Endocrinology & Metabolism 77(5): 1215-1219. 
No mechanism of effect in PCOS, oligo/amenorrhoea or 
hyperandrogenism found. 
Pygeum africanum 
(pygeum) 
Anti-androgen effects in prostatic hypertrophy  
Melo, E, Bertero EB, Rios L and Mattos Jr D (2002). "Evaluating the efficiency of a combination of Pygeum 
africanum and stinging nettle (Urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): double-
blind, randomized, placebo controlled trial." Int Braz J Urol 28(5): 418-425. 
No evidence for mechanism of effect found in PCOS, 
oligo/amenorrhoea or hyperandrogenism (in female cell 
cultures or animals). 
Serrenoa repens 
(saw palmetto) 
Anti-androgen effects in chronic pelvic pain and prostatitis 
Casner PR, Bent S, Kane C and Shinohara K (2006). "Saw palmetto for benign prostatic hyperplasia." N Engl J 
Med 354(18): 1950-1951. Morgia G, Mucciardi G, Madonia M, Castelli T, Favilla V and Magno C (2008). 
"Treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) with Serenoa repens plus selenio 
and licopene (Profluss®): a randomized multicenter placebo-controlled study." The Journal of Urology 179(4): 
32. Yang J and Te AE (2005). "Saw palmetto and finasteride in the treatment of category-III prostatitis/chronic 
pelvic pain syndrome." Current urology reports 6(4): 290-295. 
No mechanism of effect in PCOS, oligo/amenorrhoea or 
hyperandrogenism (in female cell cultures or animals). 
Silybum marianum 
(St Mary’s thistle) 
Fatty liver disease in type two diabetes  
Huseini H F, Larijani B Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat B and Raza M. (2006). "The efficacy of 
Silybum marianum (L.) Gaertn.(silymarin) in the treatment of type II diabetes: a randomized, double-blind, 
placebo-controlled, clinical trial." Phytotherapy research 20(12): 1036-1039. 
No mechanism of effect in PCOS, oligo/amenorrhoea or 
hyperandrogenism. 
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Appendix 5 Table 1 continued 
Herbal medicine Clinical evidence (or potential) for PCOS and associated oligo/amenorrhoea or 
hyperandrogenism 
Reason for non-inclusion – insufficient pre-clinical evidence for 
mechanism of effects for whole herbal extract 
Stachys lavandulifolia 
(wood betony) 
Compared with progesterone supplementation for dysfunctional uterine bleeding in women 
with PCOS  
Jalilian, N., M. Modarresi, M. Rezaie, L. Ghaderi and M. Bozorgmanesh (2013). 
"Phytotherapeutic Management of Polycystic Ovary Syndrome: Role of Aerial Parts of Wood 
Betony (Stachys lavandulifolia)." Phytotherapy Research 27(11): 1708-1713. 
No mechanism of effect studies found different clinical outcome to 
those specified. 
Urtica dioca 
(nettle root) 
Anti-androgen effects in women  
Najafipour, F., A. O. Rahimi, M. Mobaseri, N. Agamohamadzadeh, A. Nikoo and A. 
Aliasgharzadeh (2014). "Therapeutic effects of stinging nettle (Urtica dioica) in women with 
Hyperandrogenism." International Journal of Current Research and Academic Review 2(7): 153-
160. 
Anti-androgen effects through interaction with SHBG in prostate cells 
(Hryb, Khan et al. 1995, Schöttner, Ganßer et al. 1997, Zhang, Li et al. 
2008). Anti-inflammatory and anti-nociceptive effects(Hajhashemi and 
Klooshani 2013) No evidence for effects of Urtica dioca in female cell 
cultures or animals. 
Other studies that were excluded investigated herbal medicines for conditions other than PCOS, oligo/amenorrhoea and hyperandrogenism. These included investigations into Vitex agnus-
castus for pre-menstrual syndrome (He, Z., R. Chen, Y. Zhou, L. Geng, Z. Zhang, S. Chen, Y. Yao, J. Lu and S. Lin (2009). "Treatment for premenstrual syndrome with Vitex agnus castus: A 
prospective, randomized, multi-center placebo controlled study in China." Maturitas 63(1): 99-103; Lauritzen, C. H., H. D. Reuter, R. Repges, K. J. Böhnert and U. Schmidt (1997). "Treatment of 
premenstrual tension syndrome with Vitex agnus castus controlled, double-blind study versus pyridoxine." Phytomedicine 4(3): 183-189;Loch, E., K. Böhnert and M. Peeters (1991). "The 
treatment of menstrual disorders with Vitex agnus-castus tincture." Der Frauenarzt 32(8): 867-870; Loch, E., H. Selle and N. Boblitz (2000). "Treatment of premenstrual syndrome with a 
phytopharmaceutical formulation containing Vitex agnus castus." Journal of Women's Health & Gender-Based Medicine 9(3): 315-320; Ma, L., S. Lin, R. Chen, Y. Zhang, F. Chen and X. Wang 
(2010). "Evaluating therapeutic effect in symptoms of moderate-to-severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women." Australian & New Zealand Journal of 
Obstetrics & Gynaecology 50(2): 189-193 and Schellenberg, R. (2001) "Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled 
study." BMJ (Clinical research ed.), 134-137) and Vitex angus castus for mastalgia (Halaska, M., P. Beles, C. Gorkow and C. Sieder (1999). "Treatment of cyclical mastalgia with a solution 
containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study." The Breast 8(4): 175-181 and Wuttke, W. S., G. Gorkow, C. Sieder, C. (1997). "Treatment of cyclical 
mastalgia: Results of a randomised, placebo- controlled, double-blind study: Objective." Obstetrics and Gynecology 57(10): 569-574). Cimicifuga racemosa for menopausal symptoms (Wuttke, 
W., D. Seidlova-Wuttke and C. Gorkow (2003). "The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and 
bone markers." Maturitas 44: S67-S77).  
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Table 2. Herbal medicines with pre-clinical evidence in PCOS, oligo/amenorrhoea and hyperandrogenism without clinical evidence for effectiveness. 
Herbal medicine Pre-clinical evidence for (potential) effects in reproductive endocrinology in PCOS and associated 
oligo/amenorrhoea and hyperandrogenism 
Reason for exclusion 
Curcuma longa  
(turmeric) 
Anti-androgen effects  
Ohtsu, H., Z. Xiao, J. Ishida, M. Nagai, H.-K. Wang, H. Itokawa, C.-Y. Su, C. Shih, T. Chiang and E. Chang (2002). 
"Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-
prostate cancer agents." Journal of medicinal chemistry 45(23): 5037-5042. 
No clinical evidence examining effectiveness in 
women was found. 
Matricaria chamomilla 
(Chamomile) 
Reduced luteinising hormone and improved ovarian morphology in animals with PCOS  
Zangeneh, F. Z., B. Minaee, A. Amirzargar, A. Ahangarpour and K. Mousavizadeh (2010). "Effects of chamomile 
extract on biochemical and clinical parameters in a rat model of polycystic ovary syndrome." Journal of 
Reproduction & Infertility 11(3): 169. 
No clinical data found. 
Mentha piperita 
(peppermint) 
Anti-androgen effects in animals  
Akdogan, M., M. Ozguner, A. Kocak, M. Oncu and E. Cicek (2004). "Effects of peppermint teas on plasma 
testosterone, follicle-stimulating hormone, and luteinizing hormone levels and testicular tissue in rats." 
Urology 64(2): 394-398. 
No clinical data for women. 
Silybum marianum  
(St Marys thistle) 
Anti-proliferative antioxidant and biochemical effects in the liver.  
Gebhardt, R. (2003). "Antioxidative, antiproliferative and biochemical effects in HepG2 cells of a homeopathic 
remedy and its constituent plant tinctures tested separately or in combination." Arzneimittel Forschung 53(12): 
823-830. 
No clinical evidence including women was found. 
Studies investigating chemical compounds derived from the herbal medicines, included in this review but investigating different outcomes were found for Vitex agnus-castus (Webster, D., J. Lu, S.-N. 
Chen, N. Farnsworth and Z. J. Wang (2006). "Activation of the μ-opiate receptor by Vitex agnus-castus methanol extracts: Implication for its use in PMS." Journal of Ethnopharmacology 106(2): 216-
221) and Cimicifuga racemosa Burdette, J. E., J. Liu, S. Chen, D. S. Fabricant, C. E. Piersen, E. L. Barker, J. M. Pezzuto, A. Mesecar, R. B. van Breemen and N. R. Farnsworth (2003). "Black cohosh acts as 
a mixed competitive ligand and partial agonist of the serotonin receptor." Journal of agricultural and food chemistry 51(19): 5661-5670. 
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Table 3. Studies excluded due to the investigation of chemicals isolated from herbal medicines. 
Isolated chemicals Evidence for effects  
Phytoestrogens  Hormonal effects in ovarian granulosa cells  
Whitehead, S. A. and M. Lacey (2003). "Phytoestrogens inhibit aromatase but not 17β hydroxysteroid dehydrogenase (HSD) type 1 in human 
granulosa luteal cells: evidence for FSH induction of 17β HSD." Human Reproduction 18(3): 487-494. 
Berberine  Comparison with metformin in PCOS; ovarian theca cell hormone production  
Wei, W. Z., H. Wang, A. Sui, M. Liang, K. Deng, H. Ma, Y. Zhang, Y. Zhang, H. Guan, Y. (2012). "A clinical study on the short-term effect of berberine in 
comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome." European Journal of Endocrinology 166(1): 99-
105. Zhao, L., Li, Wei, Han, Fengjuan, Hou, Lihui, Baillargeon, Jean-Patrice, Kuang, Haixue, Wang, Yongyan, Wu, Xiaoke (2011). "Berberine reduces 
insulin resistance induced by dexamethasone in theca cells in vitro." Fertility and sterility 95(1): 461-463. 
Catechin derived from 
Camellia sinensis  
Effects of epigallocatechin gallate 1 on cellular metabolic endocrinology  
Kao, Y.-H., R. A. Hiipakka and S. Liao (2000). "Modulation of endocrine systems and food intake by green tea epigallocatechin gallate 1." 
Endocrinology 141(3): 980-987. 
Sapponins (derived from 
Tribulus terrestris) 
Effects on reproductive endocrinology  
Kostova, I. and D. Dinchev (2005). "Saponins in Tribulus terrestris - Chemistry and bioactivity." Phytochemistry Reviews 4(2-3): 111-137. 
Paeoniflorin, glycyrrhizin 
and glycyrrhetic acid 
Ovarian androgen production  
Takeuchi, T., O. Nishii, T. Okamura and T. Yaginuma (1991). "Effect of paeoniflorin, glycyrrhizin and glycyrrhetic acid on ovarian androgen production." 
American Journal of Chinese Medicine 19(1): 73-78.  
Isoflavones (isolated from 
Vitex agnus-castus) 
Selective oestrogen receptor activity (competitive inhibition via beta oestrogen receptors)  
Jarry, H., B. Spengler, A. Porzel, J. Schmidt, W. Wuttke and V. Christoffel (2003). "Evidence for Estrogen Receptor β-Selective Activity Agnus castus and 
isolated flavones " Planta medica 69(10): 945-947. 
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Appendix 7 
UWS HUMAN RESEARCH ETHICS COMMITTEE 
           
28 October 2011 
 
Associate Professor Caroline Smith, 
Centre for Complementary Medicine 
 
Dear Caroline and Susan, 
 
I wish to formally advise you that the Human Research Ethics Committee has approved your 
research proposal H9341  “The use of complementary medicine and self help measures by 
women with polycystic ovary syndrome“, until 30 April 2012 with the provision of a progress 
report annually and a final report on completion. 
 
Please quote the project number and title as indicated above on all correspondence related 
to this project. 
 
This protocol covers the following researchers:  
Caroline Smith, Jason Abbott, Alan Bensoussan, Susan Arentz. 
 
Yours sincerely 
 
 
Dr Anne Abraham  
Chair, UWS Human Research Ethics Committee 
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Appendix 8                                                                                                           A survey to explore the use of Complementary Medicine and self-help measures to assist with symptom management of polycystic ovary syndrome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This survey is part of a study is being carried out by the University of Western Sydney with 
the support of the Polycystic Ovary Association of Australia (POSAA) to  provide a clearer 
understanding of  the use of self prescribed therapies and complementary medicine or 
therapies  by women with polycystic ovary syndrome (PCOS). Your answers will help to 
better understand the experiences of women with PCOS and for health providers to provide 
better care. The main therapies in this questionnaire include diet, exercise and physical 
activity and complementary medicine and therapies. Many complementary medicines do 
not have a clear evidence base for their effectiveness and this study does not in any way 
imply that POSAA endorse or refute the use of these therapies.  
Your help would be appreciated in the completion of this anonymous survey. Your 
involvement is voluntary and returning the completed questionnaire will indicate your 
consent to participate in this study. It should take about 20 minutes to complete the 
questionnaire. Please note that after submission, your survey cannot be withdrawn. The 
survey is confidential and the answers given by you are not identifiable. 
When completing the survey please click on the box which best represents your answer. 
When you finish the survey, please click on the submit button. There are no right or wrong 
answers. The results will be published on the Polycystic Ovary Syndrome Association of 
Australia (POSAA) website.  
This study is being carried out by a PhD student at the Complementary Medicine Research 
Centre at the University of Western Sydney. It has been approved by the Human Research 
What is Complementary Medicine? Complementary, alternative or natural medicine or 
therapies are those may include herbal tablets or capsules, vitamins and/or mineral 
supplements, food supplements such as fish oil, lecithin, spirilina or barley greens or visiting 
a complementary, traditional medicine or alternative practitioner. In this survey, 
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Appendix 8 continued 
To start we would like to ask you some questions about your general 
health and how you experience PCOS. 
 
1. In general would you say that your physical health is (choose one only) 
  Excellent 
  Very good 
  Good 
  Fair 
  Poor 
 
 
2. Do you experience any of the following signs or symptoms that may be associated with 
PCOS? 
  A late menstrual period  
  Menstrual cramps 
  Skin breakouts or skin irritation on the face, back or chest 
  Depressed as a result of having PCOS 
  Growth of visible hair on chin or body 
  Waist larger than hips 
  Overweight 
  Very overweight 
  Metabolic syndrome or insulin and glucose (or sugar) imbalances 
  Infertility or taking longer than 12 months to get pregnant 
  Other (please specify)............................................................................................... 
  No signs or symptoms 
 
3. During the past two weeks, how much of the time have you felt worried about having PCOS 
(choose as many as relate to your symptoms) 
  All of the time 
  Most of the time 
  A good bit of the time 
  Some of the time 
  A little of the time 
  Hardly any time 
  Not any of the time 
  
4. Do you keep a record of your menstrual period? 
  Yes - always 
  Yes -sometimes 
  No 
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Appendix 8 continued 
5. Have you tried any of the following to reduce or manage PCOS symptoms  (please tick as 
many as needed) 
  Exercise /physical activity 
  Dietary changes 
  Complementary medicine or natural therapies (CM)  
  Pharmaceuticals or drugs such as Metformin or Clomid (clomiphene citrate) 
  The oral contraceptive pill 
  Fertility drugs as part of an IVF cycle 
  Surgery for PCOS such as laparoscopic ovarian drilling or bariatric (stomach) surgery 
  Other (please specify).............................................................................................. 
Now we want to ask you in more detail about ways, if any, that you 
have tried yourself to keep well or to manage the symptoms of PCOS. 
First some questions about complementary or natural therapies 
followed by some questions about diet, or the food you eat and some 
questions about exercise and physical activity.  
As a reminder, complementary medicine or therapies may be known 
to you as complementary, alternative or natural therapies. 
 
6. In the last 12 months, have you used any of the following complementary medicines or  
natural therapies (CM’s)? 
(More than once per day; daily; 4-6 times per week; 1-3 times per week; fortnightly; 
monthly; every 2nd month; 6 monthly; every 9 months; once per year) 
  Vitamins not prescribed by a doctor 
  Other natural medicines from fish, plants or animals 
  Herbal teas 
  Mineral supplements not prescribed by a doctor 
  Food supplements such as spirilina, Barley greens etc  
  Mineral supplements prescribed by a doctor 
  Herbal medicines or liquids such as Vitex agnes castus (chaste tree), Dong quai, Echinacea 
etc 
  Other herbal medicines 
  Traditional Chinese herbal tablets or teas 
  Indigenous or other traditional medicines such as Ayevedic medicine 
  Vitamins prescribed by a doctor 
  Acupuncture 
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  Reflexology 
  Aromatherapy oils for therapeutic reasons 
Appendix 8 continued 
  Homoeopathic medicines 
  Other............................................................................................................................... 
  No complementary medicines or natural health supplements used  
 
7. Do you currently take or use any of the following CM’s?  
  Vitamins not prescribed by a doctor 
  Other natural medicines from fish, plants or animals 
  Herbal teas 
  Mineral supplements not prescribed by a doctor 
  Food supplements such as spirilina, Barley greens etc  
  Mineral supplements prescribed by a doctor 
  Herbal medicines or liquids such as Vitex agnes castus (chaste tree), Dong quai, Echinacea 
etc 
  Other herbal medicines 
  Traditional Chinese herbal tablets or teas 
  Indigenous or other traditional medicines such as Ayevedic medicine 
  Vitamins prescribed by a doctor 
  Acupuncture 
  Reflexology 
  Aromatherapy oils for therapeutic reasons 
  Homoeopathic medicines 
  Other............................................................................................................................... 
  Not using complementary medicines or natural health supplements 
 
8. Have you visited any of the following complementary practitioners or therapists? 
  Acupuncturist 
  Chiropractor 
  Naturopath/western herbalist 
  Osteopath 
  Traditional Chinese medicine practitioner 
  Homoeopath 
  Other traditional medicine practitioner 
  Reflexologist 
  Massage or Bowen therapist 
  Aromatherapist 
  Iridologist 
  Kinesiologist 
  Other natural therapist (please specify)..........................................................................  
  No, I have not visited a complementary practitioner or therapist 
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Appendix 8 continued 
If you have not used, are not currently using and have not visited a 
complementary practitioner or therapist, please go to question 13. 
 
9. What area of your health are you currently using CM’s or seeing a complementary medicine 
or therapist for  
  PCOS   
  Increase energy 
  Period pain 
  PMS 
  Fertility 
  Sleep 
  Digestion  
  Constipation 
  Acne 
  Prevent getting colds and flu 
  Stay healthy 
  Depression 
  Anxiety 
  Other (please specify)......................................................................................................... 
 
10. If you are using CM’s for PCOS, what or who most influenced your decision to use 
complementary therapies? (Please tick as many as needed) 
  I self prescribed  
  Internet 
  Retail assistant 
  Family or friends 
  Medical doctor 
  Complementary medicine practitioner such as a naturopath, herbalist or acupuncturist  
  Health professional such as a nurse, chemist, psychologist, osteopath, physiotherapist or 
other health provider 
  Vitamin company hotline 
  Magazines or books 
  TV  
  Other (please specify)......................................................................... 
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11. Please tick if you have found CM’s effective for (check as many as required)  
  Reducing PCOS symptoms such as regulating menstruation, or reducing acne 
  Improving PCOS, in combination with diet and exercise 
  Improving PCOS, in combination with drugs 
  Reducing period pain 
  Reducing PMS 
  Improving general health 
  Improving fertility 
  Improving sleep 
  Enhancing weight loss 
  Other (please specify).................................................................................................................. 
  No not effective at all 
  Have not tried, so not sure 
 
12. What do you think are the advantages of CM’s? 
  More natural  
  Lack of side effects 
  Safe 
  Effective, it seems to work 
  Lasting effects 
  Holistic effects 
  Not addictive  
  Can complement existing health care 
  Can’t do harm  
  I can be responsible for my own health and well-being 
  I have not tried, so not sure 
  Other...................................................................................................................................... 
 
13. What do you think are the main disadvantages of using CM’s? 
  I don’t think there are any 
  Expensive 
  Takes longer to work 
  Lack of research on if it works 
  Lack of research on safety such as no warnings 
  Not sure if it will work 
  Not enough information 
  Taste or smell of preparations 
  Not confident to use in conjunction with medical drugs 
  Not prescribed or recommended by my doctor 
  Don’t know 
  Other please specify............................................... 
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14. Have you ever had a negative reaction or unwanted side effects, to any complementary 
therapies? 
  Yes 
  No (please go to question 17)    
 
15. If yes which complementary therapies?  
  Vitamins not prescribed by a doctor 
  Other natural medicines from fish, plants or animals 
  Herbal teas 
  Mineral supplements not prescribed by a doctor 
  Food supplements such as spirilina, Barley greens etc  
  Mineral supplements prescribed by a doctor 
  Herbal medicines or liquids such as Vitex agnes castus (chaste tree), Dong quai, Echinacea 
etc 
  Other herbal medicines 
  Traditional Chinese herbal tablets or teas 
  Indigenous or other traditional medicines such as Ayevedic medicine 
  Vitamins prescribed by a doctor 
  Acupuncture 
  Reflexology 
  Aromatherapy oils for therapeutic reasons 
  Homoeopathic medicines 
  Other............................................................................................................................... 
  No complementary medicines or natural health supplements used  
 
16. If yes, what has been the nature of the negative or unwanted side effects you experienced 
(Temporary and I continued to take the CM; temporary symptoms went after I stopped the CM; 
symptoms continued after I stopped the herbal medicine);  
  Menstrual cycle lengthened 
  Menstrual cycle changed in a way I didn’t want 
  Changes in bowel habits either looser or constipated 
  Headaches 
  Nausea 
  Vomitting 
  Skin rashes 
  Sleep changes 
  Heart beating fast 
  Excessive sweating 
  An anaphylactic reaction 
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Next, we want to know whether or not you have tried any diets to 
improve the symptoms of PCOS or to help with weight loss or general 
well-being.  
17. In the past 5 years have you used any diets? 
  Yes 
  Maybe, I eat a healthy diet but not for any particular reason (please go to question 20) 
  No (please go to question 22) 
 
18. What was the purpose or reason for using the diet? (tick as many as appropriate) 
  To lose weight 
  To improve body composition (eg build muscle mass) 
  To improve health 
  To address a health concern (such as high blood sugar or high cholesterol)  
  For social reasons, that is to enjoy with family or friends for example to encourage a family 
member to eat a particular diet  
  Other (please specify).................................................................................... 
 
19. Have you tried any of the following diets?  
  Low Glycaemic Index (low GI) as in foods that lower blood sugar or glucose and lower insulin 
  Low calorie 
  Low Fat 
  Energy restricting diet 
  High protein 
  Low carbohydrate 
  CSIRO 
  Liver detox diet 
  Palm Beach diet 
  Blood group diet 
  Anti-candida diet 
  Lean Cuisine 
  Lite and Easy 
  Protein powders 
  Meal  replacements 
  Others (please specify) .......................................................................................................... 
  No (please go to question 22) 
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20. If you were eating a special diet for a particular reason, do you feel that you achieved your 
goals?  
  Yes 
  No 
  Don’t know 
 
21. Have you experienced weight loss or weight management from any of the following diets? 
  Low Glycaemic Index (low GI) as in foods that lower blood sugar or glucose and lower insulin 
  Low calorie  
  High protein 
  Low carbohydrate 
  Mediterranean 
  Vegetarian 
  CSIRO 
  Liver detox diet 
  Palm Beach Diet 
  Blood group diet 
  Anti-candida diet 
  Lean Cuisine 
  Lite and Easy 
  Protein powders 
  Meal  replacement 
  Other............................................................................................................ 
Next are questions about exercise and physical activity, both 
moderate and vigorous activity.  Moderate activity is movement that 
causes a slight increase in your breathing and heart rate, but you 
should still be able to talk. A brisk walk, mowing the lawn, or 
vacuuming are examples of moderate activity.  
22. How many days per week do you  
(once per week; twice per week three times per week four times per week; five or six times 
per week; everyday; more than once per day) 
  Undertake moderate activity (such as walking)?  
  Undertake vigorous activity such as aerobics, circuit training and running? 
 
23. For how long do you usually undertake moderate physical activity? 
  About 15 minutes 
  About 30 minutes 
  About an hour 
  More than an hour 
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24. For how long do you undertake vigorous physical activity?  
  About 15 minutes 
  About 30 minutes 
  About an hour 
  More than an hour 
 
25. Which forms of physical activity do you currently participate?  
  Lift weights 
  Brisk Walking up hills or stairs (where your breathing is heavy, panting and puffing) 
  Run 
  Group fitness classes at gym eg spin, zumba, pump 
  Swim 
  Personal trainer 
  Dance 
  Cycle 
  Team sport such as netball, hockey etc 
  Tennis (including table tennis)  
  Incidental exercise (as part of a busy lifestyle- for example walking up stairs instead of taking 
the lift, parking the car a long way from your destination, gardening etc) 
  Other................................................ 
 
26. Why do you undertake these forms of physical activity  
  To feel better in my self 
  To develop strength 
  To lose weight 
  To prevent weight gain 
  Because I was advised to exercise by a health professional  
  Because my family or friends suggested I did 
  To meet specific goals or targets 
  To get out of the house 
  To socialise 
  To set an example for my kids, family and/or friends 
  To manage PCOS 
  Other.................................................................................................... 
 
27. Do you feel that you have achieved your health goals with your exercise and physical 
activity? 
  Yes 
  Partly 
  No  
  Don’t know 
  Comments........................................................................... 
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28. If physical activity is an ongoing part of your lifestyle, do you expect to be exercising this 
time next year? 
  Yes 
  No 
  Don’ know 
 
29. If you do not undertake moderate or vigorous activity, is there a particular reason?   
  Limited time 
  Not done before 
  Physical Injury 
  Feel self conscious or embarrassed 
  No difference to my health 
  No difference to my weight 
  Increased my weight 
  Trying to get pregnant 
  I am pregnant 
  Too difficult  
  Not convinced of the benefits 
  Limited money 
  Other............................................................................................................. 
Finally some questions about you, to help us describe the women who 
have taken part in the survey. 
 
30. Are you aged between  
  15 – 19 
  20-24 
  25-29 
  30-34 
  35-40 
  40-44 
  45+ 
 
31. Did you finish high school 
  Yes  
  No  
  Still at high school 
32. Have you completed any tertiary education 
  Yes 
  No  
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33. If yes please indicate if the qualification was  
  A qualification from TAFE or similar 
  University degree 
 
34. In which country were you born 
  Australia 
  Other please specify........................................................................................... 
 
35. Which of the following best describes your working activities (tick as many as required) 
  Home duties 
  Self employed 
  Student 
  Employed 
  Other............................................................................................................................................ 
 
36. Your occupation takes   
  1 day per week 
  2-3 days per week 
  4-5 days per week 
  6-7 days per week  
 
37. Do you have private health insurance? 
  Yes  
  No 
 
Thank you very much for your help. Please remember to click on the submit button at the bottom of 
this page.  
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Appendix 10 
UWS HUMAN RESEARCH ETHICS COMMITTEE 
           
20 December 2011 
 
Associate Professor Caroline Smith, 
Centre for Complementary Medicine 
 
Dear Caroline and Susan, 
 
I wish to formally advise you that the Human Research Ethics Committee has approved your 
research proposal H9407  “The addition of naturopathy to a lifestyle intervention for women 
with polycystic ovary syndrome (PCOS), a randomised controlled trial.“, until 31 August 2013 
with the provision of a progress report annually and a final report on completion. 
 
Please quote the project number and title as indicated above on all correspondence related 
to this project. 
 
This protocol covers the following researchers:  
Birinder Cheema, Caroline Smith, Jason Abbott, Alan Bensoussan, Susan Arentz. 
 
   
Yours sincerely 
 
 
 
Dr Anne Abraham  
Chair, UWS Human Research Ethics Committee 
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Appendix 13 
Risk analysis  
PCOS Formulation number 1 and number 2 
 
Sponsor’s name: University of Western Sydney and Mediherb Australia 
Product code: PCOS-1 and PCOS- 2 
Edition number: 1 
Release date: TBA 
Confidentiality statement 
 
This document is the property of CompleMED, University of Western Sydney and may not be 
disclosed, distributed or reproduced without the written permission of CompleMED. This 
Investigator’s Brochure is a confidential document for the sole information and use of the 
investigators’ team and the institutional ethics committee(s). 
PCOS formulation 
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1. Introduction 
 
This risk analysis describes two herbal formulas that are intended for use in a randomised controlled trial. 
There are 2 formula PCOS-1 and PCOS-2. Formula 1 is a new product not listed with the therapeutic goods 
administration and formula 2 is a listed product that available for sale in Australia. 
PCOS-1 is comprised of four plant extracts and PCOS-2 is comprised of a single herb. There is documentary 
evidence for each of the herbs in systems of traditional medicine for use in women’s health. Traditional texts 
include those of Asia, Europe and America. There is documentary evidence that the five plant extracts have 
been used over three or more generations to promote female reproductive health and to modify endocrine 
function.  
The PCOS-1 formula contains four herbal medicines that may have potential benefits for women with 
polycystic ovary syndrome (PCOS). The PCOS-1 herbal formulation is proposed to specifically targeted to 
improve reproductive hormone balance, and reproductive function and to additionally improve women’s 
general health and wellbeing.  The design of the formulation was based on traditional literature including 
monographs and pharmacopeia’s for use in women’s to improve health and wellbeing and for the 
management of symptoms associated with PCOS.   
The included herbal medicines are available in public dispensaries in China and India and in public dispensary’s 
in Europe, Eastern Europe and America.  These herbs are permitted for sale over-the-counter in Australia 
without restriction and are approved for human consumption in as listed therapeutic products by the 
Australian Therapeutic Goods Administration (TGA).[1]  All  ingredients are approved for use  as both level ‘A’, 
active; and level ‘E’, excipient[1].  As such, these herbs are permitted for use in combination by the TGA 
(including the proposed trial formulation) for over-the-counter sale.  
No herb used in this trial is a controlled substance, animal product or endangered species.  PCOS-1 and PCOS-2 
comply with all relevant dosage limitations stipulated by the TGA and the Pharmacopeia of the Peoples’ 
Republic of China, the British Herbal Pharmacopeia, the European Pharmacopeia, the British Pharmaceutical 
Codex, the British Pharmacopeia the United States Pharmacopeia and European Medicines Agency.  
Standard and acceptable daily dosage levels, as listed in therapeutic Goods Administration (TGA) approved 
pharmacopeia, including those stated in the Pharmacopeia of the Peoples’ Republic of China[2]; the British 
Herbal Pharmacopeia, and the United States Pharmacopeia as well as TGA approved monographs including the 
European Scientific Co-operative on Phytotherapy (ESCOP) as well as the European Medicines Agency[3].  This 
risk analysis highlights minimal safety concerns for the intended use and dosage of the herbs and a low 
likelihood of adverse reactions or interactions with other medications. The herbal medicine formula will be 
used over an acceptable and usual time period.   
The herbal formula will be prepared according to the therapeutic goods administration (TGA) good 
manufacturing practice (GMP) by an approved manufacturer in Queensland, Mediherb Australia. The GMP 
approval is current and to Australian TGA standards. As part of the GMP process, all raw herb starting 
materials are validated for authenticity and certified.  The finished product is certified to comply with pesticide 
residue levels, microbiological contaminants and heavy metals to standards set by the TGA.   
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2. Introduction to the research project 
This phase 2 clinical study examines the effectiveness and safety of a herbal medicine preparation in 
conjunction with lifestyle changes, for polycystic ovary syndrome (PCOS).  PCOS is a common disorder with 11-
21% prevalence in the Australian population of reproductive aged women.[4] The diagnostic criteria for PCOS 
was revised at Rotterdam in 2004 to include two of the following features; 1) oligomenorrhoea (menstrual 
cycle longer than 35 days) or amenorrhoea (no menses for 6 months or more); 2) clinical or biochemical 
hyperandrogenism; 3) polycystic ovaries on ultrasound.[5]  
Herbal medicine is emerging as one of the complementary therapies frequently used by women of 
reproductive aged women. [6, 7] Despite popularity, the scientific evidence base for herbal medicine is 
limited. The aim of this research project is to contribute to the evidence and to explore herbal 
medicine in addition to lifestyle intervention as a treatment option for women with PCOS. 
Level 1 evidence [8] (a systematic review) of traditional Chinese herbal medicines for PCOS associated 
subfertility was reported by Zhang et al in 2010. The review included randomised controlled trials (RCT) of 
Chinese Herbal Medicine as an adjunct to medical treatment for women with PCOS. The review included four 
RCT’s (344 women), comparing Chinese herbal medicine to pharmacological and surgical intervention and 
examined outcomes for ovulation and pregnancy. Significant improvements in pregnancy rates were 
demonstrated for women using Chinese herbal medicine in conjunction with a commonly prescribed ovulation 
drug, Clomiphene citrate (clomiphene), compared with clomiphene alone (OR 2.97, 95%, CI 1.71-5.17).  
Clinical trial evidence (level 2[8]) for the management of PCOS using western herbal medicine and other Asian 
herbal medicines has been examined in at least 8 clinical studies.[9-17] Evidence from placebo controlled RCT’s 
for the herbal management of PCOS, with a lower risk of bias included the management of androgens[9] and 
improving insulin sensitivity.[14] Clinical effectiveness for two RCT’s comparing herbal medicine and 
clomiphene, including oligomenorrhoeic and anovular women, suggested equivalence for herbal medicine 
with clomiphene on ovulation.[16, 17] Evidence for ovulation induction in women with PCOS for herbal medicine 
as an alternative to clomiphene, was demonstrated in one study including 80 women. Statistical equivalence 
between the two interventions (p=0.124) was demonstrated.[17] 
Randomised controlled trial (RCT) evidence supporting traditional uses of the individual Chinese herbs is 
limited and this is likely to be due in part to the complexity of the traditional way in which herbs are 
prescribed. Traditional Chinese herbal practitioners rarely use herbs in isolation. Naturopathically prescribed 
herbal medicine is also often prescribed as a complex formula.  Each herb has a variety of actions and when 
used as a formula these actions may interact synergistically or antagonistically, for example to mitigate 
undesired effects.  
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3. Properties of the Formula PCOS-1  
The design of the PCOS-1 formula (Table 1) was based on traditional naturopathic recommendations, scientific 
evidence and on the clinical practice of naturopathic herbal medicine for women with PCOS.  Herbal selection 
also depended on a preliminary safety profile. [18] 
The overall aims of the herbal medicine formula are to regulate the menstrual cycle by; 
1) Improving the ratio of FSH to LH  
2) Normalising insulin and glucose metabolism 
3) Normalising androgen levels 
These objectives will be achieved by direct actions in the female reproductive tract and by improving general 
health including improved digestion, absorption and eliminatory functions in the body and by enhancing mood 
and wellbeing. 
Research from clinical trials suggests that Paeonia lactiflora can regulate ovarian androgen production and 
regulate the menstrual cycle in women with PCOS.[19, 20] In addition aqueous, essential oil and alkaloid extracts 
of Paeonia lactiflora induced a sedative effect in mice,[21] reduced testosterone production in the ovary but not 
from adrenal glands [22, 23] and displayed a central anti-nociceptive effect mediated by activation of κ-opioid 
receptors [21].     
Research from Italy and China demonstrated that Glycyrrhiza glabra may lower androgens in women with 
PCOS,[11, 12] inhibits progesterone metabolism,[24) have a sedative effect in the central nervous system,[25, 26] and 
an anti-inflammatory effect by inhibiting the metabolism of endogenous cortisone and eicosanoid 
biosynthesis.[24] 
Clinical research from America suggests that Cinnamomum cassia may improve glucose tolerance and insulin 
sensitivity in women with PCOS.[14] 
Many women with PCOS experience psychological co-morbidities. A systematic review reported the 
prevalence of depression in women with PCOS at 25%.[27] The formula PCOS-1 contains the herb Hypericum 
perforatum, which is recommended for the treatment of mild to moderate depression. Whilst 75% of women 
with PCOS may not experience depression, the rationale for including Hypericum was due to additional 
traditional use to reduce muscular pain, a condition for which overweight women participating in an exercise 
program may be susceptible and to induce hepatic metabolism of excess androgens. The use of Hypericum 
perforatum in cases of depression is supported by a systematic review.[28] Linde and colleagues reviewed 29 
trials including 5489 participants and found that Hypericum perforatum was superior to placebo in 18 trials, 
and equal to standard drug therapy in 17 trials with significantly less side effects.  
Each of the selected herbs in the PCOS-1 formula has potentially beneficial properties for the alleviation of 
signs and symptoms associated with polycystic ovary syndrome (PCOS).  
Appendix 13 continued 
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Table 1: PCOS-1 trial formulation 
Botanical name Dose 
Grams 
/day 
Pharmacological 
& physiological 
activity 
 
Level of 
scientific 
evidence 
Type of claim Evidence to support 
claim 
Glycyrrhiza glabra 3 grams Lowered 
androgens in 
women with PCOS 
Low Treatment for 
hyperandrogenism 
in women with 
PCOS 
Level 2[29] evidence and 
level 3[11, 12] 
Paeonia lactiflora 2-6 
grams  
Enhanced 
aromatisation of 
androgens to 
oestrogens in the 
ovary and in 
adipose tissue 
Low Treatment for 
hyperandrogenism 
and raised LH in 
women with PCOS 
Level 2 evidence[29] 
Hypericum 
perforatum 
2-6 Anti depressant; 
reduced muscular 
pain 
Moderate Treatment for 
depression and 
anxiety in women 
with PCOS 
Level 1[28] 
Cinnamomum 
cassia 
3 grams Improved insulin 
sensitivity and 
glucose tolerance 
in women with 
PCOS 
Moderate Treatment for 
metabolic 
disturbances  
women with PCOS 
Level 2 evidence[14] 
Levels of Evidence:  
Level 1 The Systematic Review of the Literature; Level 2 Randomised controlled Trials; Level 3 Non-randomised, observational trials and 
Level 4 Case reports, surveys, qualitative research, anecdotes 
 
The PCOS-1 formulation is prepared in tablet form.  The dosage of 5.4g/day (3 tablets/day) is based on current 
extraction capabilities, recent clinical experience and previous clinical trials of herbal medicine for PCOS.  To 
ensure the consistency of results, a single batch of the formula as an aqueous ethanol extraction prepared 
from authenticated raw herbs will be used for the whole clinical trial.   
4. Properties of the formula, PCOS-2 
PCOS-2 is currently listed with the Therapeutic Goods Administration. The herb Tribulus terrestrus is a common 
part of a naturopathic herbalist prescriptions for women with PCOS.[30] The clinical aims of the PCOS-2 are to 
regulate the menstrual cycle by; 
1) Improving the ratio of FSH to LH and promoting ovulation. 
These objectives will be achieved by direct actions in the female reproductive tract. Research from Bulgaria, 
has demonstrated that Tribulus terrestris can induce ovulation and regulate the menstrual cycle in women 
with PCOS.[16]  
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Table 2: PCOS-2 Mediherb Tribulus forte 
Botanical 
name 
Dose 
Grams 
/day 
Pharmacologica
l & 
physiological 
activity 
 
Level of 
scientific 
evidence 
Type of claim Evidence to 
support 
claim 
Tribulus 
terrestris 
6 grams Raise FSH in 
women with 
PCOS 
Low Treatment for 
ovulation induction 
in women with 
PCOS 
level 3[16] 
Levels of Evidence:  
Level 1 The Systematic Review of the Literature; Level 2 Randomised controlled Trials; Level 3 Non-randomised, observational tr   
Level 4 Case reports, surveys, qualitative research, anecdotes   
 
 
5. Quality assurance 
 
Quality assurance for the PCOS-1 and PCOS-2 formulation was provided through several means.  The 
formulations were manufactured by an established herbal formula manufacturer in Australia (Mediherb 
Australia) according to good manufacturing practice (GMP) specified by the therapeutic goods administration 
of Australia (TGA). The GMP inspections and approval was completed in 2008 by the TGA to Australian 
standards. As part of the GMP process, all raw herbal starting material were validated and certified for 
authenticity. The finished product was certified to comply with pesticide residue levels, microbiological 
contaminants and heavy metals to standards set by the TGA. 
Mediherb has developed a method for detailed chemical analysis of the formulation which included the 
identification and quantification of at least one putative bioactive marker in each herb based on a previously 
developed rational ranking system of known constituents. Mediherb laboratories were licensed by the TGA to 
produce herbal certification under GMP requirements and verified the final formulation, ensured it met 
requirements with regards to identity confirmation and quantity of putative bio-actives.  
The analytical methods for each of the individual herbs tested (High Performance Liquid Chromatography and 
Mass Spectrometry) have been validated to TGA and European Medicines Evaluation Agency standards [31, 
32].  This approach provides the most robust indicators of herbal consistency, and quality of the trial 
formulation available. 
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Sealed Envelope randomisation sequence. 
Identifier emailed to group date Time (Greenwich 
mean time) 
Strata 
1 s.arentz@uws.edu.au Lifestyle 7-Jun-12 8:57 PM Strata: 29 to 33 
2 s.arentz@uws.edu.au Lifestyle plus naturopathy 8-Jun-12 1:30 AM Strata: 29 to 33 
3 s.arentz@uws.edu.au Lifestyle 8-Jun-12 2:04 AM Strata: >33 
4 s.arentz@uws.edu.au Lifestyle plus naturopathy 19-Jul-12 3:15 AM Strata: 29 to 33 
5 s.arentz@uws.edu.au Lifestyle 2-Aug-12 11:10 PM Strata: 29 to 33 
6 s.arentz@uws.edu.au Lifestyle 23-Aug-12 4:26 AM Strata: <29 
7 s.arentz@uws.edu.au Lifestyle plus naturopathy 1-Sep-12 1:45 AM Strata: >33 
8 s.arentz@uws.edu.au Lifestyle 1-Sep-12 2:24 AM Strata: >33 
9 s.arentz@uws.edu.au Lifestyle plus naturopathy 17-Sep-12 2:31 AM Strata: >33 
10 s.arentz@uws.edu.au Lifestyle plus naturopathy 18-Sep-12 1:03 AM Strata: 29 to 33 
11 s.arentz@uws.edu.au Lifestyle 18-Sep-12 7:25 AM Strata: >33 
12 s.arentz@uws.edu.au Lifestyle 30-Sep-12 11:19 PM Strata: >33 
13 s.arentz@uws.edu.au Lifestyle plus naturopathy 1-Oct-12 1:24 AM Strata: >33 
14 s.arentz@uws.edu.au Lifestyle plus naturopathy 1-Oct-12 5:08 AM Strata: >33 
15 s.arentz@uws.edu.au Lifestyle plus naturopathy 17-Oct-12 11:53 PM Strata: 29 to 33 
16 s.arentz@uws.edu.au Lifestyle 19-Oct-12 4:02 AM Strata: 29 to 33 
17 s.arentz@uws.edu.au Lifestyle 21-Oct-12 11:03 PM Strata: 29 to 33 
18 s.arentz@uws.edu.au Lifestyle 23-Oct-12 3:15 AM Strata: <29 
19 s.arentz@uws.edu.au Lifestyle 23-Oct-12 4:19 AM Strata: >33 
20 s.arentz@uws.edu.au Lifestyle plus naturopathy 23-Oct-12 6:10 AM Strata: >33 
21 s.arentz@uws.edu.au Lifestyle 25-Oct-12 9:18 PM Strata: 29 to 33 
22 s.arentz@uws.edu.au Lifestyle plus naturopathy 26-Oct-12 2:08 AM Strata: <29 
23 s.arentz@uws.edu.au Lifestyle plus naturopathy 2-Nov-12 5:22 AM Strata: >33 
24 s.arentz@uws.edu.au Lifestyle plus naturopathy 8-Nov-12 11:43 PM Strata: >33 
25 s.arentz@uws.edu.au Lifestyle 19-Nov-12 11:51 PM Strata: 29 to 33 
26 s.arentz@uws.edu.au Lifestyle plus naturopathy 30-Nov-12 10:08 PM Strata: 29 to 33 
27 s.arentz@uws.edu.au Lifestyle plus naturopathy 1-Dec-12 12:43 AM Strata: <29 
28 s.arentz@uws.edu.au Lifestyle 5-Dec-12 11:20 PM Strata: 29 to 33 
29 s.arentz@uws.edu.au Lifestyle 11-Dec-12 5:41 AM Strata: <29 
30 s.arentz@uws.edu.au Lifestyle plus naturopathy 14-Dec-12 7:00 AM Strata: 29 to 33 
31 s.arentz@uws.edu.au Lifestyle plus naturopathy 14-Dec-12 10:24 PM Strata: 29 to 33 
32 s.arentz@uws.edu.au Lifestyle 15-Dec-12 12:11 AM Strata: <29 
33 s.arentz@uws.edu.au Lifestyle 7-Jan-13 6:24 AM Strata: 29 to 33 
34 s.arentz@uws.edu.au Lifestyle 8-Jan-13 1:15 AM Strata: >33 
35 s.arentz@uws.edu.au Lifestyle 13-Jan-13 8:10 PM Strata: >33 
36 s.arentz@uws.edu.au Lifestyle 13-Jan-13 11:57 PM Strata: >33 
37 s.arentz@uws.edu.au Lifestyle plus naturopathy 14-Jan-13 1:11 AM Strata: >33 
38 s.arentz@uws.edu.au Lifestyle 15-Jan-13 10:27 PM Strata: >33 
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Sealed Envelope randomisation sequence 
Identifier emailed to group date Time (GMT) Strata 
39 s.arentz@uws.edu.au Lifestyle plus naturopathy 12-Feb-13 1:40 AM Strata: <29 
40 s.arentz@uws.edu.au Lifestyle plus naturopathy 19-Feb-13 6:12 AM Strata: >33 
41 s.arentz@uws.edu.au Lifestyle plus naturopathy 21-Feb-13 8:30 PM Strata: >33 
42 s.arentz@uws.edu.au Lifestyle 26-Feb-13 6:25 AM Strata: 29 to 33 
43 s.arentz@uws.edu.au Lifestyle plus naturopathy 26-Feb-13 9:37 AM Strata: 29 to 33 
44 s.arentz@uws.edu.au Lifestyle 5-Mar-13 4:21 AM Strata: 29 to 33 
45 s.arentz@uws.edu.au Lifestyle plus naturopathy 8-Mar-13 11:17 PM Strata: 29 to 33 
46 s.arentz@uws.edu.au Lifestyle 9-Mar-13 12:52 AM Strata: >33 
47 s.arentz@uws.edu.au Lifestyle 14-Mar-13 1:30 AM Strata: >33 
48 s.arentz@uws.edu.au Lifestyle 17-Mar-13 11:25 PM Strata: >33 
49 s.arentz@uws.edu.au Lifestyle 21-Mar-13 1:26 AM Strata: <29 
50 s.arentz@uws.edu.au Lifestyle 26-Mar-13 5:10 AM Strata: >33 
51 s.arentz@uws.edu.au Lifestyle plus naturopathy 26-Mar-13 7:23 AM Strata: 29 to 33 
52 s.arentz@uws.edu.au Lifestyle plus naturopathy 26-Mar-13 9:26 AM Strata: >33 
53 s.arentz@uws.edu.au Lifestyle plus naturopathy 28-Mar-13 1:14 AM Strata: <29 
54 s.arentz@uws.edu.au Lifestyle plus naturopathy 4-Apr-13 12:26 AM Strata: >33 
55 s.arentz@uws.edu.au Lifestyle 24-Apr-13 5:03 AM Strata: 29 to 33 
56 s.arentz@uws.edu.au Lifestyle plus naturopathy 29-Apr-13 6:59 AM Strata: 29 to 33 
57 s.arentz@uws.edu.au Lifestyle plus naturopathy 11-May-13 1:07 AM Strata: 29 to 33 
58 s.arentz@uws.edu.au Lifestyle 17-May-13 10:16 PM Strata: <29 
59 s.arentz@uws.edu.au Lifestyle plus naturopathy 17-May-13 10:16 PM Strata: >33 
60 s.arentz@uws.edu.au Lifestyle 25-May-13 12:55 AM Strata: >33 
61 s.arentz@uws.edu.au Lifestyle plus naturopathy 25-May-13 3:39 AM Strata: <29 
62 s.arentz@uws.edu.au Lifestyle plus naturopathy 25-May-13 4:44 AM Strata: 29 to 33 
63 s.arentz@uws.edu.au Lifestyle plus naturopathy 3-Jun-13 12:59 AM Strata: 29 to 33 
64 s.arentz@uws.edu.au Lifestyle 4-Jun-13 4:29 AM Strata: 29 to 33 
65 s.arentz@uws.edu.au Lifestyle 7-Jun-13 10:41 PM Strata: 29 to 33 
66 s.arentz@uws.edu.au Lifestyle plus naturopathy 7-Jun-13 11:38 PM Strata: >33 
67 s.arentz@uws.edu.au Lifestyle plus naturopathy 8-Jun-13 12:34 AM Strata: 29 to 33 
68 s.arentz@uws.edu.au Lifestyle 8-Jun-13 1:22 AM Strata: 29 to 33 
69 s.arentz@uws.edu.au Lifestyle 8-Jun-13 2:34 AM Strata: 29 to 33 
70 s.arentz@uws.edu.au Lifestyle 8-Jun-13 4:25 AM Strata: 29 to 33 
71 s.arentz@uws.edu.au Lifestyle 8-Jun-13 6:16 AM Strata: <29 
72 s.arentz@uws.edu.au Lifestyle plus naturopathy 8-Jun-13 7:20 AM Strata: <29 
73 s.arentz@uws.edu.au Lifestyle plus naturopathy 14-Jun-13 12:43 AM Strata: 29 to 33 
74 s.arentz@uws.edu.au Lifestyle 14-Jun-13 2:11 AM Strata: >33 
75 s.arentz@uws.edu.au Lifestyle plus naturopathy 17-Jun-13 6:52 AM Strata: 29 to 33 
76 s.arentz@uws.edu.au Lifestyle plus naturopathy 18-Jun-13 5:41 AM Strata: >33 
77 s.arentz@uws.edu.au Lifestyle plus naturopathy 20-Jun-13 1:06 AM Strata: 29 to 33 
78 s.arentz@uws.edu.au Lifestyle 24-Jun-13 1:31 AM Strata: 29 to 33 
79 s.arentz@uws.edu.au Lifestyle 24-Jun-13 5:38 AM Strata: >33 
Sealed Envelope randomisation sequence. 
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Identifier emailed to group date Time(GMT) Strata 
80 s.arentz@uws.edu.au Lifestyle 28-Jun-13 11:05 PM Strata: <29 
81 s.arentz@uws.edu.au Lifestyle 29-Jun-13 12:10 AM Strata: >33 
82 s.arentz@uws.edu.au Lifestyle plus naturopathy 29-Jun-13 12:55 AM Strata: >33 
83 s.arentz@uws.edu.au Lifestyle plus naturopathy 29-Jun-13 1:36 AM Strata: >33 
84 s.arentz@uws.edu.au Lifestyle 29-Jun-13 2:27 AM Strata: >33 
85 s.arentz@uws.edu.au Lifestyle 29-Jun-13 3:33 AM Strata: >33 
86 s.arentz@uws.edu.au Lifestyle plus naturopathy 3-Jul-13 1:15 AM Strata: <29 
87 s.arentz@uws.edu.au Lifestyle 26-Jul-13 11:11 PM Strata: >33 
88 s.arentz@uws.edu.au Lifestyle plus naturopathy 27-Jul-13 12:26 AM Strata: >33 
89 s.arentz@uws.edu.au Lifestyle plus naturopathy 27-Jul-13 2:36 AM Strata: >33 
90 s.arentz@uws.edu.au Lifestyle plus naturopathy 30-Jul-13 5:17 AM Strata: 29 to 33 
91 s.arentz@uws.edu.au Lifestyle 30-Jul-13 6:51 AM Strata: 29 to 33 
92 s.arentz@uws.edu.au Lifestyle 6-Aug-13 2:37 AM Strata: <29 
93 s.arentz@uws.edu.au Lifestyle plus naturopathy 6-Aug-13 6:53 AM Strata: >33 
94 s.arentz@uws.edu.au Lifestyle 20-Aug-13 6:39 AM Strata: >33 
95 s.arentz@uws.edu.au Lifestyle plus naturopathy 22-Aug-13 1:10 AM Strata: <29 
96 s.arentz@uws.edu.au Lifestyle plus naturopathy 27-Aug-13 8:47 AM Strata: <29 
97 s.arentz@uws.edu.au Lifestyle 28-Aug-13 12:35 AM Strata: >33 
98 s.arentz@uws.edu.au Lifestyle 28-Aug-13 5:44 AM Strata: <29 
99 s.arentz@uws.edu.au Lifestyle plus naturopathy 31-Aug-13 1:08 AM Strata: <29 
100 s.arentz@uws.edu.au Lifestyle plus naturopathy 5-Sep-13 1:21 AM Strata: 29 to 33 
101 s.arentz@uws.edu.au Lifestyle plus naturopathy 20-Sep-13 12:30 AM Strata: >33 
102 s.arentz@uws.edu.au Lifestyle 3-Oct-13 12:43 AM Strata: >33 
103 s.arentz@uws.edu.au Lifestyle plus naturopathy 8-Oct-13 5:30 AM Strata: 29 to 33 
104 s.arentz@uws.edu.au Lifestyle plus naturopathy 8-Oct-13 7:20 AM Strata: >33 
105 s.arentz@uws.edu.au Lifestyle 16-Oct-13 10:21 PM Strata: <29 
106 s.arentz@uws.edu.au Lifestyle 24-Oct-13 12:07 AM Strata: <29 
108 s.arentz@uws.edu.au Lifestyle plus naturopathy 24-Oct-13 1:02 AM Strata: >33 
109 s.arentz@uws.edu.au Lifestyle 29-Oct-13 4:16 AM Strata: >33 
110 s.arentz@uws.edu.au Lifestyle plus naturopathy 29-Oct-13 6:14 AM Strata: >33 
111 s.arentz@uws.edu.au Lifestyle 31-Oct-13 5:01 AM Strata: >33 
112 s.arentz@uws.edu.au Lifestyle 31-Oct-13 6:40 AM Strata: >33 
113 s.arentz@uws.edu.au Lifestyle plus naturopathy 31-Oct-13 8:17 AM Strata: >33 
114 s.arentz@uws.edu.au Lifestyle 31-Oct-13 9:24 PM Strata: <29 
115 s.arentz@uws.edu.au Lifestyle plus naturopathy 31-Oct-13 11:36 PM Strata: <29 
116 s.arentz@uws.edu.au Lifestyle 2-Nov-13 12:39 AM Strata: <29 
117 s.arentz@uws.edu.au Lifestyle plus naturopathy 14-Nov-13 12:07 AM Strata: >33 
118 s.arentz@uws.edu.au Lifestyle plus naturopathy 14-Nov-13 7:58 PM Strata: >33 
119 s.arentz@uws.edu.au Lifestyle plus naturopathy 18-Nov-13 12:46 AM Strata: <29 
120 s.arentz@uws.edu.au Lifestyle 27-Nov-13 5:52 AM Strata: 29 to 33 
121 s.arentz@uws.edu.au Lifestyle 6-Dec-13 1:37 AM Strata: 29 to 33 
122 s.arentz@uws.edu.au Lifestyle plus naturopathy 13-Dec-13 3:37 AM Strata: <29 
Appendix 14 continued 
 324 
 
Appendix 15 
 325 
 
 
 Information Sheet 
 
 
 
 
 
 
You are invited to participate in a study 
conducted by Susan Arentz, PhD candidate at 
the University of Western Sydney, Centre for 
Complementary Medicine Research. 
 
This study is about overweight or obese 
women with PCOS who are trying to lose 
weight, regulate their menstrual cycle and 
improve their fertility. The purpose is to 
investigate the role of naturopathy (herbal 
medicine + a consultation with a naturopath), 
in addition to diet and exercise, to find out 
whether or not naturopathy can improve 
physical characteristics, menstrual regularity 
and fertility.  
 
Although herbal medicine has been used in 
traditional societies for hundreds of years, 
there is limited scientific evidence for herbal 
medicine. This study aims to explore the 
effectiveness and safety of herbal medicine in 
women with PCOS. 
 
What does the study involve?  
The study involves your participation in a 12 
week exercise and healthy eating program, at 
the Campbelltown campus of the University Of 
Western Sydney, with the possibility of also 
taking herbal medicine and meeting with a 
naturopath once a month.  
You will be randomly assigned to one of two 
groups diet and exercise or diet and exercise 
plus naturopathy. You cannot choose which 
group you would like to be in. 
  
The diet and exercise program will be 
supervised by a qualified exercise physiologist 
and designed according to the latest evidence 
based guideline for women with PCOS. It 
recommends a healthy diet and exercising for 
150-180 minutes per week.  
 
You will be required to attend a supervised 
exercise session each week as well as do 
home-based exercise for a total of 90 minutes 
per week and will be provided with a  
pedometer. You will be required to record your 
home-based exercise in a diary.  
 
You will be asked to record your menstrual 
cycle details in a diary and use an ovulation 
test to confirm when you are fertile. 
 
You will be asked to complete 2 questionnaires 
at the beginning of the trial and 1 at 12 weeks. 
These address PCOS and how you are 
feeling. You will be interviewed for information 
in relation to your suitability, menstrual cycle 
characteristics and lifestyle habits at the 
beginning and end of the trial.  
You may be allocated to a group which also 
receives naturopathy. Naturopathy involves 
taking 4 tablets each day each containing 
herbal medicines plus another 2 tablets each 
day before ovulation.  
 
Herbal medicines have a long history of use for 
women in traditional societies. The use of 
herbal medicine common practice amongst 
naturopaths and herbalists for women with 
PCOS and for women trying to improve their 
menstrual regulation and well-being and get 
pregnant. The naturopathic consultation will 
take place at a consultation room at the 
Centre for Complementary Medicine Research 
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university for half an hour to provide 
individualised information and support.  
 
How much time will the study take?  
Overall the study will take 12 weeks. At the 
beginning and at the conclusion of the trial, you 
will be asked  to complete a questionnaire, taking 
about 20 minutes. The trial entry interview will 
take about 15 minutes. Each week will involve 
60-80 minutes at the university sports fields and 
gym as well as home based exercises for 90 
minutes in total. If you are allocated to the 
naturopathy group, 30 minutes every 4 weeks.  
 
If you have an irregular menstrual cycle you may 
be invited to do a blood test at Douglas Hanly 
Moir at the conclusion of the trial which will take 
about half an hour depending on where you live 
and the location of the blood collection rooms for 
blood tests. 
 
Will the study benefit me?   
 
Being on the study may help you loose weight 
and improve symptoms associated with PCOS 
including your menstrual regularity. 
 
Will the study involve any discomfort for 
me?  
The exercise will be supervised by a qualified 
exercise physiologist and tailored to individual 
characteristics however some people may find 
exercise uncomfortable.  
 
You will be supported and monitored throughout 
the 12 week exercise program. Warm up and 
cool down stretching may reduce muscular pain 
from exercise as can drinking water, however 
with any improvement of body composition, there 
may be some muscular discomfort. If this occurs 
please immediately inform the exercise 
physiologist and exercises will be adjusted 
accordingly. 
  
Some people experience side effects from herbal 
medicine such as nausea or headaches. These 
symptoms are usually temporary and subside if 
the dose of the herbal medicine is reduced, 
however if side effects are overwhelming or you 
cannot manage to take the herbal medicine, 
please contact the researcher Susan Arentz on 
the number or email below.  
  
If you find that you are feeling upset or distressed 
because of, or during the trial, please contact the 
researcher Susan Arentz. Alternatively if you feel 
more comfortable the free telephone counselling 
service Lifeline on 13 11 14 or contact your GP. 
  
Susan Arentz 0403 044 247 or email 
s.arentz@uws.edu. 
 
How is this study being paid for?  
 
The study is being supported by funds for Susan 
Arentz to complete her PhD. The herbal medicine 
tablets are being provided by Mediherb Australia. 
 
Will anyone else know the results?   
All aspects of the study, including results, will be 
confidential and only the researchers will have 
access to information on participants. Results will 
be presented as part of a manuscript for 
publication. Participants in the trial will receive a 
copy of the manuscript by e-mail or mail. 
Can I withdraw from the study? Participation is 
entirely voluntary: you are not obliged to be 
involved and, if you do participate, you can 
withdraw at any time without giving any reason 
and without any consequences. 
 
Can I tell  other people about the study?  
 
Yes, you can tell other people about the study by 
providing them with the chief investigator's 
contact 
details. They can contact the chief investigator to 
discuss their participation in the research project 
and 
obtain an information sheet. 
 
What if I  require further information?  
 
When you have read this information, Susan 
Arentz will discuss it with you further and answer 
any questions you may have. If you would like to 
know more at any stage, please feel free to 
contact Susan Arentz. 
 
What if I  have a complaint?  
 
This study has been approved by the University 
of Western Sydney Human Research Ethics 
Committee. The Approval number is H9407.If you 
have any complaints or reservations about the 
ethical conduct of this research, you may contact 
the Ethics Committee through the Office of 
Research Services on Tel +61 2 4736 0229 
Fax +61 2 4736 0013 or email 
humanethics@uws.edu.au
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Participant No._______________ 
ENTRY - The addition of herbal medicine to lifestyle intervention, for the 
management of women with polycystic ovary syndrome (PCOS). 
 
First name....................................................... 
 
Surname......................................................... 
Date of birth    /  /   
                         day         month    year 
Age      
 
Address...................................................... 
 
................................................................... 
Post code      
 
Phone number 
(...........).................................. 
 
Mobile........................................................ 
Entry Criteria 
 
1. Woman aged 18 – 44  
      
   Yes        no   (must be yes) 
 
2. Diagnosis of PCOS in last 6 months?    
     
   Yes        no   (must be yes) 
 
3. Body mass index greater than 25 or 
over? 
     
   Yes        no   (must be yes) 
 
4. Consent form signed? 
     
   Yes        no   (must be yes) 
 
 
 
Exclusion criteria 
 
13.  Body mass index 24.5 or less? 
      
   Yes        no   (must be no) 
 
14. Taking oral contraceptive pill? 
     
   Yes        no   (must be no) 
 
15. Using pharmaceuticals to manage 
or treat depression? 
     
   Yes        no   (must be no) 
 
16. Major medical disorders or other 
concurrent medical illnesses? 
     
   Yes        no   (must be no) 
 
 
Office use only Date Signed 
LOG   
CHECK   
Data Entry   
Queries resolved/ updated   
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5. Able to attend for allocated herbal 
medicine sessions? 
      
   Yes        no   (must be yes) 
 
6. Able to attend for exercise sessions? 
      
   Yes        no   (must be yes) 
 
7. Able to exercise at home? 
      
   Yes        no   (must be yes) 
 
 
8. Date of study entry           
  /  /   
                day         month    year 
 
9. Time of study entry  
         :   
                 24 hour clock 
 
10. Number allocated 
            
11. Group 1    Group 2   
 
12. Are you hoping to conceive during the 
next three months?  
     
               Yes        no 
If yes how long have you been trying to 
conceive? 
…………………………………………………………………………. 
Anthropometric features 
16. Body weight    kg 
17. Height            .  metres 
18. BMI                kg/m2 
19. Waist circumference   cm 
20. Hip circumference      cm 
 
21. Hip to waist ratio   :   
 
22. Blood Pressure  
diastolic 
   /systolic    
 
23. Do you drink alcohol? 
     
   Yes        no    
 
If yes how many alcoholic drinks per 
week? 
     
24. Do you smoke cigarettes? 
     
   Yes        no    
If yes how many cigarettes per day? 
   
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Now I am going to ask you some questions 
about your levels of current physical activity. 
 
25. In the last 2 weeks did you engage in any 
vigorous exercise e.g. which made you breathe 
hard? 
   Yes       No  
                     
     Occasions            Hours per occasion 
 
26. In the last 2 weeks did you engage in any 
less vigorous activity that did not make you 
breath hard?  
   Yes       No  
                     
     Occasions            Hours per occasion 
 
27. In the last 2 weeks did you walk for 
recreation or exercise?  
   Yes       No  
                     
     Occasions            Hours per occasion 
 
28. Previous use of complementary medicine?      
     
 Yes        no    
28a. Previous use of pharmaceuticals? 
         
               Yes        no    
 
If yes, type....................................................... 
Now I want to ask you some questions 
about your menstrual cycle. 
 
29. When was the last time you had a 
menstrual period? 
1.   /  /   
                day         month    year 
 
30. Are you sure or not sure 
  sure   fairly sure   not sure   
 
31. How many menstrual periods have 
you had over the past three months? 
 
 
 ………………………………………………………….. 
 
Is this your usual menstrual period 
pattern?                    
                             Yes                 No 
If no what is the shortest cycle and 
longest? 
      Shortest    Longest   
 
32. Is your period usually; 
          Scant (spotting)                      
         Light (1-2 days)               
         Medium (3-5 days)                    
         Heavy (6+ tampons/pads per day   
     
33. Do you experience any of the following 
before or during your menstrual period? 
 
             period pain                 breast pain 
             fatigue                         headaches 
            bloating                        Other - specify 
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Next I want to ask you some questions about 
your diet. Are you familiar with the healthy 
eating plan described by the Australian 
Government called Lifescripts? 
                  yes   no   
What food do you usually eat? 
Servings on a typical day 
                                                  1  2  3  4  5     
Vegetables (1/2 cup)                      
Fruit (1 medium piece)             
Bread (2 slices), cereals                 
(1 cup cooked)                            
Rice, pasta, noodles                       
(1 cup cooked)                 
Lean meat, fish,                              
poultry (100g)                            
Legumes ½ cup,                              
nuts & seeds (1/4 cup)         
Dairy and                                          
fortified milk  
substitutes (1 cup)                    
Yoghurt (1 tub),                              
cheese (2 slices)                
Oils, soft margarines                
(1 tablespoon)                 
Cakes biscuits, pies,                      
Pastries (average serve)        
Take away food                             
(eg. Fried chicken or  
fish, chips, burgers)             
Drinks (sugary soft drinks,          
juices, energy drinks (1 glass)  
 
  = optimal daily intakeChecklist 
background. This helps us to describe the diversity 
of women taking part in the survey. 
 
            mood changes             ......................... 
34. Do you have any medical test results 
or reports from the past 6 months? 
      Yes       No 
 
35. Blood tests 
• Oestradiol.......................................
. 
• FSH (day 1-8) ................................. 
 
• LH (day 1-8) ................................... 
 
• Testosterone.................................. 
 
• Free androgen 
index.............................................. 
 
• SHBG..............................................
. 
• Other androgen studies................. 
 
• Fasting glucose............................... 
 
• Fasting insulin................................ 
 
• Other insulin studies ..................... 
 
• Progesterone (after day 20)........... 
 
• Thyroid function tests.................... 
 
• Other blood tests including FBC, 
vitamin D, Iron studies, lipid 
profile 
................................................. 
 
Have you been pregnant before? 
     
               Yes        no 
If yes how many times and what was the 
outcome of your pregnancy(s)? 
………………………………………………………………. 
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37. Which of the following best describes your 
employment status? (please circle) 
 
1. Working full time (permanent or contract) 
2. Working part time 
3. Unemployed 
4. Home duties 
5. Student 
6. Permanently unable to work/ill 
7. Casual: full time 
8. Casual: part time 
9. Other 
 
38. If usually working (full or part time), what is your 
usual occupation? 
 
      Job position......................................... 
 
      Industry................................................ 
39. Did you finish high school?  
 Yes    No     N/A 
40. Have you completed any tertiary education?  
        Yes    No   
If yes is you qualification from  
    TAFE or similar  University   
Race              Caucasian                  Maori 
                      Asian                          Unknown 
                      Aboriginal/TSI          Other -              
                      Polynesian             ...................... 
 
41. Which of the following best describes your 
situation?  
    Single                  De-facto 
   Married              Separated but not   divorced 
   Divorced             Other..... ......................... 
 
 
 
 
Demographic details 
Now I would like to ask some questions about 
your 
 
 
42. Healthy eating guidelines explained 
              yes   no   
43. Pre-exercise Medical history form 
             yes   no   
44. PCOSQ and DASS 21 Questionnaire 
yes   no   
45. Instructions about  menstrual diary 
yes   no                                    
      /  /  date                                    
46. Instructions about how to use 
ovulation   test 
            yes   no   
      /  /  date                                    
                               
47. Invited to participate in blood tests?  
             yes   no   
36. SUBSET (oligomenorrhoea) 
Blood tests     Yes       No  
Insulin    .............      Glucose  ................. 
FSH   ..................      P4 .......................... 
LH   ....................      T4   ....................... 
E2  .......................    FAI  ........................ 
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Appendix 18        
Participant number_______ 
The addition of lifestyle intervention (diet and 
exercise for the management of women with 
polycystic ovary syndrome (PCOS) 
Questionnaire – 1 (trial entry) 
Questionnaire for  
Women with PCOS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Centre for Complementary Medicine  
This questionnaire is part of a study being carried out by the Centre for Complementary Medicine 
Research, at the University of Western Sydney, and forms part of a trial including  overweight women 
with polycystic ovary syndrome (PCOS). The aim of this questionnaire is to provide a clearer 
understanding for the physical and emotional experiences of women with PCOS and to assess the 
effectiveness and safety of naturopathy in women participating in lifestyle intervention (structured 
exercise programs). Your answers will help to better understand the experiences of women with PCOS 
and to explore lifestyle and naturopathy as interventions for women with PCOS. Overall hopefully this 
trial will contribute to the development of better care.  
Your help is appreciated in the completion of this questionnaire. It contains 40 questions and should 
take about 20 minutes to complete. Please note that after submission, your questionnaire cannot be 
withdrawn. The questionnaire is confidential and the answers given by you are identifiable only to the 
researcher prior to computer entry, at which point your responses will be unidentifiable. There are no 
right or wrong answers. The overall results will be presented to you in an individualised letter at the 
conclusion of the trial. 
The questions in this questionnaire focus on your expectations from being involved in the trial and your 
emotional and physical experience of the physical symptoms associated with PCOS. This questionnaire 
will be presented to you when you start the trial and a slightly adjusted at 12 weeks, which is the end of 
the trial.  
When completing the questionnaire, mark the box which best represents your answer. Please provide 
one answer to each question. When you finish the questionnaire, please pass to Susan Arentz.  
This study is being carried out by a PhD student at the Complementary Medicine Research Centre at 
the University of Western Sydney. It has been approved by the Human Research Ethics Committee 
(H9407) of the University of Western Sydney. 
If you have any questions regarding the survey please contact the researcher, Susan Arentz on 0403 
044 247 or email s.arentz@uws.edu.au. If you have any concerns or complaints about the ethical 
conduct or content of the survey, please contact the Office of Research Services on +61 2 4736 0229. 
Thank you for your participation. 
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Appendix 18 continued 
To start we want to ask you about what you expect to happen whilst on the 
trial. 
 Yes No 
Have you tied exercise and diet 
to manage PCOS before?     
Do you think these therapies will 
help?     
 
 Yes No 
Have you tied herbal medicine 
or naturopathy before?     
Do you think these therapies will 
help?     
 
Next we want to ask you questions about your physical experience of PCOS 
and how you feel about PCOS. 
To what extent have you felt that growth of visible hair on your chin has been a problem for you 
during the last two weeks: 
 A severe 
problem 
A major 
problem 
A 
moderate 
problem 
Some 
problem 
A little 
problem 
Hardly 
any 
problem 
No 
problem 
1. Growth 
of visible 
hair on 
chin? 
              
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During the past two weeks, how much of the time have you felt: 
 All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly 
any of 
the time 
None of 
the time 
2.Depressed 
as a result 
of having 
PCOS? 
              
3.Concerned 
about being 
overweight? 
              
4. Easily 
tired?               
5.Concerned 
with 
infertility 
problems? 
              
6. Moody as 
a result of 
having 
PCOS? 
              
 
In relation to your last menstruation, how much were the following issues a problem for you: 
 A severe 
problem 
A major 
problem 
 A 
moderate 
problem 
Some 
problem 
A little 
problem 
Hardly 
any 
problem 
No 
problem 
7.Headaches? 
              
8.Irregular 
menstrual 
periods? 
              
 
To what extent has growth of visible hair on your upper lip been a problem for you during the last 
two weeks: 
 A severe 
problem 
A major 
problem 
A 
moderate 
problem 
Some 
problem 
A little 
problem 
Hardly 
any 
problem 
No 
problem 
9. Growth 
of visible 
hair on 
upper lip 
              
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During the past two weeks, how much of the time have you: 
 All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly 
any of the 
time 
None of 
the time 
10. Had 
trouble 
dealing 
with your 
weight 
              
11. Had 
low self 
esteem as 
a result of 
having 
PCOS? 
              
12. Felt 
frustration 
in trying 
to lose 
weight? 
              
13. Felt 
afraid of 
not being 
able to 
have 
children? 
              
14. Felt 
frightened 
of getting 
cancer? 
              
 
Over the last two weeks, to what extent the following issues have been a problem for you: 
 A severe 
problem 
A major 
problem 
A 
moderate 
problem 
Some 
problem 
A little 
problem 
Hardly 
any 
problem 
No 
problem 
15.Growth of 
visible hair on 
your face? 
              
16.Embarrasment 
about excessive 
body hair? 
              
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During the past two weeks, how much of the time have you been: 
 All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly 
any of the 
time 
None of 
the time 
17.Worried 
about 
having 
PCOS? 
              
18.Self-
conscious 
as a result 
of having 
PCOS? 
              
 
In relation to your last menstruation, how much of the following issues were a problem for you: 
 A severe 
problem 
A major 
problem 
A 
moderate 
problem 
Some 
problem 
A little 
problem 
Hardly 
any 
problem 
No 
problem 
19.Abdominal 
bloating?               
20.Late 
menstrual 
period? 
              
21.Menstrual 
cramps?               
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Appendix 18 continued 
How much of the time in the last two weeks did you: 
 
 
 
All of the 
time 
Most of 
the time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
Hardly 
any of 
the time 
None of 
the time 
22. Feel like 
you are not 
sexy 
because of 
being 
overweight? 
              
23. Feel a 
lack of 
control over 
the 
situation 
with PCOS? 
              
24. Have 
difficulties 
staying at 
your ideal 
weight? 
              
25. Feel sad 
because of 
infertility 
problems? 
              
 
To what extent has growth of visible body hair been a problem for you during the last two weeks: 
 A severe 
problem 
A major 
problem 
A 
moderate 
problem 
Some 
problem 
A little 
problem 
Hardly 
any 
problem 
No 
problem 
26.Growth 
of visible 
body hair? 
              
 
 
 
 
 
 
  
338 
 
Appendix 18 continued 
Finally, can you please complete this form yourself? It contains 21 questions 
about how you feel generally. 
Please read each statement and circle a number 0, 1, 2 or 3 which indicates 
how much the statement applied to you in the past week. There are no right 
or wrong answers. Do not spend too much time on any statement. 
0 Did not apply to me at all. 
1 Applied to me to some degree or some of the time. 
2 Applied to me to a considerable degree or a good part of the time. 
3 Applied to me very much or most of the time. 
     
1. I found it hard to wind down. 0 1 2 3 
2. I was aware of dryness in my mouth. 0 1 2 3 
3. I couldn’t seem to experience any positive 
feeling at all. 
0 1 2 3 
4. I experienced breathing difficulty (eg excessively 
rapid breathing, breathlessness in the absence 
of physical exertion). 
0 1 2 3 
5. I found it difficult to work up the initiative to do 
things. 
0 1 2 3 
6. I tended to over-react to situations. 0 1 2 3 
7. I experienced trembling (eg in the hands). 0 1 2 3 
8. I felt I was using a lot of nervous energy. 0 1 2 3 
9. I was worried about situations in which I might 
panic and make a fool of myself. 
0 1 2 3 
10. I felt I had nothing to look forward to. 0 1 2 3 
11. I found myself agitated. 0 1 2 3 
12. I found it difficult to relax. 0 1 2 3 
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13. I felt down-hearted and blue. 0 1 2 3 
14. I was intolerant of anything that kept me from 
getting on with what I was doing. 
0 1 2 3 
15. I felt I was close to panic. 0 1 2 3 
16. I was unable to become enthusiastic about 
anything. 
0 1 2 3 
17. I felt I wasn’t worth much as a person. 0 1 2 3 
18. I felt I was rather touchy. 0 1 2 3 
19. I was aware of the action of my heart in the 
absence of physical exertion (eg a sense of my 
heart rate increasing or missing a heart beat). 
0 1 2 3 
20. I felt scared without any good reason. 0 1 2 3 
21. I felt life was meaningless. 0 1 2 3 
     
 
Thank you very much for your help by completing the questionnaire. Please 
now pass to the researcher Susan Arentz . 
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Appendix 19 
Evidence based guidelines for assessment and management of Polycystic Ovary Syndrome 
© The Jean Hailes Foundation for Women’s Health on behalf of the PCOS Australian Alliance 2011 
Evidence-based guideline for the assessment and management of polycystic ovary syndrome. Jean Hailes Foundation for Women’s Health on behalf of the PCOS Australian 
Alliance; Melbourne, 2011. Algorithm 3: Lifestyle management for women with polycystic ovary syndrome Lifestyle modification & behaviour change 
Evidence-based recommendation – Grade B 
■■Lifestyle management (single or combined approaches of diet, exercise and/or behavioural interventions) for weight loss, prevention of weight gain, or for general health benefits should be recommended in women with PCOS. 
Evidence-based recommendation – Grade C 
■■Face to face, tailored dietary advice, including education, behavioural change techniques and ongoing support should be provided to women with PCOS and a 
body mass index ≥25kg/m2 (overweight/obese). Dietary modification is the joint responsibility of all health professionals, partnering with women with PCOS. 
Clinical consensus recommendation 
■■Behaviour change techniques should target prevention of weight gain in all women with PCOS including those with a body mass index 18.5-24.9kg/m2 (lean).  Clinical practice point 
■■Behavioural change techniques, including motivational interviewing, should be used in addition to advice/education. Simple strategies, including self-monitoring, pedometers and time management techniques, should be encouraged. Interventions could be individual, group or mixed mode, in a range of settings, delivered by a range of health professionals. Individual techniques should not be used in isolation and should be part of a coherent multidisciplinary interventional model.  
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■■Key messages should be reinforced with women with PCOS, including that achievable goals (5% to 10% loss of body weight in overweight women) yield significant clinical improvements.  Combined lifestyle management 
Evidence-based recommendation – Grade C Lifestyle management targeting weight loss (in women with a BMI ≥25kg/m2 (overweight/obese)) and prevention of weight gain (in women with a BMI 18.5-24.9kg/m2 (lean)) should include both reduced dietary energy (caloric) intake and exercise and should be first-line therapy for all women with PCOS. Clinical practice point Psychological factors should be considered and managed to optimise engagement and adherence to lifestyle interventions.Diet Diet 
Evidence-based recommendation – Grade C Weight loss should be targeted in all women with PCOS and body mass index ≥25kg/m2 (overweight/obese) through reducing dietary energy (caloric) intake in the setting of healthy food choices, irrespective of diet composition. 
Evidence-based recommendation – Grade D Prevention of weight gain should be targeted in all women with PCOS through monitored caloric intake, in the setting of healthy food choices irrespective of diet composition. Clinical practice point 
Weight loss (in women with a body mass index ≥25kg/m2 (overweight/obese)) and prevention of weight gain (in women with a BMI 18.5-24.9kg/m2 (lean)) is the joint responsibility of all health professionals, partnering with women with polycystic ovary syndrome. Where complex dietary issues arise (or obesity is present), referral to a dietitian should be considered as part of an enhanced primary care plan. Tools such as Lifescripts could be used for engagement in dietary change: www.health.gov.au/lifescripts  Exercise 
Evidence-based recommendation – Grade D Exercise participation of at least 150 minutes per week should be recommended in all women with PCOS, especially those with a BMI ≥25kg/m2 (overweight/obese), given the metabolic risks of PCOS and the long term metabolic benefits of exercise.  
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Of this, 90 minutes per week should be aerobic activity at moderate to high intensity (60% - 90% of maximum heart rate) to optimise clinical outcomes. 
Evidence-based recommendation – Grade C 
Weight loss should be targeted in all women with PCOS and body mass index ≥25kg/m2 (overweight/obese) through reducing dietary energy (caloric) intake in the setting of healthy food choices, irrespective of diet composition. 
Evidence-based recommendation – Grade D Prevention of weight gain should be targeted in all women with PCOS through monitored caloric intake, in the setting of healthy food choices irrespective of diet composition. Clinical practice point Encouraging exercise is the joint responsibility of all health professionals, partnering with women with PCOS. Where appropriate, referral to an exercise physiologist or specialist could be considered as part of an enhanced primary care plan. Where there are significant co-morbidities, assessment for exercise participation should be undertaken by the relevant healthcare professionals. Tools such as Lifescripts could be used for engagement in physical activity: www.health.gov.au/lifescripts. Clinical practice point 
Weight loss (in women with a body mass index ≥25kg/m2 (overweight/obese)) and prevention of weight gain (in women with a BMI 18.5-24.9kg/m2 (lean)) is the joint responsibility of all health professionals, partnering with women with polycystic ovary syndrome. Where complex dietary issues arise (or obesity is present), referral to a dietitian should be considered as part of an enhanced primary care plan. Tools such as Lifescripts could be used for engagement in dietary change: www.health.gov.au/lifescripts.
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Screening before exercise 
 
1. List all medications you are taking along with condition for which they are taken: 
 
Medicine Reason Date commenced 
DD/MMM/YYYY 
Date ended or 
ongoing 
    
    
    
    
 
 
Next are some questions about your medical history. 
 Do you have or have you had any of the following health conditions. 
1. Diabetes?    
  Yes, type 1  
  Yes, type 2  please also answer below 
  No 
If Type 2, for how long?    
  Less than 6 months  
  7-12 months 
  1-3 years 
  More than 3 years 
2. Heart disease Yes / No 
3. Liver disease Yes / No 
4. Kidney disease  Yes / No 
5. Asthma Yes / No 
6. Thyroid disease Yes / No 
7. A stroke  Yes / No 
8. Deep vein thrombosis (DVT) Yes / No  
9. Are you or could you currently be pregnant? Yes / No 
10. During the last 12 months, have you had an attack of shortness of breath that came 
on when you were not exercising?  Yes / No  
11. Do you often feel faint or have spells of severe dizziness, particularly with exercise?  
Yes / No 
12. In the last 12 months, have you been woken at night by shortness of breath?    
Yes / No 
11. Do you experience swelling or accumulation of fluid around the ankles?  Yes / No 
12.  
To be completed by researcher: 
Participant No. __________ 
Date___________________ 
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13. Do you ever get the feeling that your heart is beating faster, racing or skipping beats, 
either at rest or during exercise?  Yes / No 
14. Do you regularly get pains in your calves and lower legs during exercise which are 
not due to soreness or stiffness?  Yes / No 
15. Do you often experience fatigue or excessive tiredness?  Yes / No 
16. Do you smoke cigarettes?  Yes / No 
If yes, how many cigarettes do you smoke each day on average? 
 If no, have you quit smoking within the last two years?  Yes / No 
 
17. Do you have a close relative who has had a stroke or heart attack?  Yes / No 
If yes, what relation was this person? 
At what age did he or she suffer a stroke/heart attack?:  
17. Did your relative die suddenly as a result of a stroke or heart attack?  Yes / No 
18. Do you have high blood pressure?    Yes / No 
19. Does your occupation involve sitting for a large part of the day?  Yes / No 
20. Are you currently involved in a regular exercise program?  Yes / No   
If yes, please describe:  
21. Have you experienced any previous injury to your body? 
If yes please describe.
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Lifescripts dietary recommendations 
Note; Red rectangle    denotes optimal daily intake. 
Number of servings on a typical day 
                                                     1  2  3  4  5     
Vegetables (1/2 cup)                        
Fruit (1 medium piece)                
Bread (2 slices), cereals (1 cup cooked)         
Rice, pasta, noodles (1 cup cooked)                
Lean meat, fish, poultry (100g)                              
Legumes ½ cup nuts & seeds (1/4 cup),               
Dairy and fortified milk substitutes (1 cup)       
Yoghurt (1 tub), cheese (2 slices)        
Oils, soft margarines (1 tablespoon)                
Cakes, biscuits, pies, pastries                        
Take away food  
(eg. Fried chicken or fish, chips, burgers)             
Drinks (sugary soft drinks,    
juices, energy drinks (1 glass)         
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 Option 1 Option 2 Option 3 Option 4 
Breakfast Oats (1 -2 cups) – eg 
porridge, raw muesli, 
bircher muesli. 
Yoghurt fruit (frozen 
raspberries, chopped 
up fresh fruit) 
Sprinkle with 
cinnamon, seeds 
(pumpkin and 
sunflower) walnuts, 
almonds.  
Toast - whole grain 
and seeded (eg. 
Burgin soy and 
linseed) with soft 
white cheese eg;  
goats, ricotta, fetta 
with sliced  tomato, 
avocado, 
mushrooms, 
capsicum  
Fruit fresh 
chopped eg apple, 
pear peaches, 
passionfruit, 
rockmelon, 
pineapple mango 
banana, kiwi, 
berries (frozen ok) 
etc with yoghurt 
with cinnamon, 
and granola or 
seeds and nuts 
Eggs – however 
you like! With 
Smoked salmon, 
wilted baby 
spinach leaves. 
Cooked onions 
with tomatoes (and 
zucchini). 
Mushrooms, Baked 
beans. Toast x 2 
slices   
Mid morning Apple Pear Banana Frozen berries 
Lunch Whole grain seeded 
bread sandwich with 
salad eg lettuce, 
tomato, avocado, 
alfalfa, white soft 
cheese and chicken, 
or tuna 
Soup – vegetable 
such as mushroom, 
celery, and chicken 
or beef. Asian soups 
such as Miso, 
noodle soup 
Salad, tuna, 
salmon, chicken, + 
all salad 
vegetables. 
Dressing vinegar 
and olive oil if 
possible!  
Brown Rice sushi, 
all flavours ok. 
Mid 
afternoon 
Trail mix - nuts 
seeds, dried fruit 
Fruit or vegetable 
sticks with humus.  
Tub of yoghurt  Nuts – brazil nuts, 
tamari roasted 
almonds, walnuts 
or other nuts. 
Dinner Fish in a bag! See 
recipes on 
www.taste.com.au. 
Place white fish such 
as flathead, 
barramundi, perch in 
an oven bag with 
lots of herbs and 
spices. Suggest 
fennel seeds garlic, 
ginger, lemongrass, 
lemon myrtle Kaffir 
lime leaves etc. 
Avoid swordfish, 
shark and fresh tuna 
more than once a 
fortnight due to 
heavy metal content. 
Fresh garden salad 
Roasted chicken. 
With a lemon inside. 
Roast on a on a bed 
of onion. Use 
turmeric, paprika to 
season (Turmeric 
very good for 
healthy liver 
function). Spray 
with rice bran spray 
oil for to crispy skin. 
Roasted vegetables 
including kumera 
and pumpkin with 
skin on, beetroot, 
turnips, parsnips, 
onions, garlic etc 
Stir fry chicken 
thighs or breast 
strips. Use lime 
juice, fish sauce 
shallots, snow 
peas or green 
beans, coriander 
and Asian mint. 
Wild, basmati 
clever of brown 
rice (rice cooker is 
fine and takes a 
while so start to 
cook this first.  
Pork can be used 
for this dish as 
well. 
Curry lean red 
meat (or fish or 
chicken). Make 
your own curry 
paste with curry 
powder, cinnamon, 
cloves, turmeric, 
etc. Add lots of 
vegetables eg 
pumpkin, kumara 
(sweet potato) 
peas, beans tomato 
zucchini capsicum. 
see recipes on 
www.taste.com.au 
 
Basmati or brown 
rice in small 
proportions. 
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 Option 1 Option 2 Option 3 Option 4 
Pre bed snack Frozen berries Fresh berries such 
as strawberries, 
blueberries and 
yoghurt (frozen is 
fine) 
Grilled (or baked) 
stone fruit or 
pears with a 
sprinkling of 
brown sugar and 
cinnamon with 
yoghurt 
Cooked apple with 
cinnamon sultanas 
slivered almonds 
General 
guidelines 
The glycaemic index 
of foods can be 
found at 
www.glycaemicindex
.com 
Drink water as much 
as possible. You can 
have as many 
vegetables as you 
want, as often as 
you want. 
Coffee is fine up 
to 2 cups per day 
but green tea is 
much better!  
Three servings of 
red meat per 
week should 
provide adequate 
iron.  
Regarding amounts 
of food – sit down 
to eat, eat slowly 
(count to ten 
between 
mouthfuls) and 
stop when you are 
full. As a guideline 
two palm sized 
servings per day of 
foods high in 
protein is sufficient 
protein intake.  
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NICM - Dispensary register Herbal medicine tablets - ARENTZ PCOS. Consultation room LG building 
5 Campbelltown Campus  
Participant 
number 
PCOS-1; three bottles of 90 
tablets. Date dispensed. 
PCOS-2: one bottle of 60 tablets.  
Date dispensed. 
LN 0010 17 th August 2012 17 th August 2012 
LN 0020 10th August 2012 10th August 2012 
LN 0030 1st September 2012 1st September 2012 
LN 0040 17th September 2012 17th September 2012 
LN 0050 18th September 2012 18th September 2012 
LN 0060 1st October 2012 1st October 2012 
LN 0070 1st October 2012 1st October 2012 
LN 0080 18th October 2012 18th October 2012 
LN 0090 23rd October 2012 23rd October 2012 
LN 0100 26th October 2012 26th October 2012 
LN 0200 2nd November 2012 2nd November 2012 
LN 0300 9th November 2012 9th November 2012 
LN 0400 1st December 2012 1st December 2012 
LN 0500 1st December 2012 1st December 2012 
LN 0600 14th December 2012 14th December 2012 
LN 0700 15th December 2012 15th December 2012 
LN 0800 14th January 2013 14th January 2013 
LN 0900 12th February 2013 12th February 2013 
LN 1000 22th February 2013 22th February 2013 
LN 2000 25th February 2013 25th February 2013 
LN 3000 26th February 2013 26th February 2013 
LN 4000 8th March 2013 8th March 2013 
LN 5000 24th March 2013 24th March 2013 
LN 6000 28th March 2013 28th March 2013 
LN 7000 4th April 2013 4th April 2013 
LN 8000 24th April 2013 24th April 2013 
LN 9000 29th April 2013 29th April 2013 
LN0001 18th May 2013 18th May 2013 
LN 0002 25th May 2013 25th May 2013 
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LN 0003 25th May 2013 25th May 2013 
LN 0004 3rd June 2013 3rd June 2013 
LN 0005 8th June 2013 8th June 2013 
LN 0006 8th June 2013 8th June 2013 
LN 0007 8th June 2013 8th June 2013 
LN 0008 14th June 2013 14th June 2013 
LN 0009 17th June 2013 17th June 2013 
LN 00001 18th June 2013 18th June 2013 
LN 00002 20th June 2013 20th June 2013 
LN 00003 29th June 2013 29th June 2013 
LN 00004 29th June 2013 29th June 2013 
LN 00005 29th June 2013 29th June 2013 
LN 00006 3rd July 2013 3rd July 2013 
LN 00007 27th July 2013 27th July 2013 
LN 00008 27th July 2013 27th July 2013 
LN 00009 30th July 2013 30th July 2013 
LN 000001 6th August 2013 6th August 2013 
LN 000002 22st August 2013 22st August 2013 
LN 000003 27th August 2013 27th August 2013 
LN 000004 31st August 2013 31st August 2013 
LN 000005 1st September 2013 1st September 2013 
LN 000006 20th September 2013 20th September 2013 
LN 000007 8th October 2013 8th October 2013 
LN 000008 8th October 2013 8th October 2013 
LN 000009 24th October 2013 24th October 2013 
LN 0000001 29th October 2013 29th October 2013 
LN 0000002 31st October 2013 31st October 2013 
LN 0000003 1st November 2013 1st November 2013 
LN 0000004 14th November 2013 14th November 2013 
LN 0000005 15th November 2013 15th November 2013 
LN 0000006 18th November 2013 18th November 2013 
LN 0000007 13th December 2013 13th December 2013 
Appendix 25 continued 
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Trial Exit Participant No________ 
The addition of naturopathy to lifestyle intervention (diet and exercise, for 
the management of women with polycystic ovary syndrome (PCOS). 
 
First name....................................................... 
 
Surname......................................................... 
Date of birth    /  /   
                         day         month    year 
Age      
 
Address.........................................................
. 
...................................................................... 
Post code      
 
Phone number 
(...........).................................. 
 
Mobile........................................................... 
17. Completed study 
     
              Yes        no    
 
Reason for early withdrawal (if not complete) 
 
……………………………………………………………………. 
18. Date of study exit           
  /  /   
               day         month    year 
 
19.  Time of study exit  
        :   
             24 hour clock 
 
20. Number allocated 
            
21. Group 1    Group 2   
 
22. Number of tablets returned 
 
………………………………………… 
 
23. Attended all exercise sessions? 
      
   Yes        no    
24. If no number of exercise sessions? 
   out of 12 
25. Exercised at home? 
      
   Yes        no    
 
26. If no, number of exercise sessions? 
 
   out of 24 
 
 
 
 
 
 
 
 
Office use only Date Signed 
LOG   
CHECK   
Data Entry   
Queries resolved/ updated   
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Anthropometric features 
10. Body weight    kg 
11. Height            .  metres 
12. BMI                  kg/m2 
13. Waist circumference   cm 
14. Hip circumference      cm 
15. Hip to waist ratio   :   
 
16. Blood Pressure  
diastolic    /systolic    
17. Do you drink alcohol? 
     
   Yes        no    
If yes how many alcoholic drinks per week? 
     
18. Do you smoke cigarettes? 
     
   Yes        no    
If yes how many cigarettes per day? 
   
 
 
 
 
 
Now I want to ask you some questions 
about your menstrual cycle. 
 
19. When was the last time you had a 
menstrual period? 
2.   /  /   
                day         month    year 
 
20. Are you sure or not sure 
  sure   fairly sure   not sure   
 
21. Number of menstrual periods during 
previous three months. 
 
……………………………………………………………….. 
                 
If yes how long was your cycle? 
  days 
 
If no what was the shortest cycle and 
longest? 
      Shortest    Longest   
22. was your period; 
          Scant (spotting)                      
         Light (1-2 days)               
         Medium (3-5 days)                    
         Heavy (6+ tampons/pads per day   
         
..................................................................... 
 
23. Do you experience any of the following 
before or during your menstrual period? 
 
             period pain                 breast tenderness 
             fatigue                         headaches 
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24. Did you have any medical tests when you 
were on the trial or any pending? 
      Yes       No 
25. Blood tests 
• Oestradiol........................................ 
 
• FSH (day 1-8) .................................. 
 
• LH (day 1-8) .................................... 
 
• Testosterone................................... 
 
• Free androgen index....................... 
 
• SHBG............................................... 
 
• Other androgen studies..................  
 
• Fasting glucose................................ 
 
• Fasting insulin................................. 
 
• Other insulin studies ......................  
 
• Progesterone (after day 20)............  
 
• Thyroid function tests......................  
 
• Other blood tests including FBC, 
vitamin D, Iron studies, lipid profile 
Pregnancy? 
......................................................... 
 
......................................................... 
 
......................................................... 
 
26. Did you conceive whilst participating in 
the trial? 
......................................................... 
 
              ......................................................... 
            bloating                        Other - specify 
            mood changes             ......................... 
Next I want to ask you some questions 
about your diet. 
 
Are you familiar with the healthy eating 
plan described by the Australian 
Government called Lifescripts? 
                  yes   no   
What food do you usually eat? 
Servings on a typical day 
                                                  1  2  3  4  5     
Vegetables (1/2 cup)                       
Fruit (1 medium piece)              
Bread (2 slices), cereals                  
(1 cup cooked)                            
Rice, pasta, noodles                        
(1 cup cooked)                 
Lean meat, fish,                               
poultry (100g)                            
legumes ½ cup,                                
nuts & seeds (1/4 cup)         
Dairy and                                           
fortified milk  
substitutes (1 cup)                    
Yoghurt (1 tub),                               
cheese (2 slices)                
Oils, soft margarines                
(1 tablespoon)                 
Cakes biscuits, pies,                      
Pastries (average serve)        
Take away food                            
(eg. Fried chicken or  
fish, chips, burgers)             
Drinks (sugary soft drinks,          
juices, energy drinks (1 glass)  
  = optimal daily intake 
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27. Did you take any medication during the 
trial? 
         yes   no   
 
If yes describe.............................................. 
 
...................................................................... 
 
28. Did you take any vitamins or other 
supplements?  
         yes   no   
If yes describe .............................................. 
 
...................................................................... 
 
29. Was your experience on the trial what 
you expected?............................................... 
 
.................................................................... 
 
30. Are you happy with your outcomes of 
trial?........................................................... 
 
..................................................................... 
 
31. How did you feel about the menstrual 
diary? 
Happy                    Annoyed       
Neutral                  Angered        
Other         ............................................ 
 
32. Any comments about the trial............. 
 
.................................................................... 
Checklist 
 
33. Health eating continued? 
            yes   no   
 
If no comments............................................ 
 
..................................................................... 
 
34. PCOSQ and DASS Questionnaire 
yes   no   
 
35. Menstrual diary returned 
yes   no                                    
  /  /  date                                    
 
36. Invited to do blood tests  
yes   no                                    
If yes, completer blood tests 
yes   no         
        if yes   /  /  date   
                     
37. SUBSET (oligomenorrhoea) 
Blood tests     Yes       No  
Insulin    .............      Glucose  ................. 
FSH   ..................      P4 .......................... 
LH   ....................      T4   ....................... 
E2  .......................    FAI  ........................ 
comments    .............................................                         
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Appendix 28 
Month (s) 
Day of your 
menstrual 
cycle 
1 2 3 4 5 6 7 8 9 1
0 
1
1 
1
2 
1
3 
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
2
1 
2
2 
2
3 
2
4 
2
5 
2
6 
2
7 
2
8 
2
9 
3
0 
3
1 
3
2 
3
3 
3
4 
3
5 
3
6 
3
7 
3
8 
3
9 
4
0 
Date                                                                                 
Ovulation 
test + or - 
                                                                                
Mood                                                                                 
Breast 
soreness 
                                                                                
Energy                                                                                  
Headaches                                                                                 
Nausea or 
vomiting 
                                                                                
Period pain 
1-10  
                                                                                
Bowel 
changes  
                                                                                
Holiday                                                                                 
Exercise  
mins 
                                                                                
Vits/mins                                                                                 
Medication                                                                                 
Herbal 
tablets - 
PCOS 1 
                                                                                
Herbal 
tablets - 
PCOS 2 
                                                                                
TTC                                                                                 
Period  X                                                                               
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Appendix 29  
Safety information for herbal medicines in polycystic ovary syndrome 
(PCOS) 
Although it is known that mild adverse reactions are common with the use of herbal 
medicines, there are few reports of adverse events or adverse drug reactions in the 
literature for women with PCOS and use of the herbal medicines investigated in this trial 
(Chapter 4). However two of the herbal medicines, Glycyrrhiza glabra and Hypericum 
perforatum, have been associated with adverse events and adverse drug reactions in other 
cohorts. G. glabra is controversially associated with an increased risk for hypertension (van 
Uum 2002) and H. perforatum is associated with adverse pharmaceutical interactions 
(Hennessy, Kelleher et al. 2002, Pfrunder, Schiesser et al. 2003, Mills and Bone 2005).  
Pharmaceuticals which may interact with H. perforatum include the oral contraceptive pill, 
and antidepressants (Borrelli and Izzo 2009). Other pharmaceuticals that women with PCOS 
were likely to have been taking included hypoglycaemic drugs such as Metformin (Norman, 
Kidson et al. 2001). At the time commencement for this present study, there were no data 
investigating the interactions between Metformin and H. perforatum. Although the 
mechanism of effect for pharmaceutical hypoglycaemics vary, there were reports of mild 
pharmacokinetic interactions (increased oral clearance) for the hypoglycaemic 
pharmaceutical Gliclazide with concurrent H. perforatum use (Xu, Williams et al. 2008), and 
alternatively no negative interactions between H. perforatum and another hypoglycaemic, 
Tolbutamide (Wang, Gorski et al. 2001). It was anticipated that adverse effects due to 
concurrent use of Metformin and H. perforatum would be mild and limited. 
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Adverse effects for G.glabra occur in response to glycyrrhizin compounds (glycorrhizic acids 
(GA)) in a linear, dose dependent pattern (Sigurjonsdottir, Franzson et al. 2001). 
Hypertensive individuals have increased sensitivity with rises in systolic blood pressure of 
15mmHg when exposed to 150mg of GA per day (Sigurjonsdottir, Manhem et al. 2003). In 
the present case the concentration of GA in the herbal tablet PCOS-1 was quantified at 0.19 
milligrams per gram or tablet, (each tablet contained one gram of G. glabra). The 
administered dose of three tablets per day was equivalent to 0.57miligrams of GA per day. 
This dose was anticipated to be under the adverse hypertensive effect of GA. However 
blood pressure was measured at enrolment and at the exit interview to assess systolic blood 
pressure and to monitor this adverse effect.  
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Appendix 30 
Primary outcome; the number of days in the menstrual cycle using modified intention to treat 
analyses 
Data of women who withdrew (or were withdrawn) following at least four weeks per 
protocol participation (test n=3, control n=2) were carried forward and included in analyses. 
Changes in the number of days in the menstrual cycle at three months within the test and 
control group using modified ITT. (Table 1). 
Table 1. Number of days in the menstrual cycle at three months within groups excluding 
participants not exposed to either intervention (modified ITT or per protocol analyses). 
Number of days in the 
menstrual cycle at three 
months 
Baseline 
mean (SD) 
Endpoint  
mean (SD) 
Mean 
difference 
P value 95% confidence 
interval 
Lifestyle program only 
(n=62) 
109.5 
(148.0) 
103.2* 
(144.8) 
1.7*** 
(53.1) 
0.82 -12.4 15.5 
Herbal medicine plus 
lifestyle program 
(n=60) 
106.0 
(123.3) 
63.8** 
(105.9) 
47.8*** 
(78.37) 
<0.001 26.6 69.0 
 
Mean difference between 
groups 
  46.2 
(12.53)**** 
<0.001 21.4 71.1 
  * n=58 
** n=55 
***paired t test means calculated for 58 pairs in control group and 55 pairs in the test group 
**** standard error of the mean difference 
 
At the end of the trial women who received the herbal medicine plus lifestyle intervention 
using modified intention to treat analyses had an average menstrual cycle length of 64 days 
compared to 103 days for women who received only lifestyle intervention. Both types of 
intention-to-treat (ITT) analyses (all randomisations and modified ITT) demonstrated the 
same statistical significance within each group over three months (control group p=0.82 and 
test group p<0.001).
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Appendix 31 
Data output, analyses of variance. 
The associations between the group of assignment (test or control group) luteinising hormone (LH), 
fating insulin and BMI with the primary outcome (number of days in the menstrual cycle). 
Differences between the groups, (one way analyses using ANOVA). 
 
ANOVA 
Difference, number of days in the menstrual cycle 
 Sum of Squares df Mean Square F Sig. 
Between Groups 60368.407 1 60368.407 13.610 .000 
Within Groups 492368.338 111 4435.751   
Total 552736.745 112    
 
The association of the group of assignment (test or control group) and reduced luteinising hormone 
(LH) with the primary outcome (number of days in the menstrual cycle). 
 
Tests of Between-Subjects Effects 
Dependent Variable:   Number of days in the menstrual cycle at 3 months   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 167226.586a 2 83613.293 9.113 .000 
Intercept 1.028 1 1.028 .000 .992 
LH concentration 125576.452 1 125576.452 13.687 .000 
Group of 
assignment 
40474.649 1 40474.649 4.411 .040 
Error 568849.659 62 9174.995   
Total 1082213.090 65    
Corrected Total 736076.246 64    
a. R Squared = .227 (Adjusted R Squared = .202) 
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The association of the group of assignment (test or control group) and reduced fasting insulin with 
the primary outcome (reduced number of days in the menstrual cycle). 
 
Tests of Between-Subjects Effects 
Dependent Variable:   Number of days in the menstrual cycle at 3 months   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 134059.424a 26 5156.132 .481 .964 
Intercept 35048.994 1 35048.994 3.272 .083 
Group of 
assignment 
28440.172 1 28440.172 2.655 .116 
Fasting insulin 104778.423 25 4191.137 .391 .988 
Error 257073.583 24 10711.399   
Total 453307.370 51    
Corrected Total 391133.007 50    
a. R Squared = .343 (Adjusted R Squared = -.369) 
 
The association for the group of assignment (test or control group) and body mass index (BMI) with 
the primary outcome (reduced number of days in the menstrual cycle). 
 
 
Tests of Between-Subjects Effects 
Dependent Variable:   Difference days   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 63145.180a 2 31572.590 7.094 .001 
Intercept 46020.291 1 46020.291 10.340 .002 
Group of 
assignment 
44833.529 1 44833.529 10.073 .002 
BMI 2776.773 1 2776.773 .624 .431 
Error 489591.565 110 4450.832   
Total 618194.870 113    
Corrected Total 552736.745 112    
a. R Squared = .114 (Adjusted R Squared = .098) 
 
 
